äºé²
ïŒïŒ
æ¥çš®ã®æ¬åœã®æå³
ïŒå€§åãªäººãå®ãããã«
ãã£ã ã»ãªã·ã¢ãŒè
ãã®æ¬ã®èªã¿æ¹
æã
ããã®æ¬ãèªãã§ããèªåã®åäŸã«äºé²æ¥çš®ãåããããã®ããããæ±ºæããããšã
ã話ãèããŸãããã¡ãããããå±ãªããšããããã§ã¯ãããŸãããããã®æ¬ã«èŒã£ãŠã
ãæ
å ±ã¯ãããããéå€§ãªæ±ºæãããã«å¿
èŠãªãããæäœéã®ç¥èã«ãããŸããããã®æ¬
ã¯ãçŸåšã®äºé²æ¥çš®ã®æ¹éã®ããæ¹ããã£ãããšåããã ããæã確ããªæ
å ±æºãç°¡åã«
èŠçŽãããã®ã§ãããäºå®äžã®åèã«ãšããããã¯ãèå¿ãªæ¬é¡ãå°ãèããèŠã€ããã
ãæ·±ããã®ãŸã§å°ãããã®åºåã®ãããªãã®ãšããŠèªãããšãæ£ãããšæãããŸãã
ããŒã¯ã»ãã¥ã¯ã€ã³ã«ããã°ãç§éã¯æ¬ãè²·ããšãããããèªãæéãè²·ã£ãŠãããããª
ã€ããã«ãªãããã§ãããéåžžãã®æ¬ãäžžããšèªã¿çµããã®ã«å¿
èŠãªæéã¯çŽ 2 æéåã°
ããã§ã1 æ©ã«ãã¬ãã«è²»ããæéãããå°ãªããã®ã§ãã倧æµã®äººã
ã¯ãæ¬ãè²·ã£ãŠãæ°
åéãã£ãšç®ãéããåŸã¯ã»ã£ããããã«ããŠããŸããã¡ã§ãããããçãããäºé²æ¥çš®
ã«çåãæããŠããŠãå»è
ãæ°èããã¯æããŠããããªã話ãããã®ã§ã¯ããšæããŠãã
ãªãã°ããã®æ¬ã¯ã»ã£ããããã«ããããã£ããèªãã§ãã ãããããããããšã§ãäœã¶
æãã®ãªãµãŒãã®æéãçããéèŠãªè«žåé¡ç¹ã«ã€ããŠç¥ãããšãåºæ¥ãŸãããã¡ããã
çãããäœã®çåãæ±ããŠããªãã£ãããåšãã«åãããããšæãã ããäºé²æ¥çš®ã«å¯Ÿã
ãŠç¡æ¡ä»¶ã«è³æãããã®åœã®å€§åã®åäŸéãšåæ§ã«ãèªåã®åäŸã®å¥åº·ãããããåé¡ã
ããæã«å§ããŠããŸãã€ãããªã話ã¯å¥ã§ãããäŸã軜ãã§ããã®åé¡ã«ã€ããŠç¥ããã
ãšæããªãããã®æ¬ãå
šéšèªã¿çµããããšã¯å¿
èŠæäœéã®ããšãšãããã§ããããå°ãªã
ãšãããäœã®æ
å ±ãªãã§ã¯ãçµæãšããŠçããããã®æ¬ãèªã¿å§ããåã«æ±ããŠããçå
ãäžå®ãžã®çããèŠã€ããããæ±ºæãäžãããšãåºæ¥ãªããŸãŸã§çµãã£ãŠããŸããŸãã
äžçäžã§èµ·ãã£ãŠããäºé²æ¥çš®ã®å®æ
ã¯ãæ¬åœã¯ããã§æžãããŠãããããé¥ãã«ã²ã©ã
ç¶æ
ã§ããçãããããããèå³ãããããåé¡ç¹ã«ã€ããŠããã£ãšæ·±ã調ã¹ããå Žåã¯ã
ãã®æ¬ã«èšèŒããåèè³æãèªãã§ããã詳ããæ
å ±ãåŸãŠãã ããã
äºé²æ¥çš®ã®çŸç¶ã¯ã幎ã
å€ãã£ãŠãããŸããããããããã¥ãŒã¹ã¯äžè¬ã®ã¡ãã£ã¢ã§ã¯æ
ããŠãããŸãããæ¬æžã§ããå·ããšã«å
šäœçãªæçŽããå ããŠããŸããããçããããæ¬
æžããåã®å·ããèªã¿ã«ãªã£ãããšããã£ãŠããããã ãã§ã¯ä»ã®æç¹ã«å¯Ÿããååãªç¥
èãšããŠã¯è¶³ããŸããã®ã§ã泚æäžããã
ããã§ã¯ããŸãéããªéšå±ã§ãéªéã®ãªãããé»è©±ã®ã¹ã€ãããåãããã¬ãã ipod ããª
ãã«ããŠããã衚çŽããè£è¡šçŽãŸã§ãäžæ°ã«èªã¿çµããŠãã ãããããããã°ããã®ãã
ãã¯ã«é¢ããå
¥éçãªç¥èãåŸãããšãåºæ¥ãã§ãããã
ã¯ããã«
1980 幎ããçŸåšã«ãããŠãäžéããã®èŠè«ããªãã®ã«ãåè¡åœã§åäŸéã«è¡ãããã¯ã¯ã
ã³æ¥çš®ã®éã 3 åã«ãå¢ããã®ã¯ãã©ãããèš³ã§ãããïŒ ãããŠä»ãã倧人ã«å¯ŸããŠã
ã¯ã¯ãã³æ¥çš®ãäŒç»ãããŠããã®ã¯ããªããªã®ã§ãããïŒ
äºé²æ¥çš®ã®è«äºã«é¢ããŠã¯ãå°ãªããšã 2 ã€ã®çžåããèŠè§£ããããŸããã²ãšã€ã¯ãç§ã
ã¡ãæ°èããã¬ããéèªãªã©ã§åžžã«ç®ã«ããèãæ¹ã§ããããçæ¹ã®èãæ¹ã¯ãå°ãæã
äžããŠã¿ãªããšèŠä»ãããªããã®ã§ãããããã§ããã£ããšããŠååšããèŠè§£ã§ãããã®
æ¬ãèªã¿ãªããå€å°ãªããšããªãµãŒããå§ãããã¡ã«ãçããã¯ããæãããªäºå®ã«æ°ä»
ãã§ãããïŒå
šãŠã®æ
å ±ãæ£ãããšããããšã¯ããåŸãªãïŒã©ããã§ã誰ããééã£ãæ
å ±ãæµããŠããããšã
ããã«é©ãã¹ãããšã«ãããããäºé²æ¥çš®ã«å察ããèŠè§£ã¯ãå¥åº·å¿åã®ã°ã«ãŒãããã
ãã®ã§ã¯ãªããäžè¬äž»æµã®ç§åŠãšè¬åŠããããŠæ³åŸãšãã£ãããŒã¿ããæãç«ã£ãŠããã®
ã§ãããã®æ¬ã¯ããããããŒã¿ãåºã«ããŠæžãããŸããã
è¡æ¶²ã¯ãéã®ããŸããšèšã£ãŠãè¯ããããããŸãããäœããã®è¬ã掻æ§å€ã§è¡æ¶²ãæ»æã
ãããšããæ¿æ²»çã«ãçµæžçã«ãäœå¶åããŠããããšã§ã倧ããããããŠãã人ã
ãæã
ãçµ¶ããªãããã§ããäžå²ãã«æåããäŸãšããŠã¯ãç ç³ãã¢ã«ã³ãŒã«ãã³ãŒããŒãé¿çã
倧麻ãã¿ãã³ãã³ã«ã€ã³ãäºé²æ¥çš®ãåæãšã¹ããã²ã³ãéå°ãªæçå€ãäžå¿
èŠãªè¬å€ãª
ã©ãæããããŸãã
åäŸã®äžçã«ãããå
ç«æ©èœã®è¯ãæªãã¯ã幌幎æã®è¡æ¶²ã®ç¶æ
ã«ãã£ãŠæ±ºãŸããŸããäœ
å
ã®å
šãŠã®çްèã¯ãçãŸããŠããæ»ã¬ãŸã§ãè¡æ¶²ã«æµžãã£ãŠããã®ã§ããããè¡æ¶²å
ã®é
ž
çŽ ãšæ é€çŽ ã®éã«ãã£ãŠããã®äººã®å¥åº·ã寿åœãå·Šå³ãããŸãããååŠç©è³ªãå€åœ¢ããã
ã¯ããªã¢ããŠã€ã«ã¹ãæ¯æ§ã®é£ã¹ç©ãäžå®å
šãªæ³šå°ãªã©ãå€éšããã®äœããã®äŸµå
¥ç©ã¯ã
æ»äº¡çãžãšã€ãªãã£ãŠããïŒãã ãããã ãã®ããšã§ãã
åäŸã¯ã ãã§ããå±å®³ããå®ãããæš©å©ãæã£ãŠããŸããäžæ¹ã§äºé²æ¥çš®ã¯å±éºã ãšäž»åŒµ
ããŠãã倧ããªå£äœããããããçæ¹ã§ã¯å®å
šã ãšäž»åŒµãã倧ããªå£äœãããå Žåã«ã¯ã
空ã£ãœã®å®£äŒæå¥ãéµåã¿ã«ããã®ã§ã¯ãªããããããã®äž»åŒµãæ ¹æ ãšãã蚌æ äºå®ãèŠ
ãŠãããªããã°ãªããŸããã
è¡æ¶²å
ã«å€éšããé²å
¥ããã«ã¯ãç®èãèºããããã¯æ¶ååšå®ãéããŠã®ãïŒã€ã®æ¹æ³ã
ããããŸããããåžžã«å€åããå±å®³ã®ããç°å¢ã«å¯Ÿå¿ããªãã人é¡ãçãå»¶ã³ãŠãããã
ã«ããã® 3 ã€ã®ããããã«ã¯ãç¬èªã®é²åŸ¡ã·ã¹ãã ãåããããŠããŸããé²åã®éçšã«ã
ããŠãé ç©äž»ã¯ãå€éšç°å¢ããè¡æ¶²ãä¿è·ããããã«æåãå°œãããŠãããŠããŸãã人ã®
è¡æ¶²ã®å€§åãã«ãèªç¶ãã®ãã®ãæ°ä»ããŠãããšããã®ã«ãç§ãã¡èªèº«ãããããããã
ã«æ±ã£ãŠè¯ããã®ã§ããããïŒ
人ã®å
ãªã䟡å€ã¯ããã®è¡ã§æ±ºãŸãïŒ
ããã«ãã£ãŠåŒ·ããã匱ããæ±ºãŸã£ãŠããŸãã®ã ã
ããã¯ã©ãã¹
ç®æ¬¡ïŒ
äºé²æ¥çš®ãšãé ïŒ
äºé²æ¥çš®ã®æŽå²ïŒãšãã¯ãŒãã»ãžã§ã㌠ïŒ
倩ç¶ç ïŒ
9/11 以éã®å€©ç¶ç ïŒïŒ
ãã¹ããŒã«ãšç
åè説 ïŒïŒ
ã¡ãµããŒã«é²è
å€ãšèªéç ïŒïŒ
æåãšæäœãææ¯çŽ ã«ã€ã㊠ïŒïŒ
èªç¶ã®å
ç« vs.人工çãªå
ç« ïŒïŒ
ã¯ã¯ãã³æ¥çš®ã¯äœæ¬å¿
èŠã ïŒïŒ
æäººçšã®æ°ã¯ã¯ãã³æ¥çš®å°å
¥ ïŒïŒ
ä¹³å
ã®çªç¶æ» SIDS ã«ã€ã㊠ïŒïŒ
ã¯ã¯ãã³æ¥çš®ãå§ãŸã以åã®ãç
æ°ã®æžå°ç ïŒïŒ
ããªãª ïŒ å°å
éº»çº ïŒïŒ
ãžãããªã¢ ïŒïŒ
çŸæ¥å³ ïŒïŒ
ç Žå·é¢š ïŒïŒ
ã¯ãã ïŒïŒ
ãããµããã ïŒïŒ
颚ç¹ãäžæ¥ã°ãã ïŒïŒ
é«èç ïŒïŒ
ã€ã³ãã«ãšã³ã¶ã®ã¯ã¯ãã³æ¥çš® ïŒïŒ
A åèç ïŒïŒ
B åèç 1ïŒïŒ
æ°Žç±ç¡ ïŒïŒïŒ
ãã¿ãŠã€ã«ã¹ ïŒïŒïŒ
èªéç ïŒïŒïŒ
æ°Žéã«ã€ã㊠ïŒïŒïŒ
åäŸã®æ» ïŒïŒïŒ
ãã¬ãããŒã¯ã¯ãã³ïŒPrevnarïŒ ïŒïŒïŒ
HPV ã¯ã¯ãã³ 1ïŒïŒ
AIDS ã¯ã¯ãã³æ¥çš®ã®å°å
¥äºå® ïŒïŒïŒ
SARS ïŒïŒïŒ
湟岞æŠäºçå矀 ïŒïŒïŒ
ã¯ã¯ãã³æ¥çš®ã å ã㪠ã å»è
ïŒïŒïŒ
ã¯ã¯ãã³æ¥çš®ã®å
é€ã«é¢ããæ³åŸ ïŒïŒïŒ
ãããã®ã¯ã¯ãã³æ¥çš® ïŒïŒïŒ
æ
è¡æã®ã¯ã¯ãã³æ¥çš® ïŒïŒïŒ
æ°çš®ã®ã¯ã¯ãã³æ¥çš® ïŒïŒïŒ
ã°ãªãŒã³ãªã¯ã¯ãã³æ¥çš® ïŒïŒïŒ
çš®ã®éžæãšãã¯ã¯ãã³æ¥çš® ïŒïŒïŒ
åèè³æ ïŒïŒïŒ
çµããã« ïŒïŒïŒ
ç§ãã¡ã®äžçã«ãæãã¹ãæŠãã®æ¥ã
ã蚪ããããšããŠããŸããåäŸéã®è¡æ¶²ãè¥²ãæ°ã
ã屿©ãããç§ãã¡èªèº«ãããåãå®ããªããã°ãªããªãæä»£ãé£ã£ãŠããã®ã§ããäºé²
æ¥çš®ãšã¯éåžžã«å²ããããžãã¹ã§ãããæ¿åºèŠå®ã®äºé²æ¥çš®ã®ãªã¹ãã«èŒãããšãæ¯å¹Žæ°
çš®ã®ã¯ã¯ãã³ãéçºããã仿¥ã§ã¯åäŸã18 æ³ã«è³ããŸã§ã«åããªããŠã¯ãªããªãäºé²æ¥
çš®ã¯ããªããš 68 åã«ããªã£ãŠããŸã£ãç¶æ³ã§ããçŸä»£ã®åäŸéã®å¥åº·ç¶æ
ãæ»äº¡çã«ã¯ã
ç®ã«äœããã®ããããŸããåãã¢ã¡ãªã«äººãçŸæ£ããäŒæç
ãå€çš®ã®ç
æ°ã¯ãæ¥éã«å¢ã
ç¶ããŠããŸãã
åŠæ ¡ã®åäŸéã®å¥åº·ç¶æ
ã¯ãæããã«æªåãã€ã€ãããŸãããªã¿ãªã³ã€ããã¶ãã¯å€, 粟ç¥
å®å®å€ãåžå
¥åšã䜿ãåäŸéããããããšããã«èŠãããŸããæŽå²äžæãå€ãã®æçç©è³ª
ãäºé²æ¥çš®ãåããŠããã«ãããããããä»ã®åäŸéã以åãããè¥æºã§ãç
æ°ãã¡ã§ã
é ã®åè»¢ãæªãïŒHarvard School [4]ïŒã®ã¯ã©ãããŠã§ãããïŒ
CDC ã«ãã忝ã®çºççã®è¡šã«ãããšã1980 幎㮠670 äžä»¶ãã 2130äžä»¶ãŸã§ã«ãå¢ããŠ
ããŸãã(162,13)
ãã®å
ã®å€§å€æ°ã¯åäŸéã§ã1200 äžä»¶ä»¥äžã«ããªããæ¯å¹Ž 5000 人以äžã忝ã®çºäœã§æ»
亡ããŠããŸããïŒBorensteinïŒ[174]ïŒé©ãããšã«ãåŠæ ¡å
ã® 4 人㫠1 人ã¯åžå
¥åšãæã¡æ©
ããŠããããšãããšãããåšãäœã§ãããããæ¯å¹Ž14 åãã«ãã®è³éãåæ¯ã®æ²»çã«è²»ã
ããŠãããšããã®ã«ã倧æµã®ãã¥ãŒã¹ã§ã¯åæ¯ããªãã®ç
æ°ãšããŠåãæ±ãã°ããã§ãã
ç°åžžãæã€åäŸéã®æ°ã¯é©ãã»ã©å€ããã¢ã¡ãªã«ã®å
¬ç«åŠæ ¡ã®çåŸã®ïŒïŒïŒ
ããäœããã®
é害ã®ããã®ããã°ã©ã ã«å ãã£ãŠããŸãã[34]ããã«ããªããšã¢ã¡ãªã«ã®åäŸéã®6 人ã«
1 人ããç¥çµçºéã«ç°åžžãèŠããããšããææ§ã§ãïŒïŒïŒGeier- IOM hearings [59]ïŒ
äºé²æ¥çš®ãåããªãããã«ã¯
çŸåšãåäŸã«èŠæ±ãããäºé²æ¥çš®ã®æ°ã«ç°è«ãå±ããå»è
ããè¬åŠç ç©¶è
ãå¢ãã€ã€ãã
ãŸãã[336] åãä»ã®ããšã¯ãšãããããããŠããåã®è¡æ¶²ã ãã¯æ¿æ²»ãéå²ãã®ç ç²ã«
ãããããªããšãäºé²æ¥çš®ã«å察ããå
é€ç³è«æžã«ãµã€ã³ãã芪éã倿°ããŸãã圌ãã¯ã
人ã®è¡æ¶²ã®å€§åããå°éããäºé²æ¥çš®ã«äžç·ãåŒããããã§ããè¡æ¶²ã«äœããæ³šå
¥ããã®
ãèš±ãããã®ã¯ãçæ»ãããã£ãŠããç·æ¥äºæ
ã®ã¿ã§ãããããŸããŠãå®éšçã§ãã£ããã
äžç¢ºããªãã®ãå±éºãªç©è³ªã泚å
¥ãããªã©ããšãã§ããªãããšã§ãã[12,361]
å€ãã®æžç©ããäºé²æ¥çš®ã¯å®å
šã§å¿
èŠãªãã®ã ãšèª¬ããŠããŸãããå¥è·¡çãªã¯ã¯ãã³ã®é
çºã«ãã£ãŠãããã«çŸä»£äººãäŒæç
ã®éæããæããããããšãã£ã話ãè³ã«ããŸããåã
åäŸéãäŒæç
ããå®ãããã«ãããã«äºé²æ¥çš®ãåããããšã倧åãããšãã話ãè¯ã
èããŸããããã«ãæ°çš®ã®äŒæç
ã«å¯ŸããŠå¹ãããããæ°çš®ã®ã¯ã¯ãã³ã®ããããè³ã«å
¥
ã£ãŠããŸãã
äºé²æ¥çš®ã«é¢ãã 2 ã€ã®çžåããæèŠã®äž¡æ¹ããã©ã¡ããæ£ããããšã¯ããããŸãããã
ããã¯ãåãªãè¬åŠäžã®ç°ãªãææ³ã§ã¯ãªããçããŠããç§éã®äœã®å®éåé¡ã«é¢ããã2
ã€ã®æ£å察ã®èŠè§£ãªã®ã§ããäž¡æ¹ã®æ¯æè
ãæã«ææ
çã«ãªã£ããããã¹ããªãã¯ã«ãªã
ãã¡ã§ãç§åŠçãªæ ¹æ ãæ¬ ããããšããã°ãã°ã§ãããäž¡æ¹ã®æèŠã®éã«ã¯å°æããŠããŸ
ãçšå€§ããªéãããããã®ã§ãã
ã€ãŸãã
ç§éã®å¥åº·ãšå®å
šãä¿ã¡ç¶ããã«ã¯ãäºé²æ¥çš®ã¯å¿
èŠäžå¯æ¬ ã§ãã
ãããã¯
äºé²æ¥çš®ã¯ãåäŸéã害ãã匱ããããŠããŸãæ¯ç©ã§ãã
ã©ã¡ãã 1ã€ã ããæ£ããããšã«ãªããŸãã
ã©ã¡ãã®åŽã«ããå€å€§ãªèª€å ±ããããããªããŒã¿ã溢ããŠãããããèŠãŠãã人ã
ã¯ãã°
ãããããšãäžæ©äžãã£ãŠããèããããã«ãªãã§ãããããã¡ãã£ãšåŸ
ã£ããäžäœããã
ãæ
å ±ã®ãã©ããã¯ã£ããæ£ãããšãããã ããïŒã
æ§ãããªææ¡
åäŸéã®è¡æ¶²ã¯æåéããç§éã®å°æ¥ãžãšã€ãªããæµããŠããã®ã§ãããããããå®ãç°
å¢ã¯ãæ±ãã倧äºã«ä¿ãããã¹ãã§ããè¡æ¶²ã«äœããã®ç°ç©ã泚å
¥ããŠããŸãåã«ã次㮠2
é
ç®ã確信ã§ããªããŠã¯ãªããŸããã
ïŒïŒãããåäŸã®å¥åº·ã«èŠæ±ããããã®ã§ããããšã
ïŒïŒäžåã®å±å®³ã®å¿é
ãç¡ãããšã
ããã«ã仿¥äžè¬ã«åºåã£ãŠãã宣äŒçãªæžç©ãšã¯éãããã®æ¬ã«èŒã£ãŠããå
šãŠã®ããŒ
ã¿ã¯ãæ
å ±æºãæããã«èšèŒããŠãããŸãã
æ°ããå±é
äºé²æ¥çš®ã®å°æ¥ã«ãšããªããæ³åŸã«ããäºé²æ¥çš®ã®çŸ©åå¶åºŠãå®å°ãããŸããã芪ãå
é€
ç³è«æžã«çœ²åããªãéããåäŸéã¯å°±åŠä»¥åã«äºé²æ¥çš®ãåããªããã°ãªããŸãããæ³åŸ
ã®æç«ã«ããã£ãŠã¯è°é¢ã«å€éšããã®å§åãããããŸãããã¯ã·ã³ãã³ã§äžçªæš©åã®ãã
å§åå£äœã¯è£œè¬ç£æ¥ã§ãã[51]
ããã ãã§ããã²ã©ãç¶æ³ã§ããâŠããŠãäŒæ¥ã®å²ããšãç§éã®åäŸéã®å¥åº·ã®ä¿éïŒã
ã® 2 ã€ã倩秀ã«ããããšãåªå
ãããã®ã¯ã©ã£ã¡ã®æ¹ã§ããããïŒã©ã¡ããïŒã€ãéžã°ãª
ããŠã¯ãããªããªããäŒæ¥ã¯ã©ã£ã¡ããšããšæããŸããïŒ
ç¥ã£ãŠãããªããã°ãªããªãããš
ãã®æ¬ãèªãã§ãã芪ã®çããã¯ã倧æµããæãã§ãããããããªããšãç§ãç¥ãå¿
èŠã¯
ãªãããå»è
ã«ä»»ããŠããã°ããããããªãããããããããããã«ã¯ 2 ã€ã®åé¡ããã
ãŸãã
ïŒïŒå»è
ã®å€§å€æ°ã¯ãã®äºå®ãç¥ããªãã
ïŒïŒãã®äºå®ãç¥ã£ãŠããå»è
ã¯ãèªåã®åäŸã«äºé²æ¥çš®ãåããããªãã[336]
ãã®ç« ã§ç޹ä»ããèŠè§£ã¯ãå°æ°æŽŸã§ããã倧ããªãµããŒããšååãªåèè³æã«æ¯ãããã
ãã®ã§ãããèªåã®åäŸãäºé²æ¥çš®ã«é£ããŠè¡ãäºå®ã®èŠªãªãã ãã§ãåŠã¶äŸ¡å€ã®ããè
ãæ¹ã§ããçããããããäœããã®ç¹ã«çåãæãããšãã¯ã
ïŒïŒåèè³æã確èªããŠã¿ã
ïŒïŒãéã®æµãããã©ã£ãŠã¿ã
以äžã® 2ã€ã詊ããŠã¿ãŠãã ããã
äºé²æ¥çš®ãšããæ°è宿
ããã§åãäžããŠãããç§éã®åäŸéã®å¥åº·ãšãã課é¡ã¯ããšãŠã倧åã§ææ
ãå
¥ããã
ããã®ã§ãããæ¿æ²»çã«ã倧ãã«åé¡ã«ãªã£ãŠãããã®ã§ããåäŸã«ãšã£ãŠäœãæè¯ãã
決ããããã«ã¯ã芪ã®åŽããäŸããããã©ããžè¡ãçãã«ããŠãæåŸãŸã§ããŒã¿ããã©ã£
ãŠè¡ãæ°æã¡ãå¿
èŠã§ãã
ãšããããªãããäºé²æ¥çš®ã«é¢ããæ£ããæ
å ±ã«å¯ŸããŠã宿çåŠä¿¡ã«äŒŒãæ¿ããæåŠã
ãã人ãããããŸããRitalin ããšã¹ããã²ã³ãæçç©è³ªã«é¢ããŠã¯ããã§ããªãã®ã«ãäº
鲿¥çš®ã®ããšã«ãªããšã人ã
ã¯ç²ç®çããã¹ããªãã¯ãªã»ã©ææ
çã«ãªã£ãŠããŸãã®ã§ãã
芪ãèªåã®åäŸãäºé²æ¥çš®ããå
é€ãããšãããæ³åŸã§ãèªããããè¡çºãè¡ã£ãããã«ã
瀟äŒçŠç¥é¢ä¿ã®çµç¹ã«åäŸãåãäžããããŠããŸã£ãã±ãŒã¹ããå®éã«å€ã
èµ·ãã£ãŠããŸ
ãã
ãªãããããªå€§ãããªããšãèµ·ããŠããã®ã§ãããïŒãªããäºé²æ¥çš®ã¯ãããŸã§å€§äºã«æ
ãŸããŠããã®ã§ãããïŒå€å€§ãªåªåãããŠãŸã§ãæ
å ±ãé ãããŸãŸã§ããã®ã¯ãªããªã®ã§
ããããïŒ
è³æ¬éåãã«åäœã®äŒæ¥ãé¢äžããŠãããä»ã®äºæãšåæ§ã«ãäºé²æ¥çš®ã«é¢ããæ
å ±ãé
åžžã«ã³ã³ãããŒã«ãããŠããŸããããããçãããäºé²æ¥çš®ã«é¢ããçå®ã調ã¹å§ãããšã
ããã«æå³çã«äžååãªæ
å ±ããåŸãããªãããã«ãªã£ãŠãããã«é©ããããéã«ãäž»ã«
ãããã®å»åŠæç®ã«ãäºé²æ¥çš®ã«å察ããè«æã倧éã«ããããšã«ç®ãèŠåŒµãã§ãããã
ãã®ãã¡ã«ã誰ãä¿¡ããã°ããã®ãåãããªããªã£ãŠããŸãã»ã©ã§ãã人ã®äœããèªåèª
身ã§å
ç«ãã€ããŠããèœåãããã®ãããããã¯ãšãŠã€ããªãç¡åã§ãå»åŠã®ç¥æµã«å©ã
ãŠããããªããšçãæ®ããªãã®ãããã®ã©ã¡ããã§ãã
å»åŠçãªçšèªã®ã¯ãªã
ããã§ã¯ãŸããã¯ã¯ãã³æ¥çš®ãšãïŒå
ç«ãã€ããïŒäºé²æ¥çš®ããšãã 2ã€ã®çšèªã«ã€ããŠè
ããŠãããŸããããç§éã¯ããã® 2 ã€ãå矩èªãšããŠèããããã«ãªã£ãŠããŸãããå®ã¯
æå³çã«ã人ã
ã«ããèããããããã«ãè«å€§ãªè²»çšããããããŠããã®ã§ãã
ã§ã¯ããã®éããšã¯ãªãã§ããããïŒèããŠã¿ãŠãã ãããå
ç«ãšã¯ãäœãèªåã§ãªãã
ãã«æµæåãã€ããããšãæããŠããŸããããã«ã¯ããã®ç
æ°ã«ãããããå°ãªããšãã
ã®ç
æ°ãšæ¥è§Šããã€ããšãå¿
èŠæ¡ä»¶ã§ãã察ããŠã¯ã¯ãã³æ¥çš®ãšã¯ãåã«èª°ãã®è
ã«éã
å·®ã蟌ãã§ãããããã¯ã¯ãã³ãšåŒã°ãã人工ç©è³ªã泚å
¥ããããšã§ãããäž¡è
ã¯ãŸã£ã
ãç°ãªãæå³ãæã£ãŠããã®ã§ãããããã®ããšãåŠãã ã®ã§ããããæ¬åœã¯ã¯ã¯ãã³æ¥
çš®ã®ããšãèšã£ãŠãããšãã«ããããäºé²æ¥çš®ãšåŒã¶ãããªããšã¯ãããŸãããã
ããããå»åŠã®äžçã§ãäžè¬ã®æžç©ã§ãããããã«ãã¯ã¯ãã³æ¥çš®ãã®ä»£ããã«ãäºé²æ¥
çš®ããšããçšèªã䜿ãããã® 2 ã€ã®çšèªããŸãã§åãæå³ã®ãããªæ¯ãããããããŸãã
åœç¶ãçŸåšã®å»åŠé¢ä¿ã®æžç©ã«ã¯ããã¯ã¯ãã³æ¥çš®ããšããçšèªã¯æ¬æ¥æ£ããçšèªã§ããã«
ãããããããã»ãšãã©äœ¿ãããŠããŸããããããäž¡è
ã«ã¯ã倧ããªéãããããŸãããã
ããããã¯ãæ°ãã€ããŠã¿ãŠãã ããã
ã¯ã¯ãã³ãšã¯äœãïŒ
ãåžéããããããã¯æ»ãã 埮çç©ãäœå
ã«ä¿çããããšâŠ ç
æ°ã®äºé²ãåã³æ²»çã®çºã«
å°å
¥ãããè¡çºã
ïŒããŒã©ã³ãã®å»åŠèŸå
žãïŒïŒïŒããŒãž [200]
çãããšã£ãâãã®èšèã®ç±æ¥ã¯ãããããæå³ã§ãããã®ã¯ã¯ãã³ããæ¬åœã«äœãã®
äºé²ãæ²»çã«åœ¹ç«ã€ãã®ãã調ã¹ãŠã¿ãŸãããã
ã¯ã¯ãã³ãšãé
ã¯ã¯ãã³ã®è©±ã«ã¯ãã©ããã£ãé¡ã®ãéãé¢ä¿ããŠããã®ã§ãããïŒ
1994 幎ãäžçäžã«æ®åããã¯ã¯ãã³ã¯
ãïŒïŒïŒçŽ 3 åãã«ãã®çšŒããããäŒæ¥ã§ããïŒïŒïŒMerck, Paster-Merieux-Connaught,
Biovine-Sclavo, Smith-KlineBeechamãWyeth-Lederle 瀟ãšãã£ããå€åœç±ã®å€§äŒæ¥ãä»
åã£ãŠãããããšãããã®ã§ããã
âPhilip K. Russell, MD [194]
Ft. Detrick ç±³è»ä»å± å»åŠç ç©¶æé·
2 幎åŸã«ã¯ãããã4 åãã«ã«å¢ãã2003 幎ã«ã¯6 åãã«ã«ããªã£ãŠããŸãã2005 幎ã«ã¯ã
幎éã®äžç売ãäžãã8 åãã«ã«ãäžããŸããã[49]
AlphaVax 瀟ãšãããå
¬çè³éããç ç©¶ã«å©çšããŠã¯ã¯ãã³ãéçºããŠãããäžçã§ãææ°
ã®ã¯ã¯ãã³ã®ç ç©¶äŒç€ŸããããŸããããã®äŒç€Ÿã®ãŠã§ããµã€ãã®äºæž¬ã«ããã°ã
ãæ°çš®ã®ã¯ã¯ãã³æè¡ã«ãã£ãŠã2010 幎ãŸã§ã«åžå Žã¯ 20åãã«ã«ãŸã§æ¥éã«çºå±ããã§
ããããšã®ããšã§ãã [44]
ããã·ã¥å€§çµ±é ã«ãã AIDS ã¯ã¯ãã³ã®ããã® 15 åãã«ã®è³éããèããŠãã2003 幎ã«
ã¯ãã§ã«ãã®äºæž¬ãè¶
ããŠãããšãããŸãã[81]
ããã²ãšã€ã®èŠæ¹ãšããŠã¯ããããªãã®ããããŸãã
ãæå³çãªã€ã³ãã¬ã§ãåäŸïŒäººãããã®ã¯ã¯ãã³è³Œå
¥ã®è²»çšã¯ã1975 幎ã®$10 ãã2001
幎ã«ã¯$385 ãŸã§å¢å€§ãããã[Davis, 137]
2020 幎㫠7 çš®ã®è¿œå ã¯ã¯ãã³ãæšå¥šããããšãååäŸã®ã¯ã¯ãã³ãžã®è²»çšã¯$1225 ã«ãªã
ãšäºæ³ãããŠããŸããïŒ(Am Journal of Pub Health) [ 137 ]ããããçŸæç¹ã«ãããŠãã
ã®äºæ³é¡ãäžåã£ãè²»çšãå¿
èŠãšãããŠããŸãã
CDC ã«ãããšã2004 幎 2 æã«ã¯ãåäŸïŒäººãããã®åºè²»ã¯$606 ãŸã§ã«ãäžã£ããšã®ããš
ã§ãã[63]
åŸã»ã©èšèŒããŠãããŸããããã§ã« 2002 幎以é 28 çš®é¡ã®æ°çš®ã¯ã¯ãã³ã远å ãããŠããŸ
ããããã« 2008幎ã«ã¯ãæäººåãã®ã¯ã¯ãã³æ¥çš®ã¯ 2åã«ãå¢ããŠããŸãã
åäŸ 1 人ãããã®ã¯ã¯ãã³ãžã®åºè²»ã¯ä»¥äžã®éãã§ãã
1975幎 $10
2001幎 $385
2004幎 $606
2009 幎 $1225
ã¯ã¯ãã³ãžã®äžççãªæ¯åºç·é¡ã®äºæ³
ããããèš³ã§ãäžççãªã¯ã¯ãã³çšç·çµè²»ãäºæ³ããã®ã¯ãéåžžã«å°é£ãªããšã«ãªã£ãŠã
ãŸãããæè¿ã®æ¿åºã®äºæ³ã§ã¯ã2007 幎以éã®æ§ã
ãªããŒã¿ãããšã«ã2012 幎ãŸã§ã« 23
åãã«ã«éããã ãã( [3]GAO Report to Congress) ãšãããŠããŸããããã㯠Forbes èª
ã«ãããã¬ãŒãã³å
åŒã®äºæ³ã«ããã°ã2011 幎ãŸã§ã« 30 åãã«ã«éããã ãããšã®ããš
ã§ãã[4]
å®ã¯ã©ã¡ããããªãäœãã®äºæ³ã§ãR&Dåºéã第äžäžçã«ãããå®éšç䜿çšãéäžåœæ¯æŽ
ããã°ã©ã ã詊éšçãªã¯ã¯ãã³äœ¿çšãªã©ãèšç®ã«å
¥ããŠãªãããã«ã倧å¹
ã«ãããŠããŸã£
ãŠããŸããã¯ã¯ãã³ã®å®è³ªã®å£²ãäžãé«ã ãã§ã¯ãã¯ã¯ãã³æ¥ç€Ÿã®äžçåžå Žã«ãããå²ã
é¡ã¯ããããŸããïŒãã®ç·é¡ã¯ãæŠç®ã ãã§ãããããæ¯å¹Ž 50 åãã«ã«ãäžããšäºæ³ã§ã
ãŸãã
æ¬åœã®å²ã
ããããããã ãã§ã¯ãããŸãããWorld Health Organization ã® 2006 幎ã®èšé²ã«ãããš
次ã®ããšãæããã«ãªã£ãŠããŸãã
äžçäžã§æ¯æ¥4300 äžã®ã¯ã¯ãã³æ¥çš®ãè¡ãããŠããã
幎éã®æ¥çš®åæ°ã¯ 16åã«ãªãã [31]
âwww.who.int/mediacentre/factsheets/fs231/en/
ããã¯ãã¯ã¯ãã³ã®ã¿ã®åé¡ã§ã¯ãããŸãããã¯ã¯ãã³ã¯ïœ¢ä¹³å
ã®å¥åº·æšé²ïœ£ããã°ã©ã å
š
äœãæ¯ããåºéã§ãããããã«å°å
ç§é¢ä¿è
ã®å
šå¡ã®ç掻費ãããã«ããã£ãŠããã®ã§ãã
ããã¯ãäœåãã«ãã®ãéã®è©±ã§ããããããåäŸïŒäººãäºé²æ¥çš®ãåãã«æ¥ãªããã°ã
åå
ã®äž¡èŠªã«ã€ã€ãŒãã¥ãŒããæçç©è³ªããã®ä»ã®è¬ãæ²»çãå ããŠå£²ãã€ããããšãåº
æ¥ãªããªã£ãŠããŸãã倧æã§ããã€ãŸãã人ã
ãäºé²æ¥çš®ãåããã«è²ã£ãŠããŸããšãçµ
æžçã«å€§ããªãã¡ãŒãžãæããšããããã§ããä¹³å
ã®å¥åº·æšé²ããã°ã©ã ã¯ã人ã
ãåã
決ããããè¬ã«é Œã£ãŠçããããã«ä»åããŠãããã®ãªã®ã§ããããåäŸãå»è
ãšè¬ã«é Œ
ããªããŠãå¥åº·ã«è²ã£ãŠããããšãããšã人ã
ã¯èªåã®äœèªèº«ã®èªç¶ãªå埩èœåãä¿¡ãã
èªå·±ç®¡çã§çããŠããããã«ãªã£ãŠããŸããŸããããä»ã¯ã¯ãã³ã§å²ããŠãã人éã«ãšã£
ãŠãããã¯å±éºãªææ³ãšãããŸããïŒ
ç§éãééã£ãæ¹åã«èªå°ããããäžæ£ãªå¶åºŠãäœã£ãããåºæ¬ç人暩ãç¯ããããªè¡çº
ãæè¿å§ãŸã£ãŠããŠããŸãããããã«å¯ŸããŠã¯äžã®ãããªäºå®ãèžãŸããŠãèå¯ããŠã¿ã
ãšè¯ãã§ãããã
éè¯å¿çãªäŒç»æ¡
ãã£ã©ãã«ãã£ã¢ã§ïŒïŒïŒïŒå¹Žã«è¡ãªãããã¯ãŒã¯ã·ã§ããã§ã¯ãããŒã«ã»ãªãã£ããå
ã³ãã®ä»ã®æ³åŸé¢ä¿è
ãšã¯ã¯ãã³è£œé æ¥è
ãéçµããçŸåšã»ãšãã©ã®å·ã«ãããã¯ã¯ãã³
æ¥çš®ã®æ³åŸçå
é€ã®å¶åºŠã廿¢ããæ¹æ³æ¡ãææ¡ããŠããŸãããã®ä»ã®ææ¡ãšããŠã¯ïŒã¯
ã¯ãã³ãæ¥çš®ããŠããªã人ã«å¯Ÿããå
¬æš©å¥å¥ªã鮿ãªã©ã®å眰å¶åºŠãç
é¢ã§ã®æ²»çãä¿å¥
å¶åºŠãåããããªãããã«ããããªã©ãæããããŸããã
ãããã®ææ¡ã¯ããŸãã«ãæ®é
·ã§ããããªã«ããã«åœèŠæš¡ã§å¶åºŠåãããå¯èœæ§ã¯å°ãªã
ã§ããããããããã¯ã¯ãã³è£œé æ¥ã®ãããã®é¢ã
ãããããææ¡ãæ¬æ°ã§ææ¡ããŠãã
ãšããäºå®ãç®ã®åœããã«ãããšã圌ããã©ãã»ã©çå£ã«ããããå¶åºŠãäœãããã£ãŠã
ãŠãæ¢åã®ããŸãã¯ã§ã£ã¡ããã®ç
æ°ã«å¯Ÿãèªåéãã€ããåºããå®éšçãªäººå·¥ç©è³ªãç§
éã®ä¹³å
ã«æ³šå°ããããã«ã¯ãç¡çãããªåŒ·å¶ææ®µããããšããªãã®ã ãšããçŸå®ã«å«ã§
ãæ°ä»ããããŸãã
äŒæç
äºåè»
äŒææ¥äºåè»ïŒããã¯ã補è¬äŒæ¥ãæèææ¡ã®äžèãåºããå®£äŒæå¥ã§ãããã¯ã¯ãã³æ¥
çš®ãåããŠãªã人ã
ãäŒæç
ã«ãããå±éºãããã®ã§ããã®ãããããã人ã
ã¯çŸä»£ã®ã¯
ã¯ãã³ãããããå¥åº·äžã®æ©æµãåãããããã°ã«ãŒãã§ãããããã§äŒæç
ãæ°Ÿæ¿«ãã
å±éºæ§ããããšããèšãåã§ãããããå®ã¯ãã®éã§ãã¯ã¯ãã³æ¥çš®ãåããåäŸéã®æ¹
ãããå
ç«æ©èœãçµç¹çã«æå§ãããŠããŠãäžçå²äžã§æãå€ãã®ã¯ã¯ãã³æ¥çš®ãåããŠ
ããã«ãããããããå¥åº·ç¶æ
ã¯æäœã§ãããã©ãã©ãæªåããŠããïŒãã®æ¬ã§ã¯ãç¹°ã
è¿ããã®ãããªææãæ²ããŠããŸãã
æŽå² – part 1
倩ç¶ç ïŒ ã¯ã¯ãã³ã®èªç
倩ç¶çã¯ãäœäžçŽãã®éãéè¡ççãªå Žæãè²§å°å±€ãæ é€å€±èª¿ãã¿ãããå°åã«ãããŠã¿
ãããæ·±å»ãªäŒæç
ã§ãããäœå人ãã®äººã
ãåœãèœãšããäœã®æ²»çæ³ããããŸããã§ã
ãã倩ç¶çã®äŒæã®æºã¯ããªãŒãœããã¯ã¹ ãŽã¡ãªãªã©ãšããèã§ãã[ 133 ] 18 äžçŽã®çµ
ããã«ã¯ããã®äŒæç
ãèªç¶ã®æãè¡ãã«åŸã£ãŠãæ¬¡ç¬¬ã«æ¶æ»
ããŠãããæãå
ç«èœåã®
匱ã人ã
ã®ã¿ãããããã®ãšãªã£ãŠãããŸãããã€ãŸãã矀ãå
šäœã«å
ç«ãã€ããããã§
ãã
倩ç¶çã¯äžè¬ã«ãäœãéã¡ããããã人ã«äžã倩眰ãšããŠèããããŠããŸããããããã
人å£éå¯ãäžè¡çãé£ã¹ç©ãé£²ææ°Žã®æ±æãæ é€äžè¶³ã«é¢ä¿ãããã®ãšã¯ã誰ãèããªã
ã£ãã®ã§ããããã§ãççãšãã°ãã軜ãç
æ°ã«ããã£ãããšã®ããä¹³æŸãã®åšéã¯ã倩
ç¶çã®å
ç«ãã€ããããšã«ãªãããšãã£ãè¿·ä¿¡ãçãŸããŸããã
ãšãã¯ãŒãã»ãžã§ããŒ
ãã®äººç©ã¯ãçããããåç¥ãããããŸãããã17 äžçŽæ«ã«ããããå€ãè¿·ä¿¡ãå©çšãã
ã€ã®ãªã¹ã®ïœ¢ãå»è
ããã§ãã圌ã¯åœæ 9 æ³ã®ä¹³æŸãåšïŒã»ã¢ã©ã»ãã«ã¡ã¹ãšãããçç
ã«äŒæãã女ã®åã®èã«ã§ããæ°Žçãããè¡æž
ãæœåºãããšããå®éšæ¡ãæãã€ããŸããã
[ 324, Miller ]ãã®äžè»œèãªããšã«ããã®æ¯èŒç軜ãç
æ°ã®ççãæ¥çš®ããããšã§ãããé
ãç
æ°ã§ãã倩ç¶çãžã®å
ç«ãã€ããããšãåºæ¥ããšãã説ãå±ããŠããã®äŒæããè¿æ±
ããŸã£ããå¥åº·ãªäººã«æ³šå°ããŠã®ããã®ã§ãã
ãžã§ããŒã®èª¬ãšã¯ããã®ççãšããç
æ°ããå®ã¯çã«ãšã£ãŠã®å€©ç¶çã ãšãã䞻匵ã§ããã
ããã«ãççã人éã«æ³šå°ãããšã軜ã倩ç¶çã«ããããšåãã ãšããã®ã§ãããã®äžã
ãã®çç¶ã¯äŒæããªãããšãŸã§äž»åŒµããŸããã
ããã«ãžã§ããŒã¯ããã£ãšãã¡ããã¡ããªããšã«ãççãšã¯å€©ç¶çãäºé²ãããã®ãªã®ã§
ã¯ãªãã倩ç¶çãã®ãã®ãªã®ã ããšãã£ã±ãæèšããã®ã§ãïŒïŒEnquiry, 1798 [136]ïŒ
åœŒã®æåã®æ£è
ãšãªã£ããžã§ãŒã ã¹ã»ãã£ããã¹ãšãã 8 æ³ã®å°å¹Žã«æ¥çš®ããåŸããžã§ã
ãŒã¯èªåã®æ³šå°ãçæ¶¯ãéããŠã®å
ç«ãä¿éãããã®ã§ããããšäž»åŒµãç¶ããŸããã
ãïŒïŒïŒççãããç¹æ®ãªã®ã¯ãããã«ããã£ãããšã®ãã人ã¯ããã®å
ãã£ãšå€©ç¶çã«äŒ
æããå¿é
ããªãããšããæ§è³ªãããããã ã
ïŒ ãžã§ããŒã1797 幎ãH.B.Anderson ã«èšèŒ [ 193 ]
ã¡ãã£ãšåŸ
ã£ãïŒ
ããããæç®ã®ïŒïŒïŒ
ã«ãããŠã¯ããžã§ããŒã¯äºé²æ¥çš®ãçºèŠïœ£ãã人é¡ã倩ç¶çããæ
ã£ã人ç©ãšããŠæãããŠããŸãããããããçŸä»£æç®ã®ã話ã«ã¯èŒããŠããªãããšã幟ã€
ããããŸãã
ïŒã¯ã¯ãã³ã«ããå
ç«ãšãããžã§ããŒã®äž»åŒµã«ãç§åŠçæ ¹æ ãäžåãªãããšã
ïŒå€©ç¶çã¯ã¯ãã³ãäœãåºãéçšããåããããŸã£ããç§åŠçã§ãªãããšã
ïŒäžå¹žã«ãããžã§ããŒã«èª¬åŸãããŠå±éºãç¥ããã«æ³šå°ãåãã圌ã®å®éšã®ç ç²ãšãªã£ã
åæã®æ£è
éã®ã²ã©ãè² å·çããæ»äº¡çã
äºå®ã調ã¹ãŠã¿ãã
ãžã§ããŒãšåãæä»£ã«çãã人éã®å€ãã¯ãç§åŠçãããã«ãããããã®è©æ¬ºã«ã ãŸãã
ãŠããŸã£ããã«é©ããèŠããŠããŸãã100 幎åã®èåãªå€ç§å»ãåå·çå®¶ãè¬åŠè
ã§ãã
ã£ããŠã©ã«ã¿ãŒã»ãããŠã§ã³å士 MD ã«ããæã粟èªãããšãããã«æžãããŠãããžã§
ããŒã®å§¿ã¯ãçŸåšã®å€§å€æ°ã®æžç©ã«æãããŠãã磚ãã®ããã£ããžã§ããŒåã»ã©ãçŽ æŽ
ããããã®ã§ã¯ãããŸããããããŠã£ã³ã¯ããžã§ããŒã®ããããããããç¹ã幟ã€ãæ
æããŠããŸãã[178 ]
ïŒãŸãããžã§ããŒã¯å€ç§å»ã§ã¯ãªãã圌ã¯ãªãã®å»åŠã®ã³ãŒã¹ãçµäºããŠããªãããã©ã
ã®å»åŠæœèšããè³æ Œãããã£ãŠãããªããçŸåšã®ã€ã®ãªã¹ãã°ããŒã»ã¹ã¿ãŒã·ã£ã€ã¢ã«
ãããžã§ããŒåç©é€šã«è¡ã£ãŠåœŒã®è³æ ŒèšŒææžãèŠããŠãããããã«é Œããšããç§éã¯ãã£
ãŠããŸããããšããçããè¿ã£ãŠããã§ãããã
ïŒãžã§ããŒã¯éã£ãããšããªãã¹ã³ããã©ã³ãã® St.Andrew 倧åŠããã15 ãã³ãã§å»åŠã®
è³æ Œãè²·ãåã£ãã(Hume, 174 ããŒãž [191], åã³ Hadwen [178179])
ïŒãžã§ããŒã¯èªèª¬ããã£ãäžäººã®æ£è
ã«ã詊ããŠãã¿ãŠãããããããŸãã®æ£è
ãäžç倩
ç¶ç
ã«ããããªãå
ç«ããã£ãããšäž»åŒµããã圌ã¯åããããå
šäººé¡ã«æå¹ãªãã®ã§ã
ããšã䞻匵ããŠãããã¡ãããšã³ã³ãããŒã«ãããèšçµè©Šéšããªããäœå¹Žãã®ç ç©¶ãã
ã£ãããã§ããªãããã£ãïŒäººã®æ£è
ãããã ããæ ¹æ ã«ã§ãïŒ
çŸä»£ã®ãéœåã®æªããšããã¯åãé€ããããŒãžã§ã³ã®è©±ã«ã¯æžããŠãããŸãããããã®åŸ
æ¯å¹Žå€©ç¶çæ¥çš®ãåãããžã§ãŒã ã¹ã»ãã£ããå°å¹Žã¯ 20æ³ã§æ»äº¡ããç¹°ãè¿ãã¯ã¯ãã³æ¥
çš®ãåãããžã§ããŒã®å®ã®æ¯åã21 æ³ã§æ»äº¡ããŸããã(Baron, vol 2 [ 225 ])
ãžã§ããŒã¯äœã®èšŒæ ããªãã«ãå
šå»åŠçãã ãŸããŠããã以æ¥ãã£ãšççã倩ç¶çãšåã
ã ãšããããŸã£ããç§åŠçã«ãŸã¡ãã£ãã§ããããéããããåŸãªãç¶æ³ãã€ãã£ãŠããŸ
ã£ãã®ã§ãããã®äžã§ãèªåã®ã¯ã¯ãã³ãæå¹ãªæ²»çæ³ã ãšããã¢ã€ãã¢ã売ãã€ãã«ã
ãããŸããã[179,291]
倧ãããã®ã¯ããŸã
ãå®éšæåãããæ°å¹ŽåŸããžã§ããŒã®è°äŒãžã®ç¹°ãè¿ãã®æé¡ãããã£ãšå®ããŸããã圌
ã®å€©ç¶çã¯ã¯ãã³ãæ³åŸã§çŸ©ååããããšã§ãäœçŸãšããè±ãã³ãã皌ãããšããããšã«ã
è±åœæ¿åºãæ°ä»ããã®ã§ããè±åœè°äŒã¯ããžã§ããŒã«ïŒïŒïŒïŒïŒãã³ããšãããè«å€§ãªå¥š
å±éãäžãããã®æè²ã®ãªãããã³åž«ã¯ããã¡ãŸã¡å声é«ãç§åŠè
ã«æãäžãããŸããã
ïŒWallace [180 ]ïŒ
ãŸããªãè°äŒã¯ããã®ã¯ã¯ãã³ã®å®å
šãæ€æ»ããããšããªãã«ããã®æ¥çš®ã倧è±åžåœå
šé
åã«ããã£ãŠçŸ©ååããæ³åŸã次ã
ãšæã¡ç«ãŠãŸããããããŠä»ã®ãšãŒããã諞åœããã
ãããŸãã®ç䌌ããå§ããã®ã§ãã
ã¯ã¯ãã³æ¥çš®ã®çŸ©ååããã©ãã»ã©çµæžã«åœ±é¿ãããã«æ°ä»ããåŸã«ã¯ãããã«å察ãã
声ã¯é®å§ãããŸãããä»ãæããã¡ãã£ã¢ã¯ããããã©ããããããªãã¯ã¯ãã³ã®æ°ã
ã
売ã£ãŠå€§ãããããããšäŒããè°äŒãšã¯ã¯ãã³äŒæ¥ã«ãã£ãŠä»åãããŠããŸãããããŠã£
ã³ã¯ãããããè©ããŠããŸãïŒ
ãæš©åè
ãæ¿åºæ©é¢ãæ³åŸåã®åœ±é¿åã¯éåžžã«åŒ·ããå人ã
ã¯èªåã§èª¿ã¹ãŠã¿ãããšã¯ã
ãã«ãããããã倧åã®äººããæ±ºããããšã«åŸãããããã®ã ãïŒïŒïŒ
ãäžæŠããäžæ£ãå°éå®¶ã«ãã£ãŠçµç¹çã«åãå
¥ããããæ¿åºã«ãã£ãŠå¶åºŠåããããšã
ãã®åŸã«ãã®éã¡ãåãé€ãã®ã¯éåžžã«å°é£ã«ãªã£ãŠããŸããã[291]
çããããæãåœããããšããããŸãããïŒç§åŠçãªèšŒæ ããªãäžãäºé²æ¥çš®ã«ããäœçŸïŒ
äœåä»¶ãã®æ»äº¡è
ãã§ãŠããã®ã«ãé¢ãããã倩ç¶çã®äºé²æ¥çš®ã®åŒ·å¶ã¯ïŒïŒïŒå¹Žéãç¶
ããã®ã§ãïŒãããŠïŒïŒïŒïŒå¹Žãã¢ã¡ãªã«ã¯åã³åãäºãå§ããŸããã
ïŒã€ã®ç°ãªãç
æ°
ã§ã¯ãã¡ãã£ãšæ»ã£ãŠãæ ¹æ¬ãšãªã£ãŠããç§åŠé¢ãèŠãŠã¿ãŸããããã ãããã«ããŠãç
çãšå€©ç¶çãšããããããã®ïŒã€ã®ç
æ°ã¯ãå
šãéããã®ã§ãããããŠã£ã³ã以äžã§è¿°ã¹
ãŠããããã«ããã®ïŒã€ã®ç
æ°ã®çç¶ã¯ãæããã«å
šãç°ãªããã®ãªã®ã§ãã
ãççãšã¯ãäœãïŒããã¯ãéçã®ä¹³æ¿ã«èµ·ããç
æ°ã§ããïŒããã¯ãéçãæä¹³æã§ä¹³
ã匵ã£ãŠãããšãã«ããèµ·ããªããã®ã§ãããããã«äœã®ããïŒéšåã«ã®ã¿ã«ã¿ãããç
ç¶ã§ãåœç¶éã®åç©ã®ã¿ããããç
æ°ã§ãããæœ°çã«ãªãããäŒææ§ã®ãã®ã§ã¯ãªãã
äžæ¹ã倩ç¶çãšã¯ãççãšã¯éããéã女æ§ã®ã¿ããããç
æ°ã§ã¯ãªãããäœã®ããïŒéš
åã«éããããã®ã§ããªããäœã«ã¯æ§ã
ãªçç¶ãçŸããããã«ããšãŠã€ããªãäŒææ§ã®åŒ·
ãç
æ°ã§ããã倩ç¶çãšççã§ã¯ãåå ãçç¶ãå
šãç°ãªããã®ã§ããã
ããã«ãäž¡è
ã«ã¯äœã®é¡äŒŒç¹ãç¡ããã[179]
ãžã§ããŒã®æä»£ã«ãããæ£çµ±æŽŸã®ç§åŠè
ã§ãã£ããã·ã£ã³ããããŠã£ã³ãã¯ã¬ã¹ããã®ä»
ã®äººã
ã¯ã倩ç¶çãšççã®éãã«é¢ããæãåºæ¬çãªäºå®ãããã ã®äžåºŠã話é¡ã«ãããª
ãããšã«å¯ŸããŠåŒ·ãæ¹å€ããŠããŸããããå
ç«åŠã®ååãæ£ãããšãããªãã°ãäžäœã©ã
ããŠãããç
æ°ã®ç
åèããå
šãç°ãªãå¥ã®ç
æ°ã«å¯Ÿããå
ç«ãšãªãããšãããåŸãã§ã
ãããïŒä»ãæãããã®çåã«é¢ããŠã¯ãå
šãç¡èŠã®æ±ãã§ãã
åœç«ä¿å¥åäŒNational Institutes of HealthïŒã®åºæ¬ããŒã¿ããŒã¹[292]ãåé¡ããªãã調
ã¹ãŠãããšãççã¯ãªãŒãœããã¯ã¹ ãŽã¡ã¯ã·ãã¢ãšãããŠã€ã«ã¹ãåå ã§ããã察ããŠ
倩ç¶çã¯ãªãŒãœããã¯ã¹ ãŽã¡ãªãªã©ãšãããŠã€ã«ã¹ãããªãããšãæããã«ææãããŠ
ããŸãããã®ïŒã€ã®ãŠã€ã«ã¹ã¯ã倧ããããéºäŒåé
åããæ§è³ªãå
šãç°ãªã£ãŠããŸãã
äž¡è
ã¯ãå®å
šã«ç°ãªãçç©ãªã®ã§ããçãã倩ç¶çã®äžçš®ã§ãããççãšããç
æ°ã«ãã
ãããšããã§ã£ã¡ãããé
·ããã®ã§ãããããã«ãã®ç
æ°ã«ããã£ã人ã
ã倩ç¶çã«å¯Ÿã
ãŠå
ç«ãæã€ããªã©ãšããã®ã¯å
šãã®å¹»æ³ã«éããŸããã
次ã®è¡šãåç
§ããŠãã ããã
çç 倩ç¶ç
éçã®ã¿ã«çºç 人éã®ã¿ã«çºç
çã«ã¯ææããªã æææ§
ãªãŒãœããã¯ã¹ ãŽã¡ã¯ã·ã㢠ãªãŒãœããã¯ã¹ ãŽã¡ãªãªã©
ïŒãã€ã¯ããœãã Encarta [155]
çŸä»£ç§åŠãããã®æçœãªççŸãã©ã®ãããªããã€ãã§æ³šéããŠãããèŠãŠã¿ãŸããããThe
Columbia Encyclopedia ã®ç¬¬ïŒå [156]ã§ã¯ã次ã®ããã«æžãããŠããŸãã
çç
ãâŠå€©ç¶çã®ãŠã€ã«ã¹ãšé¢é£ããäžçš®ã®ãŠã€ã«ã¹ã«ãšã£ãŠåŒãèµ·ããããçã®ææçããŽ
ã¡ãªãªã©ãšãåŒã°ããä¹³æ¿ãä¹³éŠã«è¿ãã åºæ¥ç©ãã¿ãããããšãç¹åŸŽã§ãããççã¯æ¥
è§Šã«ãã£ãŠäŒæãããã®ã§ãææããéçã®ä¹³çµãããã人éã®æã«è»œçã®ææãèŠãã
ãããããã人ç©ã倩ç¶çã«å¯ŸããŠå
ç«ãæã£ãŠãããšããäºå®ã«ä¿ãããŠããšãã¯ãŒãã»
ãžã§ããŒã¯å€©ç¶çã®å·å£ããæ¡åãããã®ãã¯ã¯ãã³æ¥çš®ããããšããå±éºãªããæ¹ã®ä»£
ããã«ããã®ãŠã€ã«ã¹ã䜿ã£ãŠã¯ã¯ãã³æ¥çš®ãè¡ãããšã詊ã¿ãããžã§ããŒã®æ¹æ³ã¯æå
ããããã倩ç¶çã«å¯ŸããçŸåšã®ã¯ã¯ãã³æ¥çš®ã®åºç€ãšãªã£ããã
ä»ãŸã§ã®è³æã®å€§å€æ°ã¯ã倩ç¶çã¯ã¯ãã³ã«ã¯ãã£ããšããç§åŠçãªè£ã¥ããããããšå€§
声ã§äž»åŒµããŠããŸããããäžè¬äººã®ãããã誀ã£ãèãã¯ãä»ãç¶ããŠããŸãã
倩ç¶çïŒãããšãççïŒ
ææ°ã®MSN Encarta ã®è³æã«ã¯ä»¥äžã®ããã«ãããŸãã
ãççïŒçã®ãŠã€ã«ã¹æ§ã®ææçã§ãåè¿æ§ã®åºæ¥ç©ãç¹åŸŽãççã¯ãçŽæ¥ã®æ¥è§Šã«ãã
人éã«ãææãããççã«ããã£ã人éã¯ããããšäŒŒãŠãããããæ·±å»ãªç
æ°ã§ããã倩
ç¶çã«å¯ŸããŠå
ç«ãåºæ¥ãããã®å
ç«æ§ã¯ãã€ã®ãªã¹äººã®å»è
ããšãã¯ãŒãã»ãžã§ããŒã
倩ç¶çã®äºé²æ³šå°ã®ããã«æ£è
ã«ççã®ãŠã€ã«ã¹ã䜿çšããŠçºèŠããããã
ïŒçç Cowpox, [155]
å±éºãªè¿·ä¿¡
ãžã§ããŒã®æä»£ä»¥éã倩ç¶çã¯ã¯ãã³ãå
šãŠãééã£ãã¯ã¯ãã³ããæãç«ã£ãŠããã®ã¯
ãªãã§ããããïŒããã¯ãå»åŠãé åºã«èª€ããç¶ããŠããããã§ããïŒïŒïŒïŒå¹Žã®å€©ç¶ç
ã¯ã¯ãã³ãããã¥ãªãŽã¡ãã¯ã¹åã³ã¢ã«ã³ãã¹ãã§ãããããŸã ã«ãªãŒãœããã¯ã¹ ãŽã¡ãª
ãªã©ã§ã¯ãªãããªãŒãœããã¯ã¹ ãŽã¡ã¯ã·ãã¢ããåºæ¥ãŠããç¶æ
ã§ããïŒïŒ®ïŒ¥ïŒªïŒã[127]ã
[138]ããã³ã°[98] ïŒãã®ãããªãè¿ã芪æãå士ã®ããã€ãã詊ã¿ãããã®ã¯ãä»ãŸã§
ã«å€©ç¶çã®ã¯ã¯ãã³ã®ã¿ã§ããããããããªã䌌ããããªãã®ã ããããšããèããéçš
ããã®ã¯è¿·ä¿¡ã®äžçã ãã§ã®è©±ã§ãå
ç«ã«ãããŠéçšããã¯ãããããŸããã
ãèªèã®æãïŒThe Doors of Perception ïŒ[334]ã§ãåããããã«ãäžéäžè¬ã®äººã
ã®è
ãæ¹ãè£ã§æäœããŠãã人ééã¯ã倧æµã®äººã
ãçµæžé¢ã§å€§ããªåœ±é¿ãæã€è«žèª²é¡ã®è£ã
調ã¹ãŠãããã«é ããéç§åŠçãéè«ççãªäºå®ãèŠã€ããããšã¯ããªããšããæ§è³ªãäž
æãå©çšããŠããã®ã§ãã圌ãã¯ãä»ã®ã¢ã¡ãªã«äººéããããæ¬ãèªãã§åŠã¶ããšãæ¢ã
ãŠããŸã£ããšãåãã£ãŠããããã§ãã
æåã®ã¯ã¯ãã³ããã©ããã£ãŠäœããããã
ãŠã©ã«ã¿ãŒã»ãããŠã§ã³å士ã®ç« ã«ãããšã倩ç¶çã®ã¯ã¯ãã³ãæåã«äœãããçµéã¯ã
ã£ã𿬡ã®ããã«ãªããŸãã[185]
ïŒïŒïŒã¶æã®åçãçžã£ãŠæšªãããã
ïŒïŒïŒã€ã³ãçšåºŠã®åºãå·ãïŒïŒ~ïŒïŒååçã®è
¹éšã«äœãã
ïŒïŒå€©ç¶çã®è¿ã¿ãããããã®åºãå·ã«ãããä»ããã
ïŒïŒåçãå·å£ãèããããªãããã«å¶åŸ¡å
·ãã€ããŠãããå°å±ã«æ»ãã
ïŒïŒïŒé±éåŸ
ã€ã
ïŒïŒå€©ç¶çã®è¿ã¿ãçºçããã
ïŒïŒåçãå床çžãä»ããã
ïŒïŒããããã®å·å£ãã也ããè¿ã¿ãããããšã£ãŠãæ®ã£ãè¡æ¶²ãè¡æž
ãè¿ã¿ã
å·å£ããåãé€ãã
ïŒïŒåã£ãè¿ã¿ããã€ãŒã«ãããã°ãªã»ãªã³ãã€ãªãã«äœ¿ã£ãŠå ç±ããã
ïŒïŒïŒãããæ··ããŠãæ¯ãšèçãåãé€ãããã«ããã
ïŒïŒïŒããããã¥ãŒãã«å
¥ããŠãåçã®çŽç²ãªè¡æž
ïŒå€©ç¶çã®ã¯ã¯ãã³ãšããŠå£²
ãã
ããããç§åŠçãšèšããã§ããããïŒ
1980 幎代ã®ãã¥ãªãŽã¡ãã¯ã¹ ã¯ã¯ãã³ã®æä»£ã«ããããã®åçã®è¡æž
æ¹æ³ã¯ä»£ã
䜿ãã
ãŠããŸããã[342] ïŒ/ïŒïŒã®äºä»¶ä»¥æ¥ã¯ãããããã¯ã ãã¶æŽç·Žãããã人éã®å èãã
ãã®èå
ã®çްèã«ç¹æ®ããããšããããæ¹ããšãããŠããŸãã[148]ãããŸã ã«ããã«ãã
ççã®ã¯ã¯ãã³ããŽã¡ã¯ã·ãã¢ã䜿çšããŠããããããŸã§ãã
å¿ãããã倩ç¶çã¯ã¯ãã³ã®å®æ
倩ç¶çã¯ã¯ãã³ã¯ãçãŸãããšãããçŸåšãŸã§ãã£ãšãå±éºãã€ç¡æå³ãªãã®ã§ããç¶ã
ãŠããŸãããæ¬¡ã«æããã®ã¯ã1989 幎ãŸã§ã«ãžã§ããŒããã³ãã®äžé£ã倩ç¶çã¯ã¯ãã³ã
ãšäž»åŒµããŠãææããçãç©ããæåããŠäœ¿ã£ãäŸã§ãã
ææãã銬ã®ã²ãã
人éã®å€©ç¶çã«ææããçã®è¿ã¿
ããŒã¹ã°ãªãŒã¹ãççã«æå³çã«ææããã人éããæåããè¿ã¿
倩ç¶çã«ææãã人éã®è¿ã¿
ïŒïŒBaxby[224], An Enquiry[136],[324]ïŒ
ããŒã¹ã°ãªãŒã¹ãšã¯ãã²ããã®ææçã®åŒã³åã§ããããžã§ããŒã¯ãææããã²ããã«ç
çã®èãå«ãŸããŠãããšåæã«æ³åãããããæ ¹æ ã«ææãã銬ã®ã²ããããè¿ã¿ãåã£
ãŠãå¥åº·ãªåäŸéã«æ³šå°ãããŠããã®ã§ãã[136]ããã¯ãåè«ã§ã¯ãªããæ¬åœã®è©±ã§ãã
ã§ã¯ãžã§ããŒã倩ç¶çã®è¿ã¿ããã©ãããåã£ãŠãããç¥ã£ãŠããŸããïŒå€©ç¶çã«ããã£
ãŠæ»ãã ã人éã®æ»äœããã§ãïŒ[295]
150 幎以äžãã®éã倩ç¶çã¯ã¯ãã³ãã©ããã£ãŠäœãåºãããšããæ¹æ³ã«ã¯ãå
šãäžè²«æ§ã
èŠãããŸããã§ããã[325]
ããã«é©ãããšã«ãççã¯ããèªäœãèªç¶ãªçã®ç
æ°ã§ã¯ãªãããšãåãããŸãããçç
ãšã¯ãç§å Žã®äººã
ãæ±ããæã§ä¹³çµããããŠããããšãåå ã§çãŸããä¹³æ¿éšã®ç
æ°ãªã®
ã§ããäœãã«ææããä»ã®åç©ãæŽã£ãçŽåŸããäœãç§å Žã®ä»äºãçµãããŸãŸã®æã§è¡ã£
ãŠããããšã倧æµã®åå ã§ãããã®å€§åãª[ã¯ã¯ãã³]ã®ããšã«ãªã£ãççã®åè¿éšã®è¡æž
ã
ãã¯ãæ¢
æ¯ãçµæ žãã¿ãããããšããããã£ãããã§ããïŒArning[183]ãSAV[324]ã[325]ïŒ
ãžã§ããŒåŒã®ããæ¹ã§ããã䜿ãããã®ã¯ãè
ããè
ãžãæ¹åŒã§ããïŒRains[182]ïŒ1898
幎ã«éæ³ã«ãªããŸã§ãè¿ãã ç©è³ªãåã«æ»äœã®è
ããåãåºããŠãæ£è
ã®è
ã«æ³šå°ããã®
ã§ããã¡ãªã¿ã« 1989 å¹Žã®æ³åŸã¯ã人é¡ã®éã§æ°Ÿæ¿«ããŠããæ¢
æ¯ãšçµæ žã®åºãããæããã
ãã«èšãããããšããããšã§ããïŒBaxby[224]ïŒ
ããããå€ãæŽå²ãèªãã§ãããã¡ã«ããã¯ã¯ãã³ãã®å€§å€æ°ããªãã®çç£éçšãã¡ãããš
ããæºåãç¡ãã«äœãããããšããã ãã ããšåãã£ãŠããŸãã1856 幎以åã«ã¯ãåæã®
ã倩ç¶çã¯ã¯ãã³ãã®å€§åãã人ãšåç©ã®è¿ã¿ãåæã«å¥åº·ãªåäŸéã®è¡ã«æ³šå°ããããš
ãã£ããã®ã ã£ãã®ã§ãïŒïŒSAV[325]ãwhale.to[319]ïŒ
ãçš®ã¥ããæ¹åŒ
倩ç¶çã¯ã¯ãã³ãæ°ããã²ãšã€ãŸã¿ãã€äœãã«ã¯ãååã«äœãããã¯ã¯ãã³ãããããã²
ãšã€ãŸã¿ãã€äœ¿ã£ãŠæ°ããåçãææãããŸãããããããçš®ã¥ãäœæŠã§ããããããåŸã
ã«ã¯ã¯ãã³ã[匱ã]ãªã£ãŠãã£ãããïŒäººéã®ç®èã®ãã¶ãã軜ããªã£ãã®ã§ïŒãŸãã¯ã¯ã
ã³ãäœçš®é¡ãã®åç©ïŒãããããããç¿ãçŸïŒãéããŠãããåçã«æ¥çš®ããããšã«ãªã
ãŸããããããšäººéã®ç®èã®ãã¶ããå¢ããã®ã§ãã€ãŸãã¯ã¯ãã³ã匷ããªã£ãã®ã ãšã
ãããšã«ãããã®ã§ããïŒWHOïŒHenderson[226]ïŒãã®éçšã®äžã§ãç
åèãããã«äººå·¥
çã«çªç¶å€ç°ããšããããæžå¿µãã人ã¯ã ããããªãã£ãã®ã§ãã
ãŸã£ãããå
ç«åŠè
ãã¡ããã€ãå£ã
ã«å±ããŠãããå
ã
ã®ã¯ã¯ãã³ãäŒãç¶ããŠãããäž
æ»
ã®è¡çµ±ããšããçŽç²å¹é€ã®æŠå¿µã¯äžäœã©ãã«è¡ã£ãŠããŸã£ãã®ã§ãããã
åç©ã®è¡æ¶²
ããã§ã¯ãéå» 200 幎ã®éã倩ç¶çã¯ã¯ãã³ãè£ä»ããŠããç§åŠçæ ¹æ ã®å®æ
ãèŠãŠãã
ãŸãããã人é¡ãšåç©ã®è¡æ¶²ãäœæ¶²ããç¡é äœã«æ··åãããšããè¡çºã¯ã倧æããç¶ããŠ
ããå€ãã®ææã®äŒçµ±ã«ãŸã£ããéãã£ãæŽåè¡çºã§ãããå€ãã®å®æã¯ããã®è¡çºãå
æãã§çŠããŠããŸããããã倩ç¶çã¯ãçããã®ä»ã®åç©ã«èªç¶ã«çºçããç
æ°ã§ã¯ãã
ãŸããããã人工çã«ææãããªããã°ãªããŸããã§ããããããªã«äžæ³šæã«ãç°ãªãç
ãç©ãæ··åå®éšããŠçãŸããç
æ°ãããã§ããããïŒæ¯ãªãèªç¶ãæåŒããããªããšãæ
ããªè¡çºã§ãã
1875 幎ã«ã¯ã倩ç¶çã¯æã«è² ããªãã»ã©å€æ°ã®ç°ãªãåæãšæ··åããåäœããŠããŸã£ãŠã
ãŸããããå€çš®é¡ã®åç©ãéããŠçºéããŠãããããã¯ã¯ãã³ã®å®æ
ã¯ãŸã£ããææ¡ã§ã
ãªãããããŸã§ãããäžãããã倩ç¶çã¯ã¯ãã³ãã€ã®çã§ããå Žåãããã¿çãççã
ãµã«çãããŒã¹ ã°ãªãŒã¹ããŸãã¯äººéã®å€©ç¶çã§ããå ŽåããããŸãããããããã¯ã
ããã®ããã¯ã¹ãšããããšããããŸããã[325]
ã¯ã¯ãã³ã¯æ¬åœã«å¹æããã£ããïŒç¬è£çãªããã·ã¢ã³ ã«ãŒã¬ãã
1853 幎ã«ã¯ãè°äŒãããã®å®å
𿀿»ããããŠããªãã¯ã¯ãã³ã倧è±åžåœå
šåã§çŸ©ååãã
æ³åŸãã©ãã©ãäœãå§ãããšãŒãããã®ä»ã®è«žåœããããã«ãªãããŸããã
ãããŠã§ã³ãããã® 1 äžçŽåã®è¬åŠçãªãªãµãŒããžã®ã貎éãªæããããäºã®æ³¢ã§ãªãã
ããŠããŸããªãã£ãæãéããŠãããŸãã圌ã®è©±ã¯ã1800 幎代ã«ãããŠãšãŒãããã§æã
å€ãã¯ã¯ãã³æ¥çš®ãè¡ããããã®åŸããã³ããã§ç¶ããåœãããã·ã¢ã«ãããé©ãã¹ãå®
æ
ãæããŠãããŠããŸãããããŠã§ã³ã¯ãã¡ãã£ã¢ãå±éºã«æ°ä»ããŠæ
å ±å
¥æãå¶åŸ¡ããŠ
ããŸãåã«ããããã®å»åŠããŒã¿ã調ã¹ãŠããã®ã§ããããŒã¿ãç©èªã£ãŠããäºå®ãšã¯ã
次ã®ãããªãã®ã§ããïŒHadwen[291],[295]ïŒ
ããã·ã¢ã¯ã倩ç¶çã¯ã¯ãã³ã®çŸ©ååæ³åŸãã1834 å¹Žã«æ¡çšããããã®æ³åŸãšã¯ããã¹ãŠ
ã®ä¹³å
ãã¯ã¯ãã³æ¥çš®ãè¡ããå°±åŠæã«åã³æ¥çš®ãè¡ãããšã矩åä»ãããã®ã§ãã£ãã
ããã«åæ¥æã«ããäžåºŠããããŠè»éã«å
¥ãåã«ããäžåºŠæ¥çš®ãè¡ããã°ãªããªãã£ãã
å¥åº·ãªç·æ§ã¯ãå
šå¡ãè»éã«å
¥ããã°ãªããªãããšã«ãªã£ãŠãããã¯ã¯ãã³æ¥çš®ãæåŠã
ã人ã¯ãåã¥ãã§æãããã匷å¶çã«æ¥çš®ããããã®çµæåŸ¹åºçã«ãäž¡è
ãšã 10 åãã€ã¯
ã¯ãã³æ¥çš®ã匷ããããã[291]
ïŒãã®ããšãããããã·ã¢äººã® 100%è¿ããããžã§ããŒã®å€©ç¶çã¯ã¯ãã³ãåããŠããããš
ãåãããŸãããã§ã¯ããã®ã¯ã¯ãã³æ³ã® 35 幎åŸã«ãããã·ã¢ã¯ã©ããªç¶æ
ã«ãªã£ãŠãã
ã§ããããïŒåœäžã®åœæ°ã35 幎éç¹°ãè¿ã匷å¶çã«ã¯ã¯ãã³æ¥çš®ããçµæããªããš 100 äž
ä»¶ã®å€©ç¶çã®æµè¡ãã¿ããã124,978 äººã®æ»è
ãåºãŠããã®ã§ãïŒ
殺ãã®å
èš±
ã§ã¯ãã€ã®ãªã¹ã¯ã©ãã§ããããïŒ
ã€ã®ãªã¹ã§ã¯ããžã§ããŒæ¹åŒã®ãäºé²æ¥çš®ãã®çŸ©ååã 1853 幎ã«å§ãŸããŸãããïŒMïœBean
p.13ïŒ[205]ãã以åã®ã€ã®ãªã¹ã«ãããã倩ç¶çã«ããæ»äº¡æ°ã¯ã2 幎ããšã«çŽ 2000 人ã§
ããã
ãã®ãäºé²æ¥çš®ããå§ãŸã£ãçµæã¯æ¬¡ã®éãã§ãïŒ
幎代 æ»äº¡æ°
1857ïŒ9 14,299 人
1863ïŒ5 20,059 人
ããã«å¿ããŠãè°äŒã¯ããå³ããã¯ã¯ãã³æ¥ç𮿳ãå®ããåœæ°ã® 97%ãæ¥çš®ãåããŸããã
ãã®çµæã¯ã以äžã®éãã§ãã
幎代 æ»äº¡ç
1868 44,840 人 ïŒ Null,partâ
¢ãïœ.23 [220]
å
šãããªããšããã¯ã¯ãã³ã§ãããïŒ
ã¢ã«ãã¬ããã»ã©ãã»ã«ã»ã¯ã¬ã¹ã¯1800 幎代ã®ã€ã®ãªã¹ã«ãããŠãã¯ã¯ãã³ã®çµ±èšãã©ã®
æ§ã«è£å·¥äœãããŠãããå誰ãã©ãããŠãããªããšãããŠããã®ãã«ã€ããŠãååãªèšŒæ
ä»ããæäŸããŠãããŠããŸãããšãšãŒããã倧éžã«ãããã倩ç¶çã«ããæ»äº¡çãšã
ã®ã¯ã¯ãã³ã«ããæ»äº¡çã衚ã«ããŠããŸãªãç
§åããçµæãã¯ã¬ã¹ã¯å€©ç¶çã¯ã¯ãã³ã«ã€
ããŠä»¥äžã®ãããªçµè«ãåºããŠããŸãã
ãïŒïŒïŒ å®éã«ã¯ããã®ç
æ°ã®çŸæ£çãå¢ãããŠãããïŒïŒïŒã©ã®ã±ãŒã¹ãèŠãŠããåãçµè«ã
ã§ããã€ãŸããã¯ã¯ãã³æ¥çš®ãšã¯ãå
šãã®ã§ãããã§ããããã£ã 1 人ã®åœãæã£ãããš
ããªãäžã«ãæ°ãåããªãçš®ã®ç
æ°ã®åå ã§ãããç¡æ°ã®æ»äº¡è
ãåºããç¡å®ã®äººã
ãç¡
æå³ã«èŠããŸãããã®ã§ããããšããããšã ããã£ãŠããã¯ããã®ç¡ç¥ã§åèŠã«æºã¡ãæ
代ã«ããããæå€§ã®éã¡ãä»äžçŽã«ãããæãéããã¿ãšããŠã次äžä»£ããèŠãªãããã§
ããããã ïŒ Alfred R.Wallace, Chapter â
¥ 1898 [180]
ãã£ãªãã³ã§ã®å€§å€±æ
第 1 次äžç倧æŠåŸãæªäœ¿çšã®å€©ç¶çã¯ã¯ãã³ã倧éã«æ®ã£ãŠããŸãããããã§ãç±³åœã¯ã©
ããä»ã§ãã³ã³ãããŒã«ãå¹ãåžå Žãæ¢ããŸãããããã㊠1917 幎ã«åè¡åœããã£ãªãã³
ã«å€§èŠæš¡ãªå€©ç¶çã¯ã¯ãã³ã®å¶åºŠã匷å¶åããéã«ã¯ãçŽ 2500 äžä»¶ãã®æ¥çš®ãè¡ãããŸã
ããã¯ã¯ãã³æ¥çš®åŸã163,000 人ã®ãã£ãªãã³äººã倩ç¶çã«ãããããã®ãã¡æ»è
ã¯ãã¯ã¯
ãã³æ¥çš®éå§ä»¥åã®æ»äº¡æ°ã®3 åã§ãã 75,339 人ã«ãäžããŸããããã®æ°ã¯ããããã æŠ
äºã§æŠæ»ããã¢ã¡ãªã«äººå
šå¡ã®æ°ããéãã«è¶
ãããã®ã§ãïŒã¢ã¡ãªã«ã«ãããã®ãäºé²
æ¥çš®ãããã°ã©ã ã¯ããã£ãªãã³ã«ãããŠå¹Ÿã€ãã®æãããæµè¡ææãçã¿åºããŸãããã
ãã¡ããæ¥åžžã®ãã¥ãŒã¹ã§ã¯åãäžããããŸããã§ãããïŒAnderson, p 69, W.H.Hay, å
ã³ James, p 410 [171, 221, 188]ïŒ
倱æããåŠã°ãªãã¢ã¡ãªã«
ããŸãç¥ãããŠããªãäºå®ã§ãããã¢ã¡ãªã«ã倩ç¶çã®ã¯ã¯ãã³æ¥çš®ãéå§ãã 1902 幎ã®
çŽåŸã«ã¯ãã€ã®ãªã¹ã¯ãã§ã«æ¥çš®ãåããããŠããŸãã1907 幎ã«ãã€ã®ãªã¹ã¯ãã£ãšæ¢ã
ãªããã°ãããªããšçè§£ãã倩ç¶çã¯ã¯ãã³ã®åŒ·å¶ãçµäºããŸããããªã©ã³ãã§ããåæ§
ã« 1928 幎ããªãŒã¹ãã©ãªã¢ã§ã 1925å¹Žã«æ¢ããŠããŸããïŒAnderson, p 10ïŒ[193]
ã§ã¯ãã¢ã¡ãªã«ã§ã¯æ¢ãããŸã§ã«ã©ãã ãããã£ãããšãããšãäžçã§äžçªé
ãã1971 幎
ã«ããããçµãã£ãŠããŸãã
ãããŠã1970 幎代ã«ã¯ãäŒæç
ã¯äžãåãè¿ããŸããã1950幎ãã1970 幎ãŸã§ãã¢ã¡ãª
ã«ã§å€©ç¶çã«ããã£ããšèšé²ãããŠããã±ãŒã¹ã¯ã0 ä»¶ã§ãã1970 幎以éã«ã¯æ°ä»¶ã®å€©ç¶
çææãèŠãããŸããããããã¯ã¯ã¯ãã³ãæ¥çš®ãã人éã®ã¿ã®äžããïŒïŒïŒææè
ãåº
ãŠããŸããïŒScheibnerïŒ[243]
ããã§æ³šæããŠãããªããã°ãããªãããšã¯ãã¢ã¡ãªã«ã§ã¯å€©ç¶çã®ææè
ãäºå®äž 0 ä»¶
ã«ãªã£ãåŸã30 幎éãç¶ãããããšããããšã§ããå床èšããŸããããã® 30幎éã«ããã
åè¡åœå
ã§ã®å€©ç¶çã«ããå
šãŠã®æ»äº¡è
ã®æææºã¯ãã¯ã¯ãã³æ¥çš®ã§ããïŒ Mendelsohn,
p232, World Book, 1994ïŒ[246, 252]
åè¡åœã§ã¯ 1902 幎ã«å€©ç¶çã¯ã¯ãã³æ¥çš®ã矩åãšããŠåŒ·å¶ãããŸãããã1929 幎ã«ã¯ïŒ
å·ãé€ãå
šãŠã®å·ã§ã矩ååããã§ã«å»æ¢ãããŠããããšã¯äœãç¥ãããŠããŸãããã²ã©
ãæ°ã®æ»äº¡è
ãšãç
æ°ã®è€éåãããã®çç±ã§ããïŒH.B. Anderson, p 2ïŒ[193]
çŸåšã§ã¯ã倩ç¶çãèªç¶ã«çºçããä»¶ã¯ãã©ãã«ãã¿ãããŸããã
è¿·ä¿¡ã§å€§ããã
çµå±ã®ãšããããžã§ããŒãå®éã«ããããšãšã¯ãä¹³æŸãåšã«ãŸã€ããå€ãè¿·ä¿¡ãäžæãå©
çšããŠããŸã£ããã§ãããã®ãç§åŠçãèŠç¹ããèªåãšã€ã®ãªã¹è°é¢ã®è²¡åžããµãããŸã
ããšããèš³ã§ãã[157]
ççïŒãããšã倩ç¶çïŒ
ããã§ãççããäœãããã¯ã¯ãã³ãæ¥çš®ãã人éããã©ãããŠå€©ç¶çã«ããã£ãŠæ»ãã
ã®ããšçåãæã£ãèªè
ã®çããã«ææåéïŒããæ³šææ·±ãèªãŸããŠããŸããããæãã
ãªçããšããŠã¯ãããããæ»è
ã®å
šå¡ããã¯ã¯ãã³ãåå ã§æ»äº¡ããããšããããšã§ãã
ã€ãŸãããã®ã¯ã¯ãã³ã倩ç¶çã¯ã¯ãã³ãšåŒã°ããŠããããã«ãç ç²ã«ãªã£ã人ã
ã¯ãã®
ã¯ã¯ãã³ã§å
ç«ãåºæ¥ãããšèšãããŠããç
æ°ã«ããã£ãŠæ»ãã ã®ã ããšæšæž¬ããã倩ç¶
çã«ããæ»äº¡è
ãšããé¢šã«æ°ããããèš³ã§ãã倩ç¶çã¯ã¯ãã³ã«ããæ»äº¡è
ã®æ°ã¯ãæŽå²
äžã®ã©ã®ã¯ã¯ãã³ã«ããæ»äº¡è
ãããäžåã£ãŠããŸãã
9/11 以éã®å€©ç¶çäºæ
9/11 äºä»¶ã®åŸããïŒïŒïŒïŒå¹Žã®åãã«ãããŠãäž»æµã®ã¡ãã£ã¢ã¯åœã®ç§åŠãšäžæãç·šéã
ãæŽå²ãçµã¿åãããŠãæ°ããªã§ãããã®è©±ãäœãäžããŸããïŒãããªã¹ããã倩ç¶çã
ååŠå
µåšãšããŠçšããŠã人å£ãäžæããããšããŠããããšããå
容ã§ãããããåããŠã
ç§åŠã§ã¯ãªããæ³åŸã®åŠäœãæã£ãŠããè°äŒã®ãªãŒããŒéããã¢ã¡ãªã«å
šäººå£ã«æ¥çš®ãã
ã«ååãªéã®ã¯ã¯ãã³ãæºåããããšã«æ±ºããŸããããããŠã¯ã¯ãã³æ¥çš®ãæ³åŸåããŠåŒ·
è¡ããããã«ãæåŠããå Žåã«ã¯éãå眰ãå®ããã®ã§ããïŒAltman,[360]ïŒ
ãã®æ°ããªã¯ã¯ãã³å¶åºŠãžã®æ¯åºã¯ãïŒåãã«ã«ããªããŸããããããã¢ã¡ãªã«åœæ°ã®å¥
康ãšå®å
šã«æ¯ã¹ããããéãªããŠåé¡ãããªãããšæãããç¥ããŸãããïŒ
ãšãããããã¯ããéã®åé¡ã ã£ãã®ã§ãã9/11 以éã®æ¿çã¯ããããŸã§ã«äžçãèŠãã
ãšã®ç¡ãã»ã©å€§ç¹çãªåžå Žãã€ãããããã®ã§ãããã
3 åã®å€æãã€ããã倩ç¶çãžã®å±æ©æãã€ããããããã人ã
ã«äŒãããŸããã[85] 2002
幎ãéããŠãäœãç¥ããªãäžéäžè¬ã®äººã
ã¯ãã¡ãã£ã¢ã®å·¥äœäººã«èžããããŠãçã£ãã€
ã¹ã©ã ä¿¡è
éã倧éœåžãã¿ãŒã²ããã«ããŠå€©ç¶çã®çååŠå
µåšãæãæ£ãããŠãäºé²æ¥çš®
ãããŠããªã人å£ã®éã«å±±ç«äºã®ããã«å€©ç¶çã®æµè¡ãåºãã£ãŠããã ããããšããåã«
å§çµè
ããããŠããã®ã§ããèŠããŠããŸããïŒ
ãã®ã200 幎åã®æ¿çã®äžæ°å³ãªåççã«ãããŠã¯ãç§åŠçãªäºå®ã¯èã«è¿œããããããŸã
ã§ããããåºæ¥äºãå
šãèµ·ããªãã£ããã®ããã«æ¯èãããŸããã
ïŒå€©ç¶çã¯äžçäžã§1977 幎ã«ã¯çµ¶æ»
ããã
ïŒ1970 幎以éã倩ç¶çã«ããæ»äº¡è
ã¯ãå
šå¡ã¯ã¯ãã³æ¥çš®ã«èµ·å ãããã®ã§ããã
ïŒå€©ç¶çã®ã¯ã¯ãã³ã¯ãã€ã®ãªã¹ããã©ã³ã¹ããã€ããã€ã¿ãªã¢åã³ãã£ãªãã³ã«ãããŠ
äœå人ãã®æ»è
ãåºããã
ïŒãã®ã¯ã¯ãã³ã¯ãå
šãç°ãªãç
æ°ã§ãããçã®ç
æ°ïŒãŽã¡ã¯ã·ãã¢ïŒã«å¯Ÿãããã®ã§ã
ãã
ïŒãã®ã¯ã¯ãã³ã¯ã倩ç¶çã«å¯Ÿããå
ç«ãä»ããªãã
ïŒæŽå²äžçºæãããã©ã®ã¯ã¯ãã³ãããã倩ç¶çã¯ã¯ãã³ãæ»ã«è¿œããã£ã人ã
ã®æ°ã¯äž
åã£ãŠããã
ïŒæãåœããããŠäžçã®ååœãã¯ã¯ãã³æ¥çš®ãæ¢ããçç±ã¯ãã¯ã¯ãã³ãåã«ç¡å¹ã§ãã£
ãã ãã§ã¯ãªããããèªäœã倩ç¶ççºçã®åå ã§ãããã®ä»æ·±å»ãªå¯äœçšã®åå ã§ããã£
ãããã§ããã
ïŒã©ã®æŠäºã§ãããŠã€ã«ã¹ããã¯ããªã¢ãçšããå
µåšã䜿çšããããšã«æåããäŸã¯ãªãã
以äžã«ããããããããïŒïŒšïŒšïŒ³ãåœå®¶å®å
šå±ããã®ä»ãšã€ããã«äœããã
å€ãã®ãåœæ°é²è¡ãå±ã¯ãã¢ã¡ãªã«äººå£ã280,000,000 人å
šå¡ããå®ããããã«ååãªéã®
ã¯ã¯ãã³ã 2ïŒ3ã®è£œè¬ç€Ÿãäœããšããããšã決å®ããã®ã§ãã[326] ãããã補è¬äŒç€Ÿã«
ã¯ããã©ã³ã¹ã®Aventis 瀟ãã€ã®ãªã¹ã® Acambis 瀟ãåè¡åœã®Wyeth 瀟ãå«ãŸããŸãã
åžå Žãšå£²ãäžã
人å£ã®å€©ç¶çã¯ã¯ãã³æ¥çš®ã¯ã广ãããã¯ãããªãã£ãã®ã«ã2002 幎ã®åžå Žã®è³ãçã
ãªããããªå£°é«ãªå®£äŒã®ããã§ãç§éã¯æ¬¡ã®ããšãå¿ããŠããŸã£ãŠããã®ã§ãã
ïŒå€©ç¶çã¯ãçŸåšäžçã®ã©ãã«ãã¿ãããªãããšã
ïŒå€©ç¶çã¯ã¯ãã³ã®äŒç»ã®å
šéçšããç§åŠçã«æ€èšŒãããŠããªãè«ãã€ãŸããã®æ°ããã¯
ã¯ãã³ãïŒåæ¥çš®ããããšã§ãäœã®ç
æ°ã«å¯ŸããŠããã£ãšå
ç«ãä»ããšããèãã«åºã¥ã
ãŠããããšã
ïŒãã®ãå®å
šä¿è·ãçã®ããã§ã倿°ã®äººã
ãæ»äº¡ããããã¯ç涯ç¶ãé害ã被ãã§ãã
ãããšã
çã®åæ
âŠïŒ
Acambis 瀟ã¯ã€ã®ãªã¹ã«ãããŸãããAventis 瀟ã¯ãã©ã³ã¹ã«ããã®ã«ããã®äž¡åœãšãèª
åœã§ã®éå£ã®å€©ç¶çã¯ã¯ãã³æ¥çš®ãè¡ãªã£ãŠã¯ããŸãããä»ã®ã©ã®åœããèªåœæ°ã®å€©ç¶ç
ã¯ã¯ãã³é壿¥çš®ãããŠããŸããããªããªãããã®ã¯ã¯ãã³ã®å¯äžã®åžå Žã¯ãåœã®ã¡ãã£
ã¢ãäœãäžãã屿©æã«ãã³ããåè¡åœã®ã¿ã ã£ãããã§ããèªåœã®åœæ°ã®å®å
šãç ç²ã«
ããŠã仲è¯ãã®æ§åã§ããã¢ã¡ãªã«åœæ°ã«è²ã£ãŠããããšã¯ãã€ã®ãªã¹ãšãã©ã³ã¹ã¯ãªã
ãšç¡ç§æ¬²ãªã®ã§ããããïŒããããªããšããããèãåæ
ã§ãã
èšç®è¡šãçã£ãŠãããïŒ
Aventis 瀟ããçªç¶å·å宀ã«çœ®ãå¿ããŠãã 7 åäžïœ9 åäžååã®å€©ç¶çã¯ã¯ãã³ã[çºèŠ]
ããããšãã2002 幎 3 æ 27 æ¥ã®ïŒWashington post [120]ïŒéŠ¬é¹¿ãã話ã«ããçãããç¹
ã幟ã€ããããŸãããã®äŒç€Ÿãã1幎éã§ã¯ãšããŠãçç£ããããªãéã®ã¯ã¯ãã³ã®å¥çŽã
400 äžãã«ã§çµãã ç¢å
ã«ãçªç¶èªåéã®äŒç€Ÿã®å·å宀ã§çŽå€±ãã倧éã®ã¯ã¯ãã³ãã¿ã€ã
ããªããŠããªããšãå¥åŠãªå¶ç¶ã ãšæããŸãããïŒ
倧æµã®ã¢ã¡ãªã«åœæ°ã¯ã倩ç¶çã¯ã¯ãã³ãæ¥çš®ã§ããªã
ãã®æ°ããã¯ã¯ãã³æäŸè
éã«ææãäžããã®ã¯ãã«ããåç¥ãèŒããããªã¥ãŒã¿
ãŒã®èšäºã§ã[129]ããã®åç¥å
容ãšã¯ã倩ç¶çã¯ã¯ãã³ãã
ïŒïŒšïŒ©ïŒ¶æ£è
ïŒå
ç«åå¿ãå¶åŸ¡ããè¬ããšã£ãŠãã人
ïŒæ¹¿ç¹ã¢ã¬ã«ã®ãŒã®ãã人
ã«ã¯é©ããŠããªãããšãããã®ã§ãããJournal of Allergy and Clinical Immunology èªã§
ã®ææ°ç ç©¶ã«ãããŠã㯠ã¯ã¯ãã³æ¥çš®ã«ããå¯äœçšåå¿ã«ã¯ã倱æãè² å·ããããŠ
æ»äº¡ãæãããããšè¿°ã¹ãŠããŸããã§ã¯ãã¢ã¡ãªã«åœæ°ã®ã©ãäœã該åœããã§ããããïŒ
ãæ¹¿ç¹ã¢ã¬ã«ã®ãŒãæã€äººã
ã®æ°ãèãããšãã¢ã¡ãªã«äººå£ã®ååã¯ã宿çãªå€©ç¶çã¯
ã¯ãã³ã®æ¥çš®ã«é©ããªããšããããã
ïŒJournal of Allergy and Clinical Immunologyã 2002 幎 9 æ[122]
æ£è
ãšãå
ç«åå¿ãå¶åŸ¡ããé¡ã®è¬ã䜿çšããŠããäººã®æ°ããã¯ã¯ãã³æ¥çš®ã«é©
ããªãäººã®æ å
ã§ã倧ããªå²åããããŠããŸãããã§ã¯ãå
ç«åå¿ãå¶åŸ¡ããé¡ã®è¬ãšã¯ã
ã©ãäœããããšèšããŸããšïŒå
šéšã®è¬ã該åœããã®ã§ãïŒ
ããã«ãã¡ãã£ã¢ãèšãå¿ããŠããããšã§ãããåè¡åœã§ã¯ 1971 幎ãŸã§å€©ç¶çã¯ã¯ãã³æ¥
çš®ãè¡ãªãããŠãããããçŸåšïŒïŒæä»¥äžã®ã¢ã¡ãªã«äººã®ã»ãšãã©ã¯ãã§ã«æ¥çš®ãè¡ãªã£
ãŠããŸããã§ãããããããã®ã¯ã¯ãã³ãæ¬åœã«å¹æããããªãã°ããããã®äººéã¯æ°ã
ã«æ¥çš®ããå¿
èŠã¯ãªãããã§ãããïŒ
ã¯ã·ã³ãã³å·ã«ããæ¿æ²»å®¶éã¯ã奜ãåæã«æ±ºãŸããäœãããšãã§ããŸããããããç§åŠ
ãšå»çã«é¢ããåéã§ããæã«ã¯ãå»è
ã®ååãªãã§ã¯ãã®æ±ºå®ãå®çŸããããšã¯åºæ¥ãŸ
ãããäŸãã° 2003 幎 1 æã«ã¯ããŸã 50 äžäººã®å»çé¢ä¿è
ãæåã«æ°çš®ã®å€©ç¶çã¯ã¯ãã³
ã詊çšããŠã¿ãã¹ãã ããšããããã·ã¥ã®ãŸã¬ããªäž»åŒµã«ãæåã«éžã°ãã 80 ä»¶ã®ç
é¢ã
ã¢ã«ã¢ãã圹ã«ãªãã®ãæåŠããŠå察ããããã«ããã®æ¡ã¯åŽäžãããŸãããïŒUSA Today
[79] ManningïŒãã® 3 ã€ã®çç±ãšã¯ã
ïŒå»è
éã¯ã倩ç¶çãèå»¶ãããšããè
ãã«çå®å³ãæããªãã£ãã
ïŒã¯ã¯ãã³æ¥çš®ã«ããæ»äº¡ã®å¯èœæ§ã¯ãçŸå®ã®åé¡ãšããŠèªç¥ããŠããã
ïŒã¯ã¯ãã³æ¥çš®ã«ããé害ã被ã£ãå Žåã®ããµããŒãå¶åºŠã®æ¬ åŠã
ãšãã£ããã®ã§ããã
æ¿ããå察
倩ç¶çã¯ã¯ãã³æ¥çš®ã«å¯Ÿããå察ã®å£°ã¯ãåœäžããæ¿ããæ²žãèµ·ãããŸããã2003 幎㮠2
æãŸã§ã«ãããã·ã¥ãæåã«ã¿ãŒã²ãããšããŠæ²ãã 50äžäººã®å
ãã¯ã¯ãã³æ¥çš®ãåãã
人ã¯ïŒïŒ
ã«ãæºããªãæ°ã§ãããæ¥çš®ãæåŠãã人ã
ã«ã¯
ïŒäœçŸãã®åºå¹¹ç
é¢
ïŒçè·å©Šã®é£ç
ïŒAFL-CIO
ïŒæ¿åºã®ä¿å¥å±ã®æ°ã
ïŒèŠå¯
ïŒïŒ£ïŒ€ïŒ£
ïŒãããŒã»ãã ãœã³èªèº«
ïŒWashington Post 2003 幎 2 æ 24 æ¥ [104]
倩ç¶çã«ããå¿èçºäœ
æåŸã®ãšã©ããåºããã®ã¯ã2003 幎 3æã«ã倩ç¶çã¯ã¯ãã³ã¯å¿èçŸæ£è
ã«ã¯äžé©ã§ãã
ãšçºèŠãããããšã§ããé¢é£èšäºã®èŠåºãã幟ã€ã玹ä»ããŸãã
ã倩ç¶çã¯ã¯ãã³ã®æ¥çš®åŸãæ»äº¡ããåŽåè
ã2人ç®ã
ïŒMecker, Associated Press, 2003 幎 3 æ 27 æ¥ [101]
ã倩ç¶çã¯ã¯ãã³ã®ããã°ã©ã ãå¿èçºäœã«ããæ»äº¡è
3人ã§é
å»·ã
ïŒWashington Post, 2003 幎3æ 29 æ¥ [102]
ã§ã¯ãæ¿çãèšæ£ããããã«ææ¡ããã®ã¯èª°ããšãããšïŒïŒïŒ åé¡ã®åŒµæ¬äººã§ã¯ãããŸãã
ãïŒ
ãæ°ããèšæã¬ã€ãã©ã€ã³ã«ãããšãå ç¶åèã®çŸæ£ãå¿èã®ãã£è¡ç
ãå¿èçºäœãçå¿
ç
ãæ£ã人ã¯ã¯ã¯ãã³ãæ¥çš®ããªãããã«ãšç€ºãããŠããããã®èšæ£ã¯ãHealth and
Human ServiceïŒä¿å¥çŠç¥æ©æ§ïŒã®ç§æžããããŒã»ãã ãœã³ã«ãã£ãп什ããããã
ïŒïŒMecker ïŒ[101]
ãããªäºå®ãã3åãã«ãã¡ãããšæ¶è²»ããåŸãŸã§çºèŠããªãã£ããªããŠãäžèªç¶ã ãšæã
ãŸãããïŒ
çµå±ããã®åŸã¯ã¯ãã³æ¥çš®ãåãããããšãããã®ã¯ã倧äœåœæ°äººå£ã® 10%ãšã¿ãŠåŠ¥åœã§
ãããããã£ãšããããã¯åŒ·å¶çã«å®ææ¥çš®ãåããããããŠããè»éãé€ããŠã®æ°ã§ã
ããïŒ Dr.Nass [37]ïŒ
æ¶ãå»ã£ããªãã®å±éºæ§ã®è©±
倩ç¶çã¯ã¯ãã³ã®é壿¥çš®ããã°ã©ã ã¯ã2003 幎 10 æã«ã¯åãããã«ãªããŸããã
ã®ã¬ã€ã»ã¹ãã¥ãªã«ã¹ã«ãããšã
ã倿°ã®ããŒã€ã³ã°ãåããããã°ã©ã ã¯ãæººãæ»ã«ããããšã®ããšã§ãã[79]
ãã®çç±ãšã¯ãäžèšã«ãããäºäŸã«å ããå¿èé¢ä¿ã®æ¯éããã§ãããšããããã§ãïŒå¹Ž
éã匷å¶çãªã¯ã¯ãã³æ¥çš®ããããšåœæ°ãè
è¿«ããããã«ïŒåãã«ã䜿ã£ãåŸã«ã圌ãã¯
ãã£ãããšå
šéšãåŽäžããŠããŸããŸãããã§ã¯ããã®å€©ç¶çã®çååŠå
µåšããã®å±éºã£ãŠã
ã©ããªã£ããã§ãããïŒã©ã£ãã«æ¶ãå»ã£ãŠããŸã£ãã®ãããªãã§ãã®è©±ã¯ããããã£ã±
ãæ¶ããŠããŸã£ãã®ã§ããããïŒã€ãŸãããã®è©±ã¯ã¯ã¯ãã³ã®å®£äŒéå
·ãšããŠã®äŸ¡å€ã¯ã
ã£ãŠããã¯ã¯ãã³ãã ããªç©ãšåãã£ãç¬éãããã®å±éºãäžç·ã«æ¶ãã¡ãã£ãããšãã
ããšã§ããããïŒç§éãæ²»çæ³ãèŠã€ããããªãã£ãããããããããªããªïœãšèªåãã
æ¶ãå»ã£ãŠããããªããŠã倩ç¶çããè¡åããããã®ã§ããïŒ
æåã®ããã
倩ç¶çã¯ã¯ãã³ã®è£ã¥ããšãªã£ãŠãããç§åŠçãªæµããã¿ããšãåèã«ãªãã§ããããç
ç©¶è
éã¯ãã©ã®ããã«è©Šéšäžã®ã¯ã¯ãã³ã®å¹æã確ãããã®ããã€ãŸã圌ã颚ã«èšããšãå
ã£ãŠãããäºé²æ¥çš®ã§ããããåããã®ãããèŠãŠã¿ãŸãããã
2002 幎 4 æ 25 æ¥ä»ãã® New England Journal of Medicine,ïœïŒ1266 ã«ã詊éšã®æåãèŠ
極ããæ¹æ³ãèŒã£ãŠããŸããã倩ç¶çã®ã¯ã¯ãã³æ¥çš®ã¯ã泚å°ã§ã¯ãããŸãããå
端ã«ã¯
ã¯ãã³ãå¡ã£ãäºè¡ã®éã§ãç®èã 15åçªãåºããŠãããã¶ãã®ããšã«æ°Žæ³¡ãã§ãããæ
åãããšã¿ãªãããŸããã€ãŸããè¡æ¶²æ€æ»ããæäœæ€æ»ãäžåãªãã«ãããã ãã§æ±ºããŠ
ããŸã£ãŠããã®ã§ãããã ã®ã氎泡ã ãã§ãã§ãã[134]ä¿¡ããããªãããšã§ããããã®è¿·
ä¿¡ãã¿ãèãã¯ããžã§ããŒã®æä»£ããã€ã¥ããŠãããã®ã§ããå®éããåã£ãŠããïŒa takeã
ãšã¯ããžã§ããŒãèããåŒã³æ¹ãªã®ã§ãããã ããã®è¿·ä¿¡ã¯å°ãå€åãéããŠããŸããã325ã
ä»äžçŽã®åãã®é ã«ã¯ãä»åºŠã¯ããã¶ããåºæ¥ããå
ç«ãä»ããããšãããŠã人ã
ã¯ãã
å¿
èŠãªãïŒããã¶ããåºæ¥ãïŒãšå€æããããŸã§ãæ°ã¶æããšã«ç¹°ãè¿ãç¹°ãè¿ãæ¥çš®ã
è¡ãªããªããŠã¯ãããŸããã§ããã
äœãççŸããŠãããªããšãèãã§ãããïŒ ããããããã«ã¯ç¶ãããããŸãã
å°éå®¶ã®åè«
åœæãäž»æµãšãªã£ãŠããå°éå®¶ã®éã§ããã倩ç¶çã¯ã¯ãã³ã®é壿¥çš®ã¯å€§ããªå察ãå
ããŸããã2002 幎 10 æ 8æ¥ã® New York Times[135]ã§ããžã§ã³ ãããã³ãºå€§åŠã®å°å
ç§ææã§ãããã¢ã¡ãªã«å°å
ç§åŠäŒã®ãžã¥ãªã¢ã»ããã¯ãã©ã³ã¯ããè¿°ã¹ãŠããŸãã
ããã®ã¯ã¯ãã³ã倧å¢ã«é壿¥çš®ãããšãæ»äº¡è
ãåºãã§ããããããã«ããã®ç
æ°èªäœ
ãã1970 幎代以éã«ã¯æ¶ããŠããŸã£ããã®ã§ããããšããé ã«å
¥ããŠãããã°ãªããªãã
ååšããªãç
æ°ãäºé²ããããã«ã人ã
ãæ»ãªããããšããèãã¯çè§£ãããããã®ã§ã
ããã
çè§£ããããããšããããçã£ãŠãããšãã£ãæ¹ãæ£ãããããããŸããã
倩ç¶çã®è
åšããããã«æå¹ãªããŒã±ãã£ã³ã°ã®éå
·ã§ãã£ãããå®å
šæ§ã®ä¿èšŒããªãã
广ããªãäžã人å£ã® 90%ãæ±æããã¯ã¯ãã³ã®ããã« 3 åãã«ãã®ãéãã¯ã¯ãã³çç£
äŒç€Ÿã«æã£ãããšãæ£åœåããããã«ãåºå ±å±ãçšããåå
«çªã§ãã£ããã¯ãããããèŠ
ãŠåãããšãåºæ¥ãã§ãããã
æŽå²ïŒããŒã2
ã©ãããŒãªç§åŠè
ããã¹ããŒã«
ãžã§ããŒã®æ¬¡ã«ãã¯ã¯ãã³ã§æåãªã®ã¯ãã¹ããŒã«ã§ããã«ã€ã»ãã¹ããŒã«ã¯ 1800 幎代å
ã°ã®ãã©ã³ã¹äººã®ååŠè
ã§ãçç©ã®åºæ¬çãªåé¡ã«ã€ããŠãæåã«èãåºãããã©ã³ã¹ã
ãã€ãäž¡åœã®ç§åŠè
å£äœã®äžå¡ã§ããããã®åé¡ãšã¯ã
ïŒçãç©ãçããã®ã¯ãäœãïŒ
ïŒç
åèã¯ã©ãããæ¥ãã®ãïŒ
ïŒç
åèãšãç
æ°ã®ã©ã¡ããå
ã«æ¥ãã®ãïŒ
ïŒç©äœã¯ãªããè
ããçºé
µããè§£äœããã®ãïŒ
ïŒç©ºæ°äžããŸãã¯çåœäœã®å
éšã«ãããããäœçšããã€äœããååšããã®ãïŒ
ãšãã£ããã®ã§ããã
åœæã¯ããããåºæ¬åé¡ã«å¯ŸããæŽå²äžåããŠæ§ã
ãªçºèŠããããŠããŸãããè²ã
ãªã¢ã€
ãã¢ã次ã
ãšæµ®ããã§ããŸãããããŸã æççãªãã®ã§ãããäžéã®ãäžç¢ºãããæããŠ
ããå¿å¢ãäžæãå©çšããŠãèªåãããããããåé¡ã«ã€ããŠæåã«èãåºãã人ã§ããã
å
šãŠã®èª²é¡ãçè§£ããŠããã®ã ãšäž»åŒµããã¡ãã£ããç©ãããã®ãã¹ããŒã«ã§ãã圌ã¯ã
èªåãåãããªã課é¡ã«ã€ããŠã¯äž¡æ¹ã®æèŠã®èŠæ¹ãããŠãããåŸã§çããåãã£ãæç¹
ã§ã以åã®èªçããéšåçã«åŒçšããŠãåžžã«èªåãæåã«çããçºèŠããŠãããšäž»åŒµãã
ãããšã§ç¥ãããŠããŸãããå
ã«è¿°ã¹ããããªããŸã å®éšçãªæ®µéã®ã¢ã€ãã¢ã«ã€ããŠã
ãããã®é£ç¹ãåé¡ãç ç©¶ããŠããã®ã¯ç§åŠè
éã ãã§ãåœã®æ³åŸé¢ä¿ã®äººã
ããã¹ã³ã
ã¯äœããèµ·ãã£ãŠããããšã¯åãã£ãŠããŠããå®éã«äœãèµ·ããŠããããŸã§ã¯ææ¡ããŠã
ãŸããã§ãããããã§ãä»ãæãå€ããã¬ãã®ã§ã圌ãã¯ç¥ã£ãæ¯ãã§æŒãéããŠããŸã
ããããŸãããããã人ã
ã«ãšã£ãŠãã¹ããŒã«ã®æ§ãªã«ã¡ã¬ãªã³å士ã¯ãã¡ããã©éœåã®
ããçæ¿ç·ã ã£ãããã§ãã
ããããŠãã¹ããŒã«ã¯ãã©ãèº«ãæ¯ãã°éå²ãã«ã€ãªããããå
ãä»ãããšããã®æ°ãã
æçŸ©ãããšã«ãåºäžãããæ¹æ³ãèãåºããã®ã§ãã
ç
åè説ã«ã€ããŠ
ã§ã¯ããã®ç
åè説ãšã¯ãå®éã©ããªãã®ãªã®ã§ããããïŒããã¯ããç°¡åã«èšãã°ãç
æ°ã¯ããããçš®å¥ããšã«ç°ãªããã®ã§ãããããããã®ç
æ°ãç¬èªã®åŸ®å°çç©ã«ãã£ãŠåŒ
ãèµ·ãããããã®ã ãšãã説ã§ããããã«ãããã§ç§åŠã«æ±ããããããšã¯ããããã害
ã®ããããããã®ã°ãèããæ£è
ã«ã¯å®³ãããããã«æ®ºã广ãæã€è¬ãã¯ã¯ãã³ãäœã
åºãããšã§ããã
ãã¡ããããããåºæ¥ãã°äžäº OK ãªã®ã§ãããããèªç¶ãšã¯ãããªã«ç°¡åã«çœé»ã¯ã£ã
ãã€ãããããã®ã§ã¯ãããŸããã第äžã«ããã¯ããªã¢ããŠã€ã«ã¹ã¯ãäœã¿çãç°å¢ãã
ã奜ã¿ããçãç©ã§ãããã ãããã颚éªãåŒãããã人ããããã§ãªã人ãããèš³ã§ãã
ãã¹ãã«ããã£ãŠãçãå»¶ã³ãããšãåºæ¥ã人ã
ãããã®ãããã®ããã§ãããã ããã
ããæ¯æ¥ç
æ°ã«ãããŸããŠåããŠããã«ãé¢ãããããŸã£ããç
æ°ã«ããããªãå»è
ãç
è·å©Šãããã®ã§ãã
ãã£ãŒããã¯ã»ãã§ãã©ã«ãããšãã€ã³ãã«ãšã³ã¶ã®ãŠã€ã«ã¹ãéžå¥ããŠå®éšå¯Ÿè±¡è
ã®ç²
èã«çŽæ¥æ³šå
¥ããçµæãã€ã³ãã«ãšã³ã¶ã«ããã£ãã®ã¯ãããïŒïŒïŒ
ã§ãã£ããšããããš
ã§ããïŒQuantum Healing [266]
ç
æ°ãšã¯ãäœã®æ©èœã衰匱ããæ é€äžè¶³ã§æ£åžžã«åãããšãåºæ¥ãªããªã£ããšãã«ããã
ãã®ã§ããã§ã¯ãã®åå ã«ãªããã®ãšã¯äœããšèšããšãäœã®æµæåã®åŒ±ããäžæœãªç°å¢ã
æå®³ãªé£çæŽ»ãæªãçæŽ»ç¿æ
£ããããŠå
ç«åã®åŒ±ããæããããŸãããã®ãããªç¶æ³ã§ã¯ã
è¡æ¶²ã«åŸ®çç©ããã¿ãããç¶æ
ã«ãªã£ãŠããŸãã®ã§ããåŸã«ã¯ãã¹ããŒã«ãããããã¯ã
ãªã¢ããŠã€ã«ã¹ã¯ãããèªäœã¯ç
æ°ã®åå ã§ã¯ãªããç
æ°ã«ããã£ã现èçµç¹ããŽãæŸã
ã®ããã«ããŠãããŒãé£ãååšã ãšãèªããŠããŸãã
ãã®ç
åè説ãã穎ãŒãã ããã®é Œããªã説ã§ããããšã¯ãã¹ããŒã«ãæ¿ç¥ããŠããŸããã
ããããã¡ãã£ãšèª¿ã¹ãã°åããããã«ã圌㯠PR ã«ãããŠã¯åè
ã®äººç©ã ã£ãã®ã§ãã圌
ã¯æ©äŒã®ããããšã«ãé »ç¹ã«ãšãŒãããã®æ§ã宀ã§å€äºã貎æãæ³åŸé¢ä¿è
ã«ãã¹ã£ãã
䜿ãã«ããããã®çµæããã¹ããŒã«èªèº«ã«ãçè§£ã§ããŠããªãç§åŠç諞åé¡ã«é¢ãããã
ã¹ããŒã«åŒçŸä»£ç§åŠè«ããåœã®ææš©è
éãåãå
¥ããŠããããšã«ãªããŸããã[191]
ããããŠãã¹ããŒã«ã¯ããšãŒããã諞åœã«ãããŠããããšããããç§°å·ãåèªãäžãããã
è³ãæã§åœŒã®èª¬ãåºçãããåŒçšãããããã«ãªããŸããããããŠãã€ãã«æ¿åºã®ãªãŒã
ãŒéã®éã§éå£ã¯ã¯ãã³æ¥çš®ã®æ¡ãç«ã¡äžããããã¹ããŒã«ã®æ å
ã¯å
šçæãè¿ããŸãã
ãã¹ããŒã«ã®æ¬åœã®å§¿
ïŒïŒïŒïŒå¹Žã«åºçããããããã·ã£ã³ãããã¹ããŒã«ãïŒããšãããŠããŒã¯ãªæ¬ããããŸãã
ãã®æ¬ã®çè
ã¯E. ãã°ã©ã¹ã»ãã¥ãŒã ãšãããŸãããå®ã¯å¥³æ§ã§ãããåœææ¬ãåºçãã
ããã«ç·æ§åã䜿çšããèš³ã§ãããã®æ¬ã¯ä»ãåºçãããŠããŸãã
ãã¹ããŒã«ã¯ãããŒã¿ãåœé ããããä»ã®ç§åŠè
ã®èª¬ãçãã§ããããèªèª¬ãšããŠçºè¡šã
ãããšã§æªåé«ã人ç©ã§ããã圌ãçºèŠãããšãããæåãªè«žèª¬ãå®ã¯ãåãç©ããªã®ã§
ãããããããã®äººç©ã¯ãèªåãæåã«çºèŠããããšäž»åŒµããããšã«ãããŠã¯ãæãç®ã®
ãªãããæã ã£ãã®ã§ãã[191]
ãã®æ¬ã®çè
ã¯ãä»ã«ããã¹ããŒã«ã®è£è©±ãããã€ãæããŠããŸãã®ã§ãèå³ããããã
æ¹ã¯ããã«è©³ãã調ã¹ãŠã¿ããšè¯ããšæããŸãã
ïŒãã¹ããŒã«ã¯ãã ã®ååŠè
ã§ãããå»åŠãççåŠã«ãããŠãäœã®åŠäœãååŸããŠããªãã
ïŒãã¹ããŒã«ã¯ãçç¬ç
ã®æ²»çæ³ãèŠã€ãããã®ã§ã¯ãªãçç¬ç
ãã®ãã®ãäœãåºããå¯
èœæ§ãé«ãããšã
ïŒãã¹ããŒã«ã¯åç©ã䜿ã£ãŠããããŸããæ®é
·ãªå®éšãäœåºŠãè¡ããããã«ããè§£åå®éš
ãšããè¡çºã®ç¬¬äžäººè
ã«ãªã£ãããšããã以æ¥ãçŸåšã«è³ããŸã§ãæ°ãåããªãæ°ã®å®
éšçšåç©ãããã¹ããŒã«ã®ç ç©¶æã«éããäžçäžã®å»åŠç ç©¶æã«ãããŠãç§åŠã®ããã
ãšããåã®ããšã«ãäžå¿
èŠã§ãé
·ã殺ããæ¹ãããŠããã®ã§ãã
ïŒèªåã®å®£äŒãšãæ³åŸã§åŒ·å¶ãããè¬ãã¯ã¯ãã³ã®å£²ãäžãããå²ããããšããïŒã€ã®ç®
çã®ããã«ãåœãã®å®éšçµæãåœã®ããŒã¿ã®ä¹±çšãããŠãã£ãç¹ããã¿ãŠããã¹ããŒã«
ã¯äººé¡ã®æäžè
ã§ã¯ãªããç§åŠè
ãšããããããããå売人ã ã£ãããšãããããšã
ã°ãèïŒç
æ°ã®åå ã§ã¯ãªããç
æ°ã®å
å
ãã¹ããŒã«ã®ç
åè説ã«é¢ããŠã¯ãåœæã®æåç§åŠè
éãããå€ãã®åè«ããããŸããã
åœæã®ãã©ã³ã¹ã§ãããããæãåªããç§åŠè
ã§ããããã¯ããªã¢ã®çºèŠè
ã§ããã¢ã³ã
ã¯ãŒãã»ã¹ã·ã£ã³ã¯ãªãŒã«å€§åŠã®ææã§ãããã圌ã¯ããèšã£ãŠããŸãã[205],p.183
ããã¯ããªã¢ã¯ç
æ°ã®åå ãšãªããã®ã§ã¯ãªããããã«ãè¡æž
ãã¯ã¯ãã³ã¯ç
æ°ãé²ãã
ãšããæ²»ãããšãåºæ¥ãªããã
现è説ã®çè
ã§ãããã«ãã«ãã»ããŒãã§ãŠèªèº«ããããã«è³æããŠããè¿°ã¹ãŠããŸãã
ãã°ãèã¯ã现èçµç¹ãç
æ°ã«ãããåå ã§ã¯ãªããç
æ°ã«ããã£ã现èçµç¹ãèŠã€ããŠ
äœã¿çããã®ã ã ïŒMan the Unknown [298]
ã°ãèã¯ç
æ°ã®éæè
ã§ã¯ãªãããã¿ããããããŠããã ã
åœæã®ããããŠçŸä»£ã®å€ãã®ç§åŠè
ãšåæ§ã«ãããŒãã§ãŠãæ°ä»ããããšãšã¯ã现èçµç¹
ã«ã°ãèãããããšã§ããã®çްèçµç¹ãç
æ°ã«ããã£ãŠããå°ã«ãªããšã¯èšããããã°ã
èãåå ã§çްèçµç¹ãç
æ°ã«ãªã£ãããã§ã¯ãªããšããäºå®ã§ãã匱ã£ãããç
æ°ã«ãªã£
ã现èçµç¹ã¯ã埮çç©ã«ãšã£ãŠãã£ããã®ã¿ãŒã²ããã§ãããããã«äœã¿çããŠè²ã
è¡å
ãåºããŠããã«ã¯æé©ãªç°å¢ã§ããã ãããšãã£ãŠã现èçµç¹ã匱ãŸãåå ããã°ãèã
ãšããèããšã¯ãå
šãéã話ã§ãã
çŸä»£ã®ãç
åè説ããšãªããå»è
ãçè
éã¯ãæ ¹æ ã«ãªãæ£ããäºå®ããªãã«ãå®£äŒæå¥
ãããããšå±ããä¿¡çšã§ããªãååšã§ãã圌ãã®å¯äžã®åãæã¯ã1940 幎代ã«ãµã¬ã¯ãµã³
ããŒã»ãã¬ãã³ã°ãããã·ãªã³ãçºèŠããããšã§ãããã®è¬åŠã«ãããå倧ãªå瞟ãããäž
床ãããšãã£ãæãã§ããããããèããŠäžçªæ¥ããããæãã®ã¯ããããããã¬ãã³ã°èª
身ã§ãããã圌ã¯ãäžè¬äººããã䜿ãã念ã®ããã«ãæ¹éã®ããšã§ãæçç©è³ªãè¿·ä¿¡çã«
ä¹±çšãããŠããã®çµæã¹ãŒããŒãŠã€ã«ã¹ãçºçããããšãäºæž¬ããŠããŸããã[46]
å
šãŠã®ãŠã€ã«ã¹ã«å¹ããäžè¬ãšã¯
å¥åº·ãªäººéã®çåç¶æ
ãããå€çããå³éã«å®ãããæ®ºèã«ãã»ã«ã«å
¥ããä»ã®çç©ãå
¥ã£
ãŠããããã¹ãŠäŸµå
¥è
ãšã¿ãªããŠæ®ºããŠããŸãããšãã£ãã²ã©ãè»éçãªèãæ¹ïŒ ãã
ã¯ãçŸä»£å»åŠã®ç¢ãšãèšããã»ã©ãåºæ¬ãšãããŠããèãã§ãããå®éããã¯ç§åŠçã«ã¯
éåžžã«ç¡çã®ããèãæ¹ãªã®ã§ãã
å¥åº·ãªäººéãšã¯ãçç©åã«åŸå±ããªããçããŠãããã®ã§ãããäœã®å
åŽãå€åŽããäœå
ãã®åŸ®çç©ã«ãããŸããŠããŠãããããå
šãŠãåè¡¡ãä¿ã¡ãªããå
±åããŠããã®ã§ããå
ç§ã®åŠäŒã«ãããŠæãå°äœã®ããã±ãŒã³ã»ã·ã£ããå士ã¯ãéåžžã®äººéã®å€§è
žã¯ 3 ãã³ã
ã®éãã«ããªãã400 çš®é¡ãã®æ§ã
ãªçç©ãå
å
ããŠãããšè¿°ã¹ãŠããŸãã[50] 人éã®ãŸ
ã€ãã®äžã§äžçãéãã埮çç©ãµã€ãºã®èèã ã£ãŠããã®ã§ãã[350] ãŸããç Žå·é¢šã®é
ç®ã®éã«è¿°ã¹ãããã«ãã¢ã¬ãã¯ã»ããŒãã³å士ã«ãããšç Žå·é¢šã®èã¯ãçºçã«ã¯è³ããŸ
ããããããäžè¬ã®å¥åº·ãªäººéã®èããããã«ã¯å£ã®äžã«ãŸã§ãããã®ãªã®ã§ãã[339]
ã°ãèãç¹æ®ããŠããç¶æ
ãããã£ããšããç§åŠè
éã¯ãç
æ°ã®åå ãã§ã¯ãªããç
æ°ã®
å
åããšããŠæããŠããŸãããŸããç
æ°ã«ãªã£ãŠãããããã°ãèãç¹æ®ããã®ã§ããæš©
åã®åœ±é¿äžã«ããè¬åŠäŒã§ã¯è«ããããããšããªããã®ããã·ã³ãã«ãªæŠå¿µããããã®æ¬
ã®ããŒãã€ã³ããšãèšããèãæ¹ãªã®ã§ãã
宣äŒã«ã®ã£ãšã£ãŠ
æ¿æ²»ãšã¯ããã€ã®æä»£ãå€ããã¬ãã®ã§ããå°çã倪éœã®åšããæåããŠãããšçºèŠãã
ã¬ãªã¬ãªãããµã®æå¡ã«éã蟌ããã®ãšåæ§ã«ãæš©åè
ãèªåã®é
äžã«ããè
éã®æèã
æ¯é
ããããšããïŒããããèãæ¹ããã£ãŠããããããã奜æ©ã«ä¹ããŠè¡åãããã¹ã
ãŒã«ããæ¬æ¥ãªãã°èº«ã«äœã圹å²ã§ãããçŸä»£ã®çç©å»åŠäŒã®å
é§è
ãšãã圹ã«ã€ãããš
ãåºæ¥ãããã§ãã
1995 幎ã®ãç
åèèª¬ïŒ æå³çã«ãªãããèª€å ±éããšããæ¬ã§ããã¯ãŒãã»ãã³ã±ã¯ç
å
è説ãè¿ä»£ã®è£œè¬äŒç€Ÿã«ã次ã®ãããªæ©äŒããããããšè¿°ã¹ãŠããŸãã
ãïŒïŒïŒè¥¿æŽã®äžè¬äººã«ãäœã®ç
æ°ãªã©ã«çé ãããå
šãŠã®äžèªç±ã¯å€éšããã®èŠå ã§èµ·ã
ããã®ã ãšæã蟌ã¿ãããããã身ãå®ãã«ã¯ãå人ã®èªå·±ç®¡çãäœã®æ©èœã§ã¯ãã¡ãªã®
ã ãšãèªå·±ç®¡çãšã¯é¢ä¿ãªããç§åŠçãªæ²»çãããç
æ°ããå®ã£ãŠãããã®ã ãšä¿¡ã蟌ãŸ
ããããšã[299]
ã€ãŸãå
šãŠã¯ã宣äŒã«ããã£ãŠãããšããããã§ããïŒ
E.ãã°ã©ã¹ ãã¥ãŒã ã¯ããæžããŠããŸãã
ãã¯ã¯ãã³ã倧è¡åãã«å£²ãåºãããããšããªããã°ããã¹ããŒã«ã®ç
åè説ã¯å¿åŽã®åœŒ
æ¹ã«æ¶ãå»ã£ãŠè¡ã£ãã ãããã [191]
ä¹±æŽã«æãå ããŠã¯ãããªããã®
ãŸãæåãããã©ããªçç±ã§ããèãéã§åºãããšèªäœãæžå¿µãããã¹ãè¡çºã§ãããæ
ãåºããŠã¯ãããªãäœã®ç°å¢ã§ãããåŸªç°æ©èœã«æ°çš®ã®ããã±ã質ãç©è³ªã泚å
¥ãããªã©ã
ãã£ãŠã®ã»ãã®è©±ã§ããè¡æ¶²ã«åŸ®çç©ã泚å
¥ããããšã«ã€ããŠãç§éã¯äœãèããã«ãã£
ãšç§åŠçã§å®å
šã ãããšæã蟌ã¿ãã¡ã§ãããäž»æµã®ã¡ãã£ã¢ãç§åŠèªããåãæ§ã«æ ¹æ
ããªããŸãŸæ±ºã蟌ãã§ããŸã£ãŠããŸãããå®ã¯æ³šå°ãšããè¡çºã¯ãèªç¶ã«ãããããŸã£ã
ãã®æŽåè¡çºã«ä»ãªããŸãããèªç¶ãé ãåºããç°å¢ãšã¯ãã©ããªç©ããæ¶ååšå®ãšåŒåž
åšå®ãšããæ€æ»å®€ãéããã«è¡æ¶²ã«æ··ããããããšããªãããã«ãšãã¶ã€ã³ããããã®ã
ããã§ãããããªèªç¶ã«åããè¡çºã¯ãã©ããªå£å®ãããŠã¿ãŠããç§åŠçã§ãããšããã
ãšã¯åºæ¥ãŸããã
泚å°ã«å察ãããŠãã倿°ã®ç§åŠè
ã®å
ããã幟ã€ãäŸãæããŠã¿ãŸãããã
ãäœããã®çåœäœããè¡æ¶²ãšãããããšããšããããäœãã¹ãå Žæã§ãªãç°å¢ãžæ³šå
¥ãã
ããšã¯ãããæ·±å»ãªé害ãåŒãèµ·ããå¯èœæ§ãããïŒã²ã©ãé°é¬±ã§ãæ·±å»ãªç¶æ³ã«ãªã£ãŠ
ããŸãããšãèããããã®ã ããïŒã¢ã³ãã¯ãŒãã»ãã·ã£ã³[191]
ãŠã©ã«ã¿ãŒã»ãããŠã§ã³ MD ã¯èªçã®ãæŠäºãšç
åèããšããæ¬ã®äžã§ã1 äžçŽåã®ããŒ
ã¢æŠäºæã«ãããåã¢ããªã«ã®æŠå Žã®æ§åãããæŠäºèªäœãåå ã§æ»äº¡ãã人ã
ã®æ°ã¯
86,000人ã§ãããšç€ºããŠããŸãããäºé²æ¥çš®çã100ïŒ
ã®ãã®åœã§ãããã«96,000人ã®äººã
ãç
æ°ã«ããã£ãŠæ»äº¡ããŠããã®ã§ãïŒ[300]
1915 幎ã«ã¯ãè±åœã®æ¥çãããã®å»åŠèªã§ãã Lancet èªã«ããŸãå¥ã®å»åŠè
ãèšäºãèŒ
ããŠããŸãã[301]ã¢ã³ã¿ã€ã¹å»åž«ã¯ããã¹ããŒã«åŒã®æ³šå°ãåããæ£è
ãç Žå·é¢šã«ããã£
ãã±ãŒã¹ã 21ä»¶ããã¹ãçµæãå
šãŠã®æ£è
ãããã®æ³šå°ãåå ã§ç Žå·é¢šã«ããã£ããšãã
çµè«ãåºããŠããŸããã¢ã³ã¿ã€ã¹å»åž«ã¯ãããã¹ããŒã«ã¯æ°çš®ã®ç
æ°ãã€ããåºããããšæž
ããŠããŸãã
ãã¹ããŒã«ã¯åç©ã䜿ã£ãé
·ãå®éšããè§£åãå§ãã人ç©ã§ããããŸããããããã®å®éš
ãããŸã ã«æå¹ã ãšãã蚌æã¯ãããŠããŸããããªãã ãåãããŸããïŒçããã¯ããã
ã®ç«ã«ãèªåã®é¢šéªè¬ãäžãããããŸããïŒãããããããªããšã¯ãããŸãããèªç¶ãªç°
å¢åã«ãããŠã¯ãåç©ã¯äººéãšã¯ç°ãªãç
æ°ã«ãããããã«ãªã£ãŠããã®ã§ãããã®ç¹ã
åãéããããšã§ãç§éã¯ç¡æå³ã§ãã«é«ãã ãã®ã誀ã£ãéãé²ã矜ç®ã«ãªã£ãŠããŸã
ãŸãããåç©éã«ãæ¬æ¥åœŒãããããã¯ãã®ãªãã£ãç
æ°ã眹æ£ãããŠããã®äžãããæã
人éããããç
æ°ãšåãã ãšããæ¯ãããããã®åç©ã®çç¶ãæ²»çããè¬ãäœã£ãã£ãŠã
ããã§ã©ããã£ãŠäººéã®ç
æ°ãæ²»ãããšãåºæ¥ããšããã®ã§ããããïŒããããŠäœãäžã
ãããè¬ããç§éã¯äººéã«ãåæ§ã«å¹ãã«éããªããšåæã«æã蟌ãã§ããããã§ãïŒæ¬
åœã«æããªäºã§ãããå
šãŠã®å»åŠçç ç©¶ãç ç©¶ææå
¬è¡šããããŠåŠæ¹è¬ãšããŠåæ³ãšèªã
ãããããã»ã¹ããããå
šè¬ã«ãããåºç€ãšãªã£ãŠããã®ããããŸã ã«ãã®åç©è©Šéšãªã®
ã§ããïŒãã³ãºã»ãªã¥ãŒãšãã·ã¥ïŒ[302]
æ°ããåžå Žã®éæ
ã¯ã¯ãã³ãã©ã®æ§ã«ãåãªãçŸããããšããããšã«ã€ããŠçè§£ããåç¹ãšãããããéèŠ
ãªã³ã³ã»ãããšã¯ããæŽå²äžã¯ãããŠãå»è
éã¯ãã¯ãç
人ã ãã«ã¿ãŒã²ãããçµããªããŠ
ãè¯ããªã£ãããšããããšã§ããã¯ã¯ãã³ã®ãé°ã§ãããŸãå»è
éã¯ãŸã£ããå¥åº·ãªäººã
ãŸã§ãããå¥åº·ç¶æã®ããã«æ³šå°ãå¿
èŠã ããšäž»åŒµããããšããŠããŸãã
ãããªä¿¡ããããªãã»ã©éç§åŠçãªäž»åŒµãéãããã«ã¯ããªã«ãç¬ãæãªãããé€ã®æ§ãª
ãã®ãå¿
èŠã§ããïŒããã§å»è
éã¯ããŸãã§èªåéã¯ç§åŠçã®æ¯é
è
ã§ãããçŸäžä»£ã«ã
ããå¥åº·ã®ç§å¯ã®ãã¢ããããéµã§ãçºèŠãããã®æ§ã«æ¯ãèããã芪åã«ãäžè¬åžæ°ã«
ãããããåããŠãããã ããšããèå±
ããã£ãæ¯ããããŠããŸãããã ãæéã€ãã§ã
ã§ããã
ã¯ã¯ãã³ã«ã¯ãäœãå
¥ã£ãŠããã®ãïŒ
ãžã§ããŒãšãã¹ããŒã«ã«ããæåã®ã¯ã¯ãã³åçš®ãããã³ææ°ã®ã¯ã¯ãã³åçš®ã§ããããã
ã匱ãããäŒææ§ã®ç©è³ªãå«ããç
æ°ã«ããã£ãåç©ïŒçãé³¥ãçŸãç¿ãã¢ã«ã¢ããã人
éã銬ïŒã®è
ãããã现èçµç¹ããã€ãããããã®ã«éããŸããããã®ä»ã®çš®é¡ã¯ãæ¯æ§
ã®äŒæ§ç
ç©è³ªãã¡ã¿ããŒã«é²è
å€ãšã¢ã«ãããŠã ã§äžåãããæ¯æ§ç©è³ªã§ããïŒããŒããã
PïŒ[190]
å
šãŠã®ã¯ã¯ãã³ã¯ãã¡ã¿ããŒã«é²è
å€ãã¢ã«ãããŠã ãæ°Žéããšãã¬ã³ ã°ãªã³ãŒã«ãšã
ã£ãç©è³ªãå«ã¿ããããã®ç©è³ªã¯ã¢ãžã¥ãã³ãïŒæåæ§è£åŒ·å€ïŒãšãã婿ç©è³ªãšãåŒã°
ããŠããŸããïŒPhysiciansâ Desk Reference 2007ïŒ[16]
æ°Žéã¯ããã¡ããµãŒã«ã«å«ãŸããŠãããèŽåœçãªç¥çµé害ããèªå·±å
ç«æ©èœã®ç Žå£ãåŒã
èµ·ãããŸããã¡ã¿ããŒã«é²è
å€ïŒãã«ã ã¢ã«ãããïŒã¯çºããæ§ã®é²è
å€ã§ããïŒPDR p1383
[231]ïŒã¢ã«ãããŠã ã¯åŒ·åãªç¥çµæ§ã®æ¯ç©ã§ãã¢ã«ããã€ããŒçãããéãã«éãç¥çµé
害ããããããã®ã§ããïŒSehnert, Widman, Bernard, BlaylockïŒ[199,195,166,262]
ã¯ã¯ãã³ã®æŽ»æ§ç©è³ªãšã¯ãäœããã®ç©è³ªäžã«äœãããç
åèã§ãããããã§ 2007 幎㮠PDR
èªã«æãããããçŸä»£ã®ã¯ã¯ãã³ãå¹é€ããŠããç©è³ªã®ãªã¹ããèŠãŠã¿ãŸãããã[16]
人éã®å èå
ã®èºçްè 人éã®è¡æ¶²
ã¢ããªã«ã®ã¿ã©ãç¿ã®è
è ãžãããªã¢ã®å¹é€ç©
眹æ£ãã人éã®çµå现èçµç¹ 眹æ£ããåç©ã®çްèçµç¹ïŒç¿ããã¿ãåçãã«ããªã€ã
ãŠãµã®ããã¯ããªãã¢ã«ã¢ããïŒ
äžã«æãããªã¹ããèŠãŠããããŸãããªããŸãããïŒäœã®ç§åŠçæ ¹æ ããªãã«ããªããã
ãªã«ãããŸãããã¯ã¯ãã³æ¥çš®ãå®å
šã ãªã©ãå«ã°ããŠããã®ã§ããããïŒã²ãã£ãšãã
ãšããããã¯æã
人éãæã€ãåå§çãåå§æ°æçãªãæ»ãã åç©ã®äœã®äžéšãäœæ¶²ãæ®
骞ãªã©ã«å¯Ÿããè¿·ä¿¡çãªèå³ãšé¢ä¿ãããã®ããç¥ããŸãããããããä¿¡ä»°ã¯äººé¡ã®å§ãŸ
ãããç¶ããŠãããã®ã§ãããããªã¹ãæãããã®ä»æ®ã©ã®ç°æåŸã®æåã«ãããŠãèšé²
ã«æ®ã£ãŠããŸãããããã¯ãåå§çãªè³è£ã«å»ã¿èŸŒãŸããŠãããšããèšããã§ãããã
å»åŠäžã®èãã§ã¯ãæ£è
ãã¯ã¯ãã³æ¥çš®ãšãã[ã¡ãããšã³ã³ãããŒã«ããã]ç¶æ³äžã«ãã
ãŠç
æ°ã®ã匱æ§ã®ãã¿ã€ãã«ããã£ãå Žåã«ã¯ãèªåèªèº«ã®äœå
ã§ãã®ã¯ã¯ãã³ã«å¯Ÿãã
æäœãçã¿åºããŠã次ããã¯ããããæäœãæµã®é¡ãã©ããªã ã£ãããèŠããŠããŠããã
ããçŸãããå±éºãå¶ããããã«ãªãã ãããšãããŠããŸãã[360]
ããããããã ãã§ã¯åãŸããªãäºå®ãããã®ã§ãã
æå / æäœïŒåçŽåãããèãæ¹
ãŸã第äžã«ãã¯ã¯ãã³ã®æäœãšãããã®ãå
ç«ã®å
šãŠã§ãããã©ããããšããç¹ã§ããã
çã®æèŠãäžèŽããŠããèš³ã§ã¯ãããŸãããCitizens for Health Care and Freedom ã®ãã£
ã¬ã¯ã¿ãŒã§ããã¢ã©ã³ã»ãã£ãªããã¹ãªã©ãæ°ã
ã®ç ç©¶è
ã[245]
ãèªç¶ãªå
ç«ãšã¯ãäœã®æ§ã
ãªæ©èœãå
èãé¢ä¿ããŠã§ããè€éãªçŸè±¡ã§ãããæäœç©è³ª
ãšãã£ãã人工çãªèªå ç©ã§ç䌌ã§ãããã®ã§ã¯ãªãã
ãšè¿°ã¹ãŠããŸãããããŠãããã¯æè¿ã«èšããå§ããããšã§ã¯ãªãã1950 幎ã«ãã¢ã¬ãã¯ã»
ããŒãã³å士ãšããè±åœå»åŠæ©é¢ïŒBritish Medical CouncilïŒã®ç ç©¶å¡ãããžãããªã¢ã®çœ¹
æ£ãšæäœã®æ°ã«ã¯äœã®é¢é£ããªãããšããããšãçºèŠããŠããŸãã[203]ãã®ç ç©¶å¡ã¯åã
äœå
ã®è¡æ¶²ã«æäœãäœãåºãæ©èœããããªãåäŸéããäŒæç
ã«ããã£ãŠãä»ã®çãšåæ§
ã«ç
æ°ãæ²»ããŠããããšãåºæ¥ãããšããäºå®ããèªããŠããŸããïŒNullïŒ[220]
ããã« 1972 幎ã«ã¯ãžã§ã©ã«ãã»ãšãŒãã«ãã³å士ãããå
ç«æ©èœãšã¯äžè¬ã«èšãããŠãã
æåïŒæäœãšããèãã§ã¯èª¬æããããªããã®ã ãããšããçºèŠãããŠããŒãã«è³ãåããŠ
ããŸãããšãŒãã«ãã³ã¯ãäœäžçŽãã®éã«äººéãšããŠé²åãéããçµæãç§éã®äœã«ã¯èª
çã®æç¹ã§äœçŸãšèšãæäœãååšããŠãããšããäºå®ã瀺ããã®ã§ããïŒ[131]p.17ïŒ
èªç¶ãªå
ç«æ©èœãšã¯ãã¯ã¯ãã³ã®å¶æ¥ãã³ãç§éã«èª¬ããŠãã話ããããéãã«è€éãªèª²
é¡ã§ããåŸã«æãã AIDS ã®ç« ã§ãåããããã«ãããããæåïŒæäœãšãã£ãèãã¯ã
èªç¶ã倧å¹
ã«åçŽåããããèŠè§£ãªã®ã§ããããããã»ãŒã«ã¹ãç®çãšããåºåã¯åžžã«ããæ¬
åœã®ããšãããªããããšãã£ãŠãããåºæ¥ãäœãè©±ãæšãŠãããšã¯ãªãããšããæ¹éã§é²
ããã®ã§ããç
åèã®èª¬ãšåæ§ããã®æåïŒæäœèª¬ããŸãããã¹ããŒã«ã®æä»£ãã人é¡ã®
æ»
äº¡ã®æ¥ãŸã§ã人é¡ã®è¡æ¶²ã«å€§éã®ã¯ã¯ãã³ã泚å
¥ããŠããããšããå売ã®å¿
èŠæ§ãå¯èœ
ã«ããŠããããæ Œå¥œã®æçŸ©ã ã£ãããã§ãã
èªç¶ãªå
ç«æ©èœ
èªç¶ãªå
ç«ãã€ããã«ã¯ãå®éã«ãã®ç
æ°ã«ããã£ãŠæ²»çããããæãã¯å°ãªããšããã
ã®ç
æ°ãããµããŠããç°å¢ã«ããããšããæ¡ä»¶ãå¿
èŠã§ããäŸãã° Merck Manual ãšã
ãæ¬ã® 1098 ããŒãžã«ã¯ã颚ç¹ã«é¢ããŠãïŒïŒïŒ1956 幎以åã«çãŸãã人ã
ã¯ã以åã«äŒæ
ããããšããããããå
ç«ãããã颚ç¹ã«ã¯ããããªããšãããŠããããšæžããŠãããŸãã
[280]ããã¯ã€ãŸããèªç¶ãªå
ç«æ©èœã§ããå®éã®äŒæç
ã®å Žåã«ã¯ããã®åŸ®çç©ã¯äººã®éŒ»
åãåããããŠèºã®èªç¶ãªäœå
é²åŸ¡ã®æ©èœãéãéããªããŠã¯ãªãããããã§åããŠéã
ãããã°è¡æ¶²ã«ãŸã§ãã©ãçãããšãåºæ¥ãŸããããããéçšã«ãããŠãè¡æ¶²ã«ãã©ãç
ããŸã§ã®éã«ããã®åŸ®çç©ããŸã è§£æãããŠããªã幟ã€ãã®çååŠåå¿ãäœå
ã«åŒãèµ·ã
ããèªç¶ãªå
ç«æ©èœãèªå ããŠããå¯èœæ§ã¯ã倧ãã«èããããã®ã§ãã
ã¯ã¯ãã³ãçŽæ¥è¡æ¶²ã«æ³šå°ãããšããè¡çºã¯ããè¡æ¶²ã«çªç¶ç°çç©ãæ··ããããšã§äººå·¥çã«
èªçºãããŠåºæ¥ãæäœããå
ç«ã®å
šãŠã§ããããšããããŸã£ããæ ¹æ ã®ãªã仮説ãããšã«
ããŠããŸãããããããã®ä»®èª¬ãééã£ãŠããããšã¯ãã¯ã¯ãã³ã«ãã£ãŠã¯è¿œå æ¥çš®ããª
ããã°ãããªãããšããæ±ºãŸããããåããããšã§ããããæ§ã
ãªç 究調æ»ã«ãããã¯ã¯
ãã³æ¥çš®ãåãã人ã
ã®æ¹ããæäœã®æ°ãäœããªã£ãŠããŸã£ãŠãããšããçµæãåºãããŠ
ããŸããïŒGunnïŒ[303]
æ¯ãªãèªç¶ã«åãã€ã
åžéããããšããç¶æ
ã¯ã€ãŸãåæ»ç¶æ
ã«ãããããšããããšã§ããã¯ã¯ãã³ã«å«ãŸãã
äŒæç
ã®èã¯ãéåžžã«èããããŠããŠã99,9ïŒ
ã®äººã
ã«ã¯ççåå¿ãèµ·ãããªãçšåºŠã«åŒ±ãŸ
ã£ãŠããŸããããããèªåã®äœå
ã«èãããããŠã€ã«ã¹ããã¯ããªã¢ã泚å
¥ããããšãã
è¡çºã¯ãèªç¶ãæ¬æ¥ãªãã°ç§éã«æ±ºããŠèš±ãããšã®ãªãè¡çºã§ããããã¯ãè¡æ¶²ãšãã貎
éãªèåãæ±ããŠããŸã£ãããšãªã®ã§ããããããæ··å
¥ããç
åèãèããããŠããªãç¶
æ
ã ã£ããªããèªç¶ã®å
ç«æ©èœã¯ç·åçã«äœåããŠãããã䟵å
¥è
ãæ»æããŠè¿œãåºããŠ
ããã®ã§ãããç§éã¯èªç¶ã®å
ç«æ©èœãã ãŸããŠããã¹ãŠã®ç°ç©ãæé€ãããšããã·ã¹ã
ã ãäœåãããªãããã«ããŠããŸã£ãã®ã§ãã
ããŒããŒã倧åŠã®å»åŠç§ã®ææã§ãããDr.ãªãã£ãŒãã»ã¢ã¹ã³ãŠã£ããã¯ãã¯ã¯ãã³ãç
ã¿åºãããéçšãšã¯ãã¯ã¯ãã³ãã©ãã©ãèããŠå
ç«æ©èœã®åå¿ãåŒãèµ·ãããªãçšåºŠãŸ
ã§åŒ±ããããšã ãšèª¬æããŠããŸããããã§åé¡ã«ãªãã®ã¯ãããããŠå§¿ãå€ããããç
å
èã¯ãæ¬æ¥ã®å§¿ã§ãªãã°æ±ºããŠèªç¶ã«ã¯å
¥ã蟌ããã¯ãã®ãªãçšãç§éã®çްèçµç¹ã®ããª
ã奥ã«ãŸã§äŸµå
¥ããŠããŠããŸã£ãŠãããšããç¹ã§ããããããå Žæã«æœãã§ããããã®ç
åèã¯æœåšããã¢ã¬ã«ã²ã³ïŒã¢ã¬ã«ã®ãŒãåŒãèµ·ããåå ç©è³ªïŒãšãªã£ãŠãããŸããé²åºŠ
ã®ç©ãããªãŠã€ã«ã¹ããšãã£ãå
·åã§ãããããŠäœãããã£ããã§ãããã®ãŠã€ã«ã¹ã掻
æ§åãããšãäŸãäœå¹Žãçµã£ãŠããå Žåã§ããããããŠå¥¥ã«ããŸãããŠãã埮çç©ã¯äœå
ã®ã©ã®å Žæãã©ã®åšå®ã«ãèªç±èªåšã«ç¹æ®ããéå€§ãªæ©èœéå®³ãæ··ä¹±ãåŒãèµ·ããããã
ãåå ã§é床ã®äŒæç
ã«ããã£ãããæ»äº¡ããããšããããã®ã§ãããã ãããããã®ã¯ã
ããšããšã®äŒæç
ã§ã¯ãããŸããã[192]
ã ããããã誰ãã¯ã¯ãã³ãåå ã§æ»äº¡ãããšèšŒæããããšãåºæ¥ãªãããã§ãããã¯é
åžžã«å¥œéœåãªããšã§ãã
ã¯ã¯ãã³æ¥çš®ãšããè¡çºã¯ã人é¡ã®é²åã®éã倧ããèžã¿å€ããè¡çºã§ããèªç¶ã¯çŸäžå¹Ž
ãã®å¹ŽæããããŠããããã䟵å
¥ç°ç©ã«ççåå¿ãããããŠæŠããšããå
ç«æ©èœãçã¿åº
ããŸãããããã¯ãéžå¥ããŠæŠããšãããçãæ®ãããã®æ©èœã§ããããããã® 1 äžçŽã®
éã«ãå»è
éãçªç¶ãããããäœäžçŽãã€ã¥ããŠããèªç¶ã®ç¥æµãç¡èŠããŠåœããåããš
ããæ§ã«æ¯èã£ãŠããŠè¯ããã®ã§ããããïŒ
ãŠã€ã«ã¹ãšããè² æ
äžèšã«ã¯ãã¯ã¯ãã³ã®è£œé éçšã§äœ¿ãããŠããæ¯æ§ã®åææã«é¢ãã諞åé¡ãæããŠããŸ
ãããããã§å¿ããŠã¯ãããªãããšã¯ãäŸãããããæ¯æ§ã®ç©è³ªãã¯ã¯ãã³ãããã¹ãŠå
ãé€ãããšããŠããã¯ã¯ãã³èªäœãããéããæãé倧ãªå±éºã¯æ¶ããªããšããããšã§ãã
ã€ãŸãããŠã€ã«ã¹ãè² æ
ãããšããå±éºã§ããã¯ã¯ãã³æ¥çš®ã«ãã£ãŠäººã®è¡æ¶²å
ã«æ³šå
¥ã
ããããã¹ãŠã®ç°è³ªãªãŠã€ã«ã¹ã埮çç©ã®åèšéãããã®äººã®ãŠã€ã«ã¹è² æ
éã«ãªãã®ã§
ãã
çããããåç¥ããšæããŸããããŠã€ã«ã¹ã¯åªäœãšãªã现èã® DNAãšããŸãçµåããããš
ããåä»ãªèœåãæã£ãŠããŸããç§é人é¡ã®ç·åç㪠DNA ã¯ã人éã²ãã ãšåŒã°ããŠããŸ
ããïŒBishopïŒ[214] æã
ã®åäŸéã®è¡æ¶²ã«ãäœå¹Žãã®éãå€åœ¢ããæªç¥ã®ç°ç©ãã©ãã©
ãæ··ããŠããããšã¯ããã®äººéã²ãã ã確å®ã«å€åœ¢ãããŠããŸãã§ããããæã
ã®çç©çš®
ã«ãããããããé·æçãªå€åã«é¢ããŠã¯ãããŸã ç ç©¶ããããŠããªãæªç¥ã®é åãšãªã
ãŸãã
çŸåšã¢ã¡ãªã«ã®å°±åŠå
㯠68 çš®ã®ã¯ã¯ãã³ãåããããšã«ãªã£ãŠããŸããããããããã¯ã¯
ãã³ã®æ°ã¯æãŠããªãå¢ããŠããæ§åã§ããäœåçš®ãã®ã¯ã¯ãã³ããããšã容æã«ãªã¹ã
ã«ä»ãå ããŠããŸãèšç»ããææ¡ãããŠããŸããããã§ã¯ãããããã¯ã¯ãã³ã FDA ãæ¿
èªããéã«ããã®ç¡æ°ã®ç
åèãšããè² æ
ãçºéäžã®å
ç«æ©èœã«åãŒã倧ããªå±éºæ§ãšã
ããã®ãèæ
®ãããŠããããšèšããšãé©ãããšã«ãå
šãèããããŠããªãã®ã§ãïŒCDC ãã
FDA ããNIIH ã§ããããã®å±éºæ§ã«ã€ããŠãŸã£ããç¡é¢å¿ã§ããããã«ãç§åŠçãªé¢ã«
ãåé¡ããããŸããåäŸãäºé²æ¥çš®ã®æ¥ã«ãæ¥çš®ãåããããªãã£ãå Žåãéåžžã©ã®ãã
ãªåŠçœ®ãåãããã§ããããïŒå€§æµã®å Žåãæ¬¡ã®äºé²æ¥ç𮿥ãŸã§åŸ
ã¡ãŸãããããã§ã©ã
ããããšãããšãåã®åãšåããã2 ååã®ã¯ã¯ãã³æ¥çš®ãã1 åã§å
šéšåããããŠããŸã
ã®ã§ãïŒå€ããšãã«ã¯ããªããš 14çš®ã®ã¯ã¯ãã³ããã£ãºãã«åããããããããšããããŸ
ãããããªç¡éç ²ã§ãéç§åŠçãªè¡çºãæ®éã«è¡ãããŠããŠãããã«ã¯äœã®å®å
šæ§ã®è©Šéš
ããããŠããªããšããç¶æ³ã§ãã
å®å
šãšè² è·
äžèšã«ã¯ãæ¯å¹Ž 16 åååãã®æ³šå°ããã©ã®æ§ã«ããŠããã®è¡æ¶²ã«åºãããŠãããã瀺ããŠ
ã¿ãŸãããã¯ã¯ãã³ã®å¶æ¥ç€Ÿã¯ããŠã€ã«ã¹ã®è² æ
ã«ãã DNA ã®é·æçãªå€åœ¢ã®åé¡ã«ã€ã
ãŠã¯ããŸã£ããç¡èŠãããŠããŸããPDR ã§ãããããã®ã¯ã¯ãã³ã«ã€ããŠèŠãŠã¿ããšãæ¬
åœã«ã·ã§ãã¯ãªããšã§ãããããããã®ã¯ã¯ãã³ã®çºããæ§ã«ã€ããŠãäœã®æ€æ»ãããŠã
ãªãããšçç£è
åŽãã¯ã£ãããšè¿°ã¹ãŠããã®ã§ããã€ãŸããåçš®ã®ã¯ã¯ãã³ããçã®åå
ã«ãªããã©ããã確ãã«ã¯åãããªãããšäœã£ãåŽã®åœŒããèšãæŸã£ãŠããããã§ãïŒ[16]
äžæ»ã®çްèç³»å
幎æããããŠã¯ã¯ãã³ã®æµããä¿ã€ããã«ãªãããŠãããåãè¡æ¶²çްèãç¹°ãè¿ãã€ãªã
ãŠãããäžæ»
ã®çްèç³»åã®äœ¿çšã¯ããžã§ããŒã®æä»£ãããã£ãšã¯ã¯ãã³ç£æ¥ã®éã§ç¶ãã
ããŠããè¡çºã§ãããããã«å¯ŸããŠã¯å³ããéé£ã®å£°ã倿°äžãã£ãŠããŸãã
ïŒThyagarajan[323]ïŒäžæ»ã®çްèç³»åãäœãåºãããšãšãçã®çè
«ã®çºçãšã®é¢é£æ§ã®å¯
èœæ§ããæããã«ãªã£ãŠããã®ã§ãã(McReardon[128])
ãããã»ã³ã¬ã³[173]ã¯ã¯ã¯ãã³ã«é¢ããåªããèšäºããããŠããŸããããã®äžã§ã¢ã¡ãªã«
ã®ã¯ã¯ãã³æ¥çš®ã 2 åã«ãªã£ã1960 幎ãã 1980 幎ã®éã«ãåäŸã®çæ»äº¡çãæ¥å¢ããã
ãšãææããŠããŸãã
ã¯ã¯ãã³æ¥çš®ãå§ãŸã£ã 1902 幎以éã®ã¢ã¡ãªã«ã«ãããçæ»äº¡çã®å€åã¯ãã€ãã®è¡šã§ã
ãããŸãã[195,338]
3 åã®ææ
ã¯ã¯ãã³ã«å¯ŸããæåŠåå¿ã¯ã3 çš®é¡ã«åããããŸãã
峿ã®åå¿ïŒ æ¥çš®ã® 2ïŒ3 æ¥ä»¥å
ã«ãä¹³å
ãæ»äº¡ããããæªãçç¶ãã§ããªã©ã®å Žåã
é
å»¶åå¿ãããã³æœåšçãªåå¿ïŒ äŸãã°ã¯ã¯ãã³ã«å«ãŸããæ¯æ§ç©è³ªãè³ã«äœã¿çãã
ç¥çµæ§ã®ç
æ°ã®åå ãšãªãããæ°å¹ŽåŸã«åããŠçç¶ãã§ããããªå Žåã
ã²ãã ã®ç Žå£ïŒ ã¯ã¯ãã³ãå«ãç°ç©ãæã
ã® DNA ãå€åœ¢ããããããåå ã§äººãçã«ãª
ã£ãããããã«æªãããšã«ã¯ã人éã²ãã ãšããæã
ã®çš®ã® DNA ãäžæŠã«åŒ±ãŸããããšã
ã£ãåå¿ã
ãã® 3 çš®ã®æåŠåå¿ã®å
ã3 çªç®ã®åå¿ããã³ããã«æªæ§ã®åå¿ãšèšããŸãããŽã£ãšã©ã¯ã
ããã³ããŒæ©ã®äŸã䜿ã£ãŠè¡šçŸããŠããŸããæ¯å¹Ž 16 åååã®æ³šå°ãåäŸéã® DNA ã«æã
ããŠããããšããããšã¯ãã³ããŒãããã®ãåã³ããŒãããããããã«ã³ããŒããŠããæ§
ãªãã®ã§ããã€ãŸãã人éã²ãã ãèããŠããã®ã§ããããããè¡çºã¯ãç§é人éãšãã
çš®ã«æ¥µããŠé倧ãªåœ±é¿ãäžããŸããïŒScheibnerïŒ[255]
ãŽããšããºãã®é¢ä¿
ãã 1 ã€ã®åé¡ãšããŠã¯ãç
åè説èªäœãééãã§ãããããããã¯ã¯ãã³ã«å«ãŸããŠã
ãã°ãèãããã®å¯Ÿè±¡ãšãªãç
æ°ã®åå ã§ã¯ãªãããšããããšã§ããããºããåå ã§ãŽã
ãããã®ã§ã¯ãªãããŽããæŸçœ®ãããŠããçµæãšããŠããºãããããŠããããšããåçãš
äžç·ã§ïŒJensen,[240]ïŒç
åèãšããã°ãèãåå ã§ç
æ°ã«ãªãã®ã§ã¯ãããŸãããããã
ãã°ãèã¯ããã äœã¿å¿å°ã®è¯ãå Žæãæ¢ããŠéãŸã£ãŠããã ãã§ããïŒCarrel[298]ïŒã€ãŸ
ãããŽãå±ããã®ãããªååšã§ããããããç
åèãšãã埮çç©ã¯ãç
æ°ã«ãªã£ãŠããå°
ã§ã¯ãã£ãŠããç
æ°ã®åå ã§ã¯ãªãã®ã§ãã
ãã®äºå®ã¯ãæåŸã«ã¯ãã¹ããŒã«ã§ããèªããŠããŸãã圌ããããŸã§å€§äºã«äŒããŠããç
åè説ããã€ããããŠãæ»ã®åºã§å±ããæå¥ã¯ãä»ãŸã§ã§æãé »ç¹ã«åŒçšãããŠããã»ãª
ãã®ïŒã€ã§ãã
ãå
šãŠã¯å é å°åž¯ã®è³ªã«ããã£ãŠããïŒç
åèãªã©äœã§ããªããã[191]
ããã§ãããéå²ãã®ããã«ãç§éã¯æ¬¡ã®ãããªèª€ã£ãããšãæ£åœãšããŠåãå
¥ããããš
ããŠããã®ã§ãã
ïŒïŒç¹å®ã®ç
åèãåå ã§ãç¹å®ã®ç
æ°ã«ãããã
ïŒïŒããã§ç
æ°ã®åå ã§ããªãã®ã«ãã®ç
åèã®èãããã®ããçŽæ¥çããã®è¡æ¶²ã«æ³šå°
ããŠããã®ç
æ°ã«å¯ŸããŠå
ç«ãã€ããããšã«ããã
åè¡åœã«ãããŠã¯ãããã¯ã¯ãã³ã®é壿¥çš®ãèªå¯ãããåã«ãé·æçã«æ€æ»ãè¡ãªãã
ãšã¯ã»ãšãã©ãããŸãããäŸãã°é¢šç¹ã¯ã¯ãã³ã¯ãã£ã 28 æ¥éã®æ€æ»ãããã ãã§èªå¯ã
ããŸããããïŒThrough a Glass [116]ïŒæ°Žç±ç¡ã¯ã¯ãã³ã¯ãã£ã42 æ¥éã®ãã©ã€ã¢ã«è©Šéš
ãããã®ã¿ã§èªå¯ãããŠããŸãã[88] ããããã¯ã¯ãã³ã®é·æçãªå¹æã«é¢ããŠããäžå
ãã©ããŒã¢ãããããªããŠã OK ãªã®ã§ããã ãããããã¯ã¯ãã³ã¯åžžã«å€æŽããããæ°
çš®ã®ãã®ãšåãæ¿ãããããããŠããããã§ãåäŸéã¯äžåºŠè¯ãå®éšçšã¢ã«ã¢ãããšãã£
ãæ±ãã§ãã
å
ç«ïŒèªç¶ VS. 人工
ããã§é ã«ãããŠããã¹ãç¹ã¯ãåäŸãç
æ°ã«ããããšããã®åã®äœã§å
ç«æ©èœã·ã¹ãã
ãæ°ããæ§æãããŠãèµ·åãå§ãããšããããšã§ããæ°æ¥éãããçšåºŠå
·åãæªããªãã
ããããŸããããäžèšã«ãã衚ã§ãåããããã«ã倧æµã®å Žåã¯ç
æ°ãæ²»ããŸãã匷ãè¬
ãã¯ã¯ãã³ã«éªéããããããäºãè€éåãããããšãªããäœãç¬èªã®åã§ãã®ç
æ°ãé
æ²»ããæ¹æ³ãèŠã€ãããšãå°æ¥ã«ãããŠäžçã®éããã®åã¯ãã®ç¹å®ã®ç
æ°ã«ã¯ããããª
ããªããŸãããã®åã®äœã¯ããã®ç
æ°ã«å¯ŸããŠã®éæ²»ã®ä»æ¹ïŒå
ç«ã身ã«ä»ããããšã«ãª
ãããã§ãããã®æ§ã«ãè¬ã䜿ããã«äœãç¬èªã§éæ²»æ³ãèŠããããšãèªç¶ãªå
ç«ãã€ã
ããšã«ãªããŸãããããšäœã¯ãæå®³ãªç°å¢ãã身ãå®ãããã®ãçæ°ãããæ°žé ã«äœ¿ãã
æŠåšãæã«å
¥ããŸããã ãããããã¯ã¯ãã³æ¥çš®ãåããŠããªãåäŸéã¯ãäžçã®éã«æ°Ž
ç±ç¡ã« 1 åããããããªãã®ã§ããäœãèªåã§æŠåšãå¢ãããŠããã°ããã»ã©ããã®å倧
人ã«ãªã£ããšãã«æªãç°å¢ãç
æ°ãã身ãå®ã£ãŠãããèœåãåãã£ãŠããããšã«ãªãèš³
ã§ãã
èªç¶ãªå
ç«ã¯ãæ¯èŠªããèå
ã«ãåãç¶ãããŸãã
èªç¶ãªå
ç«ãããå¯äžã®ã»ããšãã®å
ç«ãšèšããŸãããããŠãã®å
ç«ãšã¯ãç
æ°ã«çŽæ¥é¢
ãããã£ã(眹æ£ãã)åŸã«ã®ã¿ãã€ããã®ã§ãã
ããã«å¯Ÿãã人工çãªå
ç«ãšã¯ããã®ç
æ°ã®çç¶ãè¬ãã¯ã¯ãã³ãå©çšããŠäººå·¥çã«æã
ããšããæå³ã§ããå³ã錻氎ãåºãã®ã¯ãäœã䟵å
¥è
ãæéãããæé€ã·ã¹ãã ã§ãããã
錻ã¥ãŸãã®è¬ã峿¢ããççæ¢ãã®è¬ã䜿ããšå€éšããã®äŸµå
¥ç©ãæ¬æ¥ãªãã°è¡ããã¯ã
ã®ãªãäœã®å¥¥åºã«ãŸã§éããŠããŸãããšã«ãªããŸããå³ã錻ã¥ãŸããç
æ°ãã®ãã®ã ãšåœ
ã£ãŠäž»åŒµããå»è
ãã¡ã¯ã次ã®ç¹ãèŠéãããŠããŸãã
ãïŒïŒïŒããããæå§ã¯ãäœãææ³ããå¿
èŠããããã®ãå€ã«åºããªãããã«éªéãããŠã
ãŸãïŒïŒïŒãïŒJames, p42ïŒ[188]
ã¯ã¯ãã³ã«ãã£ãŠã人工çãªç
åèãŠã€ã«ã¹ãè¡æ¶²ã«æ³šå
¥ãããŸãã仮説ãšããŠã¯ããã®
èãããããŠã€ã«ã¹ã«å¯ŸããŠäœãæäœãçã¿åºããããããŠåºæ¥ãæäœãããã®åŸäžçã®
éãã®ç
åèãŠã€ã«ã¹ã䟵å
¥ããŠããéã«ã¯ãããçºèŠããŠéæ²»ããŠãããããšãããã®
ã§ãã
ãããããã®ãããªå
ç«ãšã¯ã人工çã§ãããã€ãŸãå®éã«ã¯äžé©åã ãšèšããŸãããªã
ãªããã¯ã¯ãã³ãäœã«äžããŠããå
ç«ãŸããã®æ©èœãšã¯ãèªç¶ã«çºçããç
æ°ã«å¯ŸããŠã®
å
ç«ã§ã¯ãªãã人工çãªãç§åŠè
ãç ç©¶æã§äœãäžããæ³šå°çšã®ç
æ°ã«å¹ãã ãã®ãã®ã
ããã§ãã
ã¯ã¯ãã³ã¯ãäœçŸååãäœäžå忝ã¹ãŠã¿ãŠããçåãäžèº«ã§ããã人éã®å
ç«æ©èœãã
ç
æ°ã®ãããæ¹ã¯ã1 人 1 人éããŸãããã®ç¹ããããåé¡ããããšèšããŸããã
ããã«ã人工çãªå
ç«ã¯ãæ¯ããèå
ãžãšåãç¶ãããããšã¯ãããŸããã
人工çãªå
ç«ã¯ãäžæçãªãã®ã§ãã
人工çãªå
ç«ã¯ãåŸã«å床åãç
æ°ã«ããããªã¹ã¯ãéåžžã«å€§ãããã®ã§ããç§åŠçã«ã
æå³äžæãªãè¿œå æ¥çš®ïŒbooster shotsïŒãè¡ãªãããŠããã®ã¯ãã®çç±ããã§ãã
ïŒMurphy[204]ïŒ
ã¯ã¯ãã³ã«ãã人工çãªå
ç«ã¯ãçŸä»£ã«ãããŠãæäººã«ãªã£ãŠããããšããšã®ç
æ°ãç°åžž
ãªåœ¢ã§çºçããããšããçŸè±¡ãåŒãèµ·ãããŠããŸããããã¯ãæäººã®é¢šç¹ãæ°Žç±ç¡ã®æ§ã«ã
éãã«æ·±å»ã§å±éºãªçç¶ã§ãã
æ°çš®ã®äŒæç
ãã€ããåºãããé壿¥çš®ã
ããããç°åžžãªåœ¢ã®äŒæç
ããããšããšã®äŒæç
ã«ããã£ãŠèªç¶ãªå
ç«ãã€ããŠãã人ã
ã«äžããå±éºæ§ã«ã€ããŠã¯ã誰ã話ãããšããŠããŸãããé壿¥çš®ãå§ãŸã以åã«ããçš
床ã®éãã¯ãããŸããã人éã¯å
šãŠã®äŒæç
ã«å¯ŸããŠéå£ã§å
ç«ãä»ããŠããŸããããã
ãããã¯ã200,000幎ãã®æéããããŠãã§ããå°ãèããŠèŠãŸãããããããŒããŒã æä»£
ã«çãŸããåäŸã®æã«é¢šç¹ã«ããã£ãŠãäžçã®å
ç«ãã€ãã人ãããã®äººå·¥çãªæ°çš®ã®ç°
åžžãªæäººåã®é¢šç¹ã«ãå
ç«ãããããšãããšãããã§ã¯ãããŸãããã©ãããŠã§ããããïŒ
颚ç¹ãšããäŒæç
ã¯äœäžçŽãã®ããã ååšããŠããç
æ°ã§ããããã®ç°åžžåã®é¢šç¹ãçãŸ
ããŠããã¯ããŸã 30 幎ãçµã£ãŠããªãããã§ããã¡ããã©ãæçç©è³ªã®æ°Ÿæ¿«ãã¹ãŒããŒãŠ
ã€ã«ã¹ãäœãåºããæ§ã«ãã¯ã¯ãã³æ¥çš®ãæ°ããäŒæç
ãäœãåºããŠããã®ã§ãããããã
é²åãšåŒã¹ãã§ããããïŒ
ã¯ã¯ãã³ã®è¿œå æ¥çš®ïŒå¹æã®ä¿é²çšïŒ
æåã®ã¯ã¯ãã³ãå
ç«ãä»ããŠãããçãªã®ã«ããªãåäŸé㯠1 幎åŸã«ãã 1 床åãæ¥çš®
ãããªããã°ãããªãã®ã§ãããïŒã§ã¯ã1åç®ã¯äœã ã£ãã®ã§ããããïŒå®ããããšãã©
ã®ã¯ã¯ãã³ã«é¢ããŠããã¯ã¯ãã³ã®å¹èœä¿é²çšã®è¿œå æ¥çš®ã广ã®ãããã®ã ããšèšŒæã
ãç ç©¶ã¯ãããŸã ãã€ãŠãããããšããããŸããã
ããïŒã€ã®çåããããŸããMMR ã 3皮混åãB åèçãH ã€ã³ãã«ãšã³ã¶ãªã©ã®æ°åã«
ãããæåã¯ãæ¯ååãç©ãæ¥çš®ããŸããã¯ã¯ãã³ã®çç£è
åŽã¯ãè¿œå æ¥çš®ã®ã¯ã¯ãã³ã¯ 1
幎ã»ã©ã§å¹æããªããªã£ãŠããŸããšçºè¡šããŠããŸããããããªããæåŸã«åããã¯ã¯ãã³
ãåäŸã«äžçã®éç¶ãå
ç«ãä»ãããšããç ç©¶ææã¯ãããã®ã§ããããïŒãããªãã®ã¯ã
ã©ãã«ããããŸããã倧äœã©ãããŠãæåŸãã 2 çªç®ã®ã¯ã¯ãã³æ¥çš®ã¯ 1 幎ã§å¹æãæ¶ã
ãŠãæåŸã«åããã¯ã¯ãã³æ¥çš®ã ããç¹å¥ã«äžçã®é广ãç¶ããªããŠããšãããã§ãã
ããïŒãããéèŠãªç¹ã§ããçç£è
ã¯ãã¯ã¯ãã³ã«ãã£ãŠäžçã®éå
ç«ãä»ããšã¯ã決ã
ãŠèšã£ãŠããŸãããPDR ãéããçç£è
åŽã®äž»åŒµãã¿ãŠããã¯ã¯ãã³ã®å¹åã¯éãããæ
éã§æ¶ããããšã¯ã£ããããŠããŸããäžçç¶ãããªã©ãšããã®å®£äŒãããŠããã®ã¯ãè¬ã
売ãæ
åœã®éšéïŒäŒç€ŸåŽãå®£äŒæ
åœã®æ¹ã§ãã
å
šãŠããèªåèªèº«ã«
å
ç«ãšã¯ãäœã®ååã® ID ãæç«ããä¿ã£ãŠããããã®èº«äœèœåã§ãïŒJames p105 [188]ïŒ
ïŒã€ãŸããããªãã®çްèã¯å
šãŠãããªãã® ID ãæã£ãŠããããšã«ãªããŸãããããå
šãŠãã
åã DNA ããæãç«ã£ãŠããã®ã§ãããããã®ã现èã®çµ±äžæ§ãä¿ããã®ã¯å
šãŠãå¥åº·ã
ä¿ããã®ã§ããéã«ãäœã现èã® ID ãä¿ã€ããšãéªéãããã®ã¯äœã§ããç
æ°ãä¿ããã®
ã§ãããã®ããç°¡åãªåºæºãåããã°ãã¯ã¯ãã³æ¥çš®ã«ãã人工çãªå
ç«ãããªãé·æç
ãªå¹æãæã€ããšãåºæ¥ãªãã説æãä»ãã§ãããã
ã¯ã¯ãã³ãäœãåºãããã»ã¹ã®å
šãŠã¯ãããäŒæç
ã®èãã©ãã©ã匱ããŠããããšãã£ã
ãã®ã§ããã人ã®è¡æ¶²ã«æ³šå
¥ããéã«ãäœããã®ã¯ã¯ãã³ã«åå¿ããªãçšåºŠãŸã§ããã®è
ã¯èããããŠãããŸããããã¯ã€ãŸãããã®èãéåžžã«åŒ±ããããŠããã®ã§ãäœãç°ç©ãš
ããŠæç¥ããããšãåºæ¥ãªãäœã ãšããããšã§ããã§ããããçããã®äœã®å
ç«æ©èœã¯ã
ãã€ãã©ããç°æ§ç©ã®ããã±ã質ã«åå¿ããããæ¹ã§ã¯ãããããã¯ã¯ãã³ã«åå¿ãããŸ
ãããäœããã ãŸãããŠããŸã£ãããã§ãã
æ®æ®µã®çæ
ç³»ã®äžã§ã¯ããã®ãããªåºæ¥äºã¯èµ·ããåŸãªãããšã§ãããããã¯ãŸã£ããäž
èªç¶ãªåºæ¥äºã§ãã[192]
ããã«å¯Ÿããèªç¶ã«çºããäŒæç
ã¯èããããŠããªãã®ã§ãäœã®å
ç«æ©èœã·ã¹ãã ãé çª
ã«èµ·åãããŠããã®ã«ååãªåŒ·ãããã£ãŠããŸãã
ä»äººã«èªè»¢è»ã®ä¹ãæ¹ãããããããã¬ãŒã¶ãŒåçãïŒD ã§èŠããããããšãæãããã¯
åºæ¥ãŸãããïŒãã¡ãã説æããããšã¯åºæ¥ãã§ãããããå®éã«ã¬ãŒã¶ãŒåçãèŠãã
ããã«ãªã£ãããåããŠããèªè»¢è»ã®ãã©ã³ã¹ãåãã«ã¯ã©ãäœãåããã°ããã®ããåŠ
ã¶ã®ã¯ã1 人 1 人ãèªåã§åªåããŠã¯ãããŠèº«ã«ä»ããã®ã§ãã
å
ç«ãããããšåãã§ããäœã«ãç¡çããæŒãä»ããããšã¯åºæ¥ãªãã®ã§ããäœãå®éã«ã
䟵å
¥ããç°ç©ãæç¥ããŠãããšæŠããæã¿ãèªåã®å
ç«èœåãã©ãçµã¿åãããã°ããã
ãç°ç©ãæç¥ããåãå²ãã§ãã£ã€ããããšãåºæ¥ããããèªåã§åŠãã§ãããªããã°ã
ããŸããããããããæ©äŒãäžããããå¿
èŠããããŸããããã«ã¯æéãåŽåãå¿
èŠã§ã
ããç
æ°ã«ãããå Žåã®æãããã§ããããããããéçšã¯ãçŸä»£ç§åŠã®çè§£ãã¯ããã«
è¶
ãããã®ã§ãããããããã§åŸãããå
ç«ãšã¯ãäžçã®éç¶ããã®ã§ãããããããã
å¯äžãæ¬ç©ã®å
ç«ãªã®ã§ãã
åäŸã®æã«åããã¯ã¯ãã³æ¥çš®ã¯äœåïŒ
9/11 äºä»¶ä»¥åã«ã¯ãæ¥çš®ãæå®ãããŠããã¯ã¯ãã³ã®æ°ã¯ãããšç°¡åã«åããããã«ãªã£
ãŠããŠã䞻㫠CDCã®ãŠã§ããµã€ãã«èŒã£ãŠããã¯ã¯ãã³æ¥çš®ã®äºå®è¡šãèŠãã°ããã ãã§
ããã[15]ãããã9/11 äºä»¶ä»¥éã«ã¯ãæ°çš®ã®ã¯ã¯ãã³ã®è¿œå ãæ§åã¯ã¯ãã³ã®åé€ãªã©ã
é©ãã»ã©å€æ§ãªå€æŽãæ°ã¶æããšã«è¡ãªãããããã«ãªããŸãããããã«æ··ä¹±ã«æè»ãã
ããããã«ãæè¿ã§ã¯äºå®è¡šãïŒã€ã ãã§ã¯ãªãã幎霢ããšã«åããŠãããã«ããããŠã
ãŸãã以åã«ã¯ãæªæå¹Žã«æšå¥šãããäºé²æ¥çš®äºå®è¡šãšåŒã°ãã衚ãããã ãã§ãèªçã
ã 18 æ³ãŸã§ã察象ãšãããŠããŸããããããã 2008 幎ã«ã¯çªç¶ãåäŸåãã®äºå®è¡šãé
幎æã®äºå®è¡šãè¿œå æ¥çš®ã®äºå®è¡šãæäººåãã®äºå®è¡šããããŸãã§ 20幎åãããã£ãšãã
ãããªé¡ãããŠCDC ã®ãµã€ãã«äžŠãã§ããã®ã§ãããããã®è¡šã¯éåžžã«èªã¿ã«ãããäŸå€
ã®ç¹èšãéè€äºé
ãæ²¢å±±ãããŸããããããæ°ããæ²ç€ºã®ä»æ¹ã¯äž»ã«ãåäŸã«æ¥çš®æå®ã
ããŠããã¯ã¯ãã³ã®æ°ãæ¥æ¿ã«å¢ãç¶ããŠãããšããäºå®ããããã«ããããŸããããã«
èãåºãããã§ãããããããŠãæäººçšã倿°è¿œå ãããŠããããšããããŸãããªããã°
ãããŸããããïŒ
次ã®ããŒãžã«ã¯ãäŒæç
鲿¢ã»ã³ã¿ãŒã«ããã200ïŒå¹ŽåºŠã®äºå®è¡šãèŒããŠããŸããããã
ã«ã¯ãªããšïŒïŒåãã®ã¯ã¯ãã³æ¥çš®ããåäŸæä»£ã«åããæ¥çš®ãšããŠæšå¥šãããŠããŸãã
[15]
2009 幎床 äºé²æ¥çš®äºå®è¡š
èªçæïŒ B åèç 1ïŒã¯ã¯ãã³ã®æ°ïŒ
1ïŒ2 ã¶æ B åèç 1
2 ã¶æ 3 皮混åãããªãªãPCVãRotateq 7
4 ã¶æ 3 皮混åãããªãªãHiBãRotateq 7
6 ã¶æ 3 皮混åãHiB,Rotateq 6
6 ã¶æïŒ18 æ³ ã€ã³ãã«ãšã³ã¶ ïŒæ¯å¹ŽïŒ 1
6 ã¶æïŒ18 ã¶æ Båèçãããªãª 2
12 ã¶æïŒ15 ã¶æ MMR HiB, PCVãVaricella 6
12 ã¶æïŒ23 ã¶æ A åèç ïŒ2åïŒ 2
15 ã¶æïŒ18 ã¶æ 3 皮混å 3
çåŸ 18 ã¶æãŸã§ã«ã¯ã¯ãã³æ¥çš® 36 å
4 æ³ïŒ6 æ³ äžç𮿷·åãMMRã ããªãªãVaricella ïŒ
11 æ³ïŒ12 æ³ ç Žå·é¢š ãžãããªã¢ çŸæ¥å³ HPVïŒ3ååïŒ
MCV4 7
ã¯ã¯ãã³æ¥çš® èš ïŒïŒå
è³æïŒäŒæç
鲿¢ã»ã³ã¿ãŒ www.cdc.gov [15]
ãã®äºå®è¡šã¯ã2007 幎åãã«ãã£ãšå°å»ã¿ãªã¹ã±ãžã¥ãŒã«ã«ãªããããã«9/11 ã®äºä»¶ã®åŸ
ã«ã¯ããé »ç¹ã«ãæã«ã¯2ïŒ3ã¶æããšã«äœããã®å€æŽãä»ãå ããããŠããŸãããããã
远å 㯠2007 幎ã ãã§ã3 åãè¡ãªãããŠããŠã2008幎ã«ãæŽã«è¿œå ããããŠããŸãã
ãã®è¡šãèŠããšãã¢ã¡ãªã«ã®åäŸéãäžçäžã§ 1 çªå€ãã®ã¯ã¯ãã³æ¥çš®ãåããŠããã ã
ã§ãªããæŽå²äžæãã¯ã¯ãã³æ¥çš®ããããŠããååšã ãšèšãããšãããããŸããäžçäžã©
ãã«ããã¢ã¡ãªã«ã»ã©æ¿ããã¯ã¯ãã³æ¥çš®ã®ããã°ã©ã ãçµãã§ããåœã¯ãããŸããã
ãããŠåäŸãã¯ã¯ãã³æ¥çš®ã 1 åéããšãæ¬¡ã®æã©ããªãããšèšããšãããã§ããåãæ¥
ã«å
šéšã®ã¯ã¯ãã³æ¥çš®ãããããŠåããããããã®ã§ãïŒæã«ã¯ïŒïŒçš®é¡ãã®ã¯ã¯ãã³ã
åæã«ãã§ãããããªè¡çºãå®å
šã ãšãã©ããã«èšŒæ ãšãªãç ç©¶ãããã§ããããïŒå¿è«ã
ãããŸããïŒ
68 åãšãããŸã
ãããŠãå°åã®ã¯ãªããã¯ã¯ã©ãã§ãããã€ã§ã奜ããªããã«ãã®ãªã¹ãã«å®éšçã«ã¯ã¯
ãã³ãå¢ããããšãåºæ¥ãŸãã68 åã ããã§ã¯ãªãã®ã§ãããã®ããŸãã®ã¯ã¯ãã³ã®ããš
ãã䞡芪ã«äŒããå Žåãããã°ãç¡æã§è¡ãªãããå ŽåããããŸãããããŠãã®èŠªã¯ãé
åžžã®äºå®è¡šã®ããšãç¥ããªãã»ã©ã§ããããããããããã ãã§ã¯ãããŸããã2002 幎ã®
1 æã«ã¯ãããã«æ°ããæä»£ãå§ãŸã£ãã®ã§ãã
å¶æ¥ä¿é²ã®ããã®ãæ°ã«ããŽãªãŒ
ãã®ããã€ãªã¹ã¯åºåã㯠2002 幎ã«çŸãããã®ã§ãããããã¯æ°ããã¯ã¯ãã³ã®æ¥çš®å®éš
ããããããªãããã«ä»çµãŸãããè£éãã§ãããããã«ãã£ãŠçç£è
åŽã¯å ã
ãšãå°æ¥
ãã£ãšã¯ã¯ãã³ãå¢ããç¶ããããããã«ãªã£ãŠããŸããŸãããçååŠå
µåšã®ããã«å¯Ÿã
ããã¹ããªãã¯ãªå±æ©æã®æåã«å§ãŸããããããæå£ã§ A åèçãRotateqãHPV ã®æ§
ã«ãã£ãããšæ°çš®ã®ã¯ã¯ãã³æ¥çš®ããã€ã®ãŸã«ãå ããããŠããã®ãç®ã«èŠããããã§ãã
ãªãã£ãŠãæ°çš®ã®ã¯ã¯ãã³ã远å ããããã°ããã 2,3 ã¶æåã«è©²åœããç
æ°ãããã€ãªã¹
ã¯åºåãã«èšå®ããŠããããã®åŸã§ãŸãã§åœç¶ãšããé¡ã§ããã£ãšäºé²æ¥çš®äºå®è¡šã«ä»ã
å ããŠããŸãã°è¯ãã®ã§ãããããšã£ãŠãç°¡åã§ãããäžè¬åãã«äœã®åç¥ãå¿
èŠãããŸ
ããããã䟿å©ãªæ¹æ³ã§ãããïŒ
9/11 äºä»¶ã®ãã£ãïŒã¶æåŸã«çŸãããã®æ°åºåããå®ã¯ãã®åœããšããŸããŠããç·æ¥æå¥
康ä¿è·æš¡ç¯æ³ãæåœäž»çŸ©æ³ãåœå®¶å®å
šä¿éæ³ããšãã£ãèããçãäžããã°çºè¶³ããã§ã
ãããæ§ã
ãªåœä»€ã®ãè³ç«ãŠã«éããªãã®ã§ãã[140]
ãã®æ§ãªæ³åŸã®åœä»€ãåºæ¥äžããã°ãã©ããªããšãããæ±ãåºæ¥ã絶察æåŸçãªãæ¯é
ç
ãªæš©åãäžããããããšã«ãªãããããªããšæã
ã®äžéšããããã¯å
šäººå£ã¯ã圌ããå¿
èŠ
ã ãšå€æããè¡çºã«ã¯å
šãŠãå®éšçãªã¯ã¯ãã³æ¥çš®ãå«ããåŸããªããŠã¯ãããªãããšã«
ãªããŸãã
ããã«åŸããªãè
ã¯ã眰éã眰åãæ²åœ¹ããããªãããããããã¯ç¡çããåŸãããããã
財ç£ãçŒããããæ²¡åãããããã仿ã¡ãåããã§ãããã
ãã£ãã®ããšãäžäžé¢šã«ã®ããã³å°ãå ããã°è¯ããããã§ãã
ãããªæ¥µç«¯ãªæ³åŸå¶åºŠãæ¬åœã«åºæ¥ããªããŠããªããªãä¿¡ããããªãããšã«æããã§ãã
ãããå®éã«ãã®å¶åºŠã®å¹Ÿã€ãã¯ãçŸåšã®å
šå·ã®æ³åŸã«å«ãŸããŠããã®ã§ããããããã
ããªãæãããã¹äž»çŸ©ããšããã€ã§ãã©ãã§ãããææãã®ã©ã¡ãããéžã¹ãšèšããªãã
ç§ã¯è¿·ããã«ããææã®æ¹ãéžã³ãŸããæ¿åºãã©ãã ãç§éããå®ã£ãŠãããªããããã¯
ããååã«åãã£ãŠããŸãããã
ã©ããŸã§åããã°ååãªã®ãïŒ
äžçäžããããŠæŽå²äžã§ãæãå€ãã68 åãšããã¯ã¯ãã³æ¥çš®ãæã
ã®åäŸéã«åããã
ãŠããã®ã ãããçç£è
åŽã¯ããååéã®åµã«æºè¶³ããŠããããšãæãã§ãããïŒãšãã
ããããã§ã¯ãªãã®ã§ãããããå
šãŠã®ã¯ã¯ãã³æ¥çš®ãããªããäœã«å¯ŸãããŠã€ã«ã¹ã®è²
æ
ãç ç©¶ããããæ··åæ¥çš®ã®è² æ
ã忥ã«è€æ°æ¥çš®ããããšããããè² æ
ã®ç ç©¶ãããã
ãšã¯ã決ããŠæŽå©ãããããã®æ§ãªæžå¿µã話é¡ã«ãããããšã¯ 1 床ããããŸãããããã
ããç§åŠãã«ãšã£ãŠã¯ãã©ãã ãå€ããã©ãã ãæ©ãå¢ããããããã®æ¹ã倧äºãªã®ã§ãã
9/11 äºä»¶ä»¥éã®äžéã§ã¯ãã©ããªæ¡äŸãçºè¶³ããŠããã£ãã«æè°ã®å£°ãäžãããªããªãã
ãã£ãŠã¯ã¯ãã³ã®å€§æŽªæ°Žã®å£ã¯ã倧ããéãæŸãããŠããŸããè¿å¹Žã®çŸ©åæ¥çš®ã®ã¯ã¯ãã³
ã®è¡šãèŠãŠãã ããã
1980 幎 èš 20 å
2003 幎 èš 40 å
2004 幎 èš 53 å
2005 幎 èš 58 å
2006 幎 èš 63 å
2009 幎 èš 68 å
以äžã¯ãåäŸåãã®ã¯ã¯ãã³æ¥çš®ã®ç¶æ³ã§ãããããã«ã¯ç¶ãããããŸãã
æ°èŠã®æäººçšã¯ã¯ãã³æ¥çš®äºå®è¡š
åäŸåãã®æ¥çš®äºå®è¡šããããããã«æžå¿µãããã¹ãããšãããã®æ°ããäºå®è¡šã§ãã2008
幎åãã«ãäœã®ã¡ãã£ã¢åç¥ããªãçªç¶ãã£ããçŸãããã®æäººçšã®äºå®è¡šã«ãããŠãCDC
㯠18 æ³ä»¥äžã®æäººã«å¯Ÿã 73 åã®è¿œå ã¯ã¯ãã³æ¥çš®ã奚å±ããŠããŸãã[15]ããã«ãã£ãŠã
ã¢ã¡ãªã«äººã®ã¯ã¯ãã³æ¥çš®ã®å¥šå±åæ°ã¯äžæ°ã« 2 åã«ããªã£ãŠããŸã£ãã®ã§ãã
ã§ãããããªãã¥ãŒã¹ã¯ã©ãã§ãæŸéãããŸããã§ãããïŒ
ã€ãŸããããããããšã§ããä»ãŸã§ 1 äžçŽãã®éã¢ã¡ãªã«ã®åœæ°ã«ã¯ã¯ãã³æ¥çš®ããããª
ã£ãŠããCDC ãšé¢ä¿è
ãã¡ã¯ãä»åºŠã¯åäŸéã ãã§ã¯é£œãè¶³ããã«ããã£ãšåžå Žéçºãåº
ããªããã°æ°ãããŸãªããªã£ãŠããŸã£ãïŒãããŠæãè±å¯ãªåžå Žã§ãããæäººã«ç®ãã€ã
ãããšããèš³ã§ãã
éå» 100 幎ã®éã«ãããŠãã¯ã¯ãã³ã®å¹æãçæ¶¯ç¶ãããšãã䞻匵ãããç§åŠè
ã¯ããŸã
ãã§ãããã ãããããã¯ã¯ãã³ã®è€æ°åæ¥çš®ã®å¿
èŠæ§ã®çç±ãã§ããã®ã§ããåäŸéã
ãªããåãã¯ã¯ãã³æ¥çš®ãäœåºŠãäœåºŠãåããªããã°ãããªãããããã¯ãå
ç«ããèã
ãŠããŸããããã§ãããïŒ ã§ããããæäººåãã«äºé²æ¥çš®ãç¶ããããšãããããèã
ãã°ããèªç¶ãåœç¶ãªæãè¡ãã ã£ãããã§ããã ã£ãããçæ¶¯ãã£ãšæ¥çš®ãç¶ãããã
ã°ããïŒäœã§ãã£ãšæ©ãæãã€ããªãã£ããã ããïŒ ãã®çŽ æŽãããæãã€ãã§ãå¶æ¥
广ã¯äžæ°ã« 2 åã«ãèšãäžãã£ãã®ã§ãããã
2009 幎床ã®ã¢ã¡ãªã«æäººåãã«å¥šå±ãããŠããæ¥çš®ã¯ã以äžã®éãã§ãã
ç Žå·é¢š ãžãããªã¢ çŸæ¥å³ 15 å
ããããããŒããŠã€ã«ã¹ 3 å
é¢šç¹ ãããµãé¢šéª 3 æ¥ã°ãã 6 å
Varicella 2 å
ã€ã³ãã«ãšã³ã¶ 45 å
Prevnar 1 å
Zoster 1 å
ããããæäººåãã®äºé²æ¥çš®äºå®è¡šãšã¯ããŸã£ããåäŸã®ãªããã®ã§ãããåè¡åœä»¥å€ã«
ãããªèšå®ãããŠããåœã¯ã©ãã«ããããŸãããåœæ°ã« 150 ååãã®ã¯ã¯ãã³æ¥çš®ãæšå¥š
ããåœãªããŠãä»ã«ã¯ãªãã®ã§ãããã®æ°ããæ¹éãããããã§ããã圱é¿ã¯ãããã«ã¯
æç¢ºã«ããããŸããããæ¬¡ã®ç¹ã¯ã¯ã£ããããŠããŸãããã®æäººåãã®äººäœå®éšã«äžæ³šæ
ã«ãåå ããŠããŸã£ãã¢ã¡ãªã«äººã¯ããã®æ¬ã§åãäžããŠããã¯ã¯ãã³ã«ããæ§ã
ãªå¯äœ
çšãé害ããä»ãŸã§ã®2 åã«ãè² ã£ãŠããŸã矜ç®ã«ãªãã®ã§ãã
ä¹³å
ã¯ãæäººã®ãããã¥ã¢çã§ã¯ãªã
ããïŒã€ã決ããŠèšè«ãããããšã®ãªãããšã¯ãã¯ã¯ãã³ã®æ¯æåãšãä¹³å
ã®äœã®å€§ãã
ã®å¯Ÿæ¯ã§ãããããã«ã€ããŠãã€ãã»ããŒã¬ã€å士ã¯ããè¿°ã¹ãŠããŸãã
ãäœé 6 ãã³ãã®æ°çå
ã«è¡ãã¯ã¯ãã³æ¥çš®ã® 1 ååã¯ãäœéïŒïŒïŒãã³ãã®æäººã«åæ¥
è¡ãªã 30 ååã®ã¯ã¯ãã³æ¥çš®ã«çãããã[95]
ä¹³å
ã®èº«äœããä»ã®é¡§å®¢å±€ãšåãæ§ã«æ±ããäŒæ¥çãªããªãããç¡ããã®æŠå¿µãæŒãä»ã
ãŠããã®ã«ã誰äžäººãšããŠãæ¬¡ã«æãããæãåæ©çãªè³ªåããã人ã¯ããŸããã
ä¹³å
ã¯ãäžäœäœååã«èããããšãåºæ¥ãã®ãïŒ
9/11 äºä»¶åŸã«ã¯ããããããã€ã©ããªçååŠå
µåšã®ãããèµ·ãããåãããªãããšãã¹ã³
ãã«æçºãããäžéã¯ãã¹ããªãã¯ãªç·åŒµã«æºã¡ãŠããŸããããããªïŒïŒïŒïŒå¹ŽïŒæã®
Pediatrics èªãšãããžã£ãŒãã«ã«ãè¿ãæªæ¥ã«ç§åŠãã©ããªå€åããšããããšããäºæž¬ã®èš
äºãèŒã£ãŠããŸããããããã¯æç¶ãšããå
容ã§ããããã® 124 ããŒãžã«ã¯ãçè
é£ã芪
éã«åããŠãæãåãæ²¢å±±ã¯ã¯ãã³æ¥çš®ãåããããŠããã®ã§ã¯ãªã©ãšå¿é
ããããšã¯ãª
ãããšæžããŠãããŸãããããšããã®ããæè¿ã®çºèŠã§ãä¹³å
ã10,000 åãã®æ¥çš®ã«èã
ãããããšãåãã£ãããã ããšããã®ã§ãïŒãããŠãå¶ç¶ã§ããããããã®çè
ã¯ïŒ£ïŒ€
ã®å®£äŒéšã®ã¡ã³ããŒã§ãããããŒã«ã»ãªãã£ããã§ãã
ãªãã£ããã¯ããŸã£ããå·§åŠãªå
æãæã£ããšèšããã§ããã ïŒ ãªããšèšã£ãŠã 9/11
äºä»¶ä»¥éãæšå¥šã¯ã¯ãã³æ¥çš®ã®åèšæ°ã¯ã3åã«ããªã£ãŠããã®ã§ãããïŒ[119]
æã¡æãæªããŠã¯ãåè² ã«ã¯åãŠãªã
ãããªã¯ã¯ãã³æ¥çš®ã®æ°ã
ã¯ãæ¬åœã«å¹æãããã®ã§ããããïŒç§éã®åäŸãã¡ã¯ãæ¬åœ
ã«ããããäŒæç
ã«å¯ŸããŠã®å
ç«ãã€ããã®ã§ããããïŒ
ããã广ããããã®ãªãã°ãã¢ã¡ãªã«ã®åäŸéã¯ä¹³å
ã®çåçã«ãããŠäžçïŒã§ãã£ãŠ
ããã¯ãã§ããïŒãããå®éã«ã¯ã39 äœãšããçµæã§ããïŒïŒµïŒ®ïŒ©ïŒ£ïŒ¥ïŒŠïŒ[36]ã€ãŸããä»
ã® 38 åœã®ä¹³å
éã®æ¹ãã5æ³ãŸã§çãå»¶ã³ã確ç«ãé«ãããšããããšã§ããããã«ã1997
幎ã«ã¯ç§é㯠22 äœã ã£ãã®ã§ããããé广ãè¯ããšããã§ãïŒ
ã¢ã¡ãªã«ã§ã¯æ¯å¹Žãå°ãªããšã10,000 人ã®ä¹³å
ããæµè¡ã®ãçªç¶æ»ïŒïŒ³ïŒ©ïŒ€ïŒ³ããšãã蚺
æçç±ã§æ»äº¡ããŠããŸããããã¯ã€ãŸããå¯ãåã¯å¥åº·ã ã£ãã®ã«ãèµ·ãããæ»ãã§ããã
ãããŠæ±ºãŸã£ãŠåå ã¯äžæããšãããã®ã§ãããã®çªç¶æ»ãšããèšèã¯ãã¯ã¯ãã³ã®éå£
æ¥çš®ä»¥åã«ã¯ååšããŠããŸããã§ãããïŒMendelsohnïŒ[246] å®éã®æ»äº¡å
ã®æ°ã¯ãäžæ
ã§ããçªç¶æ»ã«é¢ããããããå°éå®¶ã§ãããŽã£ãšã© ã¹ã±ã€ãããŒã¯ã圌女ã®ç涯ã«ã
ããç ç©¶ã«ãããŠãã¯ã¯ãã³æ¥çš®ãšçªç¶æ»ã®çãã®äœå°ã®ãªãé¢é£æ§ãæããã«ããŠããŸ
ãã[243]
ã¢ã¡ãªã«ã®åäŸéã®å¥åº·ç¶æ
ã¯ãæŠããŠã²ã©ããã®ã§ãã忝ãã¢ã¬ã«ã®ãŒãæäœã®ç
æ°ã
ãããŠç®èãªããšã«ãã¯ã¯ãã³æ¥çš®ãåãããã®äŒæç
ãã®ãã®ã«ããã£ãŠããåäŸéïŒ
圌ãã®æ°ã¯ãã©ãã©ãå¢ãã€ã€ãããŸãã
ãæè¿ã«ãªã£ãŠãæ¯èŒç害ã®å°ãªãåäŸã®äŒæç
ã«å¯ŸããŠè¡ãªãããã¯ã¯ãã³æ¥çš®ããé
壿¥çš®ã®éå§ä»¥éãçãçœè¡ç
ããªãŠããé¢ç¯çãå€çºæ§ç¡¬åçãçèçž®æ§åŽçŽ¢ç¡¬åçã
çŒãããã®ã©ã³ã»ãã¬ãŒçãªã©ã®æäœã®ç
æ°ãæ¥æ¿ã«å¢ããŠããããšã®åå ã§ã¯ãªãããš
ããçãã®å£°ã匷ãŸã£ãŠãããã ïŒïœ232, How To Raise⊠[246]
ã¡ã³ãã«ãœã³å士ããã®ææãããã®ã¯ã20 幎åãã®ããšã§ãããããããç
æ°ã¯ãæžå°
ããŠããã§ããããïŒæäœã®ç
æ°ããšããèšèãäžè¬å®¶åºã§è¯ãèãããããã«ãªã£ãŠã
ãŸã£ãŠããã®ã¯ã©ãããŠã§ãããïŒ ããã«ãæ
¢æ§ã®ç²åŽçãèªéçããªãã®æ
¢æ§ã®ã¢ã¬
ã«ã®ãŒãé¢ç¯çã«æ©ãŸãããŠããåäŸéããããæ°å¹Žã®éã«å¢ãç¶ããããã«ãã®å¹Žéœ¢å±€
ãäœããªãã€ã€ããã®ã¯ãã©ãããããšã§ããããïŒ æºåž¯çšã®åžå
¥åšã䜿ããªããæ ¡é
ãåºå
¥ãããåäŸéã®æ°ã¯ãæãããŠæžã£ãŠããã®ãããããšãå¢ããŠããã®ã§ããããïŒ
æ¯å¹ŽïŒïŒïŒå
ãã«ãä¿å¥è¡çã«ã€ã蟌ãã§ããã«ããŠã¯ãã©ããæã
åœæ°ã®å¥åº·ã«ææã
çŸããŠããªãããã§ããã
ä¹³å
ã®ç¹å¥ç
宀
ïŒïŒïŒïŒå¹ŽïŒæã«ã¯ãããé©ãã¹ã話é¡ããã¥ãŒã¹ã«åºãŸããããã»ãšãã©æ³šç®ã¯ãããŸ
ããã§ãããæ¿åºã®æ©é¢ã§ãåœäžã®è¬åŠé¢ä¿ã®ç ç©¶ã®å€§éšåã®è³éæŽå©ãåãç· ãŸãåœæ°
å¥åº·æ©é¢ããä¹³å
ã®çµæ«å»çã®ããã«ãïŒïŒïŒçŸäžãã«ã䜿ããšæ±ºå®ããã®ã§ããããã
ã©ãããäºãæå³ããã®ããã¡ãã£ãšèããŠã¿ãŸããããããã¯ãçããã®ä»ã®èŽåœçãª
ç
æ°ã§æ«æçç¶ã®æ£è
éãšåãçšã沢山ã®ä¹³å
ãç
æ°ã«ãã£ãŠãã£ãããšèŠãã¿æ»ãã§ã
ã£ãŠããããããŠãã®åéã®çåœç·ãã»ãããŠããããã«æ°ãã察çãå¿
èŠã ãšãæ¿åºã
倿ãããšããæå³ã§ããããã§ã¯ããã®ä¹³å
ã®ç
æ°ã«ããæ»äº¡æ°ãšã¯ïŒãªããšãæ¯å¹Ž
53,000 人ãã®ä¹³å
ããç
æ»ããŠããã®ã§ããäºæ
æ»ãã§ã¯ãªããçãŸããŠããããã£ãèŽ
åœçãªç
æ°ã«ããæ»äº¡æ°ã§ãããããã æŠäºã®ã¢ã¡ãªã«äººæ»äº¡è
ãå
šéšåãããæ°ãšåãã
åååæŠäºã®ã²ãã£ã¹ããŒã°ã§ã®æ»äº¡è
ã®çµ±èšæ°ãšåããç©åãæ°ã®ä¹³å
ãç
æ»ããŠããŸ
ããããããæ¯å¹Žããã ãã®ãä¹³å
ãç ç²ã«ãªã£ãŠããã®ã§ãã[123]æ«æçç¶ã§èŠããã§
ããä¹³å
ããã§ãã
å©ããªã©ãå¿
èŠãªãã£ãã®ã«
å»ççµ±èšåŠè
ãã€ã±ã«ã»ã¢ã«ããŒãœã³ã¯ãéå£ã®ãäºé²æ³šå°ããå§ãŸãåã«ãããã«äŒæ
ç
ã®æ°ã
ã人é¡ã®éã§æ¶ãå»ãã€ã€ãã£ãããšããäºå®ããããã瀺ããŠããŸãããã®ã
ãŒã¿ãèŠããªãã倧æµã®ç ç©¶è
éããã¯ã¯ãã³ãç¡ããŠããã»ãšãã©ã®äŒæç
ãèªç¶ã«æ²¡
æ»
ããŠãã£ãã ãããšèããããšã§ãããã
ç§éã¯ãã€ããã¯ã¯ãã³ãããã«äŒæç
ãã人é¡ãæã£ãŠãããããšãã話ãè³ã«ããŸãã
ãããã¯ãã¯ã¯ãã³å察ã®ã°ã«ãŒãããã¯ãåäžçŽã«ãããŠäŒæç
ãããã«ã¯ã¯ãã³ã®å©
ãç¡ãã§èªç¶æ¶æ»
ãããããšãã話ãè³ã«ããŸããã§ã¯ãäž¡æ¹ã®åŽã®è©±ã«ã¯ãã©ãã ãã®
蚌æ ãæããããŠããã®ã§ããããïŒ
äžäœãã©ã¡ããæ£ããã®ã§ãããïŒã¯ã¯ãã³ä»¥åã«ãäŒæç
ãèªç¶ã«æ¶æ»
ããã®ãããã
ãšãã¯ã¯ãã³ã®ãé°ã§æ¶æ»
ããã®ããã©ã¡ããªã®ã§ãããïŒãã®çåã«å¯Ÿãããæ±ºå®çãª
çãã¯æ¬¡ã®éãã§ãã
çµ±èšïŒïŒ åè¡åœ100,000 人æ¯ã«å ããæ»äº¡è
æ°
ãžãããªã¢ Pertussis é¢šç¹ ã€ã³ãã«ãšã³ã¶
1900 幎 40.3 12.2 13.3 202.2
1910 幎 21.1 11.6 12.4 155.9
1920 幎 15.3 12.5 8.8 207.3
1930 幎 4.9 4.8 3.2 102.5
1940 幎 1.1 2.2 0.5 70.3
1945 幎 1.2 1.3 0.2 51.6
1950 幎 0.3 0.7 0.3 31.3
1955 幎 0.1 0.3 0.2 27.1
1960 幎 0 0.1 0.2 37.3
1970 幎 0 0 0 30.9
衚ïŒã®è³æïŒ Historical Statistics [195]
ãã®æ¿åºåèè³æã¯ãã©ãã®å³æžé€šã§ãèŠã€ããããšãåºæ¥ãŸãã
次ã®è¡šã¯ã5 幎ããšã«ä»ãå ããããŠããããããã®äŒæç
ã«ããæ»äº¡çã®è¡šã§ãã
衚ïŒïŒ åè¡åœã®æ»äº¡è
æ°
幎代 ããªãª ãžãããªã¢ çŸæ¥å³
1901 48,839 33,094
1906 28,225 26,436
1911 20,350 20,285
1916 15,623 21,382
1921 7229 12,267 14,724
1926 6038 7074 13,047
1931 4545 4388 9850
1936 3666 2189 6809
1941 3539 1135 4399
1946 3799 467 1460
1951 3826 125 558
1956 1604 45 206
1961 1076 22 82
1966 928 15 32
1971-75 0 12 122
幎代 ç Žå·é¢š é¢šç¹ ã€ã³ãã«ãšã³ã¶
1901 28,065 11,956 15,496
1906- 16,318 10,837 10,109
1911- 11,503 7615 7086
1916- 8596 7926 54,283
1921- 7818 4919 13,673
1926- 6040 3994 17,602
1931- 4709 2957 11,191
1936- 3275 1238 8449
1941- 2384 1013 4366
1946- 1697 469 1736
1951- 1093 268 1178
1956- 788 203 938
1961- 550 162 553
1966- 282 44 633
1971-75 122 17 491
International Mortality Statistics, pp.163-189, 313,
By Michael Alderson [209]
衚ã®äžç·ãåŒããŠããæ°åã®éšåã¯ãã¯ã¯ãã³æ¥çš®ãå°å
¥ãããããããã®å¹Žä»£ã§ããã§
ãããããã®è¡šã«ãããŠäŒæç
ãèªç¶ã«æžã£ãŠãã£ãçµéãèŠãªãããåæã«ããããã®
ã¯ã¯ãã³ãäžäœãã€å§ããããã®ããç
§ããåãããããšãåºæ¥ãŸãã
ããããã®ã¯ã¯ãã³ã®æ£ç¢ºãªå°å
¥æã¯ä»¥äžã®éãã§ãã
ç
å ã¯ã¯ãã³æ¥çš®
ããªãª 1954
倩ç¶ç 1902
ãžãããªã¢ 1940 幎代åã°
çŸæ¥å³ 1940 幎代åã°
ç Žå·é¢š 1940 幎代åã°
ïŒïŒïŒ² 1978
å è¡åç
1985
åèç 1991
æ°Žç±ç¡ 1995
 2002
ã€ã³ãã«ãšã³ã¶ 2005
ããŠããã§ãå
çšã®è¡šïŒãšïŒãèŠãŠã¿ããšãããããã®ã¯ã¯ãã³æ¥çš®ãå°å
¥ããããã£ãš
以åã«ãããããã®äŒæç
ãç¡ããªããããŠããããšãåããã§ãããã
å»åŠããå¹²æžãããªãç«å Žã®è³æãããããã®æ§ãªæèŠãåºãŠããŸãã
ãïŒïŒïŒ1911 幎ãã 1945 幎ã®éã«ã1ïœ14 æ³ã®å
ç«¥ã®ãžãããªã¢ãšé¢šç¹ãçŸæ¥å³ã«ããæ»
亡æ°ã®åèšã¯ãïŒïŒïŒ
ãæžå°ãããããã¯ãã¢ã¡ãªã«åè¡åœã§éå£äºé²æ¥çš®ããã°ã©ã ã
å§ãŸã以åã®ããšã§ãããã
ïŒDublin L, Health and Progress, 1935-1945, p12 [267]
Metropolitan Life Insurance Company
çããçµ±èšïŒæ°åã䜿ã£ãŠãªãã§ãããã®ããæ¹
äžèšã®ããŒã¿ã¯ã倿§ãªè³ææºããåŸããããç¡æ°ã®çµ±èšããŒã¿ã§ãããèªåã§æãåºã
ãŠã¿ããšåããã§ããããããã®ã·ã³ãã«ãªããŒã¿ã¯ãããã«åãŸã£ãŠããŸãã
ã¯ã¯ãã³ã®èŒãããæåãå ±éããŠããäž»æµã®ã¡ãã£ã¢ã®çè
ãåè¡è
ã®åŸæãªããªãã¯
ã¯ãæ
å ±æºãæèšããã«æ°åã衚ãã§ã£ã¡ãããããšããããæ¹ã§ããããã«ããã®ãã
ãªè«ã¯ããŸã£ããç¡å¹ãšèšããŸããã©ãããããããªæ°åãæã£ãŠããã®ã§ããããïŒè¶
èœåãå¿éè¡ã§ã䜿ã£ãã®ã§ããããïŒèª°ã®äž»åŒµè«ã§ãã£ãŠããèªåã§æ
å ±æºã確ããã
ããšãåºæ¥ãªããã®ããä¿¡ããŠã¯ãããŸãããç¹ã«ããæè¿ã®ç ç©¶ã«ãããšïŒïŒïŒããšããã»
ãªãã§å§ãŸããã®ã»ã©ã泚æãå¿
èŠã§ããããã¯ãã«ãç§åŠã®ããå°è©ãªã®ã§ãã
ãããªãè©æ¬º
äºé²æ³šå°ã®æ¿æ²»çãªé¢ããèšãã°ãã¯ã¯ãã³æ¥çš®ã«ããæ»äº¡çãå¯äœçšåå¿ã®å ±éã«é¢ã
ãŠã¯ãåãããé¿ããããŠããåé¡ã§ãããåœç¶ãã¯ã¯ãã³ã売ãåŽãšããŠã¯ãååã®æ¬
ç¹ãç¥ãããŸããããã¯ãããŸããïŒãŸããããžãã¹ã®åºæ¬ã§ããããããåœã®ããŒã¿ã
äœãäžããããæªæ§åå¿ãèµ·ãã£ãããšã®æ
å ±ãé ãããããããšã¯ããŸã£ããã®åœãã
èª€å ±éãšããåŒã¹ãŸããã
1 äžçŽãåã«ããžã§ãŒãžã»ããŒããŒãã»ã·ã§ãŒããã®æŠè¡ã«æ°ä»ããŠããŸãã
ãäžçŽæ«ã®è峿·±ãæä»£ã®ç¯ç®ã«ãç§ã¯ãã³ãã³ã®ãããŒã«ãŠã³ã»ã«ã®ä¿å¥å§å¡äŒã®äžå¡
ã§ãã£ããããã§ç§ã¯ãã¯ã¯ãã³ã®ææãè¯ãèŠããããã«ãã©ã®æ§ã«çµ±èšãå·¥äœãããŠ
ããããç®ã®åœããã«ããã倩ç¶çã¯ã¯ãã³ã®åæ¥çš®ãåããªããã°ãªããªãæ£è
ã®ä»¶ã¯
å
šãŠãåè¿æ§ã®æ¹¿ç¹ãšãããŽã¡ãªãªãã€ããšãããšãããã倩ç¶ç以å€ã®çç¶ã ãšããã
ãšã«ããŠåœã®èšºæãããŠããã®ã ãã[205]ïœ64
ã€ãŸããåãªãåŒã³åã®èšãæãããšããããŸããæ¹ã§ããããã¯ãããªãªã倩ç¶çããçµ¶
æ»
ããããšçºè¡šãããåŸãåãç
æ°ãã飿§é«èçãã ãšããç¿çãã ãšãåŒã³æ¹ãå€ã
ãŠããŸãæ¹æ³ã§ããïŒïŒïŒDoley [224], [235] ïŒå®£äŒçºè¡šã®ããã«ã¯ãæ°åãè¯ãèŠããå¿
èŠãããããšããããã§ãã
ããïŒã€ãçµ±èšåŠè
ãã©ã€ã¿ãŒã®éã§ãã䜿ãããããŸããæ³ã«ããããŒã¿ã®ããéããæ³
ããããŸããããã¯ãããšã®ããŒã¿ãæ§å¥ã幎霢ã人皮ãªã©ã§ã©ãã©ã现ããåé¡ããŠã
ããããšããšã®äž»æšãåãããªããªã£ãŠããŸãæ§ã«ããããæ¹ã§ãããã®ããæ¹ã§ãéå»
50 幎éã®åè¡åœã«ãããçæ»äº¡è
ã®ç·æ°ã®å¢ãæ¹ããã¯ã¯ãã³ãç»å Žãã以åã«äŒæç
ã«
ããæ»äº¡è
ãèªç¶ã«æžã£ãŠããããŒã¿ãªã©ãç°¡åãªäºå®ãéœåãããã¿æ¶ãããšãåºæ¥ã
ã®ã§ããïŒYiamouyiannis, p 78ïŒ[210]
å»åŠé¢ä¿ã®éèªãæ¬ãèªãäººã®æ°ã¯éãããŠããŸããã倧æµã®äººã
ã¯ã€ã³ã¿ãŒãããã®ã
ã¥ãŒã¹ãéèªããã£ãšèªãã§ãããã§åŸãããããªæ
å ±ããèªåãªãã®æèŠãäœãäžããŸ
ããããã§ãäžè¬ã®ã¡ãã£ã¢ã«èŒã£ãŠããæ°åã¯ãæãæåãªå®£äŒäž»ã§ãã補è¬äŒç€Ÿã«æ
å©ãªæ°åã«ããŠããã®ã§ãã
å°å
ç§ã®åéã«é¢ããŠèšãã°ãããã¯ãã£ãšåçŽã§ãå¯äœçšåå¿ãèµ·ããä»¶æ°ã¯å
¬è¡šãã
ãç¡èŠãããŸããããã«ããã®æ§ãªã±ãŒã¹ã¯å³åº§ã«åŠèªããããããªæ®µåãã«ãªã£ãŠããŸ
ããããã¯ããå¥åº·ãªèµ€ã¡ãããããã°ã©ã ïŒã¯ã¯ãã³æ¥çš®ãšããå°å
ç§ã®å€§åãªåå
¥æºã
å®ãããã®ãçµå¶æ¹éã§ãã人ã
ãã¯ã¯ãã³ã«å¯ŸããŠå°ãã§ãçåãæã€ãããªããšãã
ãã°ãå°å
ç§å»ã¯ç掻費ã皌ããªããªã£ãŠããŸããŸãããå»çãã¹ãéæ³æ²»çã®æ³ç責任
ãåãããããšã«ãªã£ãŠããŸããŸããããããªã¹ã»ã³ãŠã«ã¿ãŒãšãã³ã»ããŒãã³ã®äž¡æ°ã¯ã
æ¯èŠªéãèªåã®åäŸãã¯ã¯ãã³æ¥çš®åŸã«å¯äœçšãèµ·ããããšäŒãã«ãã£ãŠãå³åº§ã«åŠå®ã
ããç¡æ°ã®äŸãã±ãŒã¹æŽã瀺ããŠããŸããããã¯ãæ°äŒãã§ããããããããšãæ¥åžžæ¹é
ãšã§ããããã®ã§ããããïŒ[227,108]
å¯äœçšåå¿ã®å ±å
å¯äœçšåå¿ãå ±åããããšãã£ãå»çé¢ä¿è
ã®è²¬åã¯ã©ããªã£ãŠããã®ã§ããããïŒã¢ã¡
ãªã«ã«ãããã¯ã¯ãã³é壿¥çš®ã¯ã1902 幎ã«å§ãŸã£ãŠããŸãããå»è
ãã¢ã¡ãªã«åœå
ã§èµ·
ããå¯äœçšåå¿ã®äºäŸãå ±åã§ããèšé²ç®¡çã»ã³ã¿ãŒãšãã£ããã®ã¯ã1991幎ãŸã§ååšã
ãŸããã§ãããïŒp88 [227]ïŒ1991 幎ã«ã¯ãïŒVaccine Adverse Effect Reporting
SystemïŒãèšç«ããŸããããããã¯åœã®ã¯ã¯ãã³æ¥çš®ã«ããå°å
é害æ³ã 1986 幎ã«çºè¶³
ããçµæããŸãããã®ã§ãã
1986 幎ã«ããã«ã ã¬ãŒã¬ã³å€§çµ±é ããµã€ã³ããæ³åŸãã«ã¯ãå
šãŠã®ã¯ã¯ãã³
çç£è
ã¯ãã¯ã¯ãã³é¢é£ã®ãããªãéå®³ãæ»äº¡ä»¶ã«ããæå®³ã®è²¬ä»»ãæ³åŸã§åãããããš
ã¯ç¡ããã®ãšãããããšããã補è¬äŒç€Ÿã¯ããã«ãã£ãŠãåäŸéãã¯ã¯ãã³ã®å¯äœçšã§æ»äº¡
ããŠããç¡çœªæŸå
ãšãããŸãããïŒHorowitz,p.499 [256]ïŒ
ããã«ãå¯äœçšãèµ·ããã±ãŒã¹ãèšé²ããŠããç ç©¶æ©é¢ãç¡ãã£ãã®ã§ãããã1991 幎以
åã«ãããã¯ã¯ãã³ã®å®å
šæ§ã«é¢ããçºè¡šã¯ããŸã£ããç¡æå³ãªçºè¡šã ãšããããšãåã
ããŸããã¿ããªãå£ãããããŠã¯ã¯ãã³ã¯å®å
šã ãå®å
šã ããšå±ããŠããŸããããå¯äœçš
ã«ã€ããŠã¡ãããšèšé²ããšã£ãŠãã人ã誰ãããªãã®ã«ãäžäœã©ãããŠå®å
šã ãªããŠèšã
ãã®ã§ããããïŒåäŸãã¯ã¯ãã³æ¥çš®ã®çŽåŸãïŒåãããªããã¡ã«æ»äº¡ããã£ãŠãïŒïŒïŒ
ïŒå¹Žä»¥åã«ã¯ãã®èšé²ããåãããªãã£ãã®ã§ããããã«ãå®éã®æ»äº¡ä»¶æ°ã¯ç§éã«ã¯å
ãããŸãããããã«çŸåšã«ãããŠã¯ãå»è
ã®å€§å€æ°ãã¯ã¯ãã³æ¥çš®ã«ããå¯äœçšã®ä»¶ãå ±
åããªãææ§ã§ããã®äºæž¬ã«ããã°ãã¯ã¯ãã³ã«ããæ¿ããå¯äœçšã®ä»¶æ°ã®ãã¡ã
å»è
ãå ±åããã®ã¯ããã10ïŒ
çšã ãšããããšã§ããïŒOrient, NullïŒ[177,220,245]
ã©ãããŠå»è
ãä»¶æ°ã® 10ïŒ
ããå ±åããªãããšèšããšã1 çªå€§ããªçç±ã¯æ¡ä»¶åå°ãšãã£
ãŠãããã§ããããå
ã«è¿°ã¹ãããã«ãèªåãããŠããããšã¯å®å
šã§ã¯ãªãããšèªããã
ã人ã¯èª°ãããŸãããã»ãšãã©ã®å»è
ã¯ãå®éã«å¯äœçšããããä»¶æ°ãæ£çŽã«å ±åãããã
äžè¬äººã®ã¯ã¯ãã³æ¥çš®ã«å¯Ÿããä¿¡é Œãå°ç¡ãã«ãªã£ãŠããŸãã®ã§ã¯ããšå¿é
ããŠããŸãã®
ã§ãã
ãã® 10ïŒ
ã®å ±åä»¶æ°ã¯ãããããµããŒãããç ç©¶ããªãã®ã«ããã®è³æã«ãå ±
åãããå¯äœçšã®ä»¶æ°ã®äºæž¬ãã®åç
§ãšããŠãç¡çããåŒçšãããŠé »ç¹ã«åºãŠããŸããã
ã¥ãŒãšãŒã¯ã®å»åž«é£ã®ïŒ®ïŒ¶ïŒ©ïŒ£ã®èª¿ã¹ã«ããã°ãå¯äœçšãå ±åããããšçããå»è
ã®æ°ã¯ã
å
šäœã® 2ïŒ
ã«éããªããšã®ããšã§ãããšããããšã¯ã€ãŸããã¯ã¯ãã³ã«å¯Ÿããå¯äœçšåå¿ã®
å
ãå®éã«ïŒ¶ïŒ¡ïŒ¥ïŒ²ïŒ³ã«å ±åãããã®ã¯å
šäœã®1ïŒ
ã®ä»¶æ°ã«ãããªããªãããšããå¯èœæ§ã
ååãããã»ã©ããããã§ãã[264]
å¯äœçšçºç宿°
åè¡åœã®äºé²æ¥çš®ããã°ã©ã ãšããŠ30 çš®é¡ãã®æ§ã
ãªã¯ã¯ãã³æ¥çš®ãåèš1åååãæã
ããçµæã2004 幎ã«ïŒ¶ïŒ¡ïŒ¥ïŒ²ïŒ³ã«å ±åãããå¯äœçšã®ä»¶æ°ã¯200,000 ä»¶ã§ãã(Geier,[77])
ãããå®éã® 10ïŒ
ã ãšããã°ã1991 幎以éã«ã¯ã¯ãã³ã«ããæ·±å»ãªå¯äœçšãèµ·ããä»¶æ°ã®
æ¬åœã®æ°ã¯ 200 äžä»¶ã«ãªããŸããããã«ãã®åœ¹å¡ã§ããã±ã»ã©ãŒãè¿°ã¹ãããã«ã
å®ã¯ 1ïŒ
ããå ±åãããŠããªããšããããšãªãã1991 幎以éã«ã¯ã¯ãã³ã«ããæ·±å»ãªå¯äœ
çšãèµ·ããä»¶æ°ã®å®éã®æ°ã¯ã2000 äžä»¶ã«ãäžããšããããšã«ãªããŸããããã«ã¯ãå
¥é¢
ããçæ¶¯æ®ãé床éå®³ãæ»äº¡ãªã©ãå«ãŸããŠããŸãããããªæããã被害ãçŸåšã®ã¢ã¡ãª
ã«ã§èµ·ãã£ãŠããã®ã«ãã ãããã®çœå®³ã«ã€ããŠã¯æ³šæãæãããšããŠããªãã®ã§ãïŒ
æéå¶é
ã¯ãã¯ã¯ãã³ã«ããæ¿ããå¯äœçšãå ±åããã«åœãããéåžžã«å³ããåºæºãèš
ããŠããŸãããã® 1 ã€ã«ãå ±åãèªãã匷åŒãªæå¹æéã®èšå®ããããŸãã
ãæå®³ã被ã£ãå Žåã«ã¯ãæåã®çç¶ãçŸãã 36 ã¶æä»¥å
ã«è¢«å®³ãç³åããªããã°ãªããª
ãããïŒNVIC[264]ïŒ
ããããå¯äœçšåå¿ã®å€ãã¯ããã£ãšæãçµã£ãŠããããçŸããŸãããæ¯æ§ã®æ³šå
¥ç©ãã
èµ·ãããåã«ã¯ãŸããªãææ©çã§æœåšçãªé害ãä¹³å
ã®çºééäžã®è³çްèã«é害ãäžãã
ãããªåå¿ã®çç¶ã¯ããã£ãšåŸã«ãªã£ãŠçŸããã®ã§ããã§ãããã®åºæºã«ãããšãïŒïŒã¶
æä»¥éã«çŸããçç¶ã¯ç³åããã«å€ããããã£ãŠãããªãæå®³è³ åãèŠæ±ããããšãäžå¯
èœã«ãªããŸãã
äžæ£ãªè³é
2007 幎ãŸã§ã«ãVAERS ã«å±ããæå®³è³ åã®ç³åæ°ã¯ã1äžä»¶ä»¥äžã«åã³ãŸããããããå³
ããæ¡ä»¶ãæ³çãªé害ç©ãå€ããããå¯äœçšåå¿ã蚌æããããã®å¿
èŠæžé¡ãå€ããããš
ããçç±ã®ãããå®éã«åãå
¥ãããããšãããŸã§è³ã£ãã®ã¯ãã®å
4400 ä»¶ã«ãããªããŸ
ããã[22]
ããã§ãã1991 幎以éã¯ã¯ãã³ã«ããé害ã«ããããæå®³è³ åã«äœ¿ãããè²»çšã¯ 1 å 4 å
ãã«ä»¥äžã«ããªããŸãã[114] ãããã®è³éã¯ãã¯ã¯ãã³äŒç€Ÿãæ¯æã£ãã®ã§ã¯ãªããå
¬
çè³éãããªãã¡çŽçšè
ãã¯ã¯ãã³ã«ãããçšããæ¯æãããã®ã§ããçŸåšã5 åãã«ä»¥äž
ããã®å
¬çè³éã«åœãŠãããŠããŸãã[351]
ããã§ãéèŠç¹ããŸãšããŠã¿ãŸãããã
ïŒãã®åœã§ã¯ã18æ³æªæºã®åäŸéã«å¯ŸããŠã68ååã®ã¯ã¯ãã³æ¥çš®ã矩ååãããŠããã
ïŒ1991 幎以åã«ã¯ç³åæ©é¢ãç¡ãã£ãããããã以åã«å¯äœçšåå¿ã§æ»äº¡ãããé害ãã
ã£ã被害è
ã®æ°ã¯æªæã§ããã
ïŒåºæ¬æ³ã«ãã£ãŠã補è¬äŒç€Ÿã¯äžåã®æ³ç責任ãåãããªãããšã«ãªã£ãŠããã
ïŒç³åæ©é¢ã¯ããããå®éã«æªæ§åå¿ããã£ãä»¶æ°ã®ããã 10ïŒ
ããç³åãããŠããªãã
ïŒãã®ç³åæ©é¢ã«ã¯ãå®éã«ç³åãããä»¶ã®ãã®åŸã®å¯äœçšåå¿ïŒæ»äº¡ãäžçç¶ãç¥çµé
害ãªã©ã®å ŽåãããïŒã¯å«ãŸããªãã
ïŒã¯ã¯ãã³ã®å¯äœçšåå¿ã®è¢«å®³è
ãžã®æå®³è³ åã¯ãåœæ°ã®çšéããæ¯æãããã
ããã¶ããããã£ãšããå
容ã ãšæããŸãããïŒ
èŠæ³šæã®ãããïŒãããããã
ã¯ã¯ãã³ã¯ããããšåŒã°ããåºåãããšã«çç£ãããŠããŸãã1ã€ã®ãããã§äœãããã¯ã¯
ãã³ã¯ã20,000 ãã 70,000 åå以äžã§ãããã®äžã§ããããããå
ã§äœãããã¯ã¯ãã³ã
ç°åžžã«é«ã確çã§å¯äœçšåå¿ãæ»äº¡ã®åå ã«ãªãããšããããŸããããããããããã¯ãã
ãããããããšåŒã°ããŸããè³æã«ãã£ãŠã¯ã[ãããããã]ãšã¯æ»äº¡ã 2 ä»¶ãå
¥é¢ãå¿
èŠ
ãªå¯äœçšåå¿ã10 ä»¶ãå«ããããããšãããŠããŸãã[163]ãä»ã®è³æã«ã¯äœãæ°ã®æå®ã¯
ãããŸããã
ãããŠé
·ãããšã«ããããããããããããçºèŠãããŠããããã補é è
åŽãååãã矩
åã¯ãŸã£ãããããŸãããä»ãæãããããã矩åãå®ããæ³åŸããå
šãååšããªãã®ã§
ãïŒ
ä»åºŠçããããã¯ã¯ãã³ãã©ããªã«å®å
šãããšããå®£äŒæå¥ãç®ã«ããéã«ã¯ããã®çŽã
ããªãäºå®ãæãåºããŠã¿ããšè¯ãããç¥ããŸããã
ããã§ã¯çŸåšãæ¥çš®ãè¡ãªãããŠããã¯ã¯ãã³ã®å¹Ÿã€ããåãäžããŠããã£ãšèª¿ã¹ãŠãã
ãŸããããããã¯ãæ
å ±ããããããŠããã£ãããªäœæ¥ã«èããããããããŸããããã
ããããããªãã«ãåãããããŠããã®åãã¯ã¯ãã³æ¥çš®ãåããããšããæã«ãªã£ãŠã
æã«å
¥ãæ
å ±ã¯ã¯ã¯ãã³ã§çèšãç«ãŠãŠããçç£è
åŽãæäŸããæ
å ±ããç¡ããšãããã
æ¬åœã«æ£ããæ
å ±ãèæ
®ãã倿ãåºæ¥ãã§ããããïŒ ã§ããã仿©ã¯ããã¬ãããé
ãã«ããŠãèªåã®ããã«æ
å ±ãéããŠã¿ãŸããããèªåã®åäŸã坿ããªããåœç¶ãã®å
ã®è¡æ¶²ã®å®å
šãã倧äºãªããšã§ãããããã
ããªãª
ããªãªãšã¯ãæªã ã«æªè§£æã®éšåãå€ãã骚é«ã®æªæ§ææã§ãããã¯ã¯ãã³ãçºæããã
以åã«ããæ¬æ¥ã¯ãããŸã§æ»äº¡çãå€ããã®ã§ã¯ãããŸããã§ãããããªãªã®ãŠã€ã«ã¹ã
åªäœããŠãã人㮠90ïŒ
ã¯ãäœã®çç¶ãèµ·ãããŸããã§ãããïŒBernet, p93ïŒ[203]
ã¢ã¡ãªã«ã«ãããããªãªææã®æžå°ããæ¬åœã«ããªãªã®ã¯ã¯ãã³æ¥çš®ã®ãé°ã ã£ããã©ã
ãã¯ãçããããã®ã§ãã衚ïŒã§ç€ºããããã«ãå€ãã®ç ç©¶è
ãããªãªã®æžå°ã¯ãã以å
ããèªç¶ã«å§ãŸã£ãŠãããšè¿°ã¹ãŠããŸãã[209] åã«èŒããã¢ã«ããŒãœã³ã®çµ±èšè¡šã«ãã
ãããªãªææã®å ±åæ°ã®åçãªæžå°ã¯ãã¯ã¯ãã³ã®å¹æãšããããã¯ãç³åæ¹æ³ã倧å¹
ã«
å€ãã£ãããšããæ¥ãŠãããã®ãªã®ã§ãããã®ããããã®è©³ãã説æã¯ã109 é ã®ããŠã¹ã
ããŒã® The Vaccine Guide[211]ã埡芧äžãããããã«ã¯ãæ¿åºæ©é¢ã®ãã€ãªçµ±èšåŠè
ã§ã
ã Dr.ããŒããŒãã»ã°ãªãŒã³ããŒã°ã®èšŒèšãèŒã£ãŠããŸããç°¡æœã«ãŸãšãããšãã€ãŸã 1954
幎以åã«ã¯å»è
ãããªãªãå®éãããå€ãå ±åããŠããŠããã以éã¯å®éããå°ãªãå ±å
ããŠããããšãããããã°æ¿æ²»çãªæŠè¡ãšèšãããã®ã§ããã¯ã¯ãã³ã广çã§ããããš
èŠããããã«ãããšããããããã§ããç§åŠã®ãé°ã§æ®ãããæ¹åãããã1950 å¹Žã®æç
ç©è³ªã®ããŒã ã«ç¶ããŠãã¯ã¯ãã³ã®ããŒã ãããšããèš³ã§ããã
ããã«ã€ã㊠Hygienic Care of Children ã®èè
ã§ãã ããŒããŒãã»ã·ã§ã«ãã³(å士)ã¯ä»¥
äžã®ããã«è¿°ã¹ãŠããŸãã
ãããªãªãäžèŠæžå°ãããã®ããã«èŠããã®ã¯ãããåºæ¥ãè£å·¥äœã®ãé°ã§ãããSalk ã¯
ã¯ãã³ãåãå
¥ããããåã«ã¯ãããªãªã«ææããŠããªãäœå人ãã®å¥åº·ãªåäŸéããã
ãªãªã ãšèšºæãããã
ãããŠäžæŠã¯ã¯ãã³æ¥çš®ãéå§ããããšãä»åºŠã¯ãããã£ãä»¶ãããªãªãšèšºæããããšã¯
æ¢ããããããã®ããã§èªåçã«ãããªãªã®ç³åä»¶æ°ãã»ãšãã©çç¡ã«ãŸã§æžå°ãããã®
ããã«èŠããèš³ã§ãããã [235]
1955 幎ã«ã¯ãå代 Salk ã¯ã¯ãã³ã®ãããã®å¹Ÿã€ãã«ãããåé¡ãçºçããŸãããã¯ã¯ã
ã³æ¥çš®ãåããçŽåŸã«ã80 人äœãã®åäŸéãããªãªã«ææããããã«ãã®åéããå°ãªã
ãšãä»ã® 120 人ã®åäŸéãïŒæ¬¡ææããã®ã§ããç ç²è
ã®ïŒäººã®åã¯æ»äº¡ããïŒïŒïŒ
ã¯èº«
äœéº»çºã®é害ãè² ããŸãããïŒ[256],p 487ïŒ
ããªãªãç¡ããªã£ãã®ã¯äºå®ã§ãããããªãªã¯ã¯ãã³ã®ãé°ã§ãããªã£ãã®ã§ã¯ãããŸã
ããïŒïŒïŒïŒå¹Žã«ã¯ã¯ã¯ãã³ã®çºæè
ã§ãã Jonas Salk èªèº«ãããçŸåšã®åè¡åœã§èŠãã
ãæ°ä»¶ã®ããªãªææã¯ãããªãªãšããç
æ°ã®ããã§ã¯ãªããããªãªã¯ã¯ãã³ã䜿ã£ãçµæ
èµ·ãããã®ã ããšèšŒèšããŠããŸãã(Science Abstracts ïŒïŒïŒïŒå¹ŽïŒæïŒæ¥å·) [288]
ãããŠäœãšïŒ£ïŒ€ïŒ£ã§ããããïŒïŒïŒïŒå¹Žä»¥éã«åè¡åœã§èµ·ããããªãªææã®å
šä»¶ããç
æ°
ãã®ãã®ã§ã¯ãªããã¯ã¯ãã³ã®ããã§ãããšèªããŠããæ¬¡ç¬¬ã§ãïŒ[206]
çãããã¡ãããšãèªã¿ã«ãªã£ãŠããã§ããããïŒãããŸã§ã®ïŒïŒå¹Žéã«åè¡åœã§ããã
ããªãªææã®å
šä»¶ããã¯ã¯ãã³èªäœã®ããã ãšåãã£ãŠããã®ã«ãã§ã¯ãªããç§éã¯æªã
ã«ããããïŒåãã®ããªãªã¯ã¯ãã³æ¥çš®ãåããŠããã®ã§ããããïŒïŒ
ããã§ããã¯ã¯ãã³èªäœãç¡å®³ãªãã®ã ã£ãã®ãªãããŸã 幟ãããŸãã ã£ãã§ããããã
ãã®äžããã«ïŒã€ã®å°ã£ãç¹ãæããããã®ã§ãã
ïŒããªãªã¯ã¯ãã³ã«ã¯é²è
å€ãšããŠæ°Žéããã«ã ã¢ã«ããããªã©ã®ææ¯æ§ç©è³ªã䜿ãããŠ
ããããšã
ïŒå
ã«ãªããªãªãžãã«ã®ããªãªã¯ã¯ãã³ã«ã¯ãSV-40 ç¿ãŠã€ã«ã¹ãå«ãŸããŠããããšã
æåã®ïŒç¹ç®ã«ã€ããŠã¯ãçç£è
åŽãèªããŠããã®ã§ãè°è«ã®äœå°ããããŸããã
ïŒPhysicianâs Desk Reference 2004ïŒ[251] ãåç¥ã®ããã«ãæ°Žéã¯ä»£è¬æ§ã®ææ¯ç©è³ªã§ã
è³ãè
èã骚é«ã«é害ãäžããŸãã(Widmanâs, p.691 åã³ Bernard)[196,166] åãé²è
å€ãšããŠäœ¿ããããã«ã ã¢ã«ãããã¯ãåã«ã瀺ããŠããããã«ãçºããæ§ç©è³ªãšããŠç¥
ãããŠããŸãã
åé¡ã®ïŒç¹ç®ã§ãããããªãªã¯ã¯ãã³ã SV-40 ã§æ±æãããŠããããšããç¹ã¯ããããã
åçãšãèšããã§ãããã
ïŒïŒïŒïŒïŒå¹ã®ç¿
ããã¯ãïŒïŒå¹Žä»£ã«ããªãªã¯ã¯ãã³ãäœãããã«æ®ºãããç¿ã®æ°ã§ããïŒJames,p166ïŒ[188]
ïŒïŒïŒïŒå¹Žä»¥æ¥ãäœåå¹ãã®ã¢ã«ã²ã¶ã«ãããã®è
èã䜿ã£ãŠããªãªã¯ã¯ãã³ãåªäœãã
ããã«æ®ºãããŠããŸãããïŒPDR, 1998 p.2131ïŒ[251]ããã倧å¢ã®ç ç©¶è
ããããªãªã¯ã¯
ãã³ãçºæãã人èªèº«ãããããïŒäžçŽã®éã®ããªãªã®çµ±èšãèŠãäžã§ïŒäžèšã®è¡šïŒïŒã
ãããèŠè§£ãè¿°ã¹ãŠããã®ã§ãïŒ1954 幎ãŸã§ã«ã¯ããã§ã«äººé¡ã«ãããŠããªãªãšããç
æ°
ã¯æããã«åšåã倱ãã€ã€ãã£ãã®ã§ãããªãªã¯ã¯ãã³ã®å¿
èŠæ§ã¯ç¡ãã£ãã§ãããããšã
ããããã® 25 幎çšåŸã«ããåãå¢ãã§èããŠããäºå®ãèžãŸããäžã§ãScience
Digest èªã® 1963幎å·ã®èšäºã§ã1950 幎代ã«SV-40 ãšããåã®ç¿ãŠã€ã«ã¹ããSalkã¯ã¯ã
ã³ãšãã圢ã§ãäœçŸïŒäœåããããã¯äœçŸäžäººãã®äººã
ã«äºæ
çã«æ³šå
¥ãããŠããŸã£ãã
ãšæžãããŠããã®ãèªããšã空æãããæ°æã¡ã«ãªããŸããïŒSniderïŒ[218] ãããŠããã®
äºä»¶ãã©ãã§èµ·ããããšèšããšãã¢ããªã«ã§ããªã®ã§ããïŒCurtis, p.1259ïŒ[219]ã¢ã¡ãªã«
ã§ã¯ã1955 幎ãã 1963 幎ã®éã«ãçŽ 9 å 8 çŸäžååãã® SV ãæ··å
¥ããããªãªã¯ã¯ãã³
ãåäŸéã«æ¥çš®ããŠããŸããŸããã[153]ãããã®äºå®ã¯ããããã 25幎åŸã«ïŒ¡ïŒ©ïŒ€ïŒ³ãæ°Ÿ
æ¿«ããããšãšã®ãé¢ä¿æ§ã瀺åããŠããŸãã
ãããŠã£ããã¯ã1964 幎以åã«ããªãªæ¥çš®ãåãã人å
šå¡ããïŒïŒïŒãŠã€ã«ã¹ã«ææ
ããŠããå¯èœæ§ãé«ãããšç€ºããŠããŸãã([256] p.493)
ããªãªæ¥çš®ãšãSV-40 åã³ AIDS ãšã®é¢é£æ§ã«ã€ããŠããããªã«æ²¢å±±ã®ç ç©¶è
ãææããŠ
ããã®ã§ããããèªåã®åäŸéã«ã害ã®ç¡ããããªãªã¯ã¯ãã³æ¥çš®ãåããããåã«ãã
ããã®è³æãèªãã§ãå®å
šæ§ã«çããæã£ãæ¹ãè¯ãã®ã§ã¯ããšç§ã¯æãã®ã§ãããããª
ãªãšããç
æ°ãã®ãã®ä»¥å€ã«ãããã£ãšæªè³ªãªç
æ°ãŸã§ããã£ãŠããŸãããç¥ããªãã®ã§
ããããã¯ã¯ãã³ã®å売ã§çèšãç«ãŠãŠããåŽã®äººéã«ãå
šãŠã®æ±ºæãå§ããŠããŸãã®ã¯ã
è³¢ãè¡çºãšã¯ãèšããŸããã
ããæè¿ã®ç ç©¶ã§ã¯ãSV-40ãšçã®é¢é£æ§ãçºè¡šãããŠããŸãã2002 幎 3 æã«ã¯ããããµ
ã¹å€§åŠãšãã€ã©ãŒå€§åŠã®ç§åŠè
éäž¡æ¹ããSV-40 ãš non-Hodgkinâs lymphoma ãšããåè¡
åœã§ 5 çªç®ã«å€ãçãšã®é«ãé¢é£æ§ïŒïŒïŒïŒ
ïŒãšããç ç©¶çµæããããããå¥ã
ã«ããã
ãåãæ°å€çµæãåºããŠããŸããïŒBeliïŒ[141]
æå
端ã®ç§åŠè
ã§ããããã·ã§ã«ã»ã«ãŒãã³å»åŠå士ã¯ããçŸåšãïŒïŒãã®æ§ã
ãªç 究宀ã
ãã人éã®è³è
«åã³éªšè
«çãšïŒ³ïŒ¶ïŒïŒïŒã®é¢é£æ§ã確èªããå
容ã®å ±åæžã 70 ä»¶ãå±ããŠ
ããŸããããšè¿°ã¹ãŠããŸãã[82]
ããªãªã¯ã¯ãã³ã SV-40 ãå«ãã§ããããšã«ïŒŠïŒ€ïŒ¡ãæåã«æ°ä»ããã®ã¯ 1963 幎ã§ããã
åœæã«ããããçºããæ§ç©è³ªãšããããšãåãã£ãŠãããããã¢ã«ã²ã¶ã«ã®äœ¿çšã¯æ¢ããŸ
ããããæ¢åã®ã¯ã¯ãã³ã®åšåº«ã¯ã©ããªã£ãã§ããããïŒæšãŠãããšæããŸããïŒäœçŸäž
ãã«ãã®äŸ¡å€ã®ããã¯ã¯ãã³ãïŒãåè«ã§ãããïŒããã§ã¯ãªããïŒŠïŒ€ïŒ¡ã®æçŸ©å§å¡äŒã¯
ããã§ã«åºåã£ãŠããåšåº«ããªã³ãŒã«ããŠãå
¬è¡ã«äžå®ãæ±ãããããã¯ãšããã®ãŸãŸåž
å Žã«åºãŠãããŸãŸã«æŸã£ãŠããããšã決æãããã®ã§ããïŒScience èªã p.1225,1972ïŒ[296]
ããã§ããFDAãèªåéã®èº«ã®å®å
šãæ°ã«ããŠãããŠããšæããŸããïŒ
ããã«ããžã§ãã¹ã»ãµã«ã¯ã® Salkããªãªã¯ã¯ãã³ã¯ãããŸãã®æ»äº¡ä»¶æ°ã麻çºé害件æ°ã®
å€ãã®ãããããã 17 ã¶æã§æã¡åãã«ãªããŸããã代ããã«äœ¿ãããããã«ãªã£ãã®ã¯ã
å£ããå
¥ãã Sadin çã¯ã¯ãã³ã§ãããã¯çŸåšã䜿ãããŠãããã®ã§ãããããŠãã®ã¯ã¯
ãã³ã®çºæè
ã§ããã¢ã«ããŒãã»ãµãã£ã³å»åŠå士ãã30幎åŸã«èšã£ãããšã¯ããã§ãã
ãæ£èŠã®ããŒã¿ã«ãããåè¡åœã§è¡ãªãããå€§èŠæš¡ãªã¯ã¯ãã³æ¥çš®ããå
ç«ãã€ãããšã
ããŠããç
æ°ã«å¯ŸããŠãããšãã£ã广ãçºæ®ããããšãåºæ¥ãªãããšã倿ãããèŠã
ãã«ãã¯ã¯ãã³ã¯å€±æããã®ã§ãããçŸåšã倱æäœã®ãŸãŸã§ãããã[294]
– International Assn of Scientists & Biologicals 1985 幎 12 æ 7 æ¥
ã¯ã¯ãã³ã«ãã£ãŠææããç
æ°
ãããŠçŸåšããããªãªã¯ã¯ãã³ã¯å±éºãªãŸãŸã§ãã2002 幎ã«ã¯ãã«ãªãæµ·å°åã«ãããŠã
çã¯ã¯ãã³ã®äœ¿çšã«ãã£ãŠ21 ä»¶ã®ããªãªææããããæ»äº¡ã 2 ä»¶ãããŸããã[117,113]
ããã§ãã€ã³ããªã®ã¯ããããã®ææäºä»¶ã¯å
šãŠããã£ã 1 人ã®åäŸã«äžããããã¯ã¯ã
ã³æ¥çš®ããçºçããïŒïŒïŒãšããããšã§ããã«ããã°ãã€ãŸãããã¯ã¯ã¯ãã³ãã®
ãã®ãæ°ããç
æ°ãäœãåºããŠããŸã£ãããšãææè
ããææè
ãžãšãç
æ°ãåºããŠãã
ããšãåºæ¥ããšããæå³ã§ããïŒJones,2002 幎 3 æ 18 æ¥ïŒ[129]æå±ã®ç§åŠè
ããªãª
ã³ã»ãã¥ãŒã¯ãã®ä»¶ã«ã€ããŠããè¿°ã¹ãŠããŸãã
ãïŒïŒïŒã¯ã¯ãã³ããçºçããããã®ãŠã€ã«ã¹ã¯ïŒïŒïŒäœåãéºäŒåçãªçªç¶å€ç°ãç¹°ãè¿ãïŒïŒïŒ
匷åãªæªæ§åãšãªã£ãŠãããšããšäºé²ããããã«äœãããããã®ç
æ°èªäœãåŒãèµ·ããçµ
æãšãªã£ãŠããŸã£ããã[142]
ãŠã©ãŒã«ã¹ããªãŒã ãžã£ãŒãã«èªã¯ãããã§ãã
ãç§åŠè
éã¯ããé·ãéããã®ã¯ã¯ãã³ã«å«ãŸãããŠã€ã«ã¹ãã匷åãªæªæ§åãšããŠãå
çºçããã®ã§ã¯ããšæžå¿µããŠããããããããã¯ããã¥ãŒæ°ãã€ã¹ãããªã©è«ã®å€åãå
æãããŸã§ã¯ãå®éã«èµ·ãã£ãããšã確èªãããŠããªãã£ããïŒïŒïŒãã®äºä»¶ã§ãç§åŠè
éã¯
ãŠã€ã«ã¹ãããã«ãçªç¶å€ç°ãããŠéå
é©åãããããšããå±éºãªäºå®ã«æ°ä»ããããèš³
ã§ãããã[117]
ã¯ã¯ãã³ã®æãæšãŠè¡çºã«å察ãã人ã
ã¢ã¡ãªã«åè¡åœãå®å°ããŠããã¯ã¯ãã³æ¥çš®ããã°ã©ã ã®å®æ
ãšã¯ãå
é²åœã§äžèŠã«ãªã£
ãã¯ã¯ãã³ã第 3 äžçããŽãããæ±ãããŠããã«å£²ãã€ããããã®ãã®ã ã£ããšããããš
ã«ã第 3äžçã®äººã
ãæ°ä»ãå§ããåå°ã§å察ã®å£°ãé«ãŸã£ãŠããŠããŸãã2008 幎ã«ã¯ã
ãã¹ã¿ã³ã«ãããŠãUNICEFã«ãã匷å¶çãªããªãªã¯ã¯ãã³æ¥çš®ã«å察ããéåãåçºãã
ãããã匷å¶çãªã¯ã¯ãã³æ¥çš®ãã倧鿮ºäººçãªè¡çºã ãšææããŠããŸãã[9]ããããã®
ã¯ãã50 äžäººã®äººå£ã®å
2007 幎ã«ããªãªã«ææãã人ã¯32 人ããããªãã®ã«ããã®å°å
å
šäœã«ã¯ã¯ãã³æ¥çš®ãè¡ãªããªããŠãæ£åœåããã®ã¯ç¡çãããã§ããããç¹ã«ããã®ã
ãªãªã¯ã¯ãã³èªäœããèŽåœçãªå¯äœçšã®æ°ã
ããããããšããæªåé«ããã®ã§ããå Žåã«
ã¯ããªãããã§ãã
ããªãªã¯ã¯ãã³ã¯æããã«ãæ¬æ¥ãªãã°ä»é ãšã£ãã«å®æ»
ããŠããã¯ãã®ç
æ°ããéã«åº
ããŠããŸã£ãŠããã®ã§ãã
ïŒ€ïŒ°ïŒŽïŒæãææ¯ãªã3 çš®æ··åæ¥çš®
ããŠæ¬¡ã¯ãããç¥ããã 3 皮混åïŒãžãããªã¢ãçŸæ¥å³, ç Žå·é¢šãäžèŸºã«æ³šå°ãã 3 皮混å
æåã§ãããŸããã£ãšãããããã®ç
æ°ã«ã€ããŠãå¥ã
ã«èŠãŠè¡ããŸãããã
ãžãããªã¢
ãç°è²ã®ç®èããšããæå³ã®ãžãããªã¢ã¯ãææãããšèãšåã«ç°è²ã®ç®èãã§ããŠãç
ç¶ãé²ããšæ£è
ãçªæ¯æ»ã«è³ãããç
æ°ã§ãããã®ãžãããªã¢ããŸããããªãªã倩ç¶çãš
åæ§ã«ãéå»ã®ç
æ°ã§ããã人å£éå€ãäžæ°Žèšåã®ãªãäžè¡çãªç°å¢ããæ¥ããã®ã§ãã
ã€ãŸãçŸåšã«è³ã£ãŠã¯ãå±éºæ§ã®ç¡ããã®ã§ããã¡ã³ãã«ãœã³ã«èšãããã°ãããžãããªã¢
ã§æ»ã¬ã®ã¯ãã³ãã©ã«ããŸããŠæ»ã¬ç¢ºçãšåãäœãã«äœãã®ã§ããïŒHow To, p.245ïŒ
[246]2002 幎ã®åè¡åœå
šåã«ããããžãããªã¢ææã¯ããã£ãã®ïŒä»¶ã§ããïŒ[76]ãããªã®
ã«ãäœçŸäžäººãã®äººã
ãã²ã£ãããªãã«ãã®èœã¡ç®ã®ç
æ°ã®ããã«ã¯ã¯ãã³æ¥çš®ãããŠã
ãèš³ã§ããå床ã衚ïŒãèŠããšããžãããªã¢ã®ææä»¶æ°ã®æžå°ããæ é€ãæ°Žéæœèšãäžæ°Ž
æœèšã®æ¹åã«äŒŽã£ãŠèµ·ãããã®ã§ã1940 幎代åã°ã«ã¯ã¯ãã³ãäžè¬åããããã£ãšåãã
æžã£ãŠããããšãåããã§ãããã
ã§ã¯ãžãããªã¢ã®ã¯ã¯ãã³ã¯å¹æãããã®ã§ããããïŒã¡ã³ãã«ãœã³ã¯ã16 äººã®æ»è
ãåº
ã 1969 幎ã®ã·ã«ãŽã§ã®ãžãããªã¢æµè¡ã«ã€ããŠææããŠããŸãããããã¯ããæå³å€§ãã
äºä»¶ã§ãïŒ16 人äžããªããš 9 人ããäºé²æ¥çš®ãåããŠãã人ã
ãªã®ã§ãããïŒå
ç«ããè
ããŠããããŸãããžãããªã¢ã®ã¯ã¯ãã³æ¥çš®ã®äžè¬åãããŸã åè¡åœã®ååãŸã§ããé²ã
ã§ãªãã£ãé ã«ããã¯ã¯ãã³æ¥çš®ãåããŠããå·ãšåããŠããªãå·ã«ãããŠãææç¶æ³ã®
éãã¯äœãèŠãããŸããã§ãããããã«ããã®ç
æ°ã¯ããäœå¹Žãåãã erythromycin ãšã
ãäžè¬çãªæçç©è³ªã§æ²»çã§ããããã«ãªã£ãã®ã§ããšã£ãã«ã¯ã¯ãã³æ¥çš®ãªã©å¿
èŠããª
ããªã£ãŠããã®ã§ããã¯ã¯ãã³ã¯ãå¿
èŠã§ã¯ãªãã£ãã®ã§ãã[280]
ãžãããªã¢ã®æ¥çš®ã«å¯Ÿããå¯äœçšåå¿ã®å ±åã¯ãçŸæ¥å³ã¯ã¯ãã³ã®æ§ã«ã¯äœåä»¶ããšæŒã
å¯ããŠã¯æ¥ãŸããã§ããããããã«é¢ããŠã¯ããäºå®ãæããããŸãããžãããªã¢ã¯ã¯ã
ã³ã®äœçšã«ã€ããŠã¯ãé·æçãªèª¿æ»ãä»ãŸã§ã«äœããããŠããªãã®ã§ãããšãããããŸãš
ãããšããã®åœã§ãžãããªã¢ã®ã¯ã¯ãã³æ¥çš®ãè¡ãªãç§åŠçãªæ ¹æ ã¯å
šãååšããªããšã
ãããšã§ãã
ãžãããªã¢ã¯ã¯ãã³æ¥çš®ãå¹ããããã·ã¢äººã«èããŠã¿ããšè¯ãã§ããããäœå幎ãã®éã
ãã·ã¢ã§ã¯ãžãããªã¢ã®é壿¥çš®ã宿œãããŠããŸãããããŠããã®ç
æ°ã¯ã1976 幎ã«ã¯
æ¶ãå»ã£ãŠããã®ã«ã1990 幎ãã㊠1993 幎ã«ãåããã·ã¢ã§ã¯å€§èŠæš¡ãªãžãããªã¢æµè¡
ãèµ·ããŠããã®ã§ããææä»¶æ°ã¯åãããã 1200 ä»¶ãš 6000 ä»¶ã§ãããããŠãããã®äºä»¶
ãèµ·ããã®ã¯ããžãããªã¢ã¯ã¯ãã³æ¥çš®ãå
šåœèŠæš¡ã§è¡ãªãããåŸã«ãªããŸãã
(Garrett,p.504)[223]
Pertussis çŸæ¥å³
ããã¯ã倧ç©ã§ãã
Pertussis ãšã¯ãçŸæ¥å³ã®å»åŠçšèªã§ããããã®ç
æ°ã¯éå»äœäžçŽãã®éã«ã倧å¢ã®ä¹³å
ã®
åœã奪ã£ãæ¿ããç
æ°ã§ããææã®æ©äŒãèŠã€ããŠã¯ä¹ãç§»ããB.pertussis ãšããç©ºæ°æ
æã®ãã¯ããªã¢ããåŒåžåšå®ã®äžéšã«äŸµå
¥ããŸããæ¿ããå³ã§èºã®ç©ºæ°ãå
šéšåãåºãã
ãŠããŸãã®ã§ããŸãæ¯ãåžã蟌ãããšãããšããéã«ããŒã€ãŒã€ãšæ¿ããé³ãããã®ã§ãã
ç
æ°ã«ããã£ãä¹³å
ã¯ããã®æ§ã«åŒåžãããããšããŠããéã«è骚ããããŠããŸã£ããã
ç²åŽã®äœãæ»äº¡ããŠããŸã£ããã®ã§ãã
çŸæ¥å³ããŸããä»ã®ç
æ°ãšåãããã¢ã¡ãªã«ããšãŒãããã®äººå£éå¯ã§äžè¡çãªéœåžã«çº
çããã¡ã§ããã1578 幎ã«ã¯ããªã1695 幎ã«ã¯ããŒãã1850 幎代åŸåã«ã¯ãã³ãã³ããš
ããå
·åã§ããçŸæ¥å³ã¯ãã®åŸãªã«ãä»ã®ç
æ°ïŒå€§æµã¯èºçïŒã«ãããæãããã§ã«åŒ±ã
ãã£ãæ£è
ã¯ããã§ãŸãã£ãŠããŸããŸããïŒïœïŒ [227]ïŒ
çŸæ¥å³ã¯ãè²§ãããå®å
šãªç掻氎ãä¿éãããªããäžè¡çã§äººå£éå¯ãªå°åã®ç
æ°ã§ããã
ã¢ã¡ãªã«ããšãŒãããã®åéœåžã§ãããããæªæ¡ä»¶ã®ç°å¢ãæ¹åãããã«åŸãã衚ïŒã§æ
ããã«ç€ºãããæ§ã«ãäŒæç
ã¯åçã«æžå°ããŠãããŸãããçŸæ¥å³ã«é¢ããŠã¯ããã®ã¯ã¯
ãã³ãæ¬åœã¯ãã ã®è圹ã§ãããªãã£ãããšãããã®è¡šããè¯ãåãããŸããã¹ã³ããã©
ã³ãã®ç ç©¶è
Dr.ãŽãŒãã³ã»ã¹ãã¥ã¯ãŒãã®ææã«ããã°ãäžåã®ã¯ã¯ãã³ãå§ããããå
ã«ãçŸæ¥å³ã¯ 80ïŒ
ãè§£æ¶ããŠãããšããããšã§ãã(Stewart)[238]ããã«ã¢ã¡ãªã«ã§ã¯ã
95ïŒ
è¿ããè§£æ¶ããŠããŸããã[83]
ãããªã®ã«ããªãæ®ã©ãã§ã«è§£æ¶ããŠããç
æ°ã®ã¯ã¯ãã³ãã矩ååããªããã°ãªããªã
ã£ãã®ã§ããããïŒçãã¯ããã§ãããã€ããã®æ§ã«äžå¯è§£ãªåé¡ã®éµãšãªããã®ïŒãé
ã®ãããã«ä»ãªããŸããã
çŸæ¥å³ã®ã¯ã¯ãã³ã¯ãã¢ã¡ãªã«ã§æãè³åŠäž¡è«ã®æ¿ããã¯ã¯ãã³ã§ãã
ãã® 50 幎éã«å¯äžè¡ãªããããçŸæ¥å³ã¯ã¯ãã³ã®å®å
šæ§ã®ç¢ºèªè©Šéšã¯ããºãã®å¢äœéãã¹
ããšåŒã°ããäžæç¢ºãªãã¹ãã§ãããããããç§åŠè
ããããºãã®èµ€ã¡ããã®è
¹éšã«ã¯ã¯
ãã³ã泚å°ãããã®ããºããå³åº§ã«æ»ãªãã«äœéãå¢ãç¶ããã°ããã®ã¯ã¯ãã³ã¯å®å
šã§ã
ããã人éã«ã广ãããããšãããŸããããã¯ãåè«ã§ããªãã§ããªããæ¬åœã«ããã
ãã§å€æãããŠããã®ã§ãïŒïŒCoulter,p.11ïŒ[227]ã§ããããã¯ããã¿çšã®ã¯ã¯ãã³ã§ã¯ã
ããŸããïŒäººéã®ãã¢ã¡ãªã«ã®åäŸéã«å€§èŠæš¡ãªé壿¥çš®ãè¡ãªãããã«ãäœã£ããã®ã§
ãã
ã¢ã¡ãªã«ã§äžç𮿷·åã¯ã¯ãã³ãåæ³åãããããã«èª²ããããå¯äžã®ææ¯æ§ãã¹ããã60
幎åã«è¡ãªããããã®ããºãã®å¢äœéãã¹ãã ããã ã£ãã®ã§ãããã®çµæãçŸæ¥å³ã¯ã¯
ãã³ã®æåããäœçŸäººãã®åäŸã®åœã奪ããäœå人ãã®å¯äœçšåå¿ãå ±åãããŠããã®ã«ã
ãã®ã¯ã¯ãã³ã®åæ³åãèŠçŽãããšèšã声ã¯äžãã£ãŠããŸãããä»çŸåšã«ãããŠãããã®
ããºãå¢äœéãã¹ãã¯ãçŸæ¥å³ã¯ã¯ãã³ã®å®å
šç¢ºèªãã¹ããšããŠã¡ãããšæ²èŒãããŠãã
ã®ã§ãã
ãªãã3 皮混åãªã®ãïŒ
1942 幎ã«ããŒã«ã»ã±ã³ããªãã¯ãšããç ç©¶è
ããäœã®å®å
šç¢ºèªãããªããŸãŸãå»è
ã®éœå
ã®ããã ãã«ãçŸæ¥å³ã®ã¯ã¯ãã³ããžãããªã¢ã¯ã¯ãã³ãšç Žå·é¢šã¯ã¯ãã³ã«ä»ãå ããã
ãšãæãã€ããŸããã[352] äžç³ 3 å
ãšã§ãèšããŸããããã3 çš®é¡ã®ã¯ã¯ãã³ããäžæ
ã«æã€ããã§ããïŒïŒïŒã¯ã¯ãã³ãæ··ãããšãæã
ããã¯ã¯ãã³ãå¥ã®ã¯ã¯ãã³ã掻æ§åã
ããäœçšã匷ããŠããŸãããšããããŸããã€ãŸããããã ãå±éºæ§ãå¢ãããã§ãããã
ã¯ãŠã€ã«ã¹å¹²æžïŒViral interferenceïŒãšåŒã°ãããã®ã§ãã[290]ã§ããããåœç¶ãã® 3 çš®
æ··åã¯ã¯ãã³ãæ··ããéã«å®å
šç¢ºèªãããã ããããšãæãã§ãããïŒ
ãããå°ã£ãããšã«ããã®æ··åã¯ã¯ãã³ã¯åžå Žã«åºåãåã« 1 床ããå®å
šãã¹ãããããŠ
ããªãã®ã§ãïŒããã«ã¯ãã®åŸä»ãŸã§ã®éã«ããå®å
šãã¹ã㯠1 床ãè¡ãªãããŠããŸãã
ïŒïŒïŒïŒWakefieldïŒ[290]ã§ã¯ããã®çµæãèŠãŠã¿ãŸãããã
çŸæ¥å³ã¯1949 幎åã°ã«åæ³åããããã®ãŸãŸ 3皮混åãéåžžã®ã¯ã¯ãã³æ¥çš®ãšããŠè¡ãªã
ããããã«ãªããŸããããã® 3 çš®ã®ã¯ã¯ãã³ã¯ãä¹³å
ãžã®å±éºãå¢å ããã«ããããããã
ãã å»è
ã®éœåã®ããã ãã«ãäžç·ã«æ¥çš®ããããšã«ãªã£ãã®ã§ãããã®äºå®ã¯ãæ¬æ¥ãž
ãããªã¢ãšç Žå·é¢šã® 2 皮混åã¯ã¯ãã³ã ãã§ã¯èµ·ããªãã£ãæ§ã
ãªå¯äœçšé害ã®ç³åãã
幎ã
è©°ãå¯ããŠããŠããããšãããæããã§ããïŒCodyïŒ[229]3 皮混åã®å¯äœçšåå¿ã®åå
ãããã®çŸæ¥å³ã¯ã¯ãã³æåã ãšèšãææã¯ãäœåºŠãç¹°ãè¿ããããŠããŠããã®ã§ããïŒïŒïŒã
ç Žå·é¢šã®æ¶ããªãè¬
ãã®ç
æ°ã¯äžè¬ã«ãã¯ãã¹ããªãã£ã¢ã ãããŒããšãã空æ°ãå«ãã埮çç©ãåŒãèµ·ã
ããšèšãããŠããŸããåºãå·ã«ã¯ç©ºæ°ãè§Šããªãã®ã§ããããã嫿°æ§çç©ã«ã¯ãã£ãŠã
ãã®ç°å¢ã§ããäžæ¯è
ã¯ãããããããç
æ°ã§ãããã®ç
æ°ã§ããŸããã°ãèã¯å
ç«æ©èœ
ãæã匱ã£ãŠãã人ã
ïŒè¬ç©äžæ¯è
ãäžè¡çãªç°å¢ã«äœãã§ãã人ã
ã奜ãã§çããŸãã
ïŒMerck Manual .1176ïŒ[280]
ããŒã¯ã¯ãã®ç
æ°ã«ããã£ãäººã®æ»äº¡çã 50ïŒ
ãšããŠããŸããããã®æ°åãã©ããããã
ã®ãã¯ã誰ã«ãè¬ã®ãŸãŸã§ããããããç Žå·é¢šã§æ»ãã§ããã®ã¯ã楜ãªãã®ã§ã¯ãªãããš
ã¯ç¢ºãã§ãããããèäžã暪éèã®çèã容赊ãªãçæ£ãèµ·ããç¶ããæ°æ¥åŸã«æ£è
ãã
ã«è³ããããŸãã
å床ã衚 2 ãåç
§ãããšãç Žå·é¢šã®ã¯ã¯ãã³ãåºåã以åã«ããã®ç
æ°ããŸããæ®ã©æ¶æ»
ããŠããããšãåããã§ããããç Žå·é¢šã¯ã¯ãã³ã¯ã1940 幎代ããé壿¥çš®ã«åãå
¥ãã
ããŠããŸããã1950 幎以éã«ã¯ãåäŸã18 ã¶æã«ãªãåã«ã4 åã® 3çš®æ··åæ¥çš®ãåãã
ããã«ãªããŸããããã®åŸã«ã¯ãéãèžãã ãå°ããªå·ãåºæ¥ãããã€ã§ãããæ±ºãŸãã®
ç Žå·é¢šããŒã¹ã¿ãŒ(掻æ§çšã®è¿œå 泚å°)ãåããããšã«ãªããŸããããããããã¯ãŸã£ããèš³
ãåãããŸããïŒ ã¯ãã¹ããªãã£ã¢ã èãå«ãã§ããå¯èœæ§ãã»ãšãã©ãŒãã®å·ãè² ã£
ã人ãã確å®ã«ã¯ãã¹ããªãã£ã¢ã èãããã®å¯ç£ç©ãå«ãã§ããæ³šå°ãããããšã§ãç
æ°ãå
æãããªããŠããŸã£ããççŸããèãã§ã¯ãªãã§ããïŒ
ã¯ã¯ãã³ãæªæãããåã®æç¹ã§å
ç«æ©èœãäžããŠãããããšäž»åŒµããããšã¯ããŠããã
å®éã«ææããåŸã«ãã®ã¯ã¯ãã³ã®æ³šå°ãããŠå
ç«æ©èœãä»ããããªã©ãšããèãã¯åºæ¬
ã®å
ç«ç§åŠã®çã«å®å
šã«åããŠããŸããããã¯ãå
šãè¿·ä¿¡ãã¿ãè¡çºã§ãã補è¬ç€Ÿã®ã»ã
ã§ãããã¯ã¯ãã³ã«ãç
æ°ãæ²»ã广ãããããªããŠäž»åŒµãããããšã¯ 1 床ããããŸããã
ã¯ã¯ãã³ã¯ãç
æ°ãäºé²ãããã®ã ã£ãã¯ãã§ãããïŒããã§ããã®äºé²æ¥çš®ããªã®ã§ã
ããã
ããã«ç Žå·é¢šããŒã¹ã¿ãŒã«ã€ããŠããã¡ã³ãã«ãœã³ã¯40 幎ããšãããçãæéã§æ¥çš®ãã
å¿
èŠã¯ãªãã®ã§ã¯ãªããããšçåãå±ããŠããŸããïŒHow To, p195ïŒ[246]
1995 å¹Žã«æžããããDr.ã¢ã¬ãã¯ã»ããŒãã³ã«ããçŽ æŽãããèšäºããããŸããã[339]ã
ãã§ããŒãã³ã¯æ
å ±æºãšããåèè³æããã¹ãŠæ²ç€ºããäžã§ãç Žå·é¢šã«ãŸã€ããè¬ã®è£äº
æ
ããïŒã€ïŒã€è§£æããŠããŸãïŒ
ç Žå·é¢šã®èã¯ãåšãã«ãããããããã®ã§ãããå¥åº·ãªäººã®å£ã®äžã«ããæ¶å管ãç®èäž
ã«ããæã«ããã»ããã«ãæ··ãã£ãŠãããã®ã§ããããã§ããç Žå·é¢šã«ææããããšã¯ã
æ»
å€ã«ãããŸãããæŠäºã§è² å·ããå·ã® 20ïŒ
ã«ããã®èã確èªãããŸããããç Žå·é¢šã®æ
æã¯ããŠããŸããã§ããããéã«ãå®éã«ç Žå·é¢šã«ææããäºäŸã® 50ïŒ
ã§ã¯ãèãã®ãã®
ãäœå
ã«èŠãããªãã£ãããšã®ããšã§ããã¯ãã¹ããªãã£ã¢ã èã¯ãèªç¶ãªç¶æ³ã«ãããŠ
ã¯ç¡å®³ãªååšã§ããããšããããã§ããããŸããããããŠãç Žå·é¢šã®ã¯ã¯ãã³ãç Žå·é¢šã
äºé²ãããšãã蚌æ ã«ãªããããªçµæã¯ãçŸåšã«ãéå»ã«ãäžåç¡ãã®ã§ãããã®äžãã
ã®ã¯ã¯ãã³ã¯ã²ã©ãå¯äœçšããããããæã«ã¯æ»ã«è³ãããšãããïŒïŒïŒãåãã£ãŠããŸ
ãã[349]
ããã«æè¿ã¯ãHyper-Tet ãªã©ã®æ°çš®ã®ç Žå·é¢šã¯ã¯ãã³ã«ãã£ãŠãå±éºãããã«åŒ·ãŸã£ãŠã
ãŸãããã®ã¯ã¯ãã³ã¯ãã¯ãã¹ããªãã£ã¢ã èãæ¥çš®ãã人ã®ç²ŸåããäœãããŠããŸãïŒ
èãåæŽ»æ§åããæ¹æ³ãããã匷åãªãã¯ã¯ãã³ãæåºããããã«äººäœãåç©ã®äœå
ãé
ããŠåŒ·ããããšãããå±éºã§å
šãéç§åŠçãªãžã§ããŒæ¹åŒã®ããæ¹ã§ãã([251] PDR 2007
p3248)
決ãæãšãªãã®ããã¯ãã¹ããªãã£ã¢ã èã«ææããåŸã«ç Žå·é¢šã¯ã¯ãã³ãäœã«è¶³ããŠã¿
ãããšã§ãç Žå·é¢šãçºçããããšãé²ãããšèšŒæã§ããæ£åœãªç§åŠãªã©ãã©ãã«ãååšã
ãªããšããäºå®ã§ããèããŠãèŠãŠãã ããïŒãããã§ã«ããªãã®äœå
ã§ææã®ããã»ã¹
ãå§ãŸã£ãŠãããšããã«ããã®ç
åèããç
åèããäœãããèãè¡æ¶²ã«æ³šå°ããŠå¢ãã
ãŠã¿ãŠãäœã®å©ãã«ãªãã§ããããïŒããã¯ïŒ³ïŒŠãŸããã®ãã§ããããšããèšããŸããã
ãããªã§ãããããããé¡ã§èšããã®ã¯ãå®éã«ãã®ã¯ã¯ãã³æ¥çš®ã宿œããŠãããå»è
ããéã ãã§ããããå¶æ¥ã®ããã«ããããªã§ããããŸã§äœ¿ã£ãŠããŸãã®ã§ãã
ããããŠã¿ããšã广ãã¯ã£ããããªãã¯ã¯ãã³ãåäŸéã«ãããæã£ãŠããŸãããã¯ã
æç¢ºãªèšŒæ ãååã«ãããå¿
èŠæ§ã確信ãããæã«ã®ã¿è¡æ¶²ã«æãå ããã ãã«éã£ãæ¹
ãæžåœãªè¡ãã®ããã«æããããŸããç¹ã«ããã®ç©ºæ°æææ§ã®äŒæç
ã®å
žåçãªææã«ãŒ
ãã§ãããçªãåºãå·ãšããæ¹æ³ã§è¡ãªãããã¯ã¯ãã³æ¥çš®ã«é¢ããŠã¯ããªãããã®ããš
ã§ãïŒ
ããã®åŸ®çç©ã¯ã¯ã¯ãã³ã«å«ãŸããŠããªããŠããã©ã®å·ã§ãæ©äŒãèŠã€ããŠäŸµå
¥ããŠãã
ãã®ã§ãããããã«ãã¯ã¯ãã³æ¥çš®ã®åŸã«ç Žå·é¢šã«ææããå±éºæ§ã¯ã倧ãã«æžå¿µããããã
ïŒS.ThomasïŒ[353]
èããŠãã¿ãŠãã ãããéå€ã§æ±ããã³ä»ãããéçåç©ã®çè·¡ã«ãã£ãŠã¯ãã¹ããªãã£
ã¢ã èãã¯ã³ãã£ãŠããããªéãåºããŠå·ãè² ã£ãåŸã«ãç Žå·é¢šã®æ³šå°ããããšããåŸæ¥
ã®èãããã©ããã©ããã£ãŠãå®¶ã®äžã§ããæž
æœãªãããå·çšåºŠã®å·ã®ããã«ç Žå·é¢šæ³šå°
ãå¿
èŠã ãªã©ãšããèãã«åã£ãŠä»£ãã£ãŠããŸã£ãã®ã§ããããïŒ
æããã€ãã®å»è
ã«ãæåŸã«ç Žå·é¢šã®æ£è
ã蚺æããã®ã¯ãã€ã ã£ãããããããå®¶ã§èµ·
ããåºãå·ããææããæ£è
ãæ¬åœã«ããããèããŠã¿ããšè¯ãã§ãããããããšããã®
å»è
ãæ¬åœã¯ã©ãã ãç Žå·é¢šã«ã€ããŠç¥ã£ãŠããïŒç¥ããªãïŒããããåããã«ãªãã§ã
ããã
äžç𮿷·åãå«ãæå®³ç©è³ª
ãŸããäžç𮿷·åã¯ã¯ãã³ã®ä¿åæã«ã2004 幎ãŸã§ã® 60 幎ãã®éãã¡ããµãŒã«ãšããæ°Žé
ç©è³ªã䜿ãããŠããããšãå¿ããŠã¯ãããŸããïŒãããŠä»ã§ãããã«ã ã¢ã«ããããšãã
çºããæ§ã®é²è
倿¶²ã䜿ãããŠããããšããïŒïŒ°ïŒ€ïŒ²ïŒ[16] æ°Žéã¯ãç¥çµé害ãèµ·ããç©
質ã§ããããã«ã ã¢ã«ãããã¯çãåŒãèµ·ãããŸããæ¬¡ã«æããæ§ã
ãªïŒ€ïŒ°ïŒŽã®å¯äœçšå
å¿ãšããããé¢ä¿ããŠãããã©ããã¯æããã§ããïŒ
å¯äœçšåå¿
ã§ã¯ãçŸæ¥å³ã¯ã¯ãã³ã®ã¿ã«å¯Ÿããå¯äœçšãèŠãŠã¿ãŸãããã198ïŒå¹Žã«ïŒµïŒ£ïŒ¬ïŒ¡å€§åŠãã
ãã®ïŒ€ïŒ°ïŒŽäžç𮿷·åã«å¯Ÿããå¯äœçšåå¿ãšãäºç𮿷·åã«å¯Ÿããå¯äœçšåå¿ãæ¯èŒãã
ãšãã調æ»ãè¡ãªã£ãŠããŸããããã®çµæã¯æ±ºå®çã§ããPediatrics ã® 6 ããŒãžç®ã1981
幎 11 æ 5 æ¥ã®ç®æã«ã¯ãæ¬¡ã®æ§ãªå²å衚ãèŒã£ãŠããŸãã[229]
åå¿ ïŒ€ïŒ°ïŒŽ 
çã¿ 50.9ïŒ
9.9ïŒ
çºç± 46.5ïŒ
9.3ïŒ
ç æ° 31.5ïŒ
14.9ïŒ
飿¬²äžæ¯ 20.9ïŒ
7ïŒ
ã€ãŸãããã®ããã®éšåïŒçŸæ¥å³ããåé¡ã®æ§ã§ãããããã§ããããïŒ
ã«å¯Ÿããå¯äœçšåå¿ã«ã¯ããã®ä»ä»¥äžã®çç¶ããããŸãã[229]
æ»äº¡ åå
çèçæ£ çºäœãã²ãã€ã
ç²é«ãå«ã³å£° ã¢ããã£ã©ãã·ãŒ ã·ã§ãã¯
è³çïŒè³ã®çºç±ïŒ
çµèº«ã®ç¥çµé害
ïŒCody[209]
æ¥çš®ã®çŽåŸã«ãç²é«ãå«ã³ã ããèµ€ã¡ãããåšãã«ããŸããã§ãããïŒäžç𮿷·åã®æ¥çš®åŸ
ãšããã®å
žåçãªãç²é«ãå«ã³å£°ããšããçç¶ãé¢é£ä»ããè³æã¯ãäœå幎ãã®éé »ç¹ã«
èŠãããŠããŸãã倧åŠã®èª¿æ»ã®çè
ã® 1人ã¯ããäºé²æ¥çš®ãã§ã¿ãããäžè²«ããæ
床ãéåžžã«ãã衚çŸããŠããã³ã¡ã³ããæ®ããŠããŸãã
ãäžç𮿷·åã®äºé²æ¥çš®åŸã«èµ·ããç°åžžãªç²é«ãå«ã³å£°ã®çç¶äŸã¯ã以åããäœä»¶ãå ±åã
ããŠããŠãçè
ã®äœäººãã¯ããã®çç¶ã倧ããªå¯äœçšåå¿ã®åºåã«å«ãã¹ãã ãšæããŠã
ãããããããã®åå¿ã®æ·±å»åºŠåãã«ã€ããŠã¯ãäžæã§ãããã Pediatrics [229]
äžæãã§ãã£ãŠïŒã§ã¯ãå°äžã«çãŸããŠãŸããªãå°ããªåœããæªçºéãªäžæ¢ç¥çµæ©èœã«æ¯
ãå
¥ããããŠæ¿ããèŠçã«è¥²ãããçãæ®ãããäžå®ã§æ»ã¬ã»ã©ãã³ããŠãããšããïŒïŒïŒ
ãããªèª¬ã¯ã©ãã§ããããïŒå¿è«ãããã¯ã極端ããªèª¬ã§ããã¡ããšç£ä¿®ãããç§åŠç調
æ»ãã®æ ¹æ ç¡ãã«ã¯éããªãããšèšãããã§ããããããããŸã§ã¯ãå«ã³å£°ãªã©ç¡èŠããŠã
ç¡é²åãªåäŸéãçãç¶ãããããšããããšã§ãã
ç²é«ãå«ã¶ããšããçç¶ã«ãè¬ãªã©ãããŸãããã³ãŒã«ã¿ãŒïŒïœïŒïŒïŒ[227]ã¯ãç¥çµæ©é¢
ã®èŠçãšãæ³£ããããå«ã³å£°ãäžãããšããçç¶ã®é¢é£æ§ã瀺ãèšäºãã1961 幎ãŸã§é¡ã
å»åŠèª¿æ»ã®åèè³æã瀺ããŠèŒããŠããŸããããã¯ãçŸåšã®èªéçãšæ°Žéã®é¢é£æ§ã®èª¿æ»
ãšãå®å
šã«æ¯äŸããŠããã®ã§ãã ïŒGeierïŒ[59]
ãããªããšããããªã«å匷ããªããŠãåãããšæããŸãããïŒ
äžç𮿷·åã«ããç¥çµæ©èœã®é害
äžç𮿷·åæ¥çš®ã«ããå¯äœçšã®å€ãã¯ãäžèšã®ã³ãã£ãŒæ°ãæãããããªãç¥çµæ©èœã®äžæ
çããããã¯ç涯çãªè² å·ã«ãã£ãŠèµ·ãããã®ã§ããçŸæ¥å³ ã®ãã¯ããªã¢ãåçž®ãããã®
ã¯æãææ¯ãªèŠçŽ ã®ïŒã€ãå«ãã§ããã®ã§ããã®ã¯ã¯ãã³ã®è£œé éçšã§ç±ãšãã«ã ã¢ã«ã
ããã«ããæ®ºèãã倧å¹
ã«åžéããç¶æ
ã«ããŠäœ¿ãå¿
èŠãããããšãèŠãã°ãããã¯è³æ¥µ
åœç¶ãªããšã§ãããã®çµæçãŸãããã®ã¯æ¯çŽ ãšããã«ããŽãªãŒã«å
¥ãã¯ã¯ãã³ã§ããã
ã¯åã«ãã³ã³ãããŒã«ããããæ¯ãšããæå³ã§ããããã«ãåã«ãæããŸãããããã®åŸ
äžç𮿷·åã¯ã¯ãã³ãšãªã£ãéã«ã¯ä¿åå€ãšããŠæ°Žéã䜿çšãããŸãïŒæ°Žéäžæ¯ãç¥çµçްè
ãç§åŠæ»æããŠè³ã«é害ãäžããããšã¯ãäœå幎ãã®éç¥ãããŠããããšãªã®ã«ãã§ãã
ïŒWidman ,Bernard ,CaveïŒ[196,166,172]
ããã§ãçåŸ 2 ã¶æã®ä¹³å
ã®çºéäžã®è³ãç¥çµæ©é¢ã®ããšãèããŠã¿ãŠäžãããèé«ã®ç¥
çµæ§æã¯èªçæããã¯ããŸããã®ã§ãã®ã§ããŸã ä¹³å
ã®ç¥çµã¯ãã€ãªãããªããçºéããŠ
ããéäžã§ããèµ€ã¡ããã®çºé床ã«ã¯å人差ããããæ©ãåºããã話å§ããã®ãæ©ãåã
é
ãåãããŸããç¥çµæ©èœã«ã€ããŠããåãããšãèšããŸãããããã«çåŸ 2 ã¶æã®ä¹³å
ã®ç¥çµæ©èœãããã«ã ã¢ã«ããããšæ°Žéãå«ãã ç°å¢ã«å¯Ÿå¿åºæ¥ãããšèšŒæãããããªæ€
æ»ã¯ãæªã è¡ãªãããããšããããŸããããããªæ€æ»ã¯ãä¹³å
ã®çºè²ã®å人差ãèããã°ã
ç¡çã ãšèšããã§ãããããã®çç±ããããšãŒãããã®æ®ã©ã§ã¯ãããŠå
ç«æ©èœãããçš
床ãŸã§çºéããããã«ãšãã¯ã¯ãã³æ¥çš®ã 2 æ³ããã«ããŠããã®ã§ããïŒ[227]ïœ13ïŒæ¯ã¹
ãŠã¢ã¡ãªã«ã®åäŸéã¯ã2æ³ãŸã§ã« 36åãã¯ã¯ãã³æ¥çš®ãåããŠããããšã«ãªããŸãïŒ
以åã«ç€ºãããç³åããããšæ§ããå¶åºŠãããã«ãé¢ãããã1933 幎以éïŒMadsenïŒ[237]
ã®èª¿æ»ã§ã¯ãäžç𮿷·åãåããç¥çµé害ãè² ã£ãä¹³å
ã®æ°ãç®ãèŠåŒµãã»ã©å€ãããšãå
ãã£ãŠããŸããé¢é£æ§ãã¯ã£ããããŠããã®ã«ãããã§ãç§éã¯ã¯ã¯ãã³æ¥çš®ãç¶ããŠã
ãŸãããããŠæãåè¡åœã§ã¯çŸåšãäžçã§å¯äžãæå€ã§ 5 åããäžç𮿷·åãæ¥çš®ããããš
ã«ãªã£ãŠããã®ã§ãã
äžç𮿷·åããããšã DTaP?
ãããŸã§ã«éåžžã«å€ãã®å¯äœçšè¢«å®³ããçŸæ¥å³ã®æåã®ããã ããšç³åãããŠããããã
ãããã«è£œè¬ã®å¶æ¥éšéãããããæ°çš®ã®æ¹è¯çãåºããªããã°ãšèãå§ããŸããããã
㊠1996 幎ã«çºè¡šãããã®ããçŸæ¥å³ãã¯ããªã¢ã®å现èã䜿ã£ãæ°çš®ã§ãããã®å现èã¯
ã¯ãã³ã¯çŸæ¥å³ã®ãã¯ããªã¢ããŸãããšäœ¿çšããŠããªãã®ã§å®å
šãããã§ããŠããã®éæ³
ã®æäœåå¿ãåŒãèµ·ããã«ã¯ååãªãã¯ããªã¢ã®æåãå«ãŸããŠããŠããããå€ã
äžç𮿷·åã®æã®ã²ã©ãå¯äœçšãæ»äº¡ãªã©ã®åå¿ã¯èµ·ãããªãããšå®£äŒããŠããŸãããã®æ°
çš®ã¯ã¯ãã³ã®çºè¡šã«ããã£ãŠãé·æçãªãã¹ããäœãè¡ãªãããã§ããããïŒæ°ããäžçš®
æ··åã¯ã¯ãã³ã«å«ãŸãããã¡ããµãŒã«ã®éã¯æžã£ãã§ããããïŒããããåŸã«èªéçã®é
ã§ç€ºããŠããŸããããã® DTaP äžç𮿷·åã 1 åæ¥çš®ãããšããå®ãã 1 æ¥ã®æ°Žéã®
蚱容å€ã®ã30 åããä¹³å
ã«æ¥çš®ããããšã«ãªãã®ã§ãïŒ
现èãé现èãããªããŠããããŸããã«åŒã£ããããªãããã«æ³šæããŠãã ãããæ°çå
ã®è¡æ¶²ãžã®å
šäœçãªæ¯æ§ãšããæå³ã§ã¯ããããªåºå¥ãªã©ãæå³ãç¡ããã®ãªã®ã§ãã
ããŠãDTaP ã¯ã¯ãã³ãåºãŠããæã«åšåº«ã«æ®ã£ãŠããäœçŸäžååãšãã DPT ã¯ã¯ãã³ã®
æ¹ã¯ãã©ããªã£ããšæããŸããïŒçã¯ãªããšïŒãã®ãŸãŸæ®ã£ãŠããã®ã§ããDPT ã¯ã¯ãã³
ã®å±éºæ§ãåå ã§ãæ°ãã DTaP ã¯ã¯ãã³ãäœãããšã«ãªã£ãã«ãé¢ãããããã®æ§åã®
æ°ŽéæŒ¬ãDPTã¯ã¯ãã³ã¯ãæªã ã«èš±å¯ãããŠãã補åã§ããããã䜿ãããå»è
ã¯å¥œããª
ã ã䜿ã£ãŠããããšã«ãªã£ãŠããã®ã§ãã[163]
äœã£ãåã¯ã第äžäžçã®åœã
ã«èŒžåºããã°ããã§ãããã?
çªç¶æ»(SIDS) ãš DPT äžç𮿷·å
ãªãŒã¹ãã©ãªã¢ã®ç ç©¶è
ããŽã£ãšã©ã»ã¹ã±ã€ãããŒå士ããä¹³å
ã®çªç¶æ»ãšäžç𮿷·åæ¥çš®
ã®é¢é£æ§ã«æ°ä»ããã®ã¯ãå¶ç¶ã®åºæ¥äºããã§ãã圌女ã®å€«ããçªç¶æ»ãé²ãããã®è©Šã¿
ãšããŠãä¹³å
ã®åŒåžã¢ãã¿ãŒãäœã£ãããšããã£ããã§ããã
ãŸããªãã¹ã±ã€ãããŒå€«åŠ»ã¯ãäœçŸäººãã®ä¹³å
ã芳å¯ããŠãããã¡ã«ãèŠçãèµ·ããæç¢º
ãªãã¿ãŒã³ãããããšã«æ°ä»ããŸãããäžç𮿷·åãæ¥çš®ããåŸã16 æ¥éèŠçãç¶ã
ïŒãã®ãã¿ãŒã³ã¯ãééããªãã¯ã£ããããŠããŸããããããã倫劻ã¯ãèªåéã®çºèŠãã
ããã·ãŒã§ã® 200 ä»¶ã®çªç¶æ»ã®ç ç©¶ãå«ããæ²¢å±±ã®é¢é£ããç ç©¶ã«ç
§ããåãããçµæã
ãããšåããã¿ãŒã³ãèŠãããããšã«æ°ä»ããã®ã§ãã
倧æµã®åœã§ã¯ããã®ã¹ã±ã€ãããŒã®æ¥çžŸããã£ãã«ãªã£ãŠãã¿æ¶ãããšããŠããŸããã圌
女ã¯è² ããã«åªåãã€ã¥ãããšããšããªãŒã¹ãã©ãªã¢ã§ã¯ïŒ€ïŒ°ïŒŽäžç𮿷·åæ¥çš®ã®çŸ©ååã¯
廿¢ã«ãªããŸããã[243]
1983 幎ã«ã¯ Los Angels Country Coronerâs Office ã«ãããŠããäžç𮿷·åãšïŒ³ïŒ©ïŒ€ïŒ³
ïŒä¹³å
ã®çªç¶æ»ïŒã®é¢é£æ§ã瀺ãç ç©¶ããããŠããŸãããæè¿ãæ¥çš®åŸã® 24
æé以å
ã«æ»äº¡ããŠããããã·ãŒå·ã®ä¹³å
200 人ã«é¢ãã調æ»ã宿œããã®ã§ããããã
ã«ç ç©¶å¡éãèå³ããã¡ãé¢é£æ§ãããã調ã¹ãŠã¿ãããšæãç«ã£ãã®ã§ããããã§ã
ã®ç ç©¶è
ã°ã«ãŒãã¯æè¿çªç¶æ»ã§äº¡ããªã£ã 145 人ã®ä¹³å
ã®äž¡èŠªã«äŒã£ãŠè©±ãèããŠã¿
ãŸããããã®çµæåãã£ãããšã¯ã次ã®éãã§ãã
çªç¶æ»ãã€ãã 145 人ã®ä¹³å
ã®ãã¡ã53人ãå°ãåã«ïŒ€ïŒ°ïŒŽæ¥çš®ãããã°ããã§ããã
å
èš³ïŒ
äžç𮿷·åæ¥çš®ã®åŸãïŒé±é以å
ã«æ»äº¡ããä»¶ ïŒïŒïŒ
ïŒé±é以å
ã«æ»äº¡ããä»¶ ïŒïŒïŒ
ïŒæ¥ä»¥å
ã«æ»äº¡ããä»¶ ïŒïŒïŒ
ç ç©¶å¡éã¯ããã®ããŒã¿ããæ³šç®ãã¹ãæ°ã§ãããïŒBaraffïŒ[230]ãšè¿°ã¹ãŠããŸãããç§ã«
èšãããã°ããã¯ããã¶ãæ§ãããªè¡šçŸã§ãã
æ¥æ¬ã«ããããè¯ãçãæä»£
ã¹ã±ã€ãããŒã¯èªèã®æ¬ã®æåã®éšåã§ãïŒïŒïŒïŒå¹ŽããïŒïŒïŒïŒå¹Žã®éãæ¥æ¬ããã®ç
æéã ãæ£æ°ãåãæ»ãããšè¿°ã¹ãŠããŸãããã®ïŒïŒå¹Žéã ããæ¥æ¬ã§ã¯ïŒ€ïŒ°ïŒŽäžç𮿷·å
æ¥çš®ããïŒæ³å
ãããã«å»¶æããŸãããããã®é SIDS çªç¶æ»ãçç¡ã«ãªã£ãã®ã§ããã
ããŠæ¿æ²»çãªçç±ããïŒïŒïŒïŒå¹Žã«æ¥çš®ããçåŸïŒã¶æãããã«æ»ããŸãããããã®çµæã
çªç¶æ»ããŸãèµ·ããå§ããã®ã§ãã[232]誰ãããã« æ°ä»ããªãã£ãããªããŠããšã¯ãããŸ
ããããã
äžçäžã®DPT äžç𮿷·å
DPT äžç𮿷·åãš SIDS çªç¶æ»ã®é¢é£æ§ã«ã€ããŠã¯ãä»ã«ãæ£åŒãªç ç©¶ãæ²¢å±±ãããŠããŠã
ã³ãŒã«ã¿ãŒã®èæ¬ã«ç޹ä»ãããŠããŸãã[227] äœåºŠãèšããŸãããçŸæ¥å³ã¯ããã®ã¯ã¯ãã³
ãåºåã以åã«ããã§ã«ã»ãšãã©æ¶ãå»ã£ãŠããç
æ°ã§ããDPT äžç𮿷·åã«ã¯éåžžã«æ²¢å±±
ã®åé¡ç¹ããããããçŸåšããã矩ååããŠããåœã¯ããããããã§ããã¹ãŠã§ãŒãã³ãª
ã©ã1979 幎ã«äžæ¢ããŠããŸããïŒTrollforsïŒ[231] åœæãçŸæ¥å³ã«ããã£ãä»¶æ°ã¯äžæå¢
ããŸããããçç¶ã¯ä»¥åãããã¯ããã«è»œããã®ã§ããã®åŸã¹ãŠã§ãŒãã³ã«çŸæ¥å³ã§æ»äº¡
ããä¹³å
ã¯ïŒäººãããŸããããããããã®æ§ã«ç
æ°ã«ããã£ã人ã«ã¯ãæ¬ç©ã®èªç¶ãªå
ç«
ãã€ããŸããæãåœã§ã® DPT æ¥çš®ããã°ã©ã ãªã©ãããããåŠã¶ããšãå€ã
ããããã§ã
ãã
ããã«ãæ¥æ¬ã西ãã€ããã€ã®ãªã¹ããã®ä»ãšãŒããã諞åœã«ãããŠãåæ§ã®ããšãèµ·ã
ããŸãããã¯ã¯ãã³æ¥çš®ãæ¢ãããšãç
æ°ã¯äžæŠå¢ããŸãããã以åããã軜ãçç¶ã§ã
ããããã«ãã£ãŠæ»äº¡ããä¹³å
ã¯ããªããªã£ãããšãããã®ã§ããããã§éèŠãªã®ã¯ã¯ã¯
ãã³æ¥çš®ãäžæ¢ããåŸãåéããŠããåœã¯ã©ãã«ãèŠåœãããªããšããç¹ã§ãïŒèª€ãïŒæ¥
æ¬ã¯åéããŠãããåããããŒã»ãã¬ã¢éŠçžæä»£ã«ãè±åœãåéïŒã西ãšãŒãããã§çŸæ¥å³
ã®ã¯ã¯ãã³æ¥çš®ãããŸã ã«çŸ©ååããŠããåœã¯ãã¢ã€ã¹ã©ã³ãã ãã§ããïŒ[227] p95ïŒ
ãã®ä»ã®å¯äœçšåå¿
çŸæ¥å³ã¯ã¯ãã³ã«å¯Ÿãããã®ä»ã®å¯äœçšåå¿ã¯ã以äžã®éãã§ãã
ã¢ããã£ã©ãã·ãŒ ã·ã§ã㯠è³ç
æ»äº¡ è
ç¥çµç
çºäœãããã ã®ã©ã³ ãã¬ãŒç
ãããŸãã èã®ãã ã
é¢ç¯ã®çã¿ äœè¡å§
åŒåžå°é£ å£ã®è
«ã
乳幌å
ã®ã²ãã€ã ä¹³å
ã®æ³éïŒé ã®ãŠã£ãºãïŒã®è
«ãããã
-PDR, 2002 幎 ïœ.1854 [251]
以äžã®çç¶å
šãŠã¯ãæ°Žéã«ããäžæ¯åå¿ãšå
šãåãã§ããDPT ã«ã¯ 2005 幎ãŸã§ããã¡ã
ãµãŒã«ãšããæ°Žéç©è³ªãå«ãŸããŠããã®ã§ãã(Bernard,2000) [166]
æ¥çš®ã¯ã1 床ã§é§ç®ãªããã 2 床ãšããªãããš
JAMA èªã® 1949 幎å·ã«ããã Toomey èã®èšäºä»¥æ¥ãDPT ã«ããå¯äœçšãåãæ±ã£ãå»
åŠé¢ä¿ã®èšäºã¯ã¿ãªã次ã®ç¹ã§æèŠäžèŽããŠããŸããã1 床ã§ãå¯äœçšåå¿ããã£ãåäŸã«
ã¯ãå°æ¥ 2åºŠãšæ¥çš®ãããŠã¯ãããªãããå®¶æä»£ã
ã«ç¥çµæ§ã®ç
æ°ãããã®ä»ã©ããªç
æ°ã
ã«ããã£ã人ãããåäŸã«ã€ããŠããåæ§ã§ããããã¯åŠçã®ã©ã®ç ç©¶èªã«ãããŠãå
±é
ããŠèšãããŠããããšã§ããã1975幎ããã¯WHOã®æ£åŒåºæºã«ããªã£ãŠããŸããã€ã®ãª
ã¹ãã¹ãŠã§ãŒãã³ããªã©ã³ãã«ãããŠã¯ããã®åºæºã峿 Œã«å®ãããŠããŸããïŒp129 [227]ïŒ
CDC ã®ç
æ°çŸæ£å ±åæžïŒMMWR vol.36ïŒã«ãããŠããããå®¶ç³»ã«çºäœãããããèµ·ããã
ããšããã人ãããå Žåããã®äººã DPT æ¥çš®ãåããåŸã«çºäœãèµ·ãã確çã¯ãéåžžã®9
åã«ãªããããšç€ºãããŠãããããã§ãã[234]
ããã§ãå°éå®¶ãç¡èŠããã¢ã¡ãªã«
å®éã®ã¢ã¡ãªã«ã§ã¯ã以äžã®ãããªåºæºãã¯ãªã¢ããŠãããã©ããã®èæ
®ãå
šããããŠã
ãªãã®ãçŸå®ã§ããçç£è
ãããªã¹ã¯ãé«ãããšèšã£ãŠãã察象ã®åäŸéããã¡ããšèšºæ
ããŠæ¥çš®ãè¡ãªããªãããã«ãããšããå¶åºŠããå
šç¶ãªãã®ã§ãããããªããšãããŠãã
æ¿æ²»çã«ã¯äœã®åŸã«ããªããªãã®ã§ãå°å
ç§å»ã®ã»ãããã¡ãã¡ãã®åã®å®¶ç³»ã« DPT äžçš®
æ··åãžå¯äœçšåå¿ã瀺ãã人ããããèãããããããã¯ãã®åãéäžç¥çµæ©é¢ã«é害ã
ãã£ããã以åã¯ã¯ãã³æ¥çš®ã§å¯äœçšåå¿ãããããããšããããããªã©ã®çç±ã§æ¥çš®ã
æããªããŠããšã¯ããŸããããããªããšããããããã®å»è
ã¯ãããäºãèç«ãŠãããã
åé¡å
ãšããŠã仲éã¯ããã«ãããŠããŸããŸãããã
ã¢ã¡ãªã«ã®å»è
éããäžçã§å®æœãããŠããå»åŠèŠå®ãç¡èŠããŠæ¥çš®ãè¡ãªã£ãŠãããšã
ããã®å²æ
¢ãªæ
床ãã¿ããšãããã«ãã®åœã®ã¯ã¯ãã³æ¥çš®ãæ¿æ²»è²ã«æãŸã£ãŠããããå
ãããŸããïŒå
šç±³å°å
ç§å»é£å(APA)ã¯ããå®¶ç³»ã«çæ£çºäœãç¥çµæ§ã®ç
æŽãããããšã¯ã
æ¥çš®ã®çŠå¿äºé
ã«ã¯åœãããªãããšãã声æãŸã§çºè¡šããŠããæ¬¡ç¬¬ã§ãã(APA Red
Book)[253] ãããäœã§ããã²ã©ãæ
床ã ãšæããŸãããïŒ
ã©ããïŒã€ã ãããšãããªã DPT ãå€ã
ã¯ã¯ãã³æ¥çš®ã®äžã§ãããã ãã¯çµ¶å¯Ÿãããæ¹ãããããšããã®ã 1 ã€éžã¹ãšãããããã
çãã¯DPT äžç𮿷·åæ¥çš®ã§ãã1991 幎以éãVAERS ãã¯ã¯ãã³æ¥çš®ã«ããé害ã«å¯Ÿãæ¯
æã£ãç·é¡ 15 åãã«ã®å
ãDPT äžç𮿷·åã«ããå¯äœçšåå¿ã®å¯Ÿè±¡é¡ã¯ãªããšïŒïŒïŒ
ã«ã
ãªã£ãŠããŸãã(Goodwin, Dodd [163,351])
DPT äžç𮿷·åæ¥çš®ã¯ãæ¬åœã«å¹ãç®ãããã®ãïŒ
å
šç±³ã® DPT æ¥çš®ç㯠85%ã«ããªããŸãããæªã ã«çŸæ¥å³ã®çºçä»¶ã¯æ¯å¹Ž 5000~7000 ä»¶ã¿
ãããŸããããã«ããã®çºçä»¶æ°ã¯ã1980 幎以éã確å®ã«äžæããŠããã®ã§ããïŒCDC[83]ïŒ
ãã®çç±ã¯ããå
ç«ããæ°å¹Žã§å¹æãåããããšã§ããããããŠå
ç«ãåãã人ã¯ãæäººã«
ãªã£ãŠããç
æ°ã«ç°åžžãªåœ¢ã§ææããå±éºãåºãŠããŠããŸããŸãããããããããã®ç°åžž
圢æ
ã®ç
æ°ã«ãŸã£ããæµæåã®ãªãä¹³å
ã«ãææããå¯èœæ§ãé«ãŸããŸãã
ãã 1 ã€åé¡ããããŸããã¯ã¯ãã³æ¥çš®ãåããŠããªãä¹³å
ã®æ°ã¯çŸåšå¢ãã€ã€ãããŸã
ããããããä¹³å
éããã®æ§ãªæ°çš®ã®ç°åžžåœ¢æ
ã®çŸæ¥å³ã«ææããå±éºã«ãããããŠãã
ã®ã§ãã人é¡ããã®æ°ããç°åžžåœ¢æ
ã®ç
æ°ã«å¯ŸããŠå
ç«ãè²ãã«ã¯ããŸã ããšäœäžçŽãã®
æéããããã§ãããã
ããã«NEJMèªã® 1994 幎çã®èšäºãã¿ããšãçŸæ¥å³ã«ããã£ã 5æ³æªæºå
ã® 80%ã¯ãã¯
ã¯ãã³æ¥çš®ãå
šéšåãçµããåäŸéã ã£ããšããããšã§ããç ç©¶å¡éã®éã§ããçŸæ¥å³ã¯
ã¯ãã³ã®å
ç«æ§ãäžå®å
šã§ããããšããçµè«ã«éããŠããŸãã[331]
ãã 5 幎éã«ãã³ãã©ãå·ããªã¬ãŽã³å·ãªã©ãæ§ã
ãªå°åã«ãããŠæ°çŸä»¶ã®çŸæ¥å³ã®çŸæ£
ãå ±åãããŠããŸããããããã¿ãŠããDPT äžç𮿷·åæ¥çš®ã®å¹æã¯å®£äŒã§äºãããŠããã»
ã©ã®å¹æããªãããšã¯æããã§ããå
šç±³ã§ã¯ 2005幎以æ¥ãå
童㫠5 åã®æ¥çš®ãæå®ããŠã
ãŸãã[3]ãããŠæ¥çš®åŸã«äžãäžçºç
ããå Žåãå°åã®çŠç¥æœèšã®äžè¬çãªå¯Ÿå¿ãšããŠã¯ã
æŽã«ãã 1 床æ¥çš®ãä»ãè¶³ããšãããã®ïŒãã®æãææ¯ãªã¯ã¯ãã³ãããã§ã«èš±å®¹ç¯å²ã
è¶
ããŠããä¹³å
ã®èº«äœã« 6 åç®ãšããŠè¿œå ããããšããå
容ãªã®ã§ãïŒããããå°åã®çŸ
æ£å
ã® 90%ã¯ããã§ã«æ°åã«ãããäžç𮿷·åæ¥çš®ãåããŠããã®ã«ãããããäºå®ã¯å
šã
ãæ§ãç¡ããªã®ã§ãã
ã€ãŸããããããããšã§ããåäŸéã¯ãã¯ã¯ãã³ã«ããå¯äœçšã®å±éºã«è
ããããã ãã§
ã¯ãªããããšããšçŽæãããŠããã¯ãã®ã¯ã¯ãã³ã®å¹æïŒå
ç«èªäœãå®ã¯æã«å
¥ããããš
ãåºæ¥ãªãèš³ã§ãããããªã¯ã¯ãã³ãäœåºŠãäœåºŠã远å ããŠæ¥çš®ããã£ãŠãããã§ã¯äœã®
广ããããŸããããããªã®ã«ãå§ãã«ã¯ 3 åã§ååãšããããŠããæ¥çš®åæ°ãã4 åã5
åãã€ãã«ã¯ 6 åã«ãå¢ããŠããŸã£ãŠããŸãããããŠæŽã«ãæäººæã«ã¯å ã㊠5 åã®æ¥çš®
ãå®ããããŠããã®ã§ããæ¬ç©ã®å
ç«ãšã¯ãäžçæ¶¯ã«æž¡ã£ãŠç¶ããã®ã§ããããå®éšã·ãª
ã³ããŒã®äžã§äœãåºãããããªãã®ã§ã¯ãããŸãããå»åŠããå
ç«ã®æ¬æ¥ã®æå³ãæ²ããŠ
宣äŒããŠããŸã£ãŠããã ããªã®ã§ãã
ãããããªçå
ã§ã¯ãå®éã«ç§éã¯ã©ããªå±éºãããããŠããã®ã§ããããïŒçææ§ã§æ°ã¶æãããããã
å床æ¥çš®ããªããŠã¯ãªããªããããã广ã®ãããããããå
ç«ããä»ããããã«ãçåŸ 2
ã¶æã®ä¹³å
ããå
ã«æãããããªæ§ã
ãªå¯äœçšã®å±éºã«ããã䟡å€ãæ¬åœã«ããã®ã§ãã
ããïŒçŸæ¥å³ããããæ¬æ¥ãªãèªç¶æ¶æ»
ããŠããç
æ°ã®ã¯ããªã®ã«ããããªãªã¹ã¯ãè² ã
ã®ã¯äœã®ãããªã®ã§ããããïŒ
ããã§è¿°ã¹ãã®ã¯ãçŸæ¥å³ã¯ã¯ãã³ã®åé¡ã®ãã¡ãæ°·å±±ã®äžè§ã«ãããŸãããçŸæ¥å³ã¯ã¯
ãã³ã®åé¡ããŒã¿ã¯éåžžã«å€§éã«ãããããã倧倿°ã¯äž»æµã®æ
å ±èªã«æ²èŒãããŠããã
ã®ã§ãå®éã¯ããã§ç€ºãããã®ãããã¯ããã«é
·ãçŸç¶ã§ããèå³ãããããèªè
ã®çã
ãã«ã¯ãæ¬æžã«æ²èŒããŠããæ
å ±æºã®è³æããèªèº«ã§èª¿ã¹ãŠãããæ·±ãã¬ãã«ã§èå¯ãã
ãããšããèŠãããŸãã
ã¹ãã«ã¹ ãŠã€ã«ã¹ïŒå·§åŠãªããŸãã
USC å
ç«åŠè
ã®ãžã§ã³ã»ããŒãã£ã³ããçå®ãåœè£
ããããã«ãã¿æ¶ããã人ç©ã® 1 人ã§
ããããŒãã£ã³ãçºèŠããã®ã¯ãäœã®æäœåå¿ãèµ·ãããã«äœå
ã«å¿ã³èŸŒãããšã®åºæ¥ã
ããæªæ§ã®å°ããªãŠã€ã«ã¹ã§ããã圌ã¯ãã®ãŠã€ã«ã¹ã«ã€ããŠãšãŠã詳ããã培åºããç
ç©¶è³æãçºè¡šããŸããããã®ãŠã€ã«ã¹ã¯ãã£ããå¿ã³èŸŒããããšããç¹è³ªãããã¹ãã«ã¹
ïŒã²ãããªïŒãŠã€ã«ã¹ãšåä»ããããŸããããã®ãŠã€ã«ã¹ã䟵å
¥ããŠãçºç
ããå Žåãã
ãã«ãäœå¹Žãçµã£ãŠããçºç
ããå ŽåããããŸããããèããšãªããšãªããåã«è¿°ã¹ãã¯
ã¯ãã³å
ã®èãããããŠã€ã«ã¹æåïŒ99%ã®äººã
ã«ã¯å
ç«æ©èœãåå¿ããªãããã«èããã
ãŠããïŒãæãåºããããããŸããããããããã®ã¹ãã«ã¹ãŠã€ã«ã¹ãå¥åããŒã³ã®å€§ã
ãç°ãªãç¹ã¯ãæå³çã«æ³šå
¥ããããã®ã§ã¯ãªãããšã§ãããããã¯ãã¯ã¯ãã³ããã£ã
ãæ±æããæåã§ãã¡ããã©ããããã€ã¯ãããããã«ãã¯ã¯ãã³ã«äŸ¿ä¹ããŠãã£ãŠãã
ã®ã§ãã
ãããã¯æåã®ããã«å
ç«åå¿ãåŒãèµ·ããããšã¯ãªãããã®ãã人äœã®å
ç«æ©èœã·ã¹ã
ã ã«æ°ä»ãããããšã®ãªããŸãŸäœå
ã«äŸµå
¥ããããšãå¯èœãªã®ã§ããããããççåå¿ã
åŒãèµ·ããããšãããããŸãããããã®ã¹ãã«ã¹ãŠã€ã«ã¹ã¯äººäœã®æ§ã
ãªçްèèãæ»æã
ãŠç Žå£ããããšãåºæ¥ãŸãã[58]
äŸãã°ãSV-40 ããã® 1 äŸã§ãããããã¯åã«è¿°ã¹ãããã«ããªãªã¯ã¯ãã³ã«å¯èªè
ã®ã
ãã«æœãã§ããç¿ãŠã€ã«ã¹ã§ããããïŒã€ã«ã¯ãç¿ãµã€ã¿ã¡ã¬ããŠã€ã«ã¹ïŒSCMV ãæã
ãããŸããããããç¿ããã®ãŠã€ã«ã¹ã§1972 幎ã«åããŠã¯ã¯ãã³ã«æœãã§ããããšãçºèŠ
ãããŸããããããã¯ã¯ã¯ãã³è£œé ã®éçšã§ç¿ã®äœãå©çšããŠããããã§èµ·ããçŸè±¡ã§ãã
ããŒãã£ã³ã¯ã¹ãã«ã¹ãŠã€ã«ã¹ã®ç ç©¶ã 10幎éãç¶ããŠããŸããããããªã®ã«ã圌ã®ããš
ãå
šç¶ç¥ãããŠããªãã®ã¯ãã©ãããèš³ã§ããããïŒå®ã¯ã圌ã®ç ç©¶ãäœã瀺åããã®ã
ãåãããšããã®ãšãã倧åŠåŽã圌ã®ç 究宀ãééããè³éæŽå©ãåããããäžãæè·ã
远ãåºããã®ã§ããSV-40 ã SCMV ã®ã¯ã¯ãã³æ±æã¯ããŸãç¶ããŠããç¶æ³ã§ãããŒãã£
ã³ã¯ãã®ç ç©¶ãç¶ããããŠãããããã« CDC ã FDA ã«ç¹°ãè¿ãèŠè«ããŠããã®ã§ããã
ããŸã ã«æ¿åºåŽã¯ç¡èŠãç¶ãã誰ããã®ç ç©¶ãç¶ããããšãåºæ¥ãªãããã«ãªã£ãŠããŸã
ããŒãã£ã³ã®ç ç©¶ãããã¹ãã«ã¹ãŠã€ã«ã¹ãèªéçãé¢ç¯çãè³çãçºäœãçŒããã MS
çãã¯ãããšããæ§ã
ãªç¥çµæ§ã®ç
æ°ã®åå ã«ãªãããšãåãã£ãŠããŸããããããã®ç
æ°ã¯Merck ã«ãããŠã¯ãåå äžæãšããŠèšè¿°ãããŠãããã®ã§ãã
90 幎代åã°ä»¥æ¥ãããŒãã£ã³ã¯ãã€ãŠã®ãŠã§ãŒã¯ãã£ãŒã«ããšåæ§ã«ãå人çãªè³éæŽå©
ã«é Œã£ãŠçްã
ãšç ç©¶ãç¶ããŠããŸããã圌ãã¯ããã°ãç ç©¶äŒã®éŒ»ã€ãŸã¿çãªååšã§ãã
ãã® 2 人ãçãæããããŠå
±éã«æã£ãããšã¯ãã¯ã¯ãã³ã®æ±æã«ã€ããŠãããã«ç ç©¶ã
æ³åŸã§çŠæ¢ãããŠããŠãå€éšã«æŒããªãããã«ãªã£ãŠããããšããäºå®ã§ããã¯ã¯ãã³ã¯ã
ç¹èš±åãå°å£²ååã§ãããããã®è©³çŽ°ã¯æ¥µç§ã«ããšããé
ç®ã§æå
ãé²åãããŠããã®ã§
ãã
ã§ããã®æ³åŸã¯ãåäŸéã®ããšã¯ãŸã£ããé²åããŠãããŠããªãããã§ããâŠã
ä¹³å
ã®æ¯åæ»
1990 幎代ã«ã¯ãã¡ãã£ã¢ãå°åã®æåè
ã«ãããæ°ããªç
æ°ã®æµè¡ãå ±éãããŸãããã
ã®å ±éã«ãããšã芪éãèªåã®èµ€ã¡ãããæ¿ããæºãã¶ã£ãŠæ»ã«è³ãããããšããäºä»¶ã
çªç¶ã«å€çºããŠãããšããããšã§ãããçå®å³ãå ããããã«ãããã«ã¯ Shaken Baby
Syndrome(ä¹³å
æ¯åæ»çå矀)ãšããåŒã³åãŸã§ä»ããããŸããã
Cedars Sinai ã® MD åŠå£«ã§ãããžã§ã³ã»ã¡ã³ã¯ã¹ãå§ããå€ãã®å°éå®¶ã¯ããã® Shaken
Baby Syndromeã«é¢ããŠãå°åã®åœ¹äººãæ°èã«èŒã£ãŠæåã«ãªãããã«ä»çµãã éšååã§
ãããå®éã«ã¯ DPT äžç𮿷·åã¯ã¯ãã³ã«ããèŽåœçãªå¯äœçšã®äºä»¶ãããŸããããã«ã¡ã
ã£ã¢ããããšèª€å ±ãããã®ã ãšããèŠè§£ã瀺ããŠããŸããïŒGoodwinïŒ[163]
ãµã³ãã£ãšãŽã®åœ¹äººã§ãããããŒã»ãã¬ãŒã¯ã¯å
šç±³ã®ãã®æ¯åæ»ã§ã 1 çªæã®æ³åŸå°éå®¶
ã§ãã[349]ãçŸåšåœŒå¥³ã¯ãã®ä¹³å
æ¯åæ» 400 ä»¶ãã®æ
åœä»£ç人ãšããŠæŽ»åããŠããŸãã
SBSdefence.com æ²èŒã®åœŒå¥³ã®ãŠã§ããµã€ãã«ã¯ãã³ã£ãããããããªæ°åã䞊ãã§ããŸãã
ïŒæ¯å¹Ž 1500 ä»¶ãã®ä¹³å
æ¯åæ»ãèµ·ããŠãããšã®å ±å
ïŒååæã«å
¥ãããã芪ãã¡ã®å
ãä»ãŸã§ã«åºæã§ãã人æ°ã¯ïŒïŒ
ã«ãæºããªãã
ä¹³å
æ¯åæ»ãšãããä¹³å
ã®ç¥çµç§èšºæå
容ã¯ãDPT äžç𮿷·åã¯ã¯ãã³ã«ããå¯äœçšåå¿ãš
ãŸã£ããäžèŽããŠããŸããçç¶ã®å
åã¯ãè³å
åºè¡ã鬱è¡ã§ããè³å
ã®ããå°ããªé¬±è¡ã
èŽæ»è¡çºã®èšŒæ ã ãšããŠãããŸãŸã§ã«å€§å¢ã®èŠªãã¡ã起蚎ãããŠããŸããããããæè¿
Radiology èª[23]ã®èšäºã§ãæ£åžžåºç£ã®ä¹³å
ã®ãã¡26%ã¯äœããã®è³å
åºè¡ãæã£ãŠçãŸãã
ãã®çç¶ã¯MRI æ€æ»ã§ã¯çºèŠã§ãããã®ã®ãç®ã«èŠããçç¶ã¯äžåèµ·ãããªããšããäºå®
ãçºè¡šãããŸãããããã§ã起蚎ããã®ãå€å°ã¯é£ãããªããšæããŸãã圹人ã«ãšã£ãŠã¯
æ®å¿µãªããšã«ãããããå°ããªè³å
è² å·ã¯ãã¯ã¯ãã³ã«ããå¯äœçšã§ããå¯èœæ§ãããã
ãšãšãããã«ã¯éåžžã®åºç£ã§ãèµ·ãããããã®ã ãšããããšããäžéã«çºè¡šãããŠããŸã£
ãããã§ãã
ããã«ãã£ãŠãä¹³å
æ¯åæ»é²æ¢å§å¡äŒããã£ãšåããç¥ã£ãŠããäºå®ïŒæ¯åæ»ã§èµ·èšŽãã
ãä»¶ã®ãã¡å°ãªããšã 75%ã¯ã起蚎以åã«ãã§ã«è»œåºŠã®è³å
鬱è¡ãšèšºæãããããšããã
ãšããäºå®ããæããã«ãªã£ãã®ã§ãã[349]
ã¯ãã ïŒéº»ç¹ïŒ
ã¯ãããšã¯ãåäŸæä»£ã«ããã匱ããŠã€ã«ã¹æ§ã®ã軜ãç
æ°ã§ããçç¶ãšããŠã¯ãå£ãè
ã«èµ€ã湿ç¹ãåºæ¥ããçºç±ãç²åŽãšãã£ããã®ã§ãé垞㯠1é±é以å
ã«æ²»ã£ãŠããŸããŸãã
ãããšãã£ãŠã倧ããç
æ°ã§ã¯ãããŸããããããŒããŒã æä»£ã«ç£ãŸãã1950 幎代ãåäŸ
ãšããŠéããã人ã®å€§åã¯ãã¯ããã«ããã£ãããšãããã§ããããããã®çµæãäžçã®
éç¶ãå
ç«ã身ã«ä»ããããã§ããããã¯ãèªç¶ãªå
ç«æ©èœã§ãã(Merck, p1098)[280]
äžèšã®è¡šïŒã«ç€ºãããŠããããã«ããã®ç
æ°ã¯ 1960幎代åŸåã«éå£ã¯ã¯ãã³æ¥çš®ãæ®åã
ã以åã«ãèªç¶æ¶æ»
ãã寞åã ã£ãããšãåãããŸãã
ããã§ãã»ãŒã«ã¹åŽã¯ãã¯ããã¯ã¯ãã³ã売ãåºãããã®å®£äŒæå¥ãšããŠè³çã«çç®ããŸ
ãããåœæããã®ã¯ã¯ãã³ãèªå®ãããæã«ã¯ãã¯ã¯ãã³æ¯æè
åŽã¯ã1000 åã® 1ããšã
ãæ±ºãŸãæå¥ãããå£ã«ãããã®ã§ããã€ãŸããã¯ã¯ãã³ãæ¥çš®ããªããšã1000 人㫠1 人
ã®èµ€ã¡ãããè³çã«ãããããšãã䞻匵ããããããã§ãããæ ¹æ ãšãªããããªè³æã¯ã
å
šãæããããŠããŸãããã¡ã³ãã«ãœã³ããåœéçãªçç©çµ±èšåŠè
ã®ãã€ã±ã«ã»ã¢ã«ããŒ
ãœã³ã¯ããã®æ°åã«ãåè«ããšãªããŠããŸãã1965 幎ãã 1970 幎㮠5 幎éã«ã¯ããã§æ»
亡ãã人ã 44 人ã§ãããªãã°ïŒMeldersonïŒããã£ã10 äžåã®ïŒã«ãããªããªãã®ã§ãã
ãããããŠãä»ã®ç
æ°ãšããªãããã¯ããã«ããæ»äº¡è
ã¯å€§æµã人å£éå¯ã§äžè¡ççãªç°
å¢ã«äœãã§ãã人éã§ãããã€ãŸãã©ããªç
æ°ã«ããããããããæ»äº¡ããå±éºã倧ãã
å°åããåºãŠããã®ã§ãã
1970 幎代ååã麻ç¹ã¯ã¯ãã³ã¯ MMRïŒã¯ããããããµã颚éªã颚ç¹ïŒã¯ã¯ãã³ãäžç·ã«
æ¥çš®ãããšãã圢ã§å®å°ãããŠããŸãããããããã ãã¯ã¯ãã³ã®å¹ãç®ããªãã ããªã
ã°è¯ãã£ãã®ã§ããããã®MMR ã¯ã¯ãã³ã«ã¯æ§ã
ãªå¯äœçšãããã®ã§ãã
çèã®å¶åŸ¡æ©èœã®ç Žå£ é«èç
ç¥èœçºéã®é害 ããç
è³æ§ãŸã² çæ£
å€çºæ§ç¡¬åç ã¢ããã£ã©ãã·ãŒ ã·ã§ãã¯
ã®ã©ã³ ãã¬ãŒç äžç¢
è¡æ¶²ã®ååº è³ç
– Mendelsohn,p237 [246]
ã¡ãã£ãšåŸ
ã£ãŠãã ããïŒè³çã«ããããªãããã«åããã¯ãã®ã¯ã¯ãã³æ¥çš®ãªã®ã«ãåœ
ã®å¯äœçšãªã¹ãã«ã¯ãè³çãã®ã£ãŠãããããããŸãããïŒãããªå¯äœçšã¯ãã¯ããã«ã
ãã£ãã ãã§ã¯èµ·ããªããã®ã°ããã§ããããã«ã现èèã«äœå¹Žãæœãã§ããŠããã®äººã
æé·ããŠããåŸã«çºçãããã¹ããŒãŠã€ã«ã¹ãã®ååšã¯ãæ®éã®å°å
ç§å»ã§ããç¥ã£ãŠã
ãããšã§ããã ãããããããµã³ãžã§ã«ã¹ã§ã¯å€ãã®å»è
ãèªåã®åäŸéã«ã¯ MMR ã¯ã¯
ãã³ãæ¥çš®ããããšãæåŠããã®ã§ãããã(Mendelsohn,p238) [246]
1996 幎ã«ã¯ã以äžã®ãããªèšè¿°ããããŠããŸãã
ãâŠã¯äœã®å
ç«æ©èœãæå§ãããã®çµæä»ã®ç
æ°ã«ææããå±éºã倧ããããŠããŸãã
– ClinicalImmunologyandPathology, May 1996
ã€ãŸããããããããšã§ãã麻ç¹ã¯ã¯ãã³ã¯ã麻ç¹ãäºé²ããå¹ãç®ããªãã©ããããä»
ã®ææç
ã«ãããããããããŠããŸãããšããã®ã§ãã麻ç¹ã«ãããããã麻ç¹ã¯ã¯ãã³
æ¥çš®ãåããã»ããå±éºã¯ãã£ãšå€§ããããã§ããâŠïŒ
ãããªã®ã«ããè³çã«ããããããããªãããšãã蚌æ ããªãå£å®ãã€ããŠã麻ç¹ã¯ã¯ãã³
ã®æ¥çš®ã¯çŸ©ååãããŠããŸããŸããã
ããã¯ããŒã±ãã£ã³ã°éšéã®æŠç¥åã¡ãšãããèšãããããããŸããã
ã¯ããã«é¢ããŠã¯ç¹ã«ãã¯ã¯ãã³ãæ¥çš®ããŠãäœå
ã®æäœãäœãåºãããªããšããäºå®ã
äœå幎ãåããç¥ãããŠããŸãã
ãããã«ãã¯ãããžã®å
ç«æ©èœã®ç¢ºç«ãåã³æ²»çã«éããŠæäœãäœãåºããšããè¡çºã«ã¯
æå³ããªãã
– Nobel Laureate, Sir Macfarlane Burnet, 1971 [190]
ã§ã¯ãã¯ã¯ãã³ã®éº»ç¹äºé²å¹æã«ã€ããŠèŠãŠã¿ããšã1978 幎ã«ã¯ã麻ç¹ã«ææããåäŸã®
åæ°ããã¯ã¯ãã³æ¥çš®ãåããåäŸéã§ãããšããç¶æ
ã«ãªã£ãŠããŸãããããã«ãWHO
ã®çµ±èšå ±åã«ããã°ãã¯ã¯ãã³æ¥çš®ãåããåäŸéã¯ãåããŠããªãåäŸéã® 15 åããã¯
ããã«ãããå±éºã倧ãããšããããšã§ãïŒ([246],p238)
1983 幎ãã1989幎ã«ãããŠã¯ã麻ç¹ã®ææä»¶æ°ã 10 åã«ãå¢ããŠããŸããããã«æ¬¡ã®å¹Ž
ã«ã¯ããªããšãã® 2 åã«ãªã£ãŠããææ§ã§ãïŒãããŠ1990幎ã«ã¯ãåè¡åœã«ãããã¯ãã
ææè
ã¯27000 人ã«ãæãããã®ãã¡ 100 äººã®æ»äº¡ãå ±åãããŠããŸãã(p.511)[223]
ãŸããCDC èªäœãã人å£ã®ïŒïŒïŒïŒ
ãã¯ã¯ãã³æ¥çš®æžã¿ã®å°åã«ãããŠïŒïŒïŒéº»ç¹ãæµè¡
ã£ããšããå ±åãããŠããŸããããã«å¯Ÿãã CDC ã®èª¬æã¯ã次ã®éãã§ãããâŠéº»ç¹ãã
äºé²æ¥çš®ãåãã人å£ã®éã§æµè¡ãææçãšãªã£ãããšã¯ãäžå¯è§£ãªäºæ
ã§ããã
ïŒMMWR,Oct1984ïŒ [309]
ã§ã¯ãåäŸæä»£ã«éº»ç¹ã«ããã£ãŠãèªç¶ã«å
ç«ãã€ããããšã®å€§åãã¯ãšãããšããŽã£ãš
ã©ã»ã¹ã±ã€ãããŒã¯æ¬¡ã®ããã«è¿°ã¹ãŠããŸãã
ãåäŸéã®æé·ã®äžç°ãšããŠãã¯ããã«ãããããšã¯å€§åãªçµéšã§ãããåäŸã®æé·ãé»
ãã ãããã®å
ç«æ©èœã®ç¢ºç«ãéªéããããšæã人ã¯ããªãçã ãã [255]
ãããã麻ç¹ã¯ã¯ãã³ã®æ¬åœã®æãã«ãã£ãšäžè¬ã®äººã
ãç®ãåããããã«ãªã£ãã®ã¯ã
2000 幎 4 æ 6 æ¥ã«ãã³ã»ããŒãã³ãå¬éãããèªéçã«é¢ãã代衚è
é£ã®äºæ
èŽåäŒãã®
åŸããã§ããè±åœãšã¢ã€ã«ã©ã³ãã«ãããç ç©¶ã®çµæå ±åãããè¿å¹Žã«ãããŠå€çºããŠã
ãèªéçã®åå ãšããŠãèããããæã倧ããªå¯èœæ§ã®ïŒã€ã®å
ããã®ïŒã€ã«éº»ç¹ã¯ã¯ã
ã³ã§ããããšãæããã«ãªã£ãã®ã§ãã詳ããã¯ãåŸã«åºãŠãã Wakefield ã®èšè¿°ã«ç€ºã
ããŠããŸãã
ãããµããã
ãã®ç
æ°ããŸããåäŸæä»£ã«ããã匱ããŠã€ã«ã¹æ§ã®è»œãç
æ°ã§ãåŸè
ºã®è
«ããçºç±ãé
çã䌎ããã®ã§ããã»ãšãã©ã®å Žåãããããããšããªãã1é±é以å
ã«æ²»ã£ãŠããŸããŸãã
ãããŠèªç¶ãªå
ç«ãä»ããäžçã®éã€ã¥ããŸããã€ãŸãç°¡åã«ããã°ãããããµã颚éªã«è¬
ã¯ãããªããã®ã§ãã(Mendelsohn,p234)[246]ããããŸãããããŒããŒã æä»£ã®ã»ãšãã©
ã®äººãåäŸã®æã«çµéšããç
æ°ã§ãã
ããŠããããµã颚éªã¯ã¯ãã³ã®ã»ãŒã«ã¹ãã€ã³ããšããŠã¯ã©ããªå®£äŒã䜿ãããããšãã
ãšã倧人ã«ãªã£ãŠãããããµã颚éªã«ããããšããã£ãšçç¶ãéããçŸäžžãè
«ããæãã
ããããšããã®ã§ããçæ®æ©èœããªããªãçšåºŠã§ã¯ãªããããŸãã«äžæçã«çŸäžžãè
«ãã
ããšãããããšããèšãåã§ããã§ã¯ããŸãæåã®çåã§ããâŠãªãã女ã®åãã¯ã¯ãã³
æ¥çš®ãåããªããã°ãããªãã®ã§ããããïŒæ¬¡ã«ãåäŸæä»£ã«ãããã°çç¶ã軜ããäžç
ã®å
ç«ãä»ãç
æ°ãªã®ã«ããªãã¯ã¯ãã³æ¥çš®ãå¿
èŠãªã®ã§ãããïŒåäŸæä»£ã«ããããªã
ããã«ããããïŒã€ãã§ã«å€§äººã«ãªã£ãŠããããããéçã®æäººããŒãžã§ã³ã®ãããµã颚
éªã«ããããªãããã«ïŒã§ãããã®ã¯ã¯ãã³ãæäººããŒãžã§ã³ã®ãããµã颚éªãŸã§äºé²ã
ãŠããããªããŠãã蚌æ ã¯ããŸã£ãããããŸããããããªç ç©¶ããããŠããªããã°ãå¿è«
ãããªèšŒæãªããŠã1 åããããããšããªãã®ã§ãïŒ
ã¡ã³ãã«ãœã³ã¯ã¯ã¯ãã³ã®å¿
èŠæ§ã«ã€ããŠãã©ãããŠããšèšããªãåäŸæä»£ã«ãããµã颚
éªã«ããããªãã£ããããèªç¶ãªå
ç«ãä»ããããªãã£ãç·åã«ã®ã¿ãææ¥æã«ãããã
ã£ãæã«æ¥çš®ããã ãã«ããŠããã¹ãã ãšè¿°ã¹ãŠããŸãã
ãããã¯ã¯ãã³æ¥çš®ã«ãããŠã¯ãçæ§ã¯ã»ãšãã©éããŸããããããšããããããããã¿
ããªäžŠãã§ïœïŒããšããå
·åã§ãã女ã®åããç·ã®åãã
äžæ¥ã¯ãã
ãã®ç
æ°ã¯ã»ãšãã©ã®å Žåãåã®ïŒã€ãããããã«è»œåºŠã®ç
æ°ã§ãçç¶ãšããŠã¯çºç±ã湿
ç¹ããããŠåã®çã¿ããããŸãã
äžæ¥ã¯ãããMMRïŒRã¯äžæ¥ã¯ããïŒRubbela ã®é æåïŒ3 çš®ã¯ã¯ãã³ã«å ããããã«äœ¿
ãããå®£äŒæå¥ã¯ãåŠåš 4 ã¶æä»¥å
ã®æéã«æ¯èŠªããã®ç
æ°ã«ããããšãããããªããè
å
ã«åœ±é¿ããæããããããšãããã®ã§ããããããããã®ã¯ã¯ãã³æ¥çš®ãåããã®ã¯å
äŸéã§ãããåäŸã¯åŠåš ãªããŠããŸããããïŒããã«ã©ããªãå
ç«ããããã®åéã倧人
ã«ãªããããã£ãšåã«ãå¹æãæ¶ããŠããŸãã¯ãã§ããçç£è
åŽãããã¯èªããããåŸãŸ
ããããããããæ¯èŠªã«ç§»ããªãããã«ããŸãåäŸéãææããªãããã«ããã¹ãã ããšã
ãèš³ã§ãããŸããããåºæ¥ããè¯ãã®ã§ãããããããããã®ã¯ã¯ãã³ã®å¯äœçšã«ã¯é
·ã
ãã®ããããŸãã
é¢ç¯ç
å€çºç¥çµç
ãã³ã
ããã«ãæ¯èŠªéã«ãšã£ãŠäžçªé
·ãã®ã¯ãèªåã幌å
æä»£ã«ã¯ã¯ãã³æ¥çš®ãåããããã§èª
ç¶ãªå
ç«ãä»ããããšãåºæ¥ãããã®çµæèå
ãæ¯äœããèªç¶ãªå
ç«ãåãç¶ãããšãåº
æ¥ãªããªã£ãŠããŸã£ããšããäºå®ã§ãã
ã€ãŸããããããæµãã§ããã¯ã¯ãã³ãªã©ãªãã£ãæä»£ã«ã¯ãäžæ¥ã¯ããã¯åäŸã®ããã
ãã軜ããå¿é
ã®ãªãç
æ°ã§ãåäŸéã¯ãã®ç
æ°ã«ãããããšã§äžçãã®ã®å
ç«ãã€ãã
ããšãåºæ¥ãŸããã倧人ã«ãªã£ãŠåŠåš ããŠããèªåãèå
ãå®å¿ã§ãã
ããã 1960幎代ãåœæã®äººå£ã®ïŒïŒïŒ
ãèªç¶ãªå
ç«ãã€ããŠãããšãããæä»£ã«äžæ¥ã¯ã
ãã¯ã¯ãã³ãå°å
¥ãããŸããã([222] p 240)ããããã®ã¯ã¯ãã³ã¯åäŸæä»£ã®ææãé¿ãã
ããšãåºæ¥ãŠããæäººæä»£ã®ææã¯äºé²ã§ãããããã«å¥³æ§ã«ãšã£ãŠã¯ããå¿é
ãªç
æ°ã«
ãªã£ãŠããŸããŸãããã¯ã¯ãã³ã®ããã§ãåŠåš äžã®å¥³æ§ãäžæ¥ã¯ããã«ãããå±éºæ§ã以
åããã倧ãããªã£ãŠããŸã£ãã®ã§ãã
ã¢ã¹ã³ãŠã£ããã¯ãäžæ¥ã¯ãããæ°Žç±ç¡ã麻ç¹ãšãã£ãåäŸæä»£ã®è»œãç
æ°ããã¯ã¯ãã³
ã®å°å
¥ã®ããã§ããããæ°åã®ãããéçãªæäººæã®ç
æ°ã«å€åããŠããŸã£ããšææããŠ
ããŸãã[192]ããããæäººåã®ç
æ°ã¯ãçç¶ãè€éåããããæ»äº¡ããå±éºããã£ãšå€§ã
ããã®ã§ãã
é«èç ïŒHiBïŒïŒããã¯ã¯ãã³
çŸä»£ã§ã¯ããã®é«èçã¯ã¯ãã³ïŒHiBïŒã¯çåŸ 2 ã¶æã4 ã¶æã6 ã¶æããã㊠12 ã¶æãš
宿çã«ä¹³å
ã«æ¥çš®ãããŠããŸãã
ç
åïŒHemophilis Influenzae Type B MeningitisïŒã«ã¯ã€ã³ãã«ãšã³ã¶ãšããèšèãå«ãŸ
ããŠããŸãããã€ã³ãã«ãšã³ã¶ã颚éªã®ã¯ã¯ãã³æ¥çš®ãšã¯ãŸã£ããç¡é¢ä¿ã®ã¯ã¯ãã³ã§ãã
ãããããã®ååã®ããã§ã€ã³ãã«ãšã³ã¶ãšãã® HiB ã¯ã¯ãã³ãåãééããŠããŸã人ã¯
éåžžã«å€ããå°å
ç§å»ã§ããããã話ã§ãããããã«ãå»è
ããã«ã¯ã€ãºã§åºããŠã¿ããšã
é¢çœãããç¥ããŸããã
æåã® 2 èªãHemophilis Influennzae ã®ãã¯ããªã¢ã¯ããšããšãã€ã³ãã«ãšã³ã¶ã«ææã
ã人ã®äœå
ã«ãããšèããããŠããããããã®ãããªç
åãä»ããããã®ã§ããããã®åŸ
ã®ç ç©¶ã§ãæ®éã®äººã®ç²æ¶²èã«ããããšãçºèŠãããããã§ãååã ãã¯å€ãããªãã§æ®
ã£ãã®ã§ãã
Hemophilis Influenzae ãšã¯ãåäŸã®éŒ»ãåã®è»œãææçã®æ°ã
ã«äŒŽã£ãŠèµ·ãããã®ã§ãã
(Neustadter, p161)[211] ãããããçšã«ããã®äžçš®ã§ãã Hemophilis Influenzae ã® B å
ãŠã€ã«ã¹ããé«èçã«ããã£ã人ïŒéåžžã¯åäŸïŒã®äœå
ã«èŠãããããšããããŸããå®ã¯
ããããä»¶ã 1960 幎代以éå¢ãç¶ããŠããŠãå€ãã®ç ç©¶è
ãåäŸéã®ã¯ã¯ãã³æ¥çš®ã®å®æœ
ãå¢ããããšã«åå ããããšäž»åŒµããŠããŸããã§ã¯ãããããæ£è
ã«ã©ããªå¯ŸåŠãããŠã
ãããšãããšããªããšãã 1 床ã¯ã¯ãã³æ¥çš®ãåããããŠããã®ã§ãïŒ
Hib ã¯ã¯ãã³ã«é¢ããåæçãªç ç©¶ã¯ããã£ã³ã©ã³ãã§è¡ãªãããŸããã10 äžä»¶ã®å®éšã®
çµæãHiB 㯠18 ã¶ææªæºã®å¹Œå
ã«ã¯å
šã广ããªãããšã倿ããŠããŸãã(Peltola
Pediatricsvol.60,1977)[248] ãããã¢ã¡ãªã«ã®åäŸéã¯ãçåŸ 18 ã¶æã«è³ããŸã§ã«ãã§ã«
3 åããã®ã¯ã¯ãã³ãæ¥çš®ããªããŠã¯ãããªãã®ã§ãïŒã¡ãªã¿ã«çåŸ 24 ã¶ææªæºã®åäŸã«
é¢ããŠã¯ã广ã¯ãäžæããšãªã£ãŠããŸãã
1986 幎ãNewEnglandJournalofMedicineèªããHiB ç
ã®æ£è
55 ä»¶ã®ç ç©¶ãçºè¡šããŸ
ããã該åœããæ£è
ã¯ãå
šå¡ã HiB ã¯ã¯ãã³ãæ¥çš®ãã人ã§ãããã®å
ã39 人ã¯é«èçã«
眹æ£ãã3 äººãæ»äº¡ããŠããŸãããã®ä» 6人ã¯èŽèŠæ©èœã倱ããŸããã(Granoff)[249]
1988 幎ã«ã¯ãã«ãŠã§ã€ã§ 1ïŒäž 1 åä»¶ã®å€§èŠæš¡ãªç 究調æ»ãè¡ãªããããã®çµæãã¯ã¯ã
ã³ã®å¹æã¯ããã®æ¥çš®ããã°ã©ã ãäžè¬åžæ°ã«å¯ŸããŠå¶åºŠåããã«ã¯äžé©åœã§ããããšã
ããŠããŸãã(Bjune)[308]ãã®åŸ HiBé«èçã®çœ¹æ£è
ã¯ã1988幎床㮠300 人ãã 1991 幎
床ã«ã¯ 200 人ã«ãŸã§æžå°ããŸãããã¯ã¯ãã³æ¥çš®ã®çŸ©ååãªã©ç¡ãã«ãã²ãšãã§ã«æžã£ãŠ
ãã£ãã®ã§ãã
Hib ã¯ã¯ãã³ã®åç㯠PRP ãšããã¯ã¯ãã³ã§ãããããã®å¹æã¯æããããªãããã€ãã®
ããã«ç身ã®äžè¬åžæ°ã«å®éšæ¥çš®ãè¡ãªã£ãŠã¿ããšããããã§ã« 1988幎ã«ã¯ç
æ°ã®äºé²ã©
ããããç
æ°ã®åå ã«ãªã£ãŠããŸã£ãŠããä»¶ã®ã»ããå€ããšããããšã倿ããŠããŸãã
(Osterholm)[318]ã€ãŸããéåžžãªãèªç¶ã«æ²»ã£ãŠããŸãã¯ãã®è»œãH.IfluenzaeãŠã€ã«ã¹ã«
åãéŒ»ãææããåäŸéãã以åã¯ã¯ãã³æ¥çš®ãåããããã§äœã®å
ç«æ©èœãæå¶ãããŠ
ããããã«ããã®ãŠã€ã«ã¹ãç¥çµæ©èœã®ãã奥ã®éšåã«ãŸã§äŸµå
¥ããã®ãé²ãããããã
ãŠäŸµå
¥ãããŠã€ã«ã¹ãé«èïŒéªšé«ã®ç·ç¶éšïŒã§ç¹æ®ããã®ã§ãããã® PRP ã¯ã¯ãã³ã¯ãäœ
å人ãã®åäŸéã«å®éšçæ¥çš®ãè¡ãªã£ãåŸããããŠå»æ¢ã«è³ããŸããã
ãã㊠1990 幎ã«ã¯æ¥ååã® HiB ã¯ã¯ãã³ãç»å ŽããŸããããã¯ãã¯ã¯ãã³ãèçœæ§ç©è³ª
ã«çµåããŠããç¶æ
ã®ãã®ã§ããããã®æ¥ååã¯ã¯ãã³ã¯çºç±ãæ³£ãåºããçºäœãªã©æ§ã
ãªå¯äœçšããããããŸãããããã«ãã®æ¥ååã¯ã¯ãã³ã§ã¯ãå
ç«åå¿ãããŸã掻æ§åã
ãããããé·æéã®å¹æã¯æããªãããšããããšã§ããïŒWardïŒ[250]ã¯ã¯ãã³ãäœãã«æ¥
åãããšãããã«å¯Ÿããå
ç«åå¿ã¯ãŸãã§å
šãéãç
æ°ã®ã¯ã¯ãã³ãšèšããã»ã©ã«ç°ãªã
ãã®ã«ãªã£ãŠããŸãã®ã§ãã
ããããçææ§ã®ã¯ã¯ãã³ã¯ãã¯ã¯ãã³æ¥è
ã®å£²ãçïŒçªã®å®çªååã§ããã人工çãªå
ç«ã§ããããã«å¹æã¯äžæçã§ãããããã«åæ¥çš®ãå¿
èŠãšããæ·±å»ãªå¯äœçšåå¿ã䌎ã
ãã®ã§ããããããFDAã®èš±å¯ããããããã«ã¯ããã®ïŒã€ãå¿
èŠæ¡ä»¶ã«ãªã£ãŠããã®ãã
ãšæãããããæ¬¡ã
ãšèªå¯ãããŠããŸãã
HiB ã¯ã¯ãã³ã®å¯äœçšåå¿ã®äžã§ããä¹³å
ã®ç³å°¿ç
ã¯æ§ã
ãªç ç©¶ã§ç«èšŒãããŠããå¯äœçš
ã§ãã以äžã«ãïŒã€ã®äŸãæããŠã¿ãŸããã倪åã«ãªã£ãŠãã幎å·ã¯ãHiB ã¯ã¯ãã³æ¥çš®
ãå§ãŸã£ã幎ã§ãã
å Žæ 幎 ä¹³å
ã®ç³å°¿ç
ïŒïŒïŒäžä»¶åäœïŒ
ãã£ã³ã©ã³ã ïŒïŒïŒïŒïŒïŒïŒ ïŒïŒ
ïŒïŒïŒïŒ ïŒïŒ
ïŒïŒïŒïŒ ïŒïŒ
ïŒïŒïŒïŒ ïŒïŒ
ïŒïŒïŒïŒ ïŒïŒ
è³æïŒ InfDisinClinPractvol 6 1997 p.449
ãããããŒã° ïŒïŒïŒïŒïŒïŒïŒ ïŒ
ïŒïŒïŒïŒïŒïŒïŒ ïŒïŒ
è³æïŒ DiabetesCarevol 21 1998 p.1278 [313]
ã€ã®ãªã¹ ïŒïŒïŒïŒïŒïŒïŒ ïŒïŒ
ïŒïŒïŒïŒ ïŒïŒ
è³æïŒ BigMedJ1997 p.713 [312]
ããã§æããŠããç³å°¿ç
æ£è
ãšã¯ãé©ãããšã«ïŒæ³æªæºã®èµ€ã¡ããéã§ããèµ€ã¡ããã®ç³
å°¿ç
ãªããŠãïŒïŒïŒïŒå¹Žä»£ä»¥åã«ã¯èããããšããªãçŸè±¡ã§ãããâŠã1960幎代ãã1980
幎代ã®éã«ã¯ãã¯ã¯ãã³æ¥çš®ã¯ïŒåã«ãå¢ããŠããŸãã
HiB ã¯ã¯ãã³ã«ã¯åãã¢ã«ããã¢ã ãæ°Žéãšãã£ãæ¯æ§ç©è³ªãå«ãŸããŠããŸãããããã
ã®å®³ã«ã€ããŠã¯ãåã«è¿°ã¹ããšããã§ãã
H.Influenzae ãä»ã®ã¯ã¯ãã³ãšåæ§ãå®éšã¢ã«ã¢ãããšããŠäœ¿ãããã®ã¯ãã€ã決ãŸã£ãŠ
ïŒç§éã®åäŸéã§ãã2006 幎ããã®äºé²æ¥çš®è¡šã«ãããŠãäœã®çç±ããªãã«æ¥çš®ã 4 åã
ã 3 åã«æžã£ããã2007 幎ã«å 4 åã«å¢ããŠããã®ã«ã¯èª°ãæ°ä»ããªãã£ãããã§ããã
ãããç§åŠçãªçç±ãªã©ã§ã¯ãªããæ¿æ²»ã®éœåã«ãã£ãŠå€ãã£ãã ãã®ããšã§ãã
ã€ã³ãã«ãšã³ã¶äºé²æ¥çš®
ããã¯å
ã»ã©ã®H.Influenzaeã¯ã¯ãã³ãšã¯å
šãç¡é¢ä¿ã®ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®ããš
ã§ãããããã¯æ¯èŒçæ°ããéçºããããã®ã§ãå²ããããªã倧ããªã¯ã¯ãã³ã§ãã
ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«é¢ãã誀ã£ãæ
å ±ãæ¿æ²»çãªè£å·¥äœãããã«äžéã«æº¢ããŠãã
ãã¯ãã»ãã®å°ã調ã¹ãŠã¿ãã°ããã«åããããšã§ãããã
ã€ã³ãã«ãšã³ã¶ãšã¯ããã£ã 1 ã€ã®å£ç¯ã®éã«ææè
ã®éã§åžžã«ããŒãžã§ã³ UP ãç¶ãã
ããšãåºæ¥ããŠã€ã«ã¹ã§ããã¯ã¯ãã³ã®ã»ãã«ã¯ãç
æ°ã®åå ãšãªããŠã€ã«ã¹ã®äœããŒãž
ã§ã³ç®ããèãããã®ãå«ãŸããŠãããšã®ããšã§ãããã€ã³ãã«ãšã³ã¶ã«ãããŠã¯ããã
ãŒãžã§ã³ã®ãŠã€ã«ã¹ãåãåããŠãã¯ã¯ãã³ã®è£œé äœæ¥ãçµããæ°è¡ã®æã«æž¡ã段éã«è³
ãé ã«ã¯ããããã§ã«ãã®ã¯ã¯ãã³ã§ã¯å
šç¶å¯Ÿå¿åºæ¥ãªãåã«ããŒãžã§ã³ UP ããŠããŸã£ãŠ
ããã®ã§ãïŒã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®è£œé æ¥è
ã§ããAventis 瀟㮠MDããã€ã±ã«ã»ãã
ã«ãŒããããããåãã€ããšããé ã«ã¯ããã§ã«ããã«å¯ŸããŠäœã®å¯ŸåŠãäžå¯èœã«ãªã£ãŠ
ããŸã£ãŠããããšèªããŠããŸãã[75] éãæŽå¯åã§ããã
ãŠã€ã«ã¹ã«ææãã人ã®çç¶ãéãã»ã©ããããã¯ææè
æ°ãå€ãã»ã©ãããã ããŠã€ã«
ã¹ã®ç¹æ®é床ã¯éããªããŸãããã®ãããªçŸè±¡ããç§åŠè
ã¯éºäŒåå¢å¹
ãšåŒãã§ããŸãã
(Garret,pp578,580,614) [223]
ããã«ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã¯ãææè
ã® 1 人 1 人ã«ãã£ãŠããå°åã«ãã£ãŠããã
ããå€åããŸãããããªã®ã«ã¯ã¯ãã³ã®æ¹ã¯ãã¿ããªäžç·ã«ãã£ã 1 çš®é¡ã®åãã¯ã¯ãã³
ãæ¥çš®ããã®ã§ãããšããã°âŠèªç¶ã«ã€ããå
ç«ã¯ãäžçç¶ããã®ã§ããããã®ã¯ã¯ãã³
ã ã£ãŠæ¬åœã«å¹æã®ãããã®ãªããæ¥å¹ŽãŸãæ¥çš®ãããå¿
èŠã¯ç¡ãã¯ãã§ããïŒ
ã€ã³ãã«ãšã³ã¶æ¥çš®ãå¹ããªãçç±
çããã¯ãã€ã³ãã«ãšã³ã¶æ¥çš®ããã€ãåããŠãã人éã«éã£ãŠãæ¯åã€ã³ãã«ãšã³ã¶ã«
ææããŠãããšããããšã«æ°ä»ããããšã¯ãããŸãããïŒããã¯ãããããã²ã£ãããªã
ã«æ¥çš®ãç¶ããŠããããã§äœãæ¯ãã€ãæããªããèªåã®äœå
ã§å
ç«æ©èœãå®çãããäœ
è£ããªãã®ã§ãããã
ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®ç¬¬äžã®åé¡ç¹ã¯ã補é éçšã§ããŸã ã«æ°Žéã䜿ãããŠããããš
ã§ãã(PDR,2007 p.1451)[240]ãŸãããã«ã ã¢ã«ãããããšãã¬ã³ ã°ãªã³ãŒã«ïŒææ¿æ©
ã«äœ¿ãããæ¶²äœïŒãå«ãŸããŠããŸãã[240]ãŸãã2007 幎ãŸã§ã¯ã¢ã«ãäºãŠã ãå
¥ã£ãŠããŸ
ããããåãè¿°ã¹ãããã«ãããããåšåº«ã¯æšãŠãããããšãªãã¡ãããšæ®ã£ãŠããã®ã§
ãã
ãããªã«ææ¯ç©è³ªãå
¥ã£ãŠããã®ã§ãããããã®ã¯ã¯ãã³ãã€ã³ãã«ãšã³ã¶ãäºé²ããã
ãšãåºæ¥ãªãã®ãç¡çããããŸãããCDC ããããã€ã³ãã«ãšã³ã¶æ¥çš®ã®ãæåçããã
ããïŒïŒïŒ
ãšããŠãããããã§ãã[1]ãã¡ããå®éã«ã¯ããã®æåçã¯ãã£ãšäœããªããŸ
ããCDC ããã®æåçã®è£ã¥ããšããŠãããç ç©¶ããã©ããªãã®ã詳ããã¿ãŠãããšãã
ããäœã®å»åŠçãªè©Šéšãã广ããªã¹ã¯é¢ã®å®éšããããŠããªãããšãæããã«ãªããŸãã
å¯äžè¡ãªããããå®éšãã¯ãããããšæãããã¯ã¯ãã³ãéžãã§ããããå®éã«äžè¬ã®äººã
ã«æ¥çš®ãããã®äžã§èšŒæ ããªãã幎霢å¥ãæ§å¥ã人皮å¥ãªã©ã«çްããåé¡ããŠã€ãã¿ã©ã
ãã®ãªãããŒã¿ãç·šéãçµè«ãã§ã£ã¡äžããŠããã®ã§ãã
ããããç¶æ³ã«èœèããã®ã¯ç§éã ãã§ã¯ãããŸãããã€ã®ãªã¹ã®å»åŠèªã®ãããã§ãã
BritishMedicalJournalèªã¯ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«ã€ããŠæ¬¡ã®ããã«å ±éããŠããŸ
ãã[64]
ãâŠåŸ¹åºãã調æ»çµæã®æ°ã
ããããã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®å¹æãããããããã
ããã¯çç¡ã§ããããšãåãã£ãŠãã⊠ãã®ã¯ã¯ãã³ã«é¢ããç ç©¶ã«ã¯ããã¡ããšãã
å°éçãªå
å®¹ãæ¬ ããŠããã補é åŽã®å§åã®åœ±é¿ã倧ããããããã®ã¯ã¯ãã³ã®å®å
šæ§ã«
é¢ããŠã®èª¿æ»çµæã¯ãä¿¡çšã§ãããã®ãã»ãšãã©ç¡ããã
ãã®ãããªç§åŠçãªæ¹éã®éå»ãã²ã©ãã§ãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®éçºã補é ã«
ãããŠã®æ§ã
ãªæ±è·ãè
æãç®ã«äœããŸããäŸãã°ãäžçææ°ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³
補é 瀟ã®ïŒã€ããã«ã®ãŒã® Solvay Pharmaceuticals 瀟㯠2008 幎 10 æãGAå·ããªãšãã¿
ã«æ°ããäºå®ããŠããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³å·¥å Žã®å»ºèšãäžæ¢ããŸããããåœç€Ÿã¯ãã§
ã«ã¢ã¡ãªã«æ¿åºããå·¥å Žå»ºèšã®äººä»¶è²»ã® 60%ãæŽå©ãããæŽã«ã¯äºå®ã® 2 幎ãåãªã®ã«ã€
ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®éçºè²»ãšã㊠300 çŸäžãã«ãåãåã£ãåŸã ã£ãã®ã§ãïŒ[2]éçº
äžæ¢ã®çç±ãšã㊠Solvay 瀟ã¯ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®åžå Žããäžå®å®ã§æžå°ãã¿ã§ã
ãããšããŠããŸããã€ãŸãããã¯ãã€ã³ãã«ãšã³ã¶æ¥çš®ãåããäººãæ¬¡ã
ãšã€ã³ãã«ãšã³
ã¶ã«ææããŠããã®ãç®ã®åœããã«ããŠã人ã
ãæ¬¡ç¬¬ã«ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®å¹æã«
çåãæã¡ã¯ãããŠãããšããäºå®ãåæ ããŠããã®ã§ãããã
å£²ãæ®ã£ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®æ°ã¯ã以äžã®éãã§ãã
2006 幎 121,000,000 ååã®å
ã18,000,000 åå
2007 幎 140,000,000 ååã®å
ã27,000,000 åå
ãããªå£²äžè¡šãèŠãŠã¯ãäŒç€Ÿãããæ°ããªãããŠããŸã£ãã®ã§ããããSolvay 瀟ã¯ãããž
ãã¹äŒç€Ÿã§ãããã¢ã¡ãªã«åœæ°ã®å¥åº·ã幞ããªããŠé¢ä¿ãªããå²ãã®ããã ãã«åããŠã
ãã®ã§ããããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã補é ããŠããäŒç€Ÿã¯äžçã« 5 瀟ãããªãããã
ã« Solvay 瀟ã¯ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®ã¿ã補é ããäŒç€Ÿã§ããã¯ã¯ãã³ãæ¥çš®ããåŽ
ãå±éºã«ããããŠãæ°ã¯ãšãããªãããã©ãèªç€Ÿãå±éºã«ãããã®ã¯ãã¯ãå«ã ã£ãã®ã§
ãããã
WHOãšã¯äœãïŒ
WHOãšããæ©é¢ã®éå¶æ¹éã«ã¯ãè£œè¬æ¥çãåžžã«é¢äžããŠããŸãã2006 幎㫠WHO
ã¯ãäžçååœãæ¯å¹Žèªåœã®äººå£ 75%ã«é
絊ã§ããåãç®æšãšããŠã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³
ãåšåº«ããã¹ãã ãšããã銬鹿ããæšå¥šå®£èšãããŠããŸãã[2]幞ããçç£ç€ŸåŽã売ãäžã
ã確ãã ãšåãã£ãŠããåããã€ãããªãã®ã§ãå®éã«ã¯ããã¯ç¡çãªæšå¥šãªã®ã§ããâŠã
æäººçšã®ã¯ã¯ãã³æ¥çš®ãšããã®å®£äŒç
ã¯ã¯ãã³æ¥è
ã®ãããã売ãäžãã®äŒžã³æ©ã¿ãåããŠãã2008 å¹Žã«æäººçšã®ã¯ã¯ãã³æ¥çš®
äºå®è¡šãçªç¶ãããããŸãããããã«ãããšã18 æ³ä»¥äžã®æäººã¯ãªããšèš 45åãã®ã€ã³ã
ã«ãšã³ã¶ã¯ã¯ãã³æ¥çš®ãåããããšã«ãªã£ãŠããã®ã§ãïŒ[15]宣äŒéšéã¯ç¹ã«ã幎å¯ãã«
ç®ãã€ãããã®çµæãçŸåšã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³æ¥çš®çã® 72%ã¯ã幎é
ã®äººã
ã§ãã
[2]
ãã®åã ãšããã® 2005 幎ã®ã§ã£ã¡ãããã«ã«ãã©ã«ãã¢å·ã¯ã¯ãã³åšåº«äžè¶³ããšãã£ãèŠ
ãèŠãã§å€±æã«çµãã£ã売ãäžãçãããŸãæµè¡ãããã§ãã
ããïŒã€ãã¯ã¯ãã³æ¥çã§åå
«çªã«ãªãã€ã€ã»ãŒã«ã¹çã¯ããææå€§æµè¡ã説ã§ãããã®èª¬
ã¯ãæ¬æ¥ã¯ãšãŽã£ã¢ã³ ã€ã³ãã«ãšã³ã¶ãšããæ¶ç©ºã®ææç
ã ãã®ããã«ãšã£ãŠããã¯ã
ã§ãããããã®ç
æ°ã¯äžæåã«ææã®äŒæç
ãšããŠéšãããåŸãå¿ãããã€ã€ããããã
ã¯ã¯ãã³ã»ãŒã«ã¹éšéã§ã¯ããã£ãšäžè¬ã®ã€ã³ãã«ãšã³ã¶ã«ããã®æã䜿ããããšããã
ãšã«ãªã£ãã®ã§ãã
ãšããããšã¯ãããããå¯ç£ç©ãšããŠãæ ç»ã§ããããããææç
ãã®ããæµè¡ãã§ãã
ããïŒ
ã€ã³ãã«ãšã³ã¶æ¥çš®ãšã¢ã«ããã€ããŒç
çããããæ°ã¥ãããç¥ããŸããããã¢ã«ããã€ããŒç
ã¯è¿é ã©ãã©ã身è¿ãªç
æ°ã«ãªã
ã€ã€ãããŸããå
ç«éºäŒåŠã®å
端è
ã§ãã MD.ãã¥ãŒããŒãã³ããŒã°ã¯ã2000 幎ã«
850 ããŒãžã«æž¡ãç ç©¶çºè¡šãåºããŠããŸããããããäžèªããã°ããã®ç
æ°ããããªã«æµè¡
ã£ãŠããåå ã䌺ããŸãã
ã1970 幎ãã 1980 幎ã®éã«ãç¶ã㊠5 åã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ¥çš®ãã人ãã¢ã«ã
ãã€ããŒç
ã«ããã確çã¯ãã€ã³ãã«ãšã³ã¶æ¥çš®ãåããŠããªã人㮠10 åã«ããªãã[327]
ã²ãã£ãšããŠãã¢ã«ããã¢ã ããããã§ããã®ããâŠïŒ
ã¡ãªã¿ã«æ°ããæäººåãã®æ¥çš®äºå®è¡šã§ã¯ã65 æ³ã«ãªããŸã§æ¯å¹Žã®ã€ã³ãã«ãšã³ã¶æ¥çš®ã
æšå¥šããŠããŸãã
ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®åå©
ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã¯ã20 幎éãã®æ€èšã®çµæã2002 幎 1æã«ãã£ãšçŸ©åå¶ã®æ¥çš®äº
å®è¡šã«ä»²éå
¥ãããããšãåºæ¥ãŸããããã㊠2005 幎 2 æ 7 æ¥ã«ã¯ãããŸãŸã§ã®ãã€ãªã¹
ã¯åºåãããã£ãããšå®çªã®æ¥çš®äºå®è¡šã«ç§»ã蟌ãã§ããŸããŸããããã®çµæãçŸåšã§ã¯
ãŸãçåŸ6ã¶æã«æåã®æ¥çš®ãããããã¯18æ³ã«ãªããŸã§æ¯å¹Žã®æ¥çš®ãæå®ãããŠããŸãã
ããã§ãã¢ã¡ãªã«ã®åäŸéã®æ¥çš®æå®åæ°ã¯ã40 åãã 58 åã«ãæ¥æ¿ã«å¢ããŠããŸããŸã
ãã
ãã¡ãããããããã¥ãŒã¹ã«åãäžããã¡ãã£ã¢ãªã©ãããŸããã§ãããã
A åèç
2002 幎 1 æãGlaxoSmithKline 瀟ã®é·å¹Žã®è£å·¥äœãããããå®ãçµã³ãåç€Ÿã®æ°çš®ã® A
åã¯ã¯ãã³ãæ¥çš®æå®ã®äºå®è¡šã«çµã¿èŸŒãŸããŸãããããã«ã€ããŠããå
¬è¡šãããããšã¯
ãããŸããã§ããã[304]ãã®ã¯ã¯ãã³ã®å㯠Havrix ãšãã£ãŠã2007 幎ç PDR ã® 1456
ããŒãžç®ã«æ²èŒãããŠããŸãã[251]
A åèçãšã¯äœãïŒ
ãã®ç
æ°ã¯ãæ¥æ§ã®ãŠã€ã«ã¹æ§èèç
ã§ããA åèçãŠã€ã«ã¹(HAV)ã¯ããã§ã«éé¢ããã
ããšã«ãªã£ãŠããŸãã[284]
ã§ã¯ããã®ç
æ°ã¯ã©ãçšæ·±å»ãªãã®ãªã®ã§ããããïŒ
A åèçãšããã®ã¯ã軜床ã®ãçç¶ãç©ãããªææçã§ãæ²»çããªããŠã 4~8 é±éã§èªç¶
ã«æ²»ã£ãŠããŸããŸãã倧æµã®å ŽåãææããŠãçç¶ãåºãªããããææã«æ°ä»ããªããŸãŸ
çµãã£ãŠããŸããã®ã§ãã(Merckp.377)
倧æµã®å ŽåãA åèçã«ã¯äœã®æ²»çãå¿
èŠãããŸãããåœç«å¥åº·æ©é¢ã® NIH ã§ããããA
åèçã«ããã£ãäººã®æ®ã©ã 2,3 é±é以å
ã«èªç¶ã«å埩ããããšè¿°ã¹ãŠããŸãã
[168] NIHManual
ãŸã A åèçã®ææã®æ®ã©ã¯ãã¢ã¡ãªã«åœå
ã§ã¯ãªãã第äžäžçã§èµ·ãã£ãŠããŸãããã
ãªã®ã«ããªãã¢ã¡ãªã«ã ããé壿¥çš®ãå€§èŠæš¡ã«æšå¥šããèªåœã®åäŸéã« 4 åãã®æ¥çš®ã
匷ããŠããã®ã§ããããïŒ
ãã®ã¯ã¯ãã³ãæ¯å¹Žäœåãã«ãå²ããå売ã ããã ããšæãã®ã¯ç§ã ãã§ããããïŒ
A åèçã®çç¶
Merck ã®ããã¥ã¢ã«ã«ããã°ãAåèçã®äž»ãªçç¶ã¯æ¬¡ã®éãã§ãã
飿¬²äžæ¯
NVD
ãããŸãã
é¢ç¯ã®çã¿
æ¿ãè²ã®å°¿
ãããã¿ãã°ããŸãåœã«åé¡ã®ç¡ããã®ã ãšããããšã¯ããåããã§ããããé»çžãåºã
å ŽåããããŸãããéåžžããã¯ç
æ°ãå埩ã«åã£ãŠãããšããå
åã§ããããã®çç¶ãåº
ãé ã«ã¯ãç
æ°èªäœã¯ãã§ã«ææèœåã倱ã£ãŠããã®ã§ãã
B åèçãšã¯éããA åèçã¯æ¥æ§çºç
ã®ããšãå®å
šã«æ²»çãããã®ã§ãæ
¢æ§ã®èèç
ãè
硬çã«ã€ãªããããšã¯ãããŸããããããŠäžåææããŠæ²»ã£ãŠããŸãã°ããã®äººã¯äžçç¶
ãå
ç«ãæã«å
¥ããããšã«ãªããŸããããããæ¬ç©ã®å
ç«ã§ãã
A åèçããŸããçæŽ»ãè¡çç°å¢ãæªãã人å£é床ã®è²§å°å°åã«ãããææç
ã§ãããã€ãŸ
ã第äžäžçç¹æã®ç
æ°ãšèšããŸããè¬ç©äžæ¯è
ã§ãããã¡ãããšé£ã¹ãŠããçšåºŠã®ç掻ã
ããŠããã°ããã€ãªã¹ã¯ã®åºåã«åœãŠã¯ãŸããªãã»ã©ã§ãã圌ãã¯ããããBåèçã®æ¹ã
å¿é
ã§ãã
ããäžåºŠãŸãšããŸãããAåèçã¯ã¢ã¡ãªã«åè¡åœã§ã¯çšãªç
æ°ãªã®ã§ãã
ãã®ä»ã®åå
é©ããããšã«ãB åèçã¯ã¯ãã³ãš C åèçã¯ã¯ãã³ã®äž¡æ¹ããA åèçãåŒãèµ·ããå
å ãšãªã£ãŠããŸãïŒïŒïŒãã®äºå®ã¯ãGlaxoSmithKlein 瀟ã®è£œåãHarvix ã®æ³šéã«ããã
ãïŒã€ã®èçã¯ã¯ãã³ãåå ã§èµ·ãã A åèçã«é¢ããŠã¯æ²»ç广ããªãããšã¡ãããšæž
ãããŠããã®ã§ããã§ã¯ãHarvix ãšãã A åèçã¯ã¯ãã³èªäœããèçã®åå ã«ãªãã®ã§
ããããïŒå®ã¯ããã®éãã§ããã®çç£ç€Ÿèªèº«ã 2007 幎床㮠PDR ã® 1458 ããŒãžã«èšèŒ
ããŠããããšã«ã¯ããHarvix ã®å¯äœçšã®ïŒã€ã¯ãèçã§ããããšãªã£ãŠããã®ã§ãïŒ[251]
ã§ã¯ããã®ã¯ã¯ãã³ã¯äžäœèª°ã®ãããªã®ãïŒ
2,3 é±éã§èªç¶ã«æ²»ã£ãŠããŸãããããããçšã«ããèµ·ããªãç
æ°ã®ããã«ããã§ã«åŠæ ¡ã®
åäŸéã«æ¥çš®æå®ãããŠããã¯ã¯ãã³ã«å ããŠãããäžçš®é¡ã¯ã¯ãã³ãå ããå¿
èŠã¯æ¬åœ
ã«ãã£ãã®ã§ããããïŒ
Harvix ã¯ã¯ãã³ãæ¥çš®æå®è¡šã«è¿œå ããéããã®æ°ã¯ã¯ãã³ã®å®å
šæ§ã®æ€æ»ã¯è¡ãªããã
ã§ããããïŒããããå
šããããŠããŸããããã®ããã«æ°ãã«ã¯ã¯ãã³ã®ãŠã€ã«ã¹æ¥çš®ã
远å ããããšã«ãã身äœãžã®è² æ
ã«ã€ããŠã¯ãåã«è¿°ã¹ããšããã§ãã
次ã«ãã©ã®ã¯ã¯ãã³ã«é¢ããŠãããã®å¿
èŠæ§ãæ€èšããéã«ã¯ãç
æ°ã®å®äŸããšãæ·±å»ã
ã®çšåºŠãã®ïŒã€ã®æ¡ä»¶ãèæ
®ããå¿
èŠããããŸãã
å®éã®çºç
äŸ
ãããäŸã«ãã£ãŠãäžçããã®èª¿æ»çµæã§ããHarvix 瀟㯠2002 幎床㮠Physicians Desk
Reference ã« 13 幎éã«æž¡ã調æ»çµæãæ²èŒããŠããŸãããããã«ãããšæ»äº¡ç㯠0.6%ãšã
ãããšã«ãªã£ãŠããŸãã(p1545)[251]ã€ãŸãããã¯ãA åèçã«ææãã人1000 人ã®ãã¡ã
6 人ããã®ç
æ°ãåå ã§æ»äº¡ããŠãããšããæå³ã§ãã
ãããèŠããšæ»äº¡çãããªãé«ãããã«æããã§ãããããå®ã¯ããã¯ã¢ã¡ãªã«åœå
ã®ç¢º
çã§ã¯ãªããäžçå
šäœã§ã®ç¢ºçã§ããA åèçã®ææäŸã®å€§éšåã¯ç¬¬äžäžçã«ãããŠã®ãã®
ã§ããããã€ãŸããã®æ»äº¡çãäž»ã«ç¬¬äžäžçã®äººå£ã察象ã«ãªã£ãŠããèš³ã§ãããããã
å°åã®ææè
ã¯ãè²§å°ãäžè¡çãæ é€å€±èª¿ãæ±ããŠããŠãåžžã«ããããç°å¢ã«æ©ãŸãããŠ
ãã人ã
ã§ãã®ã§ãããã¯ã¢ã¡ãªã«åè¡åœã®å€§éšåãšã¯å
šãç°ãªãç¶æ
ã§ããããããæ
å£ã¯è£œè¬äŒç€Ÿã®åå
«çªã§ããããç
æ°ãããã«æ·±å»ã§ãã¢ã¡ãªã«åœå
ã«ãããŠãã¯ã¯ãã³æ¥
çš®ãå¿
èŠã§ããããšæ¿åºã説åŸããããã«è¯ã䜿ãããæ¹æ³ã§ãã
ã§ã¯ãã¢ã¡ãªã«åœå
ã«ãããå®éã®çºç
äŸã¯ãšèšããšãããã¯éåžžã«èª¿æ»ãé£ãããã®ã§
ããæ¿åºã®èª¿æ»è¡šã¯ããã€ã決ãŸã£ãŠããæœè±¡çãªçµ±èšè¡šã§ãããäŸãã° 2000 幎床çã®
137 ããŒãžç®ã«ã¯ãã®æ§ã«èšèŒãããŠããŸãã
1980âââ29.1 / 100,000 ä»¶
1998âââ23.2 / 100,000 ä»¶ [169]
ãããèŠããšããã® 20 幎éã§ A åèçã®ææäŸã¯æžã£ãŠããããšãããããŸããããã¯ã¯
ã¯ãã³ã®ãé°ãªããã§ã¯ãããŸããããªããªããã¯ã¯ãã³ã¯ããæè¿åºãã°ããã§ãããã
ãããããã«ããŠãããã«ææçãé«ããšæããŸãããïŒïŒããã§ãã®èª¿æ»ç¥šãè¯ãèŠãŠ
ã¿ããšâŠè«çŒé¡ã§ããèŠããªãçšå°ããªæåã§ããæžããŠããã§ã¯ãããŸãããïŒ
ãåè¡åœä»¥å€ã«ãããææäŸãå«ãã
ããïŒåœå€ã«ãããææäŸãå«ããã§ãã£ãŠïŒãããããæå³ãç¡ãã§ã¯ãããŸããããA
åèçãè²§å°ãäžè¡çãæ é€äžè¯ããæ¥ãç
æ°ã§ããã倧æµã¯åœå€ã§ã®ç
æ°ã§ãããšãã
ããšããããã¿ããªç¥ã£ãŠãããã§ãããïŒããã§ãåãåœå
ã§ã®ã¯ã¯ãã³æ¥çš®ã®å¿
èŠæ§
ã説ãããã«ãäžçå
šäœã®ææäŸãåãå
¥ããŠããŸãããŠããã®ã§ãã
ã¯ã¯ãã³ã®å®æ
ããã¯ã¡ãã£ãšé¢çœãã§ãããA åèçã®ã¯ã¯ãã³ã¯ãææãã人éã®çµåçµç¹ã®çްèã
ããäœãããŠããŸããåè«ã§ã¯ãªããæ¬åœã®è©±ã§ãããã 1人ã®äººéã§ã¯ãªã 1000 人ãã®
ææããæäŸè
ã®çްèããŸãšããŠãããããã¯ã¯ãã³ãäœãåºããŠããã®ã§ãã
ïŒPediatricsïŒ[284]ããã¯ãç©åã现èããŒãã£ãŒã§ããïŒA åèçã«ææãããšå¿
ãã现
è㯠A åèçãŠã€ã«ã¹ã«æ±æããããšããããšã«ãªã£ãŠããŸããããæ±æããã现èãã
ãããšéãŸã£ãŠããã®ã§ãã
ãããŠããããã£ã«ã¿ãŒããã¢ã«ãããŠã ããã«ã ã¢ã«ãããããã§ãã¯ã»ãµããŒã«ïŒãš
ãã¬ã³ ã°ãªã³ãŒã«ã®ç§åŠåç§°ïŒãšããåçµé²æ¢å€ãªã©ã§èª¿æŽããŸãã(PDR,p1456)[251]
ã¢ã«ãäºãŠã ãšãã«ã ã¢ã«ãããã«ã€ããŠ
ã©ãã»ã«ã»ãã¬ã€ããã¯å士ãã»ãªã»ã³ã«ããŒã³ã解説ããŠããŸãããã¢ã«ãäºãŠã ã人
äœã«ãããã害ã¯ã決ããŠã¢ã«ããã€ããŒç
ã ãã§ã¯ãããŸãããã¢ã«ãäºãŠã ã¯ããã
ããç¥çµçµç¹ã®çްèã®çµåãæé·ã劚害ããããããã®æ»ææ
å¢ã¯èªç±èªåšã§äºæ³ãäžå¯
èœã§ãã(Excitotoxins,OurStolenFuture)[262,212]ã€ãŸããè¢«å®³ç¶æ³ã¯æªç¥ã®é åãªã®ã§
ãã
ãŸããã«ã ã¢ã«ãããã«é¢ããŠèšãã°ãçºã¬ã³æ§ã§ãããšããããšèªäœãæ°çå
ã®çŽç²ãª
è¡æ¶²ã«å ããã«ããŠã¯ããŸãã«ãå±éºãªãã®ã§ããçã¯ãæåã¯ãã£ãïŒã€ã®çްèããå§
ãŸããŸããã§ã¯ãæ®çãããã«ã ã¢ã«ããããåçµé²æ¢å€ãããã现èãå€åããŠçãåŒ
ãèµ·ããåå ã«ãªããªãããšããããšã蚌æããç 究調æ»ãã©ãã«ããã§ããããïŒã©ã
ã«ãããããªãã®ã¯ãããŸããã[16]
æªèª¿æ»ã®ãŠã€ã«ã¹åªäœãã°ããŸãããšããè¡çº
èŠããã«ãããŒãã€ã³ããšãªãçåã¯ãããã§ãããã¢ã¡ãªã«åœå
ã§ã¯æ®ã©èŠãããããã
ãæ¶æ»
ãã€ã€ããç
æ°ãäºé²ã§ããããšãã仮説ãçã«åããŠãåœå
ã®ãã¹ãŠã®åäŸéã«
ãã®æææ§ãŠã€ã«ã¹ã泚å
¥ããããšã¯ãæ¬åœã«å¿
èŠãªè¡çºã ã£ãã®ã ãããïŒãããããã
ã®ç
æ°ã¯è»œãç
æ°ã§ãæ
¢æ§ã®èèç
ãåŒãèµ·ããããšããªããããã«äžãäžããã£ãå Žå
ã«ã¯ããã®åŸäžçç¶ãå
ç«ãæã«å
¥ããããšãåºæ¥ããšããã®ã«ãäžäœãªãã§ãããªããš
ãããŠãããã ããïŒã
å®£äŒ VSïŒ æ
å ±
åœç«ä¿å¥åäŒïŒNIHïŒã¯ 2000幎ã«ãããã³ãã¬ãããé
åžããŸãããããã㯠2002 幎床
ã®æ¥çš®äºå®è¡šã«A åèçã远å ããããšããåœæ°ãåãå
¥ããããããããã®ãã®ã§ããã
ãA åèçã«ã€ããŠç¥ããªãããããªãããšããšãã£ããäœãšã幌çšãªã¿ã€ãã«ãã€ããã
ã³ãã¬ããã§ãããããã®ã¿ã€ãã«ããã NIHãåœæ°ã®ç¥èœã¬ãã«ãã©ãã ãäœãèŠãŠã
ãããå€ãã§ãããïŒïŒïŒæ®å¿µãªãããæ¬åœã«äœããªã£ãŠããŸã£ãŠããã®ããç¥ããŸãããã
ãã³ãã¬ããã®äžèº«ããã®èª¿åã§ãå°åŠçã«æåãè¶³åããããããªæŒãä»ãããŸããæ
ãã§æžãããŠããŸãã
ãã®äžã®äžæãæããŠã¿ãŸãã
ãã¯ã¯ãã³ã¯ãããªããå¥åº·ãªæã«ãšããšç
æ°ã«ããããªãããã«ããŠããããè¬ã§ããã
ããæ¬åœã§ããïŒãŸããã¯ã¯ãã³ã¯ãè¬ã§ã¯ãããŸãããã人ã
ãããšãããã®ã§ããã
ãŸãããæ¬¡ã¯ãç
æ°ã«ããããªãããã«ããšããç¹ã«é¢ããŠã§ããã¯ã¯ãã³ã®ããã§èªå
ã®åäŸéãèŽåœçãªé害ãåããäžç身äœãæ²»ããªããªã£ãŠããŸã£ããšãããäœå人ãã®
芪ã«ãå®éã«ã¯ã¯ãã³ãã©ãã ãç
æ°ãé²ãã§ãããã®ããèããŠã¿ããšè¯ãã§ãããã
ãããªæããããŸãã
ãã¯ã¯ãã³ã¯ããªãã®èº«äœã«ãA åèçãŠã€ã«ã¹ã®ãããªç¹å®ã®ãŠã€ã«ã¹ãšæŠãããšãæã
ãŠãããŸããã
ãã®ééã£ãä¿¡ä»°ã¯ã1797 幎ã«ãžã§ããŒã宣èšããŠãããšãããã®ãã£ãšä¿¡ããããŠãã
ãã®ã§ããããããããçå®ã§ãã£ããªããéå» 35 幎éã®å€©ç¶çãåã³ããªãªçŸæ£è
ã®å
š
å¡ãã¯ã¯ãã³æ¥çš®ãåããè
ã§ãã(Salk,Sabin)[288,294]ããšãã£ãããšãªã©èµ·ããªãã£ã
ã¯ãã§ããããã¯ãèšãèš³ã®ä»æ§ã®ç¡ãäºå®ã§ãããã
ã¯ã¯ãã³ããã¯ãç
æ°ã®ã»ããå®å¿
ç
æ°ãã®ãã®ã軜çã§ããæ²»ãããã®äžãããããšã«ãã£ãŠäžçã®å
ç«ãä»ããšãããªãã
眹æ£çã§ç€ºãããŠãã確çã«è©²åœããããäžéšã®äººã
ã ã£ãŠãç
æ°ã«ãããæ¹ãè¯ãã ã
ãããçºããæ§ç©è³ªãç¥çµäžæ¯æ§ã®ç©è³ªãäžè¬ã®çããã®è¡æ¶²ã«ã°ããŸãããã¯ãã£ãœã©
ãã·ã§ã¯ãªãã§ããããïŒ
ãŸãšã
æåŸã«ããäžåºŠãAåèçã¯ã¯ãã³ã®åé¡ç¹ããŸãšããŠèŠãŸãã
ã¢ã«ããã¢ã
ãã«ã ã¢ã«ããã
ãšãã¬ã³ ã°ãªã³ãŒã«
倿§ãªå¯äœçšåå¿ ïŒèçãå«ãïŒ
æåéã¯æšæž¬ã§æ±ºããããŠãã
A åèçã®çŸæ£è
ã®ã»ãšãã©ã¯ã¢ã¡ãªã«åè¡åœå€ã§ããã®ã«ã
ã¢ã¡ãªã«ã ããå¯äžãã®ã¯ã¯ãã³ãé壿¥çš®ããŠããããš
åäŸéã«æææ§ç©è³ªãé壿¥çš®ãšãã圢ã§å€§èŠæš¡ã«ã°ããŸããŠããããš
ãã§ã«å²äžã§æãå€ãã¯ã¯ãã³æ¥çš®ãåããŠããåäŸéã®èº«äœã«ãããã«ãŠã€ã«ã¹ã«ãã
è² æ
ãè² ã被ããããš
以äžã®ç¹ã§åé¡ãç¡ããšãããªãããã£ãŠãæ§ããŸãããã
B åèç
B åèçãšã¯èèãççãèµ·ãããã®ã§ãããã«è¬ç©äžæ¯è
ã«ã¿ãããç
æ°ã§ãã倧æµã®çœ¹
æ£è
ã¯æ
¢æ§ã®èèç
ã«ããªãããæ°ã¶æã§èªç¶ã«æ²»çããŸããèçã®ã¯ã¯ãã³ã¯æè¿éçº
ãããã°ããã§ãå¯äœçšã«é¢ããé·æçãªèª¿æ»ã¯äžåãããŠããŸããããããªã®ã« 1991 幎
ã«ã¯ãCDC åã³ AAP æ©é¢ã B åèçã¯ã¯ãã³ãå
šãŠã®ä¹³å
åãã«çµã¿ããã§ããŸããŸã
ãã( p172 [211]) ããã¯ãäžäœã©ãããŠã§ããããïŒ
1991 幎以åã«ã¯ãB åèçã¯ã¯ãã³ã®å¯Ÿè±¡ã¯ãããããã€ãªã¹ã¯åºåã®äººã
ïŒå»çæ©é¢ã®
é¢ä¿è
ãè¬ç©äœ¿çšè
ã倿°ã®ã»ãã¯ã¹ããŒãããŒããã人ãåã³ B åèçã«ããã£ãããš
ã®ãã人ã«éãããŠããŸããããã®ç
æ°ãæ¯èŠªããèå
ã«ææããããšã¯ãããŸãããæ¯
芪ãé°æ§ã®å Žåã«ã¯ããã®äººã®èµ€ã¡ããã«å€æ°ã®ã»ãã¯ã¹ããŒãããŒãããããã®åãè¬
ç©äžæ¯ã ã£ãããªããŠããšã¯ãŸããªãã§ããããããã¯ã¯ãã³ã¯å¿
èŠãªãã§ããïŒç¹ã«ã
çãŸãããŠã®ææã«æ¥çš®ãããªããŠããªãããã®è©±ã§ãã
ãããããéå²ãããããã§ãããšãããããåžžèã¯ã©ãããžå¹ã£é£ãã§ããŸããŸãã
å®éã®å²ãé¡ã¯ãšèšããšã溯ã£ãŠ1993 幎ã«ã¯ããã®æ°ããååã¯ïŒå¹Žã« 200 äžãã«ãã®å£²
ãäžããã¿ããŠããŸããïŒGaniatsïŒ[287]çŸåšã§ã¯ã売ãäžãã¯1 åãã«ã«ãè·³ãäžãã£ãŠ
ããŸãïŒïŒïŒ[310]ãªããšãªãããããæ°ãããŠããŸãããïŒ
ã§ã¯å¹èœã¯ã©ãããšãããšããã®ã¯ã¯ãã³ã®é·æçãªç 究調æ»ã¯äžåãããªãããªããŸãŸã
äžè¬ã®äººã
ã«ãã®ã¯ã¯ãã³æ¥çš®ã矩åä»ããããŠããŸã£ãã®ã§ãã (Neustaedter,
p125)[211] å°å
¥åŽã§ããããã®ã¯ã¯ãã³ã®ã¢ãã¿ãŒãè¡ãªãããã®ã¯åžå Žã«åºåããã£ã
5 æ¥åã ã£ããšè¿°ã¹ãŠããäœã§ãããïŒ(Dunbar)[175] å€ãã®ç ç©¶è
ã¯ããã®ã¯ã¯ãã³ã®
ãå
ç«ã广ã¯å¹Žæãšå
±ã«åŒ±ãŸããšãããããã«æ°åã«ãããè¿œå æ¥çš®ãçµã¿èŸŒãŸããã
ãããšèŠãŠããŸãã(Hall[254]) 倧人ã®è¬ç©äžæ¯è
ããããç
æ°ã®äºé²ãšããŠãä¹³å
ã«ã¯ã¯
ãã³æ¥çš®ãããªããŠããããªèããã©ãããŠåºæ¥ãã®ãæ¬åœã«äžæè°ãªãã®ã§ãã
Merck 瀟㯠1970 幎ååãã B åèçã¯ã¯ãã³ã®è£œé ãæãããŠããŸãããå®éšã®å¯Ÿè±¡ãš
ãªã£ãŠããã®ã¯çããŠããç¿ãšããããŠä»çããŠãã人éãç§éã§ãã(p.244)[256]äžè¬ç
ã«ãæå¶å€ããšããŠã¯ã¯ãã³ã«ãã䜿ããããã«ã ã¢ã«ãããã¯ãæ¥çš®ãã人ãèçã«ã
ãããªãããã« B åèçãŠã€ã«ã¹ãèãããšããç®çã§äœ¿ãããŠããŸããå°ãªããšããç®
çã¯ããããããšã«ãªã£ãŠããŸãã
ãã®æå¶å€ã®å¯äœçšããçºã¬ã³æ§ã§ããããšã¯ãã§ã«è¿°ã¹ãŸããã
ããã©æ¬åœã«æãã®ã¯ããã®æ°Žéãã£ã·ãã® B åèçã¯ã¯ãã³ããçãŸãããŠã®åœã«äžã
ãããããšã«ãªãããç¥ããªããšããäºå®ã§ããEPA ã§ãå®å
šããšãããŠããæ°Žéã®æå
é㯠1 æ¥ïŒïœïœã«ã€ãåäžåã®ïŒïœã§ããã2004 幎床㮠B åèçã¯ã¯ãã³ã 1 åæ¥çš®ãã
ãšããã®30 åãã®æåéã«ãªã£ãŠããŸãã®ã§ãïŒ
– FDA Hepatitis Control Report, vol.4, no.21. [293]
ä¿¡ããããªãããšæã£ã人ã¯ã倧å€çµæ§ã§ããåèè³æããèªåã§èª¿ã¹ãŠèŠãŠäžããã
ããŠãå¯äœçšã§ããããããæããããã®ã§ããNeustaedter ã¯ã1991 幎以åã«ã¯ã¯ãã³
ãæ¥çš®ããå¯äœçšåå¿ãã§ã 8äžäººã®äººã
ã®ã±ãŒã¹ã«ã€ããŠãCDC ãäœãèšè¿°ããŠããªã
ãšææããŠããŸãïŒp 175ïŒ[211] ããåæã« B åèçã¯ã¯ãã³ã®å¯äœçšã蚌æ ä»ããç
ç©¶ã®ããã€ããæããŠããŸãããã®å¯äœçšã¯ã以äžã®éãã§ãã
ã®ã©ã³ ãã¬ãŒç é¢ç¯ç
è±é«æ§çŸæ£ ã¢ããã£ã©ãã·ãŒ ã·ã§ãã¯
èªå·±å
ç«åå¿ é»çž
èŸèã®èšåŒµ
ãã®ã¯ã¯ãã³ãç¡å®³ã§ãã£ããªããããªã«ã²ã©ãããªãã®ã§ãããããã§ãããããçç¶
ã®ãã¿ãŒã³ã¯ãåã«æãããã®ä»ããããã®ã¯ã¯ãã³ã®ç¥çµãã¡ãŒãžãèªå·±å
ç«åå¿ãšã
ã£ããã®å
容ã§ãã
ããã«ã1999 幎 7 æ 8 æ¥ã«ã¯ã³ã£ãããããã¥ãŒã¹ããããŸãããã¢ã¡ãªã«å»åž«é£åãã
å±éºãªå¯äœçšããããšããçç±ã§ãå°±åŠå
ã® B åèçã¯ã¯ãã³ã®çŸ©åæ¥çš®ã峿ã«åæ¢ã
ãããã«åŒã³ãããã®ã§ããé£åã®åç· åœ¹ã§ãããžã§ãŒã³ ãªãªãšã³ã MD ã«ããè°äŒãž
ã®æ²ç€ºæã«ã¯ãB åèçã¯ã¯ãã³ã«ããå¯äœçšåå¿åã³æ»äº¡çã«ã€ããŠã
ãâŠã¯ã¯ãã³ã®å®å
šæ§ã«é¢ããæ£åŒãªé·æã®å®éšèª¿æ»ã¯æªå®ã§ãããããå ±åãããŠãã
å±éºæ§ã¯ãå®éã®å±éºæ§ããã倧å¹
ã«äžåãã[177]
ãâŠå€§æµã®åäŸã«ãšã£ãŠãã¯ã¯ãã³ã«ããæ·±å»ãªå¯äœçšåå¿ã®ãªã¹ã¯ã¯ãB åèçã«ãã
ãªã¹ã¯ã® 100 åã«ããªãã ãšãè¿°ã¹ãŠããŸãã
ããã§ãæªããç¥ããã§ãã1999 幎ã«ã¯ãB åèçã¯ã¯ãã³ã«ããæ·±å»ãªå¯äœçšåå¿ã®å ±
åä»¶æ°ããå®éã« Båèçãçºçããä»¶æ°ãäžåã£ãŠããŸã£ãã®ã§ãïŒ(Townsend Letter,
Sep 2000, p 148)[170]ãã®äºå®ããã£ããèããéã«ã倧æµã®èŠè§£ãšããŠã¯ã¯ã¯ãã³ã®å¯äœ
çšåå¿ã®å ±åä»¶æ°ã¯å®éã«å ±åãããä»¶æ°ã 10%ãæªå ±åã®ä»¶æ°ã 90%ã§ãããšããç¹ã
å¿ããªãã§äžããã
ãã©ã³ã¹ã§ã¯ 1 äž 5 å人ã®åžæ°ãæ¿åºã起蚎ããçµæãB åèçã¯ã¯ãã³ã¯ 1998 幎 10 æ
ã«åŠæ ¡ã®çŸ©åæ¥çš®ããã°ã©ã ããå§¿ãæ¶ããŸããããã®éã®çç±ã¯ãBåèçã¯ã¯ãã³æ¥çš®
åŸã«èŠããããæªå ±åã®ãç¥çµé害åã³èªå·±å
ç«åå¿ã«ããé害ãšãããŠããŸãã
(Belkin)[263]
B åèçã¯ã¯ãã³ã®å¿æŽå£
2008 幎床ã®New York Times èªã«ã¯å°ãªããšã 6åãæ±ºãŸã£ãŠéå°å¹Žä¿å¥é¢ä¿ã®ã©ã€ã¿ãŒ
ããæ±ºãŸãã«ãããããããèšäºãèŒããããŠããŸããïŒã¯ã¯ãã³ãåããŠããªãåäŸé
ã¯ãç
æ°ãå°åã«åºããŠããŸãã®ã§å±éºã ããšã
ãããã¡ãã£ã¢åŠæ ¡ã®åºå ±èªã®ãæ°ã«å
¥ãã§ãã E.L.Bernay ã®å®£äŒå¿
åæ³ããã£ããç
䌌ããŠããæ±ºãŸãã§ææ°ã®ã¯ã¯ãã³ãç ç©¶çµæãã«è§ŠããŠãã蚌æ ããŸã£ãããªãæ¶æž¬ã
çµè«ãšããŠåºãããšã§ãã¡ãã£ã¢ã«ããæèšãäœãäžããŠããŸã£ãŠããã®ã§ãã
äŸãã°è¯ãäŸãšããŠã2008 幎 10 æ 1 æ¥ã®NYT èªã«ã¯ãç ç©¶ã«ããã
B åèçãšããèçã®é¢é£æ§ãçºèŠãããããšããé¡ã§èšäºãæžãããŠããŸãã[5]
ããããããã®è¡šé¡èªäœãèª€å ±ã§ããå®éã«ã¯äœã®ç ç©¶ããããŠããããèšäºã®ã»ããäœ
ãã®é¢é£æ§ã確蚌ãããã¯ããŠããªãã®ã§ãããããã ãæŽä»£ã®ããæ£è
ã®æ¯èŒããŒã¿ã
ãªããšããç²æ«ã倧éæã«èŠãŠããäžã§ãããæ£è
ã®ããïŒã°ã«ãŒãã«ãããŠéåžžããã B
åèççŸæ£è
ãå€ãããšãèŠã€ãããšããã ãã§ããèšäºã®çè
éãããã®ïŒã€ã®ç
æ°ã
é¢é£ããŠãããšã¯æèšããããã ãæ³šç®ããã¹ãããšããšããŠåãäžããŠããŸãã[6]ã€ãŸ
ããB åèçãããèçã®åå ãšãªããã©ããã®èšŒæ ã¯äœãç¡ããããã§ã¯æ¯ç£šããããªã
ãšããèçã«ãªããããšèšã£ãã£ãŠåãããšã§ãããã®æ§ãªä»ãçŒåã®ã倧éæãªããŒã¿
æ¯èŒã¯ãã¡ãããšããç ç©¶ãšåŒã¹ããã®ã§ã¯ãããŸããããåãªãç ç©¶ã¢ã€ãã¢ã®ïŒã€ã«
éããŸããã
ããããŠèª€ã£ãæ
å ±ãåºãããã¯ããã¯ã¯ãçŸåšã§ã¯ NYT èªãã¯ãããã®ä»è«žã
ã§äœ¿ãã
ãŠããŸããããã㯠4段éããæãç«ã£ãŠããŸãã
ïŒïŒèšŒæ ã®è£ã¥ãç¡ãã«ãããäºæãäœã
ãšé¢é£ããŠããããšæèšãã
ïŒïŒãããšã¯å
šãç¡é¢ä¿ã®ããŒã¿ã䜿ã£ãŠãé¢é£æ§ã®æ ¹æ ãšãã
ïŒïŒæããã«ããŸã£ããã§ããããªééããèšã
ïŒïŒçµå±äœã®è£ã¥ãããªãã«ãçµè«ãè¿°ã¹ã
2008 幎 10 æ 1æ¥ã«åºãããããã®å°ä¹±ã ããã®èšäºã¯ã次ã®ãããªçµè«ãè¿°ã¹ãŠããŸãã
ãæ
¢æ§ã® Båèçã¯âŠãäžçäžã§ããèçã®äž»ãªåå ãšãªã£ãŠããã
ãâŠã¯ã¯ãã³ã®æäžã§ææãé²ãããšãåºæ¥ãããçãäºé²ã§ãããããããã¯ã¯ãã³ã
æ¥çš®ããŠããªã人ãèçã«ææãæ
¢æ§ã«ãªã£ãå Žåã«ã¯ãæ²»çã¯äžå¯èœããã ãæãŠã€ã«
ã¹æ§ã®è¬ã§æããããšãåºæ¥ãã±ãŒã¹ããããã
ãŸããB åèçãæ
¢æ§ã«ãªãããšã¯ãå
šäœã®ãã£ãïŒïŒ
ã§ãã[Merck p382]ããã«ããã§
ããèçãšé¢é£ä»ããããŠããã®ã¯æ
¢æ§ã® Båèçã§ãã£ãŠãéåžž B åèçã® 90ïŒ
ããã
ãããã®è»œçã§ããæ²»ãã¿ã€ãã®ç
æ°ã¯åé¡ã«ãªã£ãŠããŸãããïŒ[7] Jay Marks, MDïŒ
次ã«ãåã«æããã«ããããã«ãBåèçã¯ã¯ãã³ã«ã¯ã©ããªææçãäºé²ããå¹åã蚌æ
ãããŠããŸãããçãäºé²ããŠãããããšèšã£ãŠããŸããããããªã¯ã¯ãã³ã¯ã©ãã«ãå
åšããŸããããã£ãšèšãã°ãææçãäºé²ã§ããã¯ã¯ãã³èªäœãååšããªãã®ã§ãïŒBåè
çã¯ã¯ãã³ã®è£œé 瀟ãããã¯ã¯ãã³ãçäºé²ã«ãªããšã¯æ±ºããŠèšããªãã§ãããïŒããã¯ã
äžå¯èœãªã®ã§ãããããããªã®ã«ã©ãããŠã倧æã®å ±éèªã®èšè
ããæãæããšãããªåº
é±ç®ãªäž»åŒµãããã®ã§ããããïŒ
æåŸã«ãã¯ã¯ãã³ãåããŠããªã人ãã©ããªç
æ°ã«ææããŠãããã®äººãæ²»ãå¯èœæ§ã¯æ±º
ããŠèª°ã«ãåŒããåããŸãããã¯ã¯ãã³ãåããªãããšãããã®äººã®å
ç«æ©èœã匱ããã
ãšãªã©ããããŸããããå®ã¯ãã®éã§ãã¯ã¯ãã³ãåããäººã®æ¹ãããææçãšéãåã
匱ããªã£ãŠããŸã£ãŠããã®ã§ããä¹³å
ã®å Žåã¯ãç¹ã«ããã§ããããã¯ãå®éšçã«èãã
ãããŠã€ã«ã¹ã®æ§è³ªããå
ç«æ©èœã®æŽ»åãæããŠããŸãããšãšãææ¯æ§ã®æ·»å ç©ãåå ã§
ãããããŠå¿ããŠã¯ãããªãã®ã¯ãäžæŠããã£ãŠããŸã£ãææçã®æ²»çã«ã¯ã¯ãã³ãæäž
ãããªã©ãå
šãã®ééãã ãšèšãããšã§ãããããªéŠ¬é¹¿ãã䞻匵ãããç§åŠè
ã¯ãä»ã«ã
æã«ããããã«ããŸãããããããªæ¥ãããã䞻匵ãå ±éããŠãããŠäœãšããªãã®ã¯ããä¿
å¥éšéãã®èšè
ããããªãã®ã§ãã
NYT èªã«ã¯ãå«çã責任ã®ããå ±éãããã€ãããªã©å
šããªãã®ã§ãããæ°å¹Žéã§ã¯ããŸ
ãä¿¡ææ§ã®ãªããéšãããªèšäºã°ããã«ãªã£ãŠããŠãããšäžéã§ãèšãããŠããŸãããäœ
ããã補è¬äŒç€Ÿã®å®£äŒèªã«æãæãŠãŠããŸã£ãŠããŸããã©ã®åããšã£ãŠãã補è¬äŒç€Ÿãšä»²
è¯ããªã®ãèŠãèŠããªåºåèšäºãå
ã£ãŠããŸããäœãã®äžå·ãåœãŠã€ããšãã£ããã®ããž
ãã¹ã«ãããŠã¯ãä¿¡ææ§ãäºå®ãã§ãã¯ãªã©ã¯ããã«ãŽãç®±è¡ãã§ããã売ãäžãã®ç©å
ããã¬ãã·ã£ãŒãåããŠãããããç·šéè
åŽãããã«è«žã
ã®ã¯ã¯ãã³ãéçŸå®çã«ããã³
ãããªç©ãšããŠå£²ãåºããã«é ãããŒããç§åŠçãªæ ¹æ ãªã©ã¯ãã£ã¡ã®ãã§ãã
ãããªèæ¯ã®äžã§ããããNYT èªã® 2008 幎çã®ã©ã®ã¯ã¯ãã³é¢é£ã®èšäºãã¿ãŠãåãæ§
ã«é§ç®ãªãã®ã°ããã§ããèªè
åŽã®æèåãæ¬¡ç¬¬ã«è¡°ããŠããã®ã§ãèšè
åŽãããã«å¿ã
ãŠããã ããšãèšããŸãããã©ããåºå
ã§ãã£ãšæŸãèªã¿ããããããªã®ã ãããããã§
ãã£ãšç®ãæ¹ããŠå°è±¡ã«æ®ãèšäºãäœãã°è¯ãã ãã§ããã¡ãã¡äž»åŒµãè£ä»ããããä¿¡é Œ
ã§ããå
容ã«ããå¿
èŠã¯ãªãã ãããšèããŠããã®ã§ãã
æ°Žç±ç¡
æ°ŽçïŒã¿ããŒãããïŒãšã¯ããšããšãåäŸã®æã«ããã£ãŠå
ç«ãã€ããé¡ã®ã軜çã§ãã
æ²»ãç
æ°ã§ããããã®ããšã¯ãMerck ãèªããŠããŸãã[280]ãã®æ¬ãèªãã§ããæ¹ã
ã®å€
ããããã®èŠªåŸ¡ããéã®äžä»£ã¯ãåäŸæä»£ã«æ°Žç±ç¡ã«ããã£ãŠããã§ããããããã®éã«
倧ããèŠåŽããªãã£ãã§ããããæ°æ¥éã«ã©ãã³æŽæµå€ããæ¿¡ãããã¹ãã³ãžã§æããã
ããŠãç±ããè¶ã§ã飲ãã°ãåäŸéã¯ãŸãããå
æ°ã«ãªã£ãŠããŸããã®ã§ãã
ãããªã®ã«1995幎ã«çªç¶ãæ°Žç±ç¡ã¯ã¯ãã³ãåŠæ ¡ã§æ¥çš®æå®ãšãããã®ã§ããããã¯äžäœã
ãªãã§ããããïŒéå» 2 äžçŽã®éãã¢ã¡ãªã«ã§ã¯åäŸæä»£ã«ããããã®ãšããŠå
šãåé¡ãª
ãåãå
¥ããããŠãããã®ç
æ°ãããªãã¯ã¯ãã³æ¥çš®ãå¿
èŠãšãããã®ã§ããããïŒ
æ°Žç±ç¡ã®åç§°ãvaricalla ããŠã§ãã§æ€çŽ¢ããŠã¿ããšãäžè²«ããŠãåäŸéãæ°Žç±ç¡ã®æªåã«
ããæ»äº¡ããå®ãããã«ã¯ãæ°Žç±ç¡ã¯ã¯ãã³ãå¿
èŠã§ããããšãã誀ã£ã䞻匵ãããŠãã
ãŠã§ããµã€ãããã£ãš 200 ã»ã©èŠãããŸãããã®æ§ã«ééã£ãæ
å ±ããããŠäººã
ã«åºãã
ããæ¹ã«ã¯ã坿°ãããŠããŸããŸããéã«ãæ£ããæ
å ±ãç¥ãããã«ã¯ãªãµãŒãã¯éåžžã«
å°é£ã«ãªããŸããããã®éã«ã¯æ¬¡ã® 4 é
ç®ã調ã¹ãŠããããšã«ãªãã§ãããã
ã¯ã¯ãã³ã¯æ¬åœã«å¹æãããã®ãïŒ
ã¯ã¯ãã³ãäœããäœãããŠããã®ãïŒ
ã¯ã¯ãã³ã®å¯äœçšã¯äœãïŒ
å
¬è¡ã«æ¥çš®çŸ©ååãããåã«ãã©ããªèšåºæ€æ»ãè¡ãªãããã®ãïŒ
ããã§ã¯ãŸãã1 çªç®ã®é
ç®ããèŠãŠãããŸããããã广ãããã®ãïŒã
ãã®è³ªåã®æå³ãããã®ã¯ã¯ãã³ã«ãäžçã®éæ°Žç±ç¡ã«ãããã®ãäºé²ãã广ãããã®
ããããšããæå³ãªãã°ãçã㯠NO ã§ããçç£å
ã§ããMerck 瀟ã¯ããå
ç«æ©èœãã 5 幎
éãšäž»åŒµããŠããŸããããŠãã¯ãããšåæ§ã«ãæ°Žç±ç¡ãåäŸæä»£ã«ãããã°ãªããšãç¡ã
ç
æ°ã§ããã倧人ã«ãªã£ãŠããææãããšçç¶ãæªåãããèŽåœçãªããšã«ãªã確çãé
åžžã«é«ããªãç
æ°ã§ãããããã人工çã«å
ç«ãã€ããçµæã§ãã
Physicians Desk ReferenceïŒPDRïŒ ã«ã¯ã以äžã®ãããªèšè¿°ããããŸãã
ãåäŸã®æ°Žç±ç¡ãããªãæªåçç¶ïŒè³çãèçåã³èºçãªã©ïŒã®äºé²çã«ã€ããŠã¯ãåå
ãªããŒã¿ãåŸãããªãã p 1901 [251]
æªåçç¶ã«é¢ããããŒã¿ãäžååïŒãããªããªãã¯ã¯ãã³ã䜿ã£ãŠãã®ã§ããããïŒ
ãã®ã¯ã¯ãã³ã®å¯äžã®äŸ¡å€ã¯ãæ°Žç±ç¡ããèµ·ãããããããªããšãããŠãããããããæª
åçç¶ãäºé²ãã广ã ã£ãã¯ãã§ãããã®æªåçç¶ãæãã°ãæ°Žç±ç¡èªäœã¯åã®ããŒãž
ã§ PDR ã«èšè¿°ãããŠããéãããæŠããŠè»œçã§ãããæ²»çããç
æ°ããªã®ã§ãããã
次ã«ããã¯ã¯ãã³ãäœããäœãããŠããã®ãïŒãã§ããå®ã¯ã1995 幎ã«å°å
¥ããããã®æ°Ž
ç±ç¡ã¯ã¯ãã³ã®è£œé éçšã¯ã¡ãã£ãšå€ãã£ãŠããŠãå èãã人éã®èå
ã®äœã§å¹é€ãããŠ
ããã®ã§ããåã ãšæããªãã補è¬ç£æ¥ã®ãã€ãã«ã§ãã PDR ã® 2007 幎床çã2100ããŒ
ãžç®ãã芧ã«ãªã£ãŠäžããã[251]
ãããªå€ãè¿·ä¿¡ã¿ãããªæ¹æ³ããšãæããããããŸãããããŸããç§éã¯çç©ååŠã§å士
å·ãªã©åã£ãŠãªãã§ããïŒïŒïŒããããããšãå èãããèå
ã®èº«äœã§å¹é€ããããŠã€ã«ã¹
ããçããŠããä¹³å
ã®è¡æ¶²ã«æ³šå
¥ãããšãæãããç
æ°ããå®ã£ãŠããããšãããã®è«ç
ã«ã¯ãã²ãã£ãšããŠãç§éã«ã¯ããããªãçéãããã®ã§ããããïŒïŒïŒ[319]
ããããã®ãæ¿åºã®è¿·ä¿¡ããã®ãŸãŸéµåã¿ã«ããŠããŸãã«ã¯ã幟ã€ãã®åé¡ç¹ãããã®ã§
ãããŸããã¯ã¯ãã³ã®å¿
èŠæ§ã蚌æããããã«ã¯ãæ°Žç±ç¡ã§æ»äº¡ãããšããã 3 人ã®ä¹³å
ã®ç ç©¶ã瀺ãããã®ã§ããããã®ç¹ããã調ã¹ãŠãããã¡ã«ã3人ã®ä¹³å
ã®æ»äº¡ã®åå ã¯ã
ã€ã¯æ°Žç±ç¡ãªããã§ã¯ãªãã匷åãªæçç©è³ªãè§£ç±å€ãççãæããã¹ããã€ãå€ãšãã£
ãæ¯æ§ç©è³ªããæªçãªèº«äœã«ã€ã¥ãããŸã«æå
¥ããããã§ã®äžæ¯æ»ã ã£ãã®ã ãšæ°ä»ããŠ
ãã£ããããŠããŸããŸãã(MMWR,vol.47,1998)[233]
ããã§ãããšãããããã®ãæ¯å¹Ž 100 人ã®ä¹³å
ãæææ»ãããšãããŠããæ°Žç±ç¡ãé²ãã
ãã«ãäœçŸäžäººãã®ä¹³å
ãã¹ãŠã«ã¯ã¯ãã³æ¥çš®ãå¿
èŠã ãšããç¡è¬ãªèª¬ããæãåã£ãŠå
ãå
¥ãããšããŸããããã§ã¯ããã®å®å
šæ§ãäžç¢ºããªã¯ã¯ãã³ã«ãããå¯äœçšã¯ã©ãã§ã
ãããïŒå床ã2007幎床㮠PDRã«æ»ãã2102 ããŒãžç®ã«è£œé å
ãèšè¿°ããå¯äœçšã®å
容
ãèŠãŠã¿ãŸãããã
泚å°ããéšåã®çã¿ã赀㿠å³
åŒåžåšå®ã®äžéšã«ãããçºç ç²åŽãåšå®ã®äžæçæ©èœéº»çº
åºæ¿ãçç äžç¢
飿¬²äžæ¯ åå
é¢ç¯ã®çã¿ æ
¢æ§ç¡¬èäžè¡è
«
è³ç(!) ãããŸãã é ç
ã¢ã¬ã«ã®ãŒåå¿ å¯æ° è
¹éšã®çã¿
è
ºã®è
«ã 湿ç¹[251]
æåŸã«ããã¡ãã£ãšèžã¿èŸŒãã§ãåäŸéã®è¡æ¶²ã«æ³šå
¥ããŠè¯ãããšæ³åŸã§æ±ºããåã«ãã¯
ã¯ãã³ã®å¹æã«ã€ããŠãäœãããã®é·æçãªæ€æ»ãè¡ãªãããããã調ã¹ãŠã¿ãŸãããã
çãã¯ãNo ã§ãããããªæ€æ»ã¯ãäžåºŠããããããšããããŸããã以äžã¯ã2000 幎床ã®
PDR ããã®æžãåºãã§ãã
ãâŠãã®ã¯ã¯ãã³ãçšããâŠçè¬å®éšã¯äœãè¡ãªãããŠããªãã[251] (p 1901)
ãŸã£ãããããããã話ã§ãã
ç ç³ã§åºæ¥ãé å€ã®ã«ãè¬ãããããã®ã¯ã¯ãã³ã®æ¹ã广ããããšãã蚌æãããããŠ
ããªãã®ã§ããã€ãŸãã»ãã®ã¯ã¯ãã³åæ§ããã®æ°Žç±ç¡ã¯ã¯ãã³ãããšãããã矩ååã
ãŠããŸã£ãŠããäžè¬ã®äººã
ã®ç身ã®äœã§å®éšããŠããŸããããšããæ¹éãªã®ã§ããã©ãã
ãã®å£ããããåã¯ã¯ãã³å£äœã®ãã€ãããå€ããè
ã®èªç¶çæ³å£«ä»¥å€ã¯ãã¿ããªããã«
泚æãæã£ãŠããªãã ãããšã補è¬é¢ä¿è
éã¯å€ã£ãŠããã®ã§ããããããã§ãããèã
ãŠèŠãªããã°ãããªãã®ã¯ãã誰ãã¡ãã£ã¢ãæã£ãŠããã®ãïŒããšããããšã§ããå®éã«
ã¯ãMerck 瀟ã®ãåãããããæ¿åºã Go ãµã€ã³ãããã£ãåŸããã®ã¯ã¯ãã³ãããæ¥çªç¶ã
å
¬ã®å ±éã¯äžåãªãã§ãæ¥çš®æå®åãããã®ã§ã¯ãªãã£ãã§ããããïŒãããªå€§è¢è£ãªã
ãšãæããããããŸããããã§ã¯ãåœç¶ããã¯ãã®å»åŠçãªé·ææ€æ»ããã©ãã«ãèŠåœã
ããªãã®ã¯ã©ãããèš³ã§ãããïŒãèªåã®æ
åœå»ããåŠæ ¡ã§ã¯ã¯ãã³æ¥çš®ãè¡ãªã£ãŠãã
çè·å©Šããããã¯æ¿åºã® CDC ã«èããŠããé·ææ€æ»ãããããšã¯å¿ããããªãã¯ãã§ãã
ããã«ããã®æ°Žç±ç¡ã¯ã¯ãã³ã¯ã2002 å¹ŽåºŠã®æ¥çš®æå®äºå®è¡šã«ãããŠãäœã®çç±ããªãã«
2 åã®æ¥çš®ãã 1åã«æžããããŠããŸãããããŠãŸã2007 幎ã«ã¯ã2 åã«æ»ã£ãŠããŸããã
ãããã倿Žã¯ç§åŠçãªçç±ã§ã¯ãªããæ¿æ²»æ¹éãåå ãªã ãã§ãã
ãã¿ãŠã€ã«ã¹
ããã¯ä¹³å
ã®ã軜çã§ããæ²»ãçšåºŠã®äžç¢ã䌎ãç
æ°ã§ã詳ããããšã¯ãŸã è§£æãããŠã
ãŸããããã®ç
æ°ã§äžçªå¿é
ãããã®ã¯ãåäŸãè±æ°Žçç¶ãèµ·ããå¯èœæ§ã§ãããããã
ãã±ãŒã¹ã¯ããçšãªãã®ã§ããæã¯ãã ãççãšåŒã°ããŠããŠã倧æµã®å Žåçæéã§æ²»ã£
ãŠããŸãç
æ°ã§ããããçšã«ãã®ç
æ°ã§æ»äº¡ããããšããããŸãããæ»äº¡è
ã¯äžçäžã§ã
æãç°å¢ã®æªãå°åãã€ãŸãè²§å°ãšäŒæç
ãèå»¶ã£ãŠãããããªå Žæã§åºããã®ã§ããã¯ã¯
ãã³ã«ããæ»äº¡ä»¶ã®90ïŒ
ã¯ã¢ãžã¢ãã¢ããªã«ã§èµ·ãã£ãŠããŸããã[24]ã¢ã¡ãªã«åè¡åœã«ã
ããæ»äº¡è
ã¯ãæãäžè¡çãªç掻ç°å¢ã®å°åããæäººã®çºç
è
ãèæ
®ã«å
¥ããŠããããã
幎㫠20 人çšåºŠã§ãããã[25]
A åèçã®é
ç®ã§ããã§ã«æããããã«ãåœå
ã§ã¯ã¯ãã³ã売ãåºãéã«äžçå
šäœã®çµ±èšã
çšããã»ãŒã«ã¹æ¹æ³ã¯è¯ã䜿ãããŠããŸããã1998 幎ã«ãã¿ãŠã€ã«ã¹ãæ¥çš®æå®ã®äºå®è¡š
ã«è¿œå ãããèæ¯ã«ã¯ãç§åŠçæ ¹æ ã§ã¯ãªããæ¿æ²»çãªãããšãã絡ãã§ããã®ã§ããçŸ
åšã® Merck 瀟ã®ããã¥ã¢ã«ã«ãããŠãããã¿ãŠã€ã«ã¹ã¯æ·±å»ãªäŒæç
ãšããæ±ãã¯ãããŠ
ããŸãããç¡çåæ§ã®ä¹³å
ã¯ããããã¿ãŠã€ã«ã¹ã«ããããã®ã§ãã([280],p2173)ã
ãã®ç
æ°ã¯å€§ããç
æ°ã§ã¯ãªããããå¯äžããããããŠããæ²»çã¯ãä¹³å
ã«ãã³ãã³æ°Žå
è£çµŠãããŠãããããšãããã§ãã
人ã
ãé©ããããã«äžçèŠæš¡ã®çµ±èšã䜿ã£ããã補è¬äŒç€ŸãåºéãäŸåºããŠããããéã«
åããã®å®éšèª¿æ»ã§ã广ç㯠95ïŒ
ã ãšã絶察ã«å®å
šã ãšã䞻匵ããŠããšããšã 1998 幎
ã«ã¯ Rotashield ãšãããã¿ãŠã€ã«ã¹ã®ã¯ã¯ãã³ãæ¥çš®æå®ãããŠããŸããŸããããããã
ã¯ã¯ãã³æ¥çš®ã®åŸã§è
žéç©çãšãããèŽæ»ããããšãããè
žã®æ©èœé害ã蚎ããçäŸãé
åžžã«å€ãããããã®ä»ã®é害ã®èšŽããçµ¶ããªãã£ããããå§ããŠãããã£ã 11 ã¶æåŸã®
1999 幎å€ã«ã¯ãCDC ã Rotashield ã¯ã¯ãã³ãåžå Žæ€å»ããããšã«ãªã£ãã®ã§ãã
(Newsweek, 13 Sep pp)[239]
ããã§è³ªåã§ãããŒãã£ã 1 幎ã§åãããã«ããŠããŸãçšããã¿ãŠã€ã«ã¹ã¯ã¯ãã³ã«ã€ã
ãŠæ¿åºã® FDA å±ãè¯ãããã£ãŠããªãã£ãã®ãªãããªãã§æåãã 3 åãïŒçåŸ 2 ã¶æã
4 ã¶æã6ã¶æïŒæ¥çš®ããããã«èŠãããããã®ã§ããããïŒ
CDC æ©é¢ã®ã¢ããã€ã¶ãŒã§ãã£ãããŒã«ã»ãªãã£ããã¯åœæãã¿ãŠã€ã«ã¹ã¯ã¯ãã³ãæ³åŸ
ã§èªå¯ããããã«åŸæŒãããå°éå®¶ã§ããã圌ã¯è°äŒã«ãããŠãã¯ã¯ãã³ã®è£œé 瀟ã§ãã
Merck 瀟ããå ±é
¬ãåŸãŠããããšãããªããšå°å£²æš©ãŸã§æã«å
¥ããããšãŸã§èªããŠããã®
ã§ãïŒåœæ°ãäŒæç
ããå®ãããšããæ©é¢ã®æ¹éãšã圌ã®è¡çºãççŸããŠãããšæããªã
ããšå°ãããã圌ã¯ããã€ããŸãããããå¿ããŠããŸãã
ãç§ã¯ãã¿ãŠã€ã«ã¹ã¯ã¯ãã³ã®å°å£²æš©ä¿æè
ã® 1 人ã§ããããã®ã¯ã¯ãã³ã宿çã«æ¥çš®
矩ååãããã°ãåœç¶ããããå©çãåŸãããšã«ãªããŸããå®å
šé¢ã®ããŒã¿ãåã調ã¹ã
éã«ãããã²ããããããã§ãã£ãŠïŒããããçãã¯ç°¡åã§ããNOïŒã
ãã¯ã¯ãã³ãåŸæŒãããŠãã人éãšãã¯ã¯ãã³è£œé 瀟ã®éã§ãäžå¥å
šãªååé¢ä¿ãçµã°ã
ãŠããããã§ãã£ãŠïŒããããçã㯠NO ã§ããã
ãªãã£ããã¯ãMerck 瀟ãããã¿ãŠã€ã«ã¹ã¯ã¯ãã³ã®åŸæŒãããã代ããã«ãéå» 17 幎ã
ã®éå ±é
¬ããããç¶ããŠããŸããããŸããå°å£²æš©ãæã£ãŠããäžããã¿ãŠã€ã«ã¹ã¯ã¯ãã³
ã®éçºå¥šå±éãšã㊠350 äžãã«ãã®ããŒãã¹ãåãåã£ãŠããŸãã[30]
ããã¯ããããã ã®ããžãã¹ã§ãããããŸãããã¯ã¯ãã³æ¥çã«ãããŠã¯ãããããäŸã¯
ãã¯ãåœããåã®ããšã«ãªã£ãŠããŸã£ãŠããŸãããã®ç¹ã«ã€ãã代衚åç· åœ¹ã®ãã³ã»ããŒ
ãã³ã¯ä»¥äžã®ããã«è¿°ã¹ãŠããŸãã
ãã¢ããã€ã¶ãŒå§å¡äŒãšã¯ãæ°ã¯ã¯ãã³ã®æšå¥šãåãæ±ºãããCDC æ©é¢ã«ãããŠåœ±é¿åã®
匷ãå§å¡äŒã§ããããCDC ã¯å®æçã«ãæããã«ççŸããç®çãæ±ããŠããç§åŠè
ããã®
å§å¡ã«éžæããŠãããããšãããŒãã³ã¯ UPI ã«è¿°ã¹ãŠããŸããããããŠããããç§åŠè
ã¯ã
æ¬æ¥ãªãã°å
¬å¹³ã«å€æããŠã¢ããã€ã¹ãããçã®ããã®å¯Ÿè±¡ã§ãã補åïŒåã³è£œé 瀟ïŒã«
çµæžçã«æŽå©ãåããããåŠåäžã§ææºããŠãããéã§çžãããŠããããã®ä»è«žã
ã®å©ç
ããã®è£œåã«ãããŠãããšãã£ãææ§ã§ãããã[354]
ROTATEQ
1999 幎ã®Rotashield ã¯ã¯ãã³ã®å€§å€±æã®åŸã圌ããåãã£ã¬ã³ãžãããªã©èª°ã«ãäºæ³ã§ã
ãªãã»ã©ã§ãããã9/11 äºä»¶åŸã®æŠåå€äº€ã®ããªã 2007 幎å§ãã«çªç¶ããã®æ°ããŒãžã§ã³
ã®ãã¿ãŠã€ã«ã¹ã¯ã¯ãã³ãçŸããFDA ã®ç«å·»ããšãçŽ æ©ãèš±å¯ãåŸãŠãæ¥çš®æå®ã®äºå®è¡š
ã«çµã¿æ»ãããŸãããä»åºŠã¯æ°ãããRotateq ãšããååã§ãã
ããã§æ°ã«ãªãã®ãããã® Rotateq ã®ããã¥ãŒã«äŒŽãã9 幎åã«åã®ã¯ã¯ãã³ã§çºçããã®
ãšåãå¯äœçšåå¿ã次ã
ãšå ±åãããŠãããšããäºå®ã§ããã€ãŸããè
žéç©çã§ãããã
ã¯æãšããŠæ»ã«è³ãããšãããã倧æµã®å Žåæè¡ãå¿
èŠãªçç¶ã§ãããããšããšãã¿ãŠã€
ã«ã¹ã®ç
æ°ãšã¯äœã®é¢ä¿ããªãããã ãã®ã¯ã¯ãã³é¢é£ã§åºãŠããŸããã®ãªã®ã§ãã
Rotateq ã¯ã¯ãã³ã«ãããã以å€ã®å¯äœçšãšããŠã¯ãNDV, äžè³ç, åœé çãæ°ç®¡æ¯çæ£
ãªã©ãæããããŸãã
Rotateq ã®æé²
Rotateq ã®è£œé å
ã§ããMerck ç€Ÿãæ²èŒããŠãããèšåºæ€æ»ã®äž»ãªç ç©¶çºè¡šãã2005 幎 1
æã« New England Journal of Medicine èªã«èŒããããŸããã[28]ãããã®ç ç©¶ã®è³éæŽ
å©ã¯Merck 瀟ã§ãããMerck ç€Ÿã®æ€æ»æé ã«åŸããå
±èè
ã¯ãšèšãã°ããªãªãžãã«ã®ã¯ã¯
ãã³åã³æ°ããŒãžã§ã³ã®ã¯ã¯ãã³äž¡æ¹ã®å°å£²æš©æåŸè
ãšããå
·åã§ããæåŸã®æ¹ã«ãèè
ã®æ®ã©ã Merck 瀟ããè³éæŽå©ãåããŠãããšããã®èè
åãšå
±ã«èšããŠãããŸãããã¡
ããããããç ç©¶å
容ãå·Šå³ããããšã¯ãç¡ãããã§ããïŒïŒïŒ(?)
ãã®ã¯ã¯ãã³ã¯ã»ãšãã©åã®ãšå€ããã¯ç¡ããéããšããã°æ°ããªãŠã€ã«ã¹ãïŒç³»çµ±è¿œå
ãããããšãšããµã«ã®ä»£ããã«äººéã®èµ€ã¡ããã§å®éšããŠããããšããç¹ãããã§ããã
ãã[251]ã¡ãªã¿ã«ãã®ç 究調æ»ã«ãããŠäœ¿çšãããåèè³æã®æ®ã©ã¯ã1999幎ã«çŠæ¢ãã
ããã®ãªãªãžãã«ã®ã¯ã¯ãã³ã«é¢ããç ç©¶è³æã§ãã£ãããšããèŒããŠãããŸãã
ãããªèš³ã§ãåœç¶ãªããæ°ã¯ã¯ãã³ã®æ¹ãåãæ§ãªçµæã§ããã
ã9605 人ã察象ã«ïŒã¯ã¯ãã³æ¥çš®ã 4806 人ãåœè¬ã®ç ç³ãã«ã4799 人ïŒè©³ããç ç©¶ãã
ãçµæãã¯ã¯ãã³æ¥çš®ããã°ã«ãŒããšç ç³ãã«ã飲ãã ã°ã«ãŒãã§ã¯ãã»ãšãã©åã確ç
ã§æçšåŸ42 æ¥ä»¥å
ã«çºç±ãååãäžç¢ã®çç¶ãèŠãããããšããããšã§ãã
ãã®äžãã¯ã¯ãã³ãæ¥çš®ãã 34,035 人ã®ãã¡ 803 人ïŒ2.4ïŒ
ïŒã®æ·±å»ãªå¯äœçšåå¿ãå ±å
ãããŠããŸãããã¯ã¯ãã³æåããæ¹ã® 24äººãæ»äº¡ããŠããŸãã
æ»äº¡ä»¶æ°ã®ãã¡ãäžçªå€ãã£ãã®ãä¹³å
ã®çªç¶æ»ã«ãããã®ã§ãã¯ã¯ãã³æ¥çš®è
ã®ãã¡ 7
åã«ããªããŸããã
ãã®ç ç©¶çºè¡šã§ã¯ããªãªãžãã«ã®ã¯ã¯ãã³ã«ããæãå±éºãªå¯äœçšãè
žéç©ã«ã€ããŠæå
ããçµãããŸã§ããã€ããã»ã©è§ŠããŠããŸãããã®æ°ããç ç©¶å ±åã§ã¯ãè
žéç©ã®çºçäº
ä»¶ãç¹ã«ç°åžžãªåºæ¥äºã§ã¯ãããŸããã§ãããšããã¯ã¯ãã³ãåå ã§è
žéç©ã«ãªã£ãã®ã§
ã¯ãããŸãããšããäœåºŠãäœåºŠãç¹°ãè¿ããŠããŸãã[28]ããšããšã10 幎åã«ä»¥åã®ã¯ã¯
ãã³ã廿¢ã«ãªã£ãäž»ãªåå ãè
žéç©ã ã£ããããèè
ã®é¢ã
ããçã§å£èª¿ãåãããŠæ°
ã¯ã¯ãã³ã®å£²ãäžããåºããªããã°ããšæã£ãã®ã§ããããããã®èšäºã¯ã©ãèŠãŠãæ£ã
ãå»åŠè©è«ã§ã¯ãªããã»ãŒã«ã¹å®£äŒã®ãããªæããªã®ã§ãã
ãããªã®ã«ãã¯ã¯ãã³ãæ¥çš®äºå®è¡šã«è¿œå ãããŠãããã£ã 1 ãµæåŸã«ãFDA ãèªãä¹ã
åºããŠããã®æ°ãã Rotateq ã¯ã¯ãã³ãåã®ãšåãå¯äœçšãããããå±éºã ãšãåœæ°ã«å
ããŠèŠåçºè¡šããŠããã®ã§ããããé©ããŠããŸããŸãïŒããã«ããã°ãæ°ãã« 28 ä»¶ã®çºç
ããã£ããšã®ããšã§ããã
ããã®çç¶ã¯è
žéç©ãšåŒã°ãã8 幎åã«æåã®ãã¿ãŠã€ã«ã¹ã¯ã¯ãã³ã廿¢ãããã«è³ã£ã
åå ã§ããçç¶ãšåããã®ã§ããã(AssociatedPress, 13 Feb 07[13])
ãããåŠèªãã Merck 瀟ãšããã®äŒç€Ÿã®å·®ãéã§ãã CDC 圹å¡éã®ã»ãªãã¯ãæ²ããã
ãšã«æã£ããšããããæ±ºãŸãã®ã»ãŒã«ã¹æå¥ã§ããé¢é£æ§ã®èšŒæ ã¯ãªãããšãããªã¹ã¯ãã
ãå¹èœã®æ¹ãäžåãããšãããã®ã§ããã
æ°ããååãšãå€ãå®£äŒæ³
PDR ã® 2007 幎床çã§ã¯ããã€ãã®ã決ãŸãã®èª¿åã§ããã®æ°ã¯ã¯ãã³ã®å®å
šæ§ã广ã
ããã£ãŠããŸãããã®å»æ¢ããã Rotashield ã¯ã¯ãã³ã®æãšåã䞻匵ããé«ãå¹èœæ§ãæå°
éã®å¯äœçšããšããæ±ºãŸãæå¥ã§ããRotashield ã¯ã¯ãã³ã¯ãããããæ¥çš®æå®ãããŠã
ãæéäžã« PDR ã«èšèŒãããããšã®ãªãã£ãå¯äžã®ã¯ã¯ãã³ã§ãããèããŠã¿ããšããŸã
ã§åœŒãã¯åããããã®ã¯ã¯ãã³ã廿¢ãããããšãèŠéããŠããããã§ãæ°å³ãæªãæã
ãããŸããçŸåšã§ã¯ãRotashield ã¯ã¯ãã³ãååšããŠããããšã蚌æããå
¬åŒãªè³æãèŠ
ã€ããããšèªäœãæ®ã©äžå¯èœã«ãªã£ãŠããŸã£ãŠãããããã§ãã
Rotashield ã¯ã¯ãã³ã¯ãæ°ãã Rotateq ã¯ã¯ãã³ãšã¯ãã»ãã®å°ãã ãéã£ãŠããŸããã
Rotashield ã¯äººéãšç¿ãåªäœãšããŠäœ¿çšããŠããã®ã«å¯ŸããRotateq ã®ã»ãã¯äººéãšçäº
ç§ã®åç©ãåªäœã§ããããšããéãã§ãããã以å€ã¯ãRotateq ã¯ã¯ãã³ã®è¬³ãæå¥ãã»ãš
ãã©åãã§ãã95ïŒ
ã®å¹æçã絶察ã«å®å
šãæ¬åœã«å¿
èŠããšãã䞻匵ã§ãã
èªç¶ãªç
æ°ãããããšã人ãäœã£ãç
æ°ãïŒ
2007 幎床ã®PDR ã«ã¯ã次ã®ãããªç¹ç°ãªæç« ãèšèŒãããŠããŸãã
ãçããã¯ã¯ãã³ãŠã€ã«ã¹ããã¯ã¯ãã³æ¥çš®ãåããŠããªã察象ã«ããã£ãŠããŸãâŠå±éº
ããããèªç¶ãªãã¿ãŠã€ã«ã¹ã«ææããå±éºæ§ãšãã¯ã¯ãã³ã®ãŠã€ã«ã¹ã«ææããå¯èœæ§
ã®å±éºãšãæ¯èŒæ€èšããå¿
èŠãããã([251] p2076)
ã§ã¯ããã®æã«ã€ããŠã¡ãããšèããŠã¿ãŸãããããŸãããã®æã«ã¯èª€èšããããŸããã
ã£ãŠãåäŸããåäŸã«ãŠã€ã«ã¹ãææž¡ããããªããŠãããããŸããããïŒèµ€ã¡ããéã«ã
ãŠã€ã«ã¹ã®è©Šéšç®¡ã§ããããªãããããªãããšã«ãªããŸããããã€ãŸããæ£ããèšè¿°ã¯ã
ãããããçããã¯ã¯ãã³ãŠã€ã«ã¹ããã¯ã¯ãã³æ¥çš®ãåããŠããªãå¯Ÿè±¡ã«ææããŠããŸã
å±éºãããããšãªãã¹ãã§ãããããããŠãã®çããã¯ã¯ãã³ãŠã€ã«ã¹ã¯ãèªç¶ã®ãã¿ãŠ
ã€ã«ã¹ã®ç³»çµ±ãã人工çã«äœããã系統ãã5çš®é¡ãå«ãã§ããã®ã§ããåäŸãèªç¶ã«ãã®
ç
æ°ã«ããã£ãéã«ã¯ãã£ãïŒç³»çµ±ãªã®ã«æ¯ã¹ãŠã倧ããªéãã§ãããŸãè¯ããšããŠãã
ããã圌ãã䞻匵ããŠããã®ã¯ãäœäžçŽãã®éãåäŸæä»£ã«ããã軜ããŠããæ²»ãææç
ã ã£ãèªç¶ã®ãã¿ãŠã€ã«ã¹ã«ææããå Žåã®å±éºæ§ãšãäžèšã§ç€ºãããããªã¯ã¯ãã³ã®æª
åçç¶ã®å±éºæ§ãæ¯èŒæ€èšããããšããããšã§ãããïŒçãã¯ãæããã§ããããPDR ã®
ç·šéè
ãããã®æç« ãããå°ããæåã§èšèŒããããã«ããã®ãããããæ°ãããŸããã
ããªã«å°ããªæåã§æžããŠããã°ã誰ãããããèªãããšã¯ããªãã ããããšç¢ºä¿¡ããŠã
ãã®ã§ããããã
æ°çš®ã®æ··åæ¥çš®ã¯ã¯ãã³
ãã® 7 幎éã®ãã¡ã«ãæ°ããã¯ã¯ãã³åæ³ãåºãŠããŸããããããã¯æ°çš®ã®ã¯ã¯ãã³ãšå€
ãã¯ã¯ãã³ãåãããŠãå
šãæ°ããæ··åã¯ã¯ãã³ã«ããŠããŸãããšããæ¹æ³ã§ããçŸåšã®
æç¹ã§ã¯ãå°ãªããšã3 çš®é¡ã®æ··åã¯ã¯ãã³ãåºãŠããŸãã
Pediarix
Twinvax
Comvax
Pediarix ã¯ãGlaxoSmithKline 瀟ã®çºæã§ãDTap äžç𮿷·åãB åèçãããªãªãå®éšç
ã«æ··åãããã®ã§ã2002 幎㮠1 æã«èªå¯ãããŠããŸãããã® 5çš®é¡ã®ã¯ã¯ãã³ãæ··ãåã
ãããšãå®å
šã ãšããèšåºäžã®èšŒæã¯ãäžåãããŸããã
ãã®è£œè¬äŒç€Ÿã®ãŠã§ããµã€ããèŠããšããšããã«åé¡ç¹ãèŠã€ãããŸãããšããã®ããåœ
瀟èªèº«ããã®ã¯ã¯ãã³ãè³ã«é害ãäžããå±éºæ§ãåŠããªãããšèªããŠããã®ã§ãã
ãæ¥æ§ã®è³èé«çãæä¹
çãªç¥çµé害ããPediarix ã®å¶åºŠåãšé »ç¹ã«é¢é£ããŠãããšãã
å ±åã¯ãªããâŠãããä»ãŸã§ã«åŸã Pediarix ã«é¢ããç¥èã§ã¯ããã®å¯èœæ§ãåŠå®ããã«
ã¯äžååã§ãããã [42]
ããã§ãããããã¯çµæ§ãªããšã§ãâŠã
æåã®è©Šéšæ¥çš®ã§ã¯ããã®ã¯ã¯ãã³ã«ãã£ãŠ5 人ã®åäŸãæ»äº¡ããŸããã[42]
ãã®è£œè¬äŒç€Ÿã¯ãŸãããã®ã¯ã¯ãã³ãçãèªçºããããåã³ãçæ®æ©èœäžå
šãããããã
ãã©ãããšããå±éºæ§ã«é¢ããŠãååãªè©Šéšãè¡ãªã£ãŠããªããšãè¿°ã¹ãŠããŸãã[42]
Pedriax ã®å¯äœçšããã幟ã€ããæããŠã¿ãŸãããã
ãâŠãããŸãããå£ã®è
«ããåŒåžå°é£ãäœè¡å§çâŠäžè
ç¥çµçãã®ã©ã³ ãã¬ãŒçå矀ã
è±é«æ§çŸæ£,âŠç¡åçãçºç±ãä¹³å
ã®çªç¶æ»ããã¢ããŒãŒãæ°Žè
«ãè
¹éšã®çã¿ã飿¬²äžæ¯ã
è
žéç©,ææ¡è
ºã®è
«ããé»çžãèèæ©èœæ€æ»ã®ç°åžžçµæãã·ã§ãã¯ãæè¶³ã®èšåŒµãæ¿ããå
æžãè³ç, åŒåžåšå®ã®ææçãè±æ¯âŠã
ãã®äžãèªå¯ãããã°ããã§æªç¥ã®äºã ããã®ãã®å®éšçæ··åã¯ã¯ãã³ã¯ããã§ã« 5 çš®é¡
ãã®ã¯ã¯ãã³ãæ··ãã£ãŠããã®ã«ãhemophilus BïŒHibïŒãš PrevnerïŒPCVïŒãšåæã«æ¥
çš®ããããšãæšå¥šãããŠããã®ã§ãïŒ
CDC ã¯ãããããè³ªåæ¬ã®ããŒãžã§ãPediax ãš Hib ã¯ã¯ãã³ãPCVãåæã«æ¥çš®ããå Ž
åã®å®å
šæ§ã¯ã©ããïŒããšãã質åã«å¯Ÿãã岿
¢ã«ãããå¿ããŠããŸãã
ããããã®ã¯ã¯ãã³ã 1 åã®èšªåã§åæã«åããããšãå¯èœã§ãããããããPedriax ãš
HibãPCV ãåææ¥çš®ããå Žåã®âŠå®å
šæ§ã«é¢ããæ
å ±ã¯ãŸã ç¡ããã[355]
ããïŒåè«ã§ãããïŒ7çš®ã®ã¯ã¯ãã³ãåæã«æ¥çš®ããŠãè¯ããšOKãµã€ã³ãåºããŠãããª
ããããã®å Žåãã®åãã©ããªããã¯å
šç¶ããããªããã§ãã£ãŠïŒå®å
šæ§ã®æ
å ±ãäžåç¡
ãã®ãªããäœã§ãããªåææ¥çš®ãå®å°ããŠããã®ã§ããããïŒ
æ¬åœã«ãä¿¡ããããªãâŠãã¿ãŠã€ã«ã¹ãè±ã€ã³ãã«ãšã³ã¶ããµãªããã€ããªã©ããããã
äŸã«æãåœããããããŸãããïŒ
ãã®æ··åã¯ã¯ãã³ãåäŸéã«äžãã圱é¿ã¯ãå
šç¶ããããªããç¹ã«ãã®ä» 2 çš®é¡ã®ã¯ã¯ã
ã³ãåææ¥çš®ããå Žåã®ããšã¯ä¿èšŒã§ããªãããšèšã£ãŠãããªãããåäŸéããã£ãçåŸ 6
é±éã10 é±éã6 ã¶æã®æç¹ã§ 3åãã¯ã¯ãã³æ¥çš®ãããŠããŸããããã¯ããäžäžäžããã
ãšããå
·åã§ãã
èªéç
ãŸããèªéçã«ã€ããŠç«¯çã«ãŸãšããŠã¿ãŸããããèªéçãšã¯ã©ããªç
æ°ãªã®ã§ããããïŒ
èªéçãšã¯ã2æ³å
ã«ãããæè¿ã®è³æ©èœé害ã§ããã
èªéçã¯ã1978 幎ã«ã¯ã¢ã¡ãªã«ã®åäŸ 1 äžäººã« 1 人ã ã£ãã®ã«å¯Ÿããä»ã¯ 67 人ã«ïŒäººãš
ãã確çã§èµ·ãã£ãŠããããŸãã«æä»£ã®å€§æµè¡ç«ç
ãšåŒã¹ããã®ã§ããã([35][67])
å»åŠçã®äž»æµæŽŸã¯ãèªéçã®åå ãäžæã ãšããŠããã
å»åŠçã®äž»æµæŽŸã¯ããã®åå ãè§£æããããšããŠããªãã
æ²»çæ³ã¯ãªãã
çŸåšã¢ã¡ãªã«ã§ã¯ã1000,000ïœ4000,000 人ã®èªéçæ£è
ãããã
çãŸãã€ãã®ç
æ°ã§ã¯ãªããåäŸé㯠2æ³ãŸã§ã¯æ®éã«ããããŠããã
èªéçã®åäŸã®ãã¡åæ°ã¯ãå
šã話ããªããªã£ãŠããŸãã
åäŸãèªéçã«ãªã£ãŠããŸã£ãå®¶æã¯ã倧ããªå¿åŽãæ±ããããšã«ãªãã
èªéçã®åäŸã®75ïŒ
ã¯ãäžçãèªæŽ»ã§ããªããªãã
èªéçã«ããæå®³ã¯ãäœå
ãã«ãã®ãéã«é¢é£ããŠããã
çºçä»¶æ°ã«ã€ããŠ
èªéçã®æ£ç¢ºãªä»¶æ°ãç¥ãããšã¯å€§å€å°é£ã§ããå®éã«èªéçã«ãªã£ãéã«ãå ±åã§ãã
圹æããååšããªãã®ã§ããããããã«ããã®ä»¶ã«é¢ããæ¿æ²»çå§åãããå ±åæ°ãããª
ãå°ãªãã«ããŠããããšãèããããŸãã
ããã§ã2006 幎 4 æã«ã¯ãCDC ããèªéçã50 äžäººä»¥äžãããšèªããŠããŸããã[35]ã
ã㯠2004 幎ã«çºè¡šãããæ°åãããŸã£ããå€ãã£ãŠããŸããã
äžæ¹ãã¢ã¡ãªã«ã®æè²çã«ããé害å
ã®çµ±èšè¡šãããããä¿¡ææ§ã®ããäºæž¬ãããããšã
åºæ¥ãŸãã[26]ãã®çµ±èšè¡šã«ããã°ã1993 幎ãã2006幎ã«ãããŠãèªéçã¯å
š 50 å·ã«ã
ããŠéåžžãªå¢ãã§å¢ããŠãããšããã®ã§ãããã®è¡šã§ã¯å
šäœä»¶æ°ã® 15ïŒ
ã ããåã調ã¹ãŠ
ããå·ããšã«å¹³å 1700ïŒ
ã®å²åã§èªéçãå¢å ããŠããããšç€ºãããŠããŸãã[18]ãã®çµ±
èšè¡šã® 2002 幎ã®å¹³åã¯714ïŒ
ã§ãã
ãã®å
šäœã® 15ïŒ
ã§ããçµ±èšæ°ããèããŠãçŸåšã®åè¡åœã«ãããèªéçã®åäŸæ°ã¯çŸäžäºº
ãããªãäžåãæ°ã ãšæšæž¬ã§ããŸãããŸããä»ã®èª¿åã§å¢ãç¶ããŠãããšããã°ã2013 幎
ã«ã¯åçŸäžäººã«ããªãäºå®ã§ãã[26]
1990 幎代åå以éã«ãããŠã¯ãèªéçã¯æããã«å€§æµè¡ã®äŒæç
ãšããŠåºåãããã¹ãã
ã®ã§ãããäž»æµæç®ã§èªéçã«ã€ããŠæžãæã«ã¯ã絶察ã«ãã®ãäŒæç
ããšããèšèãšãèª
éçããšããèšèãåäžã®æç« å
ã«çšããªãããã«æ³šæããŠããããã§ãã
èªéçã®åå ãšããŠèãããããã®ïŒMMR ãšæ°Žé
ä»ãŸã§éèªã FOX ãã¥ãŒã¹ã§äœãšèšãããŠãããšããŠããèªéçã®å€§æµè¡ã®èŠå ãšããŠæ
ãå¯èœæ§ã®å€§ããïŒèŠçŽ ãMMRãšæ°Žéã¯ãã©ã¡ããã¯ã¯ãã³ã®ãã®ã§ããMMR ã¯ã¯ãã³
ã¯æ°Žéãå«ã¿ãŸããããæè¿ã®æ°å¶ã®å人調æ»ã«ãããšãèªéçãšã®å¯æ¥ãªé¢é£æ§ã瀺ã
ããŠããŸãããŸãæ°Žéã®æ¹ã¯ããã¡ããµãŒã«ãšãã圢ã§ã¯ã¯ãã³ã«å«ãŸããŠããŸããäž¡æ¹
ã®åå ç©è³ªã¯ãåœäŒã®æ§ã
ãªå§å¡äŒããæ°å¶æ©é¢ã®ç ç©¶ã«ãããŠåºã調ã¹ãããŠããŸãã
110,66ãããªã®ã«ãç§åŠã®äž»æµæŽŸã§åãäžããããããšã¯ã1床ããªãã®ã§ãã
ã§ã¯æåã«ãã¯ããã®MMR ã¯ã¯ãã³ãšã®é¢é£æ§ããèŠãŠãããŸãããã
MMR(ã¯ããããããµãããã颚ç¹)ã¯ã¯ãã³
MMR ã¯ã¯ãã³ã¯ã¢ã¡ãªã«ã§ã¯ 1978 幎ã«ããã£ã 28 æ¥éã®æ€æ»ãããã ãã§èªå¯ããã
æ¥çš®æå®è¡šã«è¿œå ãããŸããã[116]ããããæ¥ãè¶³ã®ã»ãŒã«ã¹æ¹æ³ã¯ãåã«ãæããŸãã
ããçŸåšã«è³ããŸã§ãMMR ã¯ã¯ãã³ã®é·æçãããã¯äžæçãªæ€æ»ã¯äžåºŠãè¡ãªãããŠã
ãŸããã
éå£å
ç«
MMR ã¯ã¯ãã³æ¥çš®ãé²ãã§ããã«ã€ããä»ãŸã§ 2000幎ãã®éç¶ããŠãããéå£ãšããŠèª
ç¶ã«ä»ããŠããå
ç«ãšãããã®ã¯ãæãæšãŠãããŠããŸããŸãããã¯ã¯ãã³ãåºãåã¯ã
ãã®ïŒçš®é¡ã®ã軜ãç
æ°ã®ããããã«ããã£ã人ã¯äžçãã®ç
æ°ã«å¯ŸããŠå
ç«ãä»ããã
ã®ã§ããããããããã¯ããã®æä»£ã¯çµãããŸããïŒã¯ã¯ãã³æ¥çš®ã 20 幎ç¶ããçµæãä»
ã§ã¯ãããšããšã®ç
æ°ãå€åããæ°åããŒãžã§ã³ã§ãæäººã眹æ£ããç
æ°ãåºæ¥ãŠããŸã£
ãã®ã§ããããã¯ã人ãã€ããåºããç
æ°ã§ãã
éå£ã§ã€ããå
ç«ããšãããã®ã¯ãã¯ã¯ãã³ããããã£ãšé·ãç¶ããŠããŸãããå°å
ç§å»
ããããéå£å
ç«ãšã¯å€§å¢ãäžæ°ã«ã¯ã¯ãã³æ¥çš®ãããçµæãšããŠå
ç«ãä»ãããšã ãšã
ããããªè©±ãæ¹ãããŠããŸãããããã«ããŸããããªãããã«æ³šæããŠãã ãããã¯ã¯ã
ã³æ¥çš®ãåããŠããªãåäŸã¯ãã¯ã¯ãã³ãé壿¥çš®ããã°ã«ãŒããåŸãæ©æµã«ãããããª
ãïŒããã¯ãçãããæ¬åœã®éå£å
ç«ãšã¯ã©ããªãã®ããç¥ããªããã°ããã®ããŸããã®
æ¹ãä¿¡ããŠããŸãã ãããšããèšç®ã®ããšã«ãã§ã£ã¡ãããããåœãã®çè«ã§ããããã
ä»ãããã®åœã®å®£äŒã¯ãéåžžã«åºã浞éããŠããŸã£ãŠããŸããéå£å
ç«ãšã¯æ¬æ¥ãããäŒ
æç
ãããéå£ã«ãããŠèªç¶æ¶æ»
ããããšãæãããã¹ãã倩ç¶çãããã¹ãšãã£ãç«ç
ãè¯ãäŸã§ããããã¯ããã®éå£ã®å
šå¡ãç
æ°ã«å¯ŸããŠå
ç«ãä»ããããã«èµ·ãããŸãã
èªç¶é¶æ±°ãããã¯èªç¶ã«ä»ããå
ç«ã§ããã人工çãªã¯ã¯ãã³ãšã¯ç¡é¢ä¿ã§ãããããã
ã¯ãã ãŸãããªãããã«ã泚æäžããã
倧人ã«ãªã£ãŠããã¯ããããããµã颚éªã颚ç¹ã«ããããšãæ·±å»ãªé害ãè² ã£ããæ»äº¡ã
ã確çãé¥ãã«å€§ãããšããããšã¯ãåºã蚌æãããŠããäºå®ã§ãã(Merck)[280]ãããã«
å ããŠãããšããã®æäººããŒãžã§ã³ã®ç
æ°ã¯ãåäŸã®æã®ææã人工çã«é
ãããããšã§
ããšããšã®ç
æ°ãå€åœ¢ããŠããŸã£ãŠåºæ¥ãç
æ°ãªã®ã§ããã€ãŸãããã¯ãåäŸã®æã«ææ
ããŠäžçã®å
ç«ãã€ããŠããŠãããã®äººã¯ãããããã¯ã¯ãã³ã®é壿¥çš®ã®ããã§çãŸã
ãæ°åããŒãžã§ã³ã®ç
æ°ã«ã¯ææããŠããŸãå¯èœæ§ããããšããããšã§ãã
ããã§ã¯ãMMRãšèªéçãé¢é£ä»ããããŒã¿ãèŠãŠã¿ãŸãããã
ã¢ã³ããªã¥ãŒã»ãŠã§ãŒã¯ãã£ãŒã«ãã¯ããã³ãã³åšäœã®å€ç§å
Œãèè
žå°éå»ã§ããã1996
幎ã圌ã®ããšã«èªéçã®åäŸãæã€èŠªéãæ¬¡ã
ãšãåäŸãæ¿ããè
žã®çã¿ã§å°ã£ãŠããã
ãšçžè«ã«æ¥ãŸããããããã芪éã«ãŸããŠã§ãŒã¯ãã£ãŒã«ãã¯ããã®åã®äž»æ²»å»ã¯äœãšèš
ã£ãŠãããããšèããŠã¿ãŸããããçãã¯ãã€ã決ãŸã£ãŠããã€ãã®ãå»è
ããã«ã¯ãèª
éçãªãã ããåäŸã«è
žã®çã¿ãåºãã®ã¯åœããåã ããšèšãããããšã®ããšã§ããã芪
éãããããŠè¿œãè¿ãããŠããŸãã®ãç®ã«ããŠããŠã§ãŒã¯ãã£ãŒã«ãå»åž«ã¯ä»ãŸã§ä»ã®å»
è
ãã ããããããšããªãã£ãããšãè¡ãªã£ãŠã¿ãŸãããå®éã«ããã®åäŸãæ€æ»ããŠã¿
ãã®ã§ããåäŸéã®äž»æ²»å»ã®ãã¡èª°ããæãåæ©çãªè
¹éšã®æ€æ»ïŒãè
¹ãæã§è§Šã£ãŠãæ
ãããªé害ç©ããªãã調ã¹ãããšããããšãããããªãã£ãäºã«ã圌ã¯é©ããæããŠããŸ
ãã1 人ïŒäººã®åäŸã®è
žæ€æ»ãé²ããŠãããšã次ã«ã¯åäŸéã®å€§è
žã«åºè¡éšåãããã¿åã£
ãŠå€§ããªåºãŸãã«ãªã£ãŠãããšãããä»ãŸã§ã«èŠãããšãç¡ãçç¶ãèŠã€ãããŸããã
ãã®çç¶ã¯ãåè
žãªã³ãçµç¯æ§é圢æãšåŒã°ããçç¶ã§ãåºè¡ããŠè
«ãããããææãã
çµç¯ç¶ã®åºãŸãã倧è
žã«è©°ãŸã£ãŠãµããã§ããŸãããã乳幌å
ã«ãšã£ãŠã¯æ¥µããŠæ¿ããç
ã¿ã䌎ããŸããäžæ¹ã身äœã¯ãã®çµç¯ãæåºç©ã ãšæã£ãŠè
žããæŒãåºãããšããŸããã
ããããçµç¯ã¯å€§è
žè
ºãšãã£ã€ããŠããŸã£ãŠãããããçµæãšããŠå€§è
žãç°åžžã«å§çž®ãã
ãæãããã¿ç¶æ
ã«ãªã£ãŠããŸãã®ã§ãããã®çç¶ã¯è
žéç©ãšåŒã°ããæã«ã¯èŽåœçãªã
ã®ã§ãã
ãŠã§ãŒã¯ãã£ãŒã«ãã¯ãã®æ°ããè
žã®ç
æ°ããèªéçè
žçãšåŒã¶ããšã«ããŸããããã®ç
ç¶ã¯ããµã€ãã®ä¹³å¹Œå
ã®è
¹çãã倧è
žã®åºæ¿ãã¯ããŒã³ç
ãšã¯å
šãç°ãªããã®ã§ã調ã¹ã
å
šãŠã®èªéçå
ã®å€§è
žã«ã¯ãããç¹ç°ãªæ§è³ªãèŠãããã®ã§ãã
è
žã®å
åŽã®è
ºãè©°ãŸããççãããããŠããããš
åè
žãªã³ãçµç¯æ§é圢æ
ãŠã€ã«ã¹ææ
身äœã®èªåçãªå
ç«åå¿
2 æ³ã®åã®å€§è
žãèªããæ»æããããã«ãªã£ãŠããŸã£ãã®ã¯ãäœãåå ãªã®ã§ããããïŒ
ãŠã€ã«ã¹ãšã®é¢é£æ§
ãããããã¯è¯ã質åã§ãããããªã³åšäœã®ååçç©åŠè
ã®ãžã§ã³ã»ãªã¬âãªãŒïŒ°hã¯ã
ãã®è¬ããšãéµãïŒã€äžããŠãããŸããããããã§ã®åœŒã®è²¢ç®ãšã¯ãTAQMANãšåŒã°ãã
éåžžã«æŽç·Žãããæ°åæè¡ã§ãããããã¯ãããŠã€ã«ã¹ãšãå¥ã®ãŠã€ã«ã¹ãå®ç§ãªæ£ç¢ºã
ã§åºå¥ããããšãåºæ¥ãæè¡ã§ããããã«ãã£ãŠãæ®ã©å
šãŠã®èªéçå
ã®è
žã«ãã¯ãããŠ
ã€ã«ã¹ãããããšãå€ããŸãããããããã®ãŠã€ã«ã¹ã¯ãã¯ããã®ç
æ°ããã®ãŠã€ã«ã¹ã§
ã¯ãããŸãããããã§ã¯ãªããããã¯ç¢ºå®ã«ïŒïŒïŒ²ã¯ã¯ãã³æ¥çš®ã«å«ãŸããã¯ããã¯ã¯ã
ã³ã®ãŠã€ã«ã¹ã ãšããããšã倿ãããã®ã§ãã(Uhlmann)[125]
ãã£ãªã¢ã®å±æ©
ãã®çºèŠãçºè¡šããããšã§ããŠã§ãŒã¯ãã£ãŒã«ãã®ãã£ãªã¢ã¯å€§ããå·Šå³ãããŸããã圌
ã¯ãã ãããããæ°ããçºèŠãã倿ããŠãèªéçãšïŒïŒïŒ²ã¯ã¯ãã³ã®é¢é£æ§ããã£ãšçª
ãè©°ããŠç ç©¶ããå¿
èŠãããããšææ¡ããã ãã§ããããïŒWakefield â LancetïŒ[290]ãã
ããšãã§ããªãããšã«ãªã£ãã®ã§ãã圌ã¯çªåŠãšããŠãäžçäžã®å»åŠçããã®æããšéé£
ã®æšçã«ãªã£ãŠããŸããŸããã圌ã¯èªåã®ããããšïŒã¯ã¯ãã³ãšãããå»åŠçã«ãããŠã¯
èãªãååšãããããšãªãã«æ¹å€ããŠããŸã£ãããšããã©ãã ãããºã€ããšã ã£ãããå«
ãšããã»ã©æãç¥ããŸããããããæã¯ãã§ã«é
ããã§ãããããŸã§ãã奜調ã§ãã£ãã
ã£ãªã¢ãããã®æä»¥æ¥ã©ãã©ãäžãåã«ãªããäºåºŠãšåŸ©æŽ»ããããšã¯ãããŸããã§ããã
ããããã£ãšææ°å°ãªãã®äººã ã£ããªãããã®æç¹ã§è¬çœªã§ãããŠåŒãäžãã£ãã®ã§ãã
ãïŒå®éã圌ã®å
±èè
éã¯çãããããã®ã§ããããããããŠã§ãŒã¯ãã£ãŒã«ãã¯ãç§åŠ
çããã®çã®éã£ãæšæž¬è«ãç¡èŠããããšããŠããã®ãç®ã«ããŠã決æãåºããŸãããã
ã圌ã®èª¬ãæ£ããã£ãå Žåããã®çºèŠã¯ãšãŠãéèŠãªäŸ¡å€ã®ãããã®ã ãšããããšãåã
ã£ãŠããããã§ããããããèªéçãšïŒïŒïŒ²ã¯ã¯ãã³ãšã®é¢é£æ§ã蚌æããã«ã¯ããŠã§ãŒ
ã¯ãã£ãŒã«ãã¯æéãããããæµè¡é
ããªç§åŠçæ¹æ³ã䜿ããªããã°ãªããŸããã§ããã
ã€ãŸããåäžã®æ¡ä»¶äžã«ãããŠã¯åäžã®çµæã«ãªããšããçè«ã«åŸã£ãŠãå®éšãçµ±èšåæ
ãè¡ãªã£ãããã§ãã
ããºã«ã®æåã® 1 ã³ãïŒä¿¡ææ§
ãŠã§ãŒã¯ãã£ãŒã«ãããŸãæåã«èããç¹ã¯ããã¯ããã¯ã¯ãã³ã®ãããªãŠã€ã«ã¹åªäœãã
èªéçã®ãããªç¥çµé害ã®åå ã«ãªããšãã説ã¯ãæãåŸããïŒããšãããã®ã§ããã
è
žãšãè³ãšã®éã«ãäœãç¥ãããŠããé¢é£æ§ã¯ãªãã ãããïŒ
ããã«é¢ããŠã¯ãããè²ã
ç¥ãããŠããŸããã¢ã¹ããªã³ã¯èè
žãéããŠè¡æ¶²ã«æµžéããé
çãæ²»ããŸããããŒã«ã飲ããšè¡æ¶²ã«åžåããããã®äººã®æ°åãå€ãããŸãããæãã€å€
ã®ããã¶ãã¯ã飲ãã°æ¶ååšå®ã«åžåãããããããã®äººã®æ°åãå€ããŸããäœãæ¯ç©ã
é£ã¹ãã°ããã®äººãçããŠããã®ã«å¿
èŠäžå¯æ¬ ãªè³ã®éšåããã¡ãŒãžãåããããšããã
ãŸãã
ãã®ããã«ãè
žãšè³ãšã®é¢é£æ§ã¯ãå»åŠçã«ãããŠéåžžã«è¯ãç ç©¶ããç¥ãããŠãŸããäœ
幎ãåã®ããšã§ãããããè³ã®ååŠç©è³ªãæ¶ååšå®å
šäœã«ãæ£ãã°ã£ãŠããŠããããã€ã
ã«ãäºãã«æ
å ±ãéããã£ãŠãããšãããšãã話ãã³ãã©ãããŠããŸãããïŒChopraïŒ[266]
粟ç¥ç¥çµå
åŠ(å¿çãšç¥çµæ©èœãå
ç«ç³»ã®é¢é£æ§ã®åŠååé)ã¯çŸåšãéåžžã«å€§ããæ±ãããŠ
ããåéã§ããããã®åéã«ãããŠãããããå
ç«ç³»ã®åšå®ãšè
žãè³ãã©ã®æ§ã«ã€ãªããã
çžäºã«æ
å ±ã亀æãåã£ãŠããããšããç ç©¶ãæ¬¡ç¬¬ã«æããã«ãªãã€ã€ãããŸããã·ã§ãª
ãŒã»ããžã£ãŒãºå»åŠåå£«ã®æ§ãªäž»æµèªã®ç ç©¶è
ã§ãããããå
ç«æ©èœåšå®ã®ååã¯ãè
žã«ã
ããšããã£ãããªã©ãšçºè¡šããŠãããããã§ãã[39]
ããºã«ã®ãããïŒã³ã
ãŠã§ãŒã¯ãã£ãŒã«ãã¯ãåè¡åœãšïŒµïŒ«ã«ãããŠïŒïŒïŒ²ã¯ã¯ãã³ãéå§ãããçŽåŸã®èªéç
ã®çºççã衚ã«ãããšã10 幎éã®å·®ã§ãã£ããã®åœ¢ã§æ¥æ¿ã«äŒžã³ãŠãããšç€ºããŠããŸãã
ã衚ã
å·Šã®ã°ã©ãã 1978 幎ã®åè¡åœã§ãå³ã®ã°ã©ãã 1988 幎ã®ïŒµïŒ«ã§ãããããèŠããšã確ã
ã«é¢ä¿ããããããªæ°ãããŸãããïŒ
èªéçã®ç ç©¶ã«ãããŠãå
端ã®ç§åŠè
ã§ãããžã§ãã»ãã©ããã¹ããªãŒãå»åŠå士ã¯ãèª
éçå
ã®å
ã®äœäººãã¯ãåã«ã¯ããã¯ã¯ãã³ã®ãŠã€ã«ã¹ã身äœããæåºããã®ããæ®éã
ãé
ãåäŸãã¡ãªã®ã§ã¯ããšãã仮説ãç«ãŠãŠããŸãã
ãâŠäœå
ããã¯ã¯ãã³ç³»ã®ãŠã€ã«ã¹ãæé€ããèœåãæ¬ ããŠããããšãâŠãã®åäŸéã®çº
çã®çŽæ¥åå ã§ãããããããåäŸéãéºäŒåçã«åŒ±ãå
ç«¥ãšãããµãã»ããåºåã«èšå®
ããããšãææ¡ãããã[67]
ãããªã«éèŠãªç ç©¶ããNIH ã¯ã©ãããŠæ¯æŽããªãã®ã§ããããïŒ
ãŠã€ã«ã¹æ§åŠšå®³
3 çš®é¡ãæ··ããŠã¯ã¯ãã³æ¥çš®ããããšããå»è
ã®éã§ã¯ trivalents ãšåŒãã§ããŸããïŒïŒïŒ²
ã¯ã¯ãã³ã®ããã«ã3çš®é¡ã®ã¯ã¯ãã³ãæ··ããŠäžåºŠã«æã£ãŠããŸãéã«ããã®æ··åç©ã®å®å
š
æ§ã®æ€æ»ãäœãããªãã§æ¥çš®ããŠããŸããšãã£ãéç§åŠçãªè¡çºã«ããŠã§ãŒã¯ãã£ãŒã«ã
çåãæããŠããŸãããŠã€ã«ã¹äœãè¡çªãããšãã«çžäºã«äžãã圱é¿ã¯äºæ³ãåºæ¥ãªãã
çžæã®ãŠã€ã«ã¹ãå±éºãªæªæ§ã«å€ããŠããŸã£ãããçžæã®ãŠã€ã«ã¹ããããã¯ã¢ãŠãããŠ
ããŸããŸãããŠã€ã«ã¹äœãæ··ãåãããããšã«èµ·å ãããããããã©ã³ãã ãªçµæã¯ãŠã€
ã«ã¹ã€ã³ã¿ãŒãã§ã¬ã³ã¹ïŒãŠã€ã«ã¹æ§åŠšå®³ïŒãšåŒã°ããŠããŸããããã¯ãç§åŠç ç©¶äŒã®é
ã§ã¯è¯ãç¥ãããŠããçŸè±¡ã§ããã2000 以äžãã®èšäºã§åãäžããããŠããŸãã
ïŒWakefield[116]ïŒ 1+1+1 ïŒå¿
ãããïŒããšããçãã§ã¯ãªããšããããšã§ãã
ã¯ããããããµã颚éªãäžæ¥ã°ããã® 3 皮混åã¯ã¯ãã³ãïŒïŒïŒ²ãšã¯ã3 çš®é¡ã®æææ§ãŠã€
ã«ã¹ã®äººå·¥çãªç³»çµ±ãæ··ãåãããŠäœã£ããã®ã§ããã€ãŸããèªç¶ã«èµ·ããææç
ã®ç³»çµ±
ã§ã¯ãªãã人工çã«äœãäžãã系統ã䜿ã£ãŠããŸããåæã®ç ç©¶è
éã¯ããã®ïŒçš®é¡ãäž
ç·ã«äœ¿çšããéã«ã©ã®æ§ãªçžäºäœçšãããã®ãã調ã¹ãããšãéèŠã ãšææããŠããŸããã
(Buynak,1969[279],Minayama-1974)ãã以éã®ç ç©¶è
éãåã3 çš®æ··åæ¥çš®ã¯ã¯ãã³ã«é¢
ããŠã¯ããã®ãŠã€ã«ã¹ã€ã³ã¿ãŒãã§ã¬ã³ã¹ã培åºçã«ç ç©¶ããå¿
èŠãããããšå床䞻匵ã
ãŠããŸããïŒHalsey,1999ïŒ[187]ããããæŽä»£ã®ç ç©¶è
éãæèšããŠããã«ããããããã
çŸåšã«è³ããŸã§ãããããç ç©¶ã¯äžåè¡ãªãããŠããŸããããããªã®ã«ãäœãšãéç§åŠç
ãªããšã§ãããçŸåšã®ã¢ã¡ãªã«ã®åäŸéã察象ãšããæ¥çš®æå®äºå®è¡šã«ã¯ãå
šå¡ã®åäŸé
ã 1 人æäœ 7 åãã® 3 çš®æ··åæ¥çš®ãåããããã«æšå¥šãããŠããã®ã§ãã[15]
ã¯ããã¯ã¯ãã³ãšèªå·±å
ç«ç
ãŠã¿å·ã®å°éå®¶ V.ã·ã³ã° PhDã¯ãäœçŸä»¶ãã®èªéçã±ãŒã¹ãç ç©¶ããçµæãçºçããåäŸ
éãèªå·±å
ç«çãèµ·ãããŠããããšãçºèŠããŸãããããã¯ã€ãŸãã身äœãèªåã®äœå
ã®
ç¥çµæ©é¢ã®å
å£ã«ãããããšãªã³ãšããèãæ»æããŠããŸãçç¶ã§ããã·ã³ã°å士ã¯ãã
ã®çç¶ããã¯ããã¯ã¯ãã³ã«å¯Ÿããé床ã®èªå·±å
ç«åå¿ããšããæµè¡ç
ã ãšåŒãã§ããŸãã
ã¯ã¯ãã³ã«äœ¿çšãããŠããæ°Žéããã¯ããã¯ã¯ãã³ãå¯äœçšãšããŠãã®ãããªç¥çµãã¡ãŒ
ãžãåŒãèµ·ããããšã¯ãããç¥ãããŠãããã®ã§ããã·ã³ã°å士ã¯ãã¯ã¯ãã³ãã©ã®æ§ã«
ããšãªã³ãäžå®å
šã«ããŠããŸãããæããã«ç€ºããŠããŸããããšãªã³ãšã¯ãã³ã³ãã¥ãŒã¿
ãŒã®çµ¶çžäœã¯ã€ã€ãŒã®ãããªãã®ã§ãçãŸããã°ããã®åäŸã®ããšãªã³ã¯æªå®æãªç¶æ
ã§
ãããããŠãä¹³å
ã®ããšãªã³ãçºéããŠããéçšã§ããã®æ§é ã«åé¡ãçããã°ããã®çµ
æãšããŠãåäŸæä»£ãããã¯æé·ããŠãããç¥çµæ§ã®é害ãèµ·ããããã®ã§ãã
åŠå®ãªããæ¯æãšããã»ã©ãããŠããã®ã«
ãã® 13 幎éãšãããã®ãäž»æµã¡ãã£ã¢èªã«ã¯æ¯æã®ããã«ããããããå°éå®¶ãã«ãããæ°
ç ç©¶ãã§èªéçã®æµè¡ãšã¯ã¯ãã³ãšã®é¢é£æ§ã¯ãªãããšèšŒæããããšããå
容ã®èšäºãæž
ãããŠããŸãã(NEJM, 7 Nov 02 â Danish study [118])ã§ããæ°çš®ã®æµè¡ç
ãç ç©¶ããã®
ã«ãŸããã²ããããåå ã§ã¯ãªããããšã®è©±ã°ãããããªãã§ãå€ã ãšæããŸãããïŒå®
éã«èªéçã®åå ã§ãããã®ãè§£æããããã®ç ç©¶ã¯ãäžäœã©ãã«ããã®ã§ããããïŒ
ãã®ãããªèšäºã¯æ±ºãŸã£ãŠãæ°ŽéãšïŒïŒïŒ²ã¯ã¯ãã³ãèªéçã®åå ã§ãããšãã蚌æã¯ã©
ãã«ããªãããããªããšãèŒã£ãŠããç§åŠçãªæç®ãªã©ç¡ãã®ã ããããšäž»åŒµããŠããŸã
ããããã¯èª€ãã§ããã€ãŸãããã¯æãã«ããæãããªäºå®ãç¡èŠããŠããã®ã§ãããã¡
ãããæ°ŽéãšïŒïŒïŒ²ã¯ã¯ãã³ãèªéçã®åå ã ãšèšŒæããæç®ãªã©ãéå»ã«ããããã¯ã
ããŸããïŒã ã£ãŠãããã远æ±ããã®ã¯ããŠã§ãŒã¯ãã£ãŒã«ããšååéãæåã ã£ãã®ã§
ããããããŠãä»®ã«ååãªè³éæŽå©ããã£ããšããŠããæ°ãã仮説ãç ç©¶ããã®ã¯ãšãŠã
å°é£ãªãã®ã§ãããè³éããªãäžã«äžçäžã®å»åŠçããå£ã
ã«éŠåãã®åã ããšå«ã°ããŠ
ããã®ã§ã¯ãéæ¹ããªãè³é£ã®æãšãããŸãã
ã§ã¯ã確å®ãªããšãšã¯ïŒ
çŸæç¹ã§ã¯ããŠã§ãŒã¯ãã£ãŒã«ããã·ã³ã°ãåã³ãã®ä»æ°äººã®ç ç©¶è
ã®ãé°ã§ã以äžã®ç¹
ã¯ç§åŠçã«åŠ¥åœæ§ããããšèšããã§ãããã
èªéçå
ã¯ãåæã®çºè²ã¯æ£åžžã§ãã£ãããš
ïŒïŒïŒ²ã®åŸãèªéçã«ãªã£ãŠããããš
æ£åžžãªåäŸéã«ã¯èŠãããªããæ°çš®ã®ïŒ§ïŒ©çç¶ã®å
å
åšæçã«åçºããææçç¶
è³å
äžæ¯çç¶ãšäžèŽããç¥çµæ§ã®çç¶
ã¯ã¯ãã³ã«åå¿ããŠèµ·ãããè
žå
ã«ãããé床äœçš
å
ç«æ©èœé害 / èªå·±å
ç«çç¶
誀ãã蚌æãã
éå» 10 幎ãã®éããŠã§ãŒã¯ãã£ãŒã«ããæ»æãæé€ãç¶ããŠãããžã£ãŒãã«èªã®èšäºã¯ã«
ããïŒããŒã¹ãçãªã決ãŸãã®å
容ã§ããããããã©ãããŠãäžæè°ãªã®ã¯ãå»åŠç ç©¶ã®
ããã«NIHããäœåãã«ãã®è³éæŽå©ãããã®ã«ã圌ã®äž»åŒµãééã£ãŠãããšèšŒæã§ãã
ç ç©¶ããã©ãã«ãèŠåœãããªãããšã§ãããŠã§ãŒã¯ãã£ãŒã«ãã®ç ç©¶æ¹æ³ãééã£ãŠãã
ã®ãªãããã®èª€ãããã£ããæžãåºããŠã決å®çã«åœŒã®è©å€ãèœãšãã°è¯ãã§ã¯ãããŸã
ããïŒãããªããšãªãã25äžãã«ãããã§åºæ¥ãã¯ãã§ãã(Weldon)[110] ã ããã©ãã
ãããŠã§ãŒã¯ãã£ãŒã«ãã®èª¬ãæ£ããã£ããšãããïŒ67 人㫠1 人ã®ä¹³å
ã被害ã«ãã£ãŠã
ãæµè¡ç
ãªã®ã ãããç ç©¶ããã«å€ãããšã¯æããŸãããïŒã§ãå®éã«ã¯ãç§åŠçãªæ ¹æ
ãªã©äžåãªããå人çãªæå¥ã銬鹿ããé飿»æã°ããããããŠããã®ã§ãããŸã£ããã
9/11 äºä»¶ã®ãäºå®èª¿æ»ãããããæªè³ªã§ãã
次ã«ãæ°Žéã«ã€ããŠ
ããŠãæ°Žéãšã¯ã©ããªãã®ã§ãããïŒãã®éå±ã¯å°åŠæ ¡ã§ãç¿ãã¬ãã«ã®ãã®ã§ãéåžžã¯
æ¶²äœã§ãããæããã¯ã€ãã¯ã·ã«ããŒãšãåŒã°ããŠããŸãããæ°Žéã¯ã人é¡ãç¥ãäžã§ 3
çªç®ã«åŒ·ãæ¯æ§ç©è³ªã§ãéæŸå°æ§ç©è³ªã®äžã§ã¯ãæãæ¯æ§ã®åŒ·ãéå±ã§ãã(Bernard)[166]
æ°Žéãæ¯ã§ããããšã¯ãç§åŠè
ã®éã§ã¯ããäœå幎ãã®éç¥ãããŠããäºå®ã§ãããä»ãŸ
ã§ã®ç ç©¶ã®ã»ãšãã©ã¯éã®æ°Žéæ±æã ãšãå·¥å Žããã®æŒæŽ©ã«ããç°å¢æ±æã«é¢ããç ç©¶ã§
ããã¯ã¯ãã³ã«ã¯ãåã«è¿°ã¹ãããã«æ°Žéãæåã® 49.5ïŒ
ã§ããããã¡ããµãŒã«ãšãã圢
æ
ã§æ°Žéãå«ãŸããŠããŸããããã¯ãšãã«æ°Žéãšããã人工çã«äœãåºãããç¥çµæ§æ¯ç©
ïŒç¥çµãæ®ºãæ¯ïŒã§ãããç¡æ©è³ªã®æ°Žéã«æ¯ã¹ãŠé¥ãã«åŒ·ãæ¯æ§ãæã£ãŠããŸãã
(Koos)[306]æ°çå
ãçãŸãããã®æ¥ã®ãã¡ã«ïŒ¢åèçã¯ã¯ãã³ãæ¥çš®ãããŸãããããã«
å«ãŸãããã¡ããµãŒã«ã¯çãŸãããŠã®æªå®æãªãŸãŸã®çްèèïŒå€§è
žåã³å°è
žã®å
èãèèã
è³ãç¥çµç³»ïŒã«çŽæ¥ãæ¥è§Šããããšã«ãªããŸãã
1997 幎以éãå
¬åŒãªçºè¡šã§ã¯æ±ºãŸã£ãŠãæ¯æã®ããã«ããã¡ããµãŒã«ãèªéçããã®ä»ã®
ç
æ°ã®åå ã§ãã蚌æ ã¯ç¡ãããšåãã»ãªããç¹°ãè¿ãããŠããŸããããŸãã§ãšãã¯ãŒã
ã»ããŒããŒæŠæ³ã決ã蟌ããã®ããã«ãã§ãããã®å±ãæå¥ãã»ãã®ã¡ãã£ãšå€ããã°ã
ãããããã¡ããµãŒã«ãèªéçããã®ä»ããããç¥çµé害ã®åå ãšãªãåŸããšãã蚌æ ã¯å±±
ã»ã©ããããšãããªããããã¯çå®ãªã®ã§ããã
è£œè¬æ¥è
ã¯ããªããšèšã£ãŠãããïŒ
ã¯ã¯ãã³ã«ã€ããŠèª¿ã¹ãéã«é¥ãããããã¹ãšããŠãã¯ã¯ãã³ãåæ³åããããšã§çèšã
ç«ãŠãŠããé¢ã
ããã®æ
å ±ã°ããã«é Œããã£ãŠããŸããšããç¹ãæããããŸããå®éã«ã¯ã
補è¬ç€ŸåŽãäœãšèšã£ãŠããã®ãã調ã¹ãæ¹ãè¯ãã§ãããã
Eli Lilly 瀟㚠EMD Chemicals 瀟ã¯ãã¡ããµãŒã«ã®çç£ãè¡ãªã£ãŠãã 2 瀟ã§ããã圌ã
ã®èªç€Ÿçšã®å®å
šããŒã¿è¡šã«èšèŒãããŠããå
容ã¯ãããã§ãã
Eli Lilly ç€Ÿãæ¥è§Šããéã®åå¿ãšããŠã¯âŠã¢ã¬ã«ã®ãŒæ§ç®èçâŠæ°Žéäžæ¯çç¶ã®å±éºãã
ãâŠæäººã«ãããŠã¯ãèŠçããã°ãŸããé ã®å
端ãæè¶³ã®å
端ããã³ãããªã©ã®ç¥çµæ§ã®
å
åããããåå®®å
ãåäŸã®äœå
ã§æ¥è§Šããå Žåã«ã¯ã軜床ïœé床ã®ç²Ÿç¥çºéé害ãã身
äœã®åäœæ©èœã«è»œåºŠïœé床ã®é害ãçããããšããããã[94]
EMD Chemicals 瀟ãå±éºïŒæ¯ç©ïŒåžåŒããã³ç®èããã®åžåã飲çšã¯æ»äº¡ããå±éºããã
ã®ã§æ³šæããããšãç®ãç®èã®ãã¶ããé害ãèµ·ããå¯èœæ§ã®ããåšå®ã¯æ¬¡ã®éãã§ããã
èèãåŒåžåšå®ãç®èãç®ãäžæ¢ç¥çµç³»ãæ°Žæ¶äœããããã¯è§èã倧éã®æåºã¯ãç°å¢æ±
æã®å®³ãäžããå±éºããããæ³šæäºé
ïŒãã®è£œåã¯ãã«ã«ãã©ã«ãã¢å·ã§ã¯åºç£é害ãã
ãã®ä»çæ®æ©èœã«é害ãäžãããšãããŠããååŠç©è³ªãå«ãã§ãããã[343]
ãªãã»ã©ãããã§ã¯æããã«ããã¡ããµãŒã«ã¯èªéçãåŒãèµ·ããå±éºããããšãããã
ã§ããïŒãã®ããã«ãã«ç®ç«ã£ãŠãããæãããªäºå®ããã现å¿ã®æ³šæããã£ãŠæžãäžã
ããããèæ¡ããã©ãããã¥ãŒã¹èšäºãé¿ããŠéã£ãŠããäºå®ãªã®ã§ãããã¡ããµãŒã«ã
èªéçã®åå ã ãšãã蚌æ ããªããã§ãã£ãŠïŒäœããåœé 宣äŒã§ãããïŒãããªãã®ã«ã
éšãããŠã¯ãããŸããã
æ°Žéã®äœçšãšã¯ïŒ
ãµãªãŒã»ããŒããŒãã¯ã2000 幎ã«ãèªéçïŒç¹ç°ãªæ°Žéäžæ¯çããšããè¯è³ªãªç ç©¶è«æã
åºããŠããŸããããã®æžã«ã¯ãæ°Žéã®èµ·æºãšããã®æŽå²ãé ã
ã«æžãåºãããŠããŸãã圌
女ã¯ãæ°Žéäžæ¯çãšèªéçãšããïŒã€ã®ã·ã§ããã³ã°ãªçç¶ãæ¯èŒããäžã§ããã®äž¡è
ã
圱é¿ãäžãã身äœåšå®ã¯ãåãïŒåšå®ã§ãããšææããŠããŸãããããã¯ä»¥äžã®éãã§ãã
å
è çèã®å¶åŸ¡åšå®
è³ å
ç«ç³»
ç® çºè©±åšå®
ããŒããŒãã¯ãèªéçã®çç¶ã®ïŒã€ïŒã€ãšãæ°Žéäžæ¯çã®çç¶ã®ïŒã€ïŒã€ããããããå
š
ãŠäžèŽããŠããããšã瀺ããŠããŸãããããèŠãã°ããã®äž¡è
ãå®ã¯åãç
æ°ã§ããããš
ã¯ããããªã«é ã䜿ããªããŠãåããã¯ãã§ãã[166]
1930 幎以éãïŒã€ãã®æ¿åºæ©é¢ãããããæ°Žéã®æ¯æ§ã¬ãã«ãèšå®ããŠããŸããæ¯ç§ã®ã¢
ãã«ã¬ã ïŒæ°Žéãšä»ã®éå±ãšã®åéïŒãšãã¯ã¯ãã³ã«å«ãŸãããã¡ããµãŒã«ã¯ãã¢ã¡ãªã«
ã®åäŸéãæãæ°Žéãšæ¥è§Šããããšãå€ãïŒã€ã®åœ¢ã§ãããé©ããããšã«ãããããæ¿åº
ã®è¡šã®ã©ããããã® 2ç¹ãæ±ã£ãŠã¯ããŸããã[166]
äžæ¢ç¥çµç³»
ã¯ã¯ãã³ã§ãç°åžžããçºçããå Žåãæãé »ç¹ã«èµ·ããæªåçç¶ã¯ãäžæ¢ç¥çµç³»ã«é¢ãã
ç
æ°ã®ããã§ãããã®çç±ã¯ãç¹ã«åäŸã®å Žåã«ã¯ç°¡åã§ãã¯ã¯ãã³æ¥çš®ã®æ¹éãæ±ºãã
åŽãäŸãäœãšèšãããšããåäŸã¯åãªã倧人ã®ãããã¥ã¢çã§ã¯ãªãããã§ããåäŸéã®
ç¥çµç³»ã¯ããŸã ãŸã æªå®æã®ç¶æ
ã§ãããç¥çµçްèèãšã¯å®å®ã«ãããã®ã®äžã§ 1 çªãšèš
ã£ãŠããããããéåžžã«ããªã±ãŒãã§å·ã€ãããããã®ã§ããç¥çµã®åšãã®çµ¶çžäœãããš
ãªã³ã¯ãçãŸããã°ããã®æç¹ã§ã¯ãŸã äœãããŠããŸããããã®ããšãªã³ã宿ãããŸã§
ã¯ãç¥çµçްèèã¯ãã®ç°å¢ã«ã»ãã®ããããªç°å€ããã£ãã ãã§ãéåžžã«ææã§ãå·ã€ã
ãããç¶æ
ã§ãããããžãè¡æ¶²äžã«æ°Žéã人工çã«æ··å
¥ãããšãæ£åžžãªç¥çµçºéãæ¢ãŸã£
ãŠããŸãã®ã§ãã(University of Calgary video[108])ããã¯ããã埮éã®æ°Žéã§ãåãã§ã
ãããå®å
šãªèš±å®¹éã¯ããããŸããã
ææ¯ãªç©è³ªãç¥çµã®çºéç°å¢ãæ±æããŠããŸãéããã®ã¿ã€ãã³ã°ãã©ãçšéèŠãªåœ±é¿ã
ãããããã«ã€ããŠã¯ãã»ãªã»ã³ã«ããŒã³ãæç¢ºã«èª¬æããŠããŸããæºïŒæ³å
ã«ãšã£ãŠã¯
å
šã害ã®ãªãç©è³ªã§ããçåŸ 1æ¥ç®ã2ã¶æç®ã6 ã¶æç®ãªã©ã®ä¹³å
ã®äžæ¢ç¥çµç³»ã«ãšã£ãŠ
ã¯èŽåœçã§ãçæ¶¯æ²»ããªãææã«ãªãå±éºãããã®ã§ãã(Colborn,p113)[212]ãã®çµæã
èªéçããåŠç¿æ©èœé害ãå€çºæ§ç¡¬åçãFoxspeakãã®ã©ã³ã»ãã¬ãŒçå矀ãçè
çž®æ§åŽçŽ¢ç¡¬åçãªã©ããããšããããç¥çµæ§ã®ç
æ°ãåŒãèµ·ããããããšã«ãªããŸãã
ææ©è³ª  ç¡æ©è³ª
æµ·ã®éãé£ã¹ãããšã§æåããæ°Žéãããããã¡ããµãŒã«ã®æ¹ãé¥ãã«å±éºãªæ¯æ§ã®æ°Žé
ã§ããããšã®çç±ã«ã€ããŠãããŒããŒãã¯åžåããããã¡ããµãŒã«ãè¡æ¶²ããæé€ããã®
ãå°é£ã§ããããšãšé¢é£ããŠãããšè¿°ã¹ãŠããŸãããã¡ããµãŒã«ãšã¯ãšãã«æ°Žéã§ãç¥çµ
现èãå¥œãææ©äœã§ããè¡æ¶²ãšè³ã®éã®é²å£ãè¡æ¶²è³é¢éç¡ãã§ã¯ãä¹³å
ã®è³ãèé«ã¯ã
ã¡ããµãŒã«ã®æ°å¥œã®é€ã«ãªã£ãŠããŸããŸãããããŠãã£ããç¥çµçްèã«äŸµå
¥ãããšãæ°Žé
ã¯éåžžã«åŒ·ãçµã³ã€ããŠããŸããããããŠæ°Žéã¯äœå¹Žãã®éããŸãã§æéç匟ã®ããã«çް
èã«èç©ããå
šãäºæ³å€ãªåœ¢ã§è³çްèã®çºéã«é害ãèµ·ããç¶ããã®ã§ãã[166]
以äžãã倧ãããªã£ãŠããçªç¶ãµããã«çºçããããããšããããç¥çµæ§é害ã®é ããå
å ã¯ãããããã¡ããµãŒã«ã«ããããšã®çç±ã§ãããããŠçºçããæç¹ã§ã¯ããããã®å
å ã蚌æããããšã¯äžå¯èœã«ãªã£ãŠããŸã£ãŠããŸããäŸãã°ãã€ã±ã«ã»ïŒªãã©ãã¯ã¹ã¯ 28
æ³ã§ããŒãã³ãœã³ç
ãçºçããŸãããããããè¯ã 1 äŸã ãšæããŸãããïŒ
æ°Žéã¯ãçåœäœã®äžã§èç©ããçç©ã§ãã人éã®å Žåãèèªçްèã«èç©ããã幎ã
ãšå¢å¹
ããŠããããšã«ãªããŸãã[166]
å®å
šç¢ºèªãã¹ããšãç¬
åœäŒè°å¡ã§ãããã³ã»ããŒãã³ã¯ãåäŸéã«äžããããã¯ã¯ãã³ã«å«ãŸããŠããæ°Žéã®å®
å
šæ§ã«ã€ããŠããã® 8 å¹Žéæ¿åºãã©ãã ãç¡é äœãªæ
床ãåã£ãŠãããã圹人ããèããŠã
ãããã«å°ã
è
¹ãç«ãŠãããã§ãã
ããšããããšã¯ãæã
ã1929 幎以æ¥ãã£ãšäœ¿ã£ãŠãããã¡ããµãŒã«ã®å®å
šæ§ã«ã€ããŠãã
ãªãéãç¥ã£ãŠããå®å
šæ§ãã¹ããšã¯æåã®1929幎ã«å®å°ããããã®ã ãã ãšèšããã§ã
ãïŒãã®å®é𿀿»ã§ã¯ãå
šå¡ãé«èçã«ããããæ»äº¡ããŠãããããªããïŒã
ïŒBarton, 19 Jun 02 [124]
ãã®å®å
šæ§ãã¹ãã¯ããã¡ããµãŒã«ãçºæãã Eli Lilly瀟ãè¡ãªã£ããã®ã§ããããã®å¹Ž
ã«æåã®ãã¡ããµãŒã«å
¥ãã¯ã¯ãã³ã®èªå¯ãç³è«äžã§ãã£ããããå®é𿀿»ã®çµæã¯é æ»
ãããŸããã[48]
ãããŠããšãäžæè°ãªããšã«ãããããä»ãŸã§ã® 80 幎éã«ãããŠããã¡ããµãŒã«ã®å»çã
ã¹ããè¡ãªãããããšã¯åã³ãªãã£ãã®ã§ãïŒ ïŒV. Williams [124]
ããŠã㯠1992 幎ãç¬çšã¯ã¯ãã³ã«ã¯ãã¡ããµãŒã«ãå
¥ããªãããã«åãæ±ºããŠããŸ
ããã人éã®åäŸéçšã®ã¯ã¯ãã³ã«ã¯ãã®ãŸãŸå
¥ããŠããããšããæ¹éã«ã¯ãšã£ãŠãçå
ãæããŸãããïŒ[124]誰ããããã«ã€ããŠèª¬æããŠãããªãã§ããããïŒ
å®éã«ãä¹³å
ã«äžããããæ°Žéã®éã¯ã©ãããããïŒ
1999 幎çJournaloftheAmericanMedicalAssociationèªã®ããèšäºã«ãèšå®ãšã
ãŠãå®å
šãªãæ°Žéæåã®èš±å®¹é㯠0.1mcg/kg/day ã ãšèŒã£ãŠããŸããã[187](Halsey)ãã
ã¯ã€ãŸãã1æ¥ã®èš±å®¹éãäœé1kgããã0.1ãã€ã¯ãã°ã©ã ã ãšããããšã§ããããã§ã¯ã
2005 幎ãŸã§ã«ã¢ã¡ãªã«ã®åäŸéã®è¡æ¶²ã«å®éã©ããããã®éãæ³šå
¥ãããŠããã®ãããå®
å
šèš±å®¹éã«ç
§ããåããã衚ãèŠãŠã¿ãŸããããããã¯ïŒŠïŒ€ïŒ¡ãèšèŒããŠãã衚ã§ãã
çãŸããæ¥ïŒ ïŒ¢åèç ïŒ æ°Žé 12 mcg å®å
šèš±å®¹éã® 30 å
çåŸ 4 ã¶æïŒ ïŒ€ïŒ°ïŒŽäžç𮿷·åãš HiB ïŒ æ°Žé 50mcg
å®å
šèš±å®¹éã® 60 å
çåŸ 6 ã¶æïŒ Båèçãšããªãª ïŒ æ°Žé62.5mcg
å®å
šèš±å®¹éã® 78 å
– FDA Centre for Evaluation and Biologics Research [293]
ããã§æ³šæããªããã°ãããªãã®ã¯ããã®ïŒ¥ïŒ°ïŒ¡èšå®ã®å¯Ÿè±¡ãšãªã£ãŠããã®ãæµ·ã®éã«å«
ãŸããæ°Žéãäœæž©èšãå£ãããã®ãªã©ã®ãç¡æ©è³ªãªæ°Žéã§ããããšã§ããããã«ãããã¯
倧人ã®å®å
šèš±å®¹éã§ããããšãå¿ããªãã§äžããã
ããã«å¯ŸããŠãã¯ã¯ãã³å
ã®ãã¡ããµãŒã«ã¯ææ©è³ªã®æ°Žéã§ãããç¡æ©è³ªãããé¥ãã«å€§
ããªå±å®³ã人éã®çްèèã«äžãããã®ã§ããç¹ã«è³çްèã¯ã²ã©ã被害ãåããŸãã[296]
ãããŠãããããã¯ã¯ãã³ãåããã®ã¯ãä¹³å
ãã¡ã§ãã
ã§ã¯ 2005 幎以åãäžäœã©ãã ã蚱容ç¯å²ãè¶
ããéã®æ°ŽéãæåããŠããã®ã§ãããïŒ
ãâŠåè¡åœã®åäŸéããåäŸæä»£ã®äºé²æ¥çš®ã«ãã£ãŠæåããæ°Žéã®éã¯ãåè¡åœïŒ¥ïŒ°ïŒ¡
å®å
šã¬ã€ãã©ã€ã³ã®èšå®ãã 1 æ¥ã®æå€§èš±å®¹éãšæ¯èŒããçµæãããããã®å¹Žéœ¢ããšã«èš±
容éã® 11 åïœ150 åã§ããã – Geier [77]
ãªããããªããšã«ãªã£ãã®ãã¯ã2003 幎ã®AAPSJournalèªã®èšäºã§åãããŸãã
ãâŠã¯ã¯ãã³ã«å«ãŸããæ°Žéã¯ãå£ããå
¥ãã代ããã«æ³šå°ã«ãã£ãŠæåãããšãæåé
ãããã«ã²ã©ããªã… ããºãå®éšã«ãããŠãç°ç©ãæ··å
¥ããéã®ãã®æµžééã¯âŠçµå£ã®å Ž
åã«æ¯ã¹ãŠæ³šå°ããå Žåã«ã¯ãäœå
åšå®ã«ãããŠæ¡éãã®æ¿ãã§ãã£ããã[77]
æ¡éãïŒããã£ãŠãäœåãäœçŸãäœâŠåãã®å·®ããã£ããšããããšã§ãããïŒ
æ°Žéãšèªéçã®é¢é£æ§ã瀺ãããŒã¿
æ°Žéãšèªéçã®é¢é£æ§ã«èšŒæ ããªããªã©ãšæžããŠããèšè
éã¯ããã ã®ãã¿ã©ã¡å±ã§ãã
ãªãã£ãŠã2003 幎æ¥çã®JournalofAmericanPhysiciansandSurgeonsèªã«ã¯ãæ°Žéãš
èªéçãé¢é£ä»ãã衚ãã¡ãããšèŒã£ãŠããã®ã§ãããã[77]
ãã®è¡šãèªãã®ã«ãç¹å¥é£ããããšãªããŠãããŸãããïŒæããã«ãæ°Žéã®éã«æ¯äŸããŠ
èªéçãå¢ããŠããŸãã
2004 幎 2 æ 9 æ¥ã«ãIoM å»åŠæ©é¢é£ã«åãããã©ããã¹ããªãŒããã«ããç ç©¶çºè¡šããã
ãŸããããããã«ã¯ä»¥äžã®ããã«ç€ºãããŠããŸããã
ãåäŸæä»£ã®ãã¡ããµãŒã«å
¥ãã¯ã¯ãã³æ¥çš®ã«ããæ°Žéæåéã®å¢å ã¯ãåäŸéã®ç¥çµçº
éé害ãšçŽæ¥ã«é¢é£ããŠããã[67]
蚌æ ããŒã¿ãäœãã«ãåšããããããããªã®ã§ããã®ç ç©¶ã¯ä»¥äžã®ããã«ãŸãšããããŠã
ãŸãã
ããã¹ãŠã®çç©çãªè£œåããããã ã¡ã«æ°Žéãæé€ãã¹ãã§ãããã
ããã¯ãã£ãããã®ãŸãŸãã1999幎ã«è£œè¬æ¥çã«ãã¡ããµãŒã«ãå
¥ããªãããã«ãé Œ
ãã ãéã«èšã£ãã»ãªãã§ããããŸããCDC ãšAPA ããã®ãæšå¥šãã«å
±é³ŽããŠããŸããã
[88]ãããŸã§ãããé Œãã ãã ãã§ãã
ããã©çµå±ãã¡ããµãŒã«ãçŠæ¢ãããããšã¯ãªãããããããçŠæ¢ãããèŠèŸŒã¿ã¯ãªãã§
ãããã
è¡æ¶²è³é¢é
äœå
ãæµããè¡æ¶²ã¯ãè³ã«ãæµããŠãããŸããããããè³ã¯ç¬ç¹ãªç°å¢æ¡ä»¶ãå¿
èŠã§ãã
ãããè³çްèãè¡æ¶²äžã®å
šãŠã®æåã«èªç±ã«æ¥è§Šããããšã¯åºæ¥ãªãããã«ãªã£ãŠããŸãã
ç§éã¯ææ¥æã«ãããŠãããããäœã®ãµãã€ãã«æ©èœãçºéãããŠã決ããããæåã®ã¿
ãè³ãšçŽæ¥æ¥è§Šã§ãããããªã¡ã«ããºã ã身ã«ä»ããŠãããŸãããã®éžæçãªåžåããã»
ã¹ã¯ãè¡æ¶²è³é¢éãšåŒã°ããŠããŸãã(Guyton p788)[189]
è³ã«è¿ã¥ãããšã®åºæ¥ãªãæå®³ãªååããå»è
ã®éã§ã¯ç¥çµæ¯ãšåŒãã§ããŸããããã¯ã
ããããæåãè³çްèãæ®ºããŠããŸããšããæå³ã§ããç¥çµæ¯ã® 1 éšãšããŠã次ã®ãããª
ãã®ãæããããŸãã
ã¢ã«ãäºãŠã
æ°Žé
ã¢ã¹ãã«ããŒã ïŒäººå£ã®ç峿ïŒ
ïŒïŒ³ïŒ§ïŒèª¿å³æãªã©ã«å«ãŸããïŒ
ãã«ã ã¢ã«ããã
– Excitotoxins , The Crazy Makers [262]
乳幌å
ã«ãšã£ãŠã¯ã¯ãã³ãæå®³ã§ããæå€§ã®çç±ã¯ãã¯ã¯ãã³ã®æ·»å ç©ã«ããããç¥çµæ¯
ãå«ãŸããŠããŠããããçºè²éäžã®è³çްèèã«äžããæªåœ±é¿ã倧ããããšã§ããäžéãªã
ãšã«ãçãŸãããŠã®èµ€ã¡ããã«ã¯è¡æ¶²è³é¢éããããŸããã(Blaylock,p.71)[262]è¡æ¶²è³é¢
éã¯ã倧人ã«ãªãããšããããåºæ¥äžããã®ã§ãããããã¯ã¯ãã³æ¥çš®ã§ã¯ãæ°Žéãã¢ã«
ããã¢ã ããã«ã ã¢ã«ãããã®ãããªæ·»å ç©ã¯ãè³ã«çŽæ¥ã¢ã¯ã»ã¹åºæ¥ãŠããŸããŸããã
ã®ãããªç¥çµæ¯ã®å¯äœçšãšããŠã¯ã次ã®äºã€ãèããããŸãã
ïŒæ¢åã®è³çްèãæ®ºããŠããŸãããš
ïŒããšãªã³ãšè³å
æ
å ±ç¶²ã®çºéã劚害ããŠããŸãããš
è³å
æ
å ±ç¶²ãããã¯ã€ãŸãè³ã®åŠç¿èœåãé¢ãã£ãŠããŸããç©äºã®é¢é£ä»ããããèœåã
ããã°æ°ããããŒããã©ã€ããããã°ã©ã ããèœåãå±éºã«ãããããèš³ã§ãã
ïœïŒãã¬ã€ããã¯ã¯ç¥çµæ¯ã®åœ±é¿ããããã«ã§ã¯ãªãæãçµãŠããçŸããçç±ã«ã€ããŠã
ãã説æããŠããŸãã
ãâŠè³ã®ããããã®å°éæ©èœãèµ·åãå§ããã¿ã€ãã³ã°ã«ãããã®ã ãã
(p.71[262])
äŸãã°èµ€ã¡ãããæ©ããããã«ãªãããã«å¿
èŠãªè³ã®é åãçºè©±ãåŠç¿ã«é¢ããé åãªã©ã
ãããã®éšåããã¡ãŒãžãåããå Žåã«ã¯ãäœå¹Žãåé¡ãæããã«ãªããªãããšããããŸ
ããåŸã«ãªã£ãŠãããããèœåã«é害ãããããšãããã£ãæç¹ã§ã¯ãå»è
ã®æ¹ã¯æè¿ã«
äœããã£ãã®ãã©ããã ããã調ã¹ãŸãããããã§ã¯ãããé
ãããã®ã§ãã害ã¯ãã§ã«
ãªãããäºã¯çµãã£ãŠããŸã£ãŠããã®ã§ãããã
å€åœäºæ
ãã·ã¢ããã³ããŒã¯ããªãŒã¹ããªã¢ãã€ã®ãªã¹ãæ¥æ¬ãã¹ã«ã³ãžããã¢ã§ã¯ãã¯ã¯ãã³ã«
ã·ã¡ããŒãµã«ãå
¥ããããšã¯20 幎åã«çŠæ¢ãããŠããŸããã©ãããå€åœã§ã¯ã¢ã¡ãªã«ã»ã©ã
åäŸã®å¥åº·ã«ç¡é¢å¿ã§ã¯ãªãããã§ãã
èªéçã«å¯Ÿãããè°äŒã®èŠè§£
è¡æ¿æ¹é©äžé¢å§å¡äŒã¯ 2000幎以æ¥ããã£ãšèªéçã«çç®ããŠããŸããããã³ã»ããŒãã³ã®
ææ®ã®äžã§ãããããã€ãã®éããã ã®ããŸããããšããããã§ã¯ãããŸããããªãã£ãŠã
圌ã®å«ãèªéçã«ããã£ãŠããŸã£ãããã§ãã
ãã³ã»ããŒãã³ã«ããèŽèäŒã®å§ãã®èšèã¯ã次ã®éãã§ãã
ãFDA ãè°äŒã®çŸ©åã«ã®ã£ãšã£ãŠã補è¬åã«å«ãŸãããã¡ããµãŒã«ã調æ»ããŠããå
ã«ã
ã®å¥šå±åºæºã«åŸã£ãŠåäŸéã«ã¯ã¯ãã³æ¥çš®ã宿œããå Žåãåè¡åœå
ã§ 1 æ¥ã« 8000
人ãã®åäŸãåœã®ã¬ã€ãã©ã€ã³ã®å®å
šåºæºãè¶
ããéã®æ°Žéãæåããããšã«ãªããšå€æ
ããŸãããæ°Žéãšããæ¯ã®ããããæåç¶æ³ãšãèªéçã®æµè¡ã¯é¢ä¿ããŠããã§ããããïŒ
ã[114]
ãã®èŽè¬ã®å
å®¹ãæŽã«è©³ããç¥ãããæ¹ã¯ãã©ã€ãã»ãããŒã§ãèŠãããŠããŸããïŒã»ãã
ãŒã¯ããã®æ¬ãææãšããå
容ã§ããïŒ
éºäŒåã§ãç
ã«å·»ã
ãŸã è¬ãå¯ŸåŠæ³ãåºãŠããªãç
æ°ã«ã€ããŠè©±ãéã«ãäž»æµã®ã¡ãã£ã¢åã³ç§åŠçãããã«
ãéºäŒåããšããèšèã䜿ã£ãŠããããèŠãŠã¿ãŸããããç
æ°ã®æ²»çæ³ã ãšèšã£ãŠéå²ã
ãåºæ¥ãªãã®ã§ãããã§ã¯ããããç
æ°ã¯ãéºäŒåã®ãç
æ°ãã€ãŸãç
æ°ã®åå ã¯æ£è
ãš
ç¡é¢ä¿ã®ãäºæ³äžå¯èœã§æã«è² ããªãäœãã§ãããšããããšã«ããŠããèš³ã§ãã
èªéçãããã®åºåã«å
¥ããããŠããŸããèªéçãæ²»ãè¬ããŸã ãªãããããã£ãšéºäŒå
ã®ç
æ°ã«éããªãããšããã®ã§ãã
ããããŠã¿å·ç«å€§åŠã® V.ã·ã³ã°å士ã¯ãèªéçã®æµè¡ãéºäŒåã®ç
æ°ã§ã¯ããããªãçç±
ããæ¬¡ã®ããã«èª¬æããŠããŸããèªéçã«ããã£ãåäŸéã¯ã2æ³ã«ãªããŸã§ã¯æ£åžžã§ãã£
ããããããã®åŸãè³ã«èªéçãšããé§ãç«ã¡ãããäžçæ²»ããªããªã£ãŠããŸãã人ã
ã®
éã«éºäŒåé¢é£ã®åºæ¥äºãèµ·ããéã«ã¯ããããªåœ¢ã§ã¯èµ·ãããªãã[111]
次ã¯ã1993 幎ãã 2006幎ã®éã«ãèªéçãæ¥æ¿ãªå¢ãã§å¢ãç¶ããããšã«é¢ããŠãã§ãã
[26]ããã¯ãéºäŒåã®å€åã«ããŠã¯æ©éããŸããéå£äººå£ã«ãããŠãéºäŒåé害ã人ã
ã®é
èŠãããããã«ãªãã«ã¯ã9 幎éããããã£ãšé·ãæéããããã®ã§ããéºäŒåæ§ã®å€åã¯ã
æ©ããã®ã§ãïŒïŒ
å¢ããã®ã« 100 幎以äžããããŸãããã9 幎ã§714ïŒ
å¢ããããšã¯ããã
ãŸãããïŒ Geier[59]ïŒæåŸã«ãéºäŒåã®ç
æ°ã®å€§æµè¡ãšãããã®ã¯ããã®äžã«ååšããŸããã
ïŒYazbak[84]ïŒ
èªéçã¯ãéå» 20 幎ã«ãããŠçªç¶ã©ããããçŸããç
æ°ã§ããéºäŒåæ§ã ãªã©ãšèšã£ãŠã
ããç°¡åã«çä»ããŠããŸãããã®ã§ã¯ãããŸããããããªèŠãéããããŸããã«ãåŒã£ã
ãããªãããã«æ°ãä»ããŠãã ããã
宿²»äžå¯èœãªé害
ä»®ã«ææ¥ãèªéçã®åå ã蚌æãããåé¡ã®ç©è³ªãæ ¹ãããçŠæ¢ãããšããŠãããã®åœã«
ãããèªéçã®å·è·¡ã¯ããã®åŸäœå幎éãç¶ãããšã§ããããããŒãã³ãèšã£ãŠããŸããã
èªéçã¯ããããªã«ç°¡åã«è§£æ±ºãããã®ã§ã¯ãªãã®ã§ãã
ãã®å
äœå¹Žãã®éãèªéçå
ã®èŠªéã¯èŠãã¿ç¶ããç§éã®ç€ŸäŒã¯äœå
ãã«ãã®è² æ
ãè² ã
矜ç®ã«ãªãã®ã§ããééäžã®åé¡ã ãã§ã¯ãªããéå²ããããŠããåŽã¯èªéçã®æ¬åœã®å
å ãç ç©¶ãããªãããã«æãå°œããã§ããããããæ¯å¹Žæ¯å¹Žãäœå人ãã®è¢«å®³è
ãå¢ãç¶
ããããšã«ãªããŸãã
ããããç
æ°ãšããã®æ²»çè¬ã調æ»ããŠã³ã³ãããŒã«ãã圹ç®ã¯ãFDAãNIH åã³ CDC
ãšããæ¿åºæ©é¢ãæ
ã£ãŠããŸããããããã®æ©é¢ã®åœ¹å¡éã¯ãèªåéã®ããã¹ã®æ¥çžŸã°ã
ãæ°ã«ããŠå®éã«ã¯ãã¡ããšããä»äºãããªã人ã°ã£ããã§ãããã£ãšå
·äœçã«èšããšã
圌ãã®å°éåéã¯ã¢ã¡ãªã«åœæ°ã®å¥åº·ãå®ãããšã«ããã¯ããªã®ã«ã倧æµã¯å¥åº·ãããæ¿
çãééã§ç©äºã決ããããŠããŸãã®ã§ããèªéçã®æ¬åœã®åå ã調ã¹ãç ç©¶ãè¡ãªãã
ãããšã«å¯ŸããŠããããã®æ©é¢ã¯çããã£ãŠå察ãã黿¢ããããšåãå°œãããŠããŸãã
HHS æ©é¢ããåãããšã§ãã2002 幎 12 æ 10 æ¥ã®è°äŒã§ããã³ã»ããŒãã³ã¯ä»¥äžã®ãã
ã« HHS ãæ¹å€ããŠããŸãã[108]
ãã¯ã¯ãã³ãšèªéçã«äœããã®é¢é£æ§ãããå¯èœæ§ã«ã€ããŠãHHS ã®åœ¹äººéã¯æ¿ããåŠå®
ãããŸããã圌ãã¯ãããŸã ç§åŠçã«è§£æãããŠããªããã®èª²é¡ã«å¯Ÿããåæã«ïŒã€ã®è
ããçããšããŠæŒãä»ãããã£ã³ããŒã³ãè¡ããŸãããããã®ããã§åœæ°ã®ä¿¡çšâŠã¯ã¯ã
ã³ã®å®å
šæ§ãšäºé²æ¥çš®ã®æ®åãæ
åœããŠãããçŠç¥æ©é¢ã®åœ¹äººéãžã®ä¿¡çšã¯ããèœã¡ã«ãª
ã£ãŠããŸããŸãããã
ãã¡ããµãŒã«ã«é¢ãã HHS ã®ä¿ç®¡ææžã«ããã°ãã âŠæåããå Žåã®çç¶ãšããŠã¯ãåäŸ
éã®ç²Ÿç¥çºéé害ãè©±ãæ¹ãæžãæ¹ãžã®äžå
·åãæ©è¡é害ãæèã®æ··æ¿ãè奮æ§ãæªåã
ãã°é¯ä¹±ç¶æ
ã«é¥ãççªããªã©ãããããšæžããŠãããŸãã[146]
ããã£ãŠãèªéçã®çç¶ã ãšæããŸãããïŒ
æŽã«ã²ã©ãããšã«ãããããæ¿åºæ©é¢ã¯ãèªéçã®æµè¡ã®çå®ãçªãæ¢ããããšèª°ã®æŽå©
ãåããã«é 匵ã£ãŠããããããªç ç©¶è
éããã²ã£ãããªãã«æ»æããŠããŸããæããã
è£œè¬æ¥çãªããŠãããã®ã¯ããã£ãã«ç
æ°ã®æ¬åœã®åå ãçªãæ¢ããããšã¯ããŠããŸãã
ã§ããã圌ãã®é¢å¿äºã¯ãç
æ°ã®æ²»çæ³ããããšãã£ãŠè¬ã宣äŒããããšã§ãããããã
å¹ããå¹ããªããã¯é¢ä¿ãªãã®ã§ãããªããªããããã¯ãéå²ãã®åé¡ãªã®ã§ãããã
å°ããèããŠã¿ãŠäžãããããæ¬åœã«ãèªéçã®äž»ãªåå ãã¯ã¯ãã³ã«ãããšãããïŒ
ãããªããšã誰ãç§éã«æããŠãããã§ãããïŒãªããšèšã£ãŠããã¯ã¯ãã³ã¯å»åŠçã®è
ãªãååšãªã®ã§ããããã¯ã¯ãã³ã®ãé°ã§ã人ã
ã¯äžçè¬ã«é Œããªããã°çããŠãããªã
ãªãã®ã§ãããããããªã¯ã¯ãã³ãæ¹å€ããããæªå£ããã£ããããã®ã¯ãã£ãŠã®ã»ãã§
ããç§åŠçãªå»åŠã®èªãã§ããã¯ã¯ãã³ããç
æ°ã®åå ã«ãªããªããŠããããŸããïŒãšã
ãããšã§ãããããªçåã¯æã£ãŠããããªãããèããŠããããªã質åãªã®ã§ããã¢ã¡ãª
ã«ã®ç§åŠã¯ãã¯ããå®å
šã«çµæžã®æ¯é
åã«çœ®ãããŠããŸããã©ã®è£œè¬äŒç€Ÿãããæè³ããŠã
ããæ ªäž»ã«ãå©çãè¿ãããšãã第äžçŸ©çã«éèŠã ãšè¿°ã¹ãŠããŸãããããªç¶æ³ã«ãããŠ
ã¯ãçã®ç§åŠççºèŠã¯ã倧ããªé害ãåããããšã«ãªããŸãã
ãšããã®èŠªåã®åœä»€
2004 幎 4 æ 4 æ¥åè¡ã®LATimesèªã®ããã³ãããŒãžã«ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«å«ãŸ
ããæ°Žéæåã«ã€ããŠããããèšäºãæ²èŒãããŠããŸããã[56]ãã®ã床èãæããããã
ãééãã ããã§ãã¡ããã¡ããªèšäºãèªãã§ãããã¡ã«ãæ°Žéæåãå«ãŸãªãæ°çš®ã®ã€
ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãéçºãããããšãããããŸãããã§ããCDC ã¯ãã®ã¯ã¯ãã³ã®æš
å¥šãæžã£ãŠããŸããã©ãããŠã ãšæããŸããïŒããããããšã«ãçŸåšåºåã£ãŠãããæ°Žé
å
¥ãã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®å£²ãäžããæããã®ã§ãïŒãªã«ããäœçŸåæ°åãã®åšåº«
ãæ®ã£ãŠããã®ã§ããããåœæ°ãäŒæç
ããå®ãããã®æ¿åºæ©é¢ããäžäœäœãåªå
ããŠã
ãã®ã§ããããâŠã
Dr.ããŒã¬ã€ã«ããããã¡ããµãŒã«è«
UK ã®ååŠçã®äŒé·ã§ãããã€ãã»ããŒã¬ã€å士ã¯ããã¡ããµãŒã«ã®ææ¯æ§ã®ç ç©¶ã«ãããŠ
ééããªãäžçã§æå
端ãè¡ãå°éå®¶ã§ããã圌ãé·å¹Žãã®åéã§ç ç©¶ãéããçµæåºã
ãçµè«ããããã€ãæããŠã¿ãŸãããã
ããã¡ããµãŒã«ã«å¯ŸããççåŠçåå¿ã¯éåžžã«åçã§ãããå§åãããŠããŸããã®ã§ãã
ãã¡ããµãŒã«ãèªéçã®åå ãšããŠæãå¯èœæ§ãé«ããšããããšãåŠå®ãã人ã¯ããšãŠã
æãã§ãããããããã¯èªåã®ç ç©¶çµæãçè§£ãããããã®èœåã¯ãã£ãŠãéåžžã«äžæ£çŽ
ã§ããããã©ã¡ããã§ããããã
ããã¡ããµãŒã«ãå®å
šã ãšèšŒæããç ç©¶ãªã©ãåãããäžå¯èœã§ãããããããããã¡ã
ãµãŒã«ãšããã®ã¯ææ¯ãªã®ã§ããããåç©ã«ãã¡ããµãŒã«ã泚å°ãããšãè³ãç
æ°ã«ãªã
ãŸããçãã现èèã«æ¥çš®ãããšã现èã¯æ»ãã§ããŸããŸãããããªç¿ã«å
¥ãããšãäžã®
掻æ§èã¯æ»ãã§ããŸããŸãããããªç©ãä¹³å
ã«æ³šå°ããŠé害ãèµ·ããªãã£ããããã®æ¹ã
é©ãã§ããã[95]
ãäœé 6 ãã³ãã®æ°çå
ã«ã¯ã¯ãã³æ¥çš®ã 1åããããšã¯ãäœé 180 ãã³ãã®æäººã«30 å
åãã®ã¯ã¯ãã³ãåãæ¥ã«ãŸãšããŠæ¥çš®ããã®ã«çãããã
ããã§ããã¡ããµãŒã«ãååšããçç±
2004 幎 4 æ 2 æ¥ãïŒïŒïŒïŒãšããæ³æ¡ãè°äŒã§æ±ºãŸããŸãã[34]ã2006幎ãŸã§ã«ã¯ã¯
ãã³ããå
šãŠã®æ°Žéæåã®æ³šå
¥ãçŠæ¢ãããšããæ³æ¡ã§ããããã¯åãªã宣äŒè¡çºã§ãä»
ãšãªã£ãŠã¯ããã ã®è£è¶³çãªè¡çºã«éããªãã§ãããã
ãã㊠2005 幎ã«ã¯ãäœç€Ÿãã®è£œè¬äŒç€Ÿãããããããã匵ãè©°ããå£èª¿ã§ã¯ã¯ãã³ããã
ã¡ããµãŒã«ãç¡ããããã«ãšãã䞻匵ããããããã«ãªããŸãããæ°Žéãææ¯ç©è³ªã§ããã
ä¿åå€ãšããŠäœ¿çšããã®ã¯äžå¯èœã ãšããããšããç§åŠçã«ã¿ãŠããã¯ãæããã§ãããã
äžéã®æ³šç®åºŠãæ¹å€ã®å£°ãå¢ããŠããŠããããã¢ã¡ãªã«äžè¬äººããŒãã£ãšããŠãããããš
ãã£ãŠããã®åé¡ã«æ°ä»ããããã«ãªã£ãããã§ãã(Baskin [115])
ãã¡ããµãŒã«ãã²ã©ãå±éºã§ãããèªéçãåŒãèµ·ããå¯èœæ§ããããšããããšã¯ããã®
80 幎ãã®éãç§åŠçãªèšŒæ ã«ãã£ãŠèšŒæãããŠããŸãããããã§ä»ã補è¬äŒç€Ÿãã¡ã¯ãã¯
ã¯ãã³ã«å
¥ãããã¡ããµãŒã«ãæäœéã®éã«æžãããããããã¯å
šãå
¥ããªããæ¯ããã
ãããšã«ããã®ã§ãã[16]ã€ãŸãããã¡ããµãŒã«ãå±éºã ããšããèŠè§£ã«å¯ŸããŠããã¯ãã
æã
ã¯ãã¡ããµãŒã«ãæ¢ããŸãããã倧äžå€«ã§ããããšæ°ããåãä¿¡ã蟌ãŸãããšããã
ãæ±ºãŸãã®è§£æ±ºæ³ã䜿ã£ãããã§ãã
ãããªããã§ãã®æ°å¹Žéãšãããã®ãã¡ãã£ã¢ã¯çå£ãæããŠããã¡ããµãŒã«ã®å±éºãã
人ã
ããã£ãšè§£æŸããããã ãšãããã¡ããµãŒã«ã®å±éºæ§ã«ã€ããŠã¯çç¥ãããŠããã察
åŠãé²ãã§ããããªã©ãšå®£äŒããŠããŸãã
ãã®åã¯ããŸãã«ã培åºããŠåºããããã®ã§ãæå¥ã®æãŠã«ã¯ãäž»æµã®ã¡ãã£ã¢ãå°å
ç§
å»ã®å€ããããã®æ°å¹Žéäžã®èŠªãã¡ã«åã£ãŠããã¯ãã¯ã¯ãã³ã«ã¯ãã¡ããµãŒã«ãå«ãŸã
ãŠããŸããããšééã£ãæ
å ±ãäŒããŠããŸããããã«ãªããŸãããçŸåšãäžã®äžã®å€§éšå
ã®äººãããã¯ããã¡ããµãŒã«ãåé¡èŠããå¿
èŠã¯ãªããªã£ããšèããããã«ãªã£ãã®ã¯ã
ããããèš³ã§ãã
ã§ã¯çŸåšãã©ãäœã®éã®æ°Žéãã¯ã¯ãã³ã«å«ãŸããŠããã®ãïŒ
倧è¡çãªå ±éãåçš®æ¿åºã®å ±åæžã«ã¯ãããŸã ã«æ¬¡ã
ãšãã¯ã¯ãã³ã«å«ãŸãããã¡ããµãŒ
ã«ã®éãæžã£ããšããèšäºãæžãããŠããŸãããã§ã¯å®éã«çŸåšã®ã¯ã¯ãã³ã«èš±å¯ãããŠ
ãããã¡ããµãŒã«ã®éã¯ãšãããšâŠãã¡ããµãŒã«ã«é¢ããã®ãŠã§ãããŒãžã®äžçªäž
ã®è¡šã«é ããããã«ããŠãã瀺ãããŠããŸãã
DTaP 0.3mcg
DT 25mcg
Td 8.3mcg
TT 25mcg
B åèç 1mcg
A åèç 1mcg
ã€ã³ãã«ãšã³ã¶ 25mcg
[8]
ããã¯ã2008 幎 3 æ 14 æ¥ã®æç¹ã§ãã
äžäœã©ãããŠã圌ãããã¡ããµãŒã«ã廿¢ãªã©ããã§ããããïŒãã¡ããµãŒã«ãéæ³ãšã
ããããšã¯ 1 床ããªããããããããããªããšã«ã¯ãªããªãã®ã§ããããã¢ã¡ãªã«æ¯ç§å»
åž«äŒæ¯ã®è©°ãç©ã«ã¢ãã«ã¬ã ã䜿çšããããšãçŠæ¢ããªãã®ãšããŸã£ããåãã§ããæ¯ç§
ã«ãšã£ãŠãå»åŠçã«ãšã£ãŠããããããæ¯æ§ç©è³ªã¯å€§é»æ±ãšãããã倧äºãªååšãªã®ã§ã
ãããã¯ãããŸã§ 1 åºŠãæ°Žéã®åé¡ã远åããããšã¯ãããŸããããæ³åŸã§çŠæ¢ã
ããããšããããŸããã1930 幎以æ¥ãã¯ãåœæ°ãç¥çµæ¯ããå®ããããšããèªãã®ä»»
åã 1 床ãæãããŠããªãã®ã§ããæ¬æ¥ãªãã°ïŒŠïŒ€ïŒ¡ãç£èŠããã¯ãã®åŒè·å£«ã補è¬äŒç€Ÿ
å¯ãã®äººéããã®å
åŽã«ããããå±
ãããã§ããã®æ¿åºæ©é¢ããã¡ããµãŒã«ã廿¢
ããããšã¯äžå¯èœãªã®ã§ãã
ããã©ããä»®ã«ä»æ¥ãã¡ããµãŒã«ãçŠæ¢ããããšããŠããç§éã®çããŠããéã«ã¯ããŸã
倧ããªå€åã¯èŠãããªãã§ãããããªããšãã£ãŠããäœå幎åãã®åšåº«ãæ®ã£ãŠããã®ã§
ããããä»ãŸã§ã«ãå£²ãæ®ã£ãã¯ã¯ãã³ã®åšåº«ãåŠåãããããšãªã©ããã£ã詊ãããã
ãŸããããŸããŠããå®éã«ãã¡ããµãŒã«ãçŠæ¢ã§ããã¯ãã¯ãªãã®ã§ããããçŸåš
è¡ãªãããŠããããã«ãããããå
ããã£ãšãåãå
¥ããŠãããã¯ãªããã¯ãããéãã
ãã¡ããµãŒã«å
¥ãã®ã¯ã¯ãã³ã¯å£²ãã䜿ãããŠããã§ãããã1960 幎代ã«äœãããå€ã倩
ç¶çã¯ã¯ãã³ã®å»æ£å¯žåã«ã2002 幎ã®å€©ç¶çéšãã仿ããããããã«ãããããã¯ã¯ã
ã³ã¯æ°žé ã«äœ¿ããç¶ããŠããã®ã§ãã
ããã«ãå€ããªã£ãã¯ã¯ãã³ã¯ãä»ãŸã§ã©ãããã¢ã¡ãªã«åœæ°ã®è¯å¿ã®èšŒããšããŠè²§å°åœ
ã«ãã¬ãŒã³ãããã°ããã§ããâŠã[48]
ã±ããã£ãŒå ±å
ããŠããããã® 80 幎éããã¡ããµãŒã«å¯Ÿçãæ ã£ãŠããããšã¯å
ã»ã©è¿°ã¹ãŸããã
ãã®æ¿åºæ©é¢ãåœæ°ãå®ã£ãããšãªã© 1 床ããããŸããããããŸã ã«åãç¶æ
ã§ãããã®
åœã§ã1 æ¥ã«8000 人以äžã®åäŸéããæ¿åºãå®ããå®å
šèš±å®¹éãã¯ããã«è¶
ããéã®æ°Žé
ãæ¥çš®ããŠããããšãªã©ã㯠90幎代åæãããã£ãšç¥ã£ãŠããã®ã§ãã[114]èªçºç
ã«äœçš®é¡ãã®ã¯ã¯ãã³ã«ã¯ãã¡ããµãŒã«ã䜿ããªãããã«ããŠãã補è¬äŒç€ŸãåºãŠããä»
ã§ãããã¡ããµãŒã«ã¯æ³åŸäžã§ã¯èš±å¯ããããŸãŸã§ãããã®æ¯æ§ã«é¢ããŠãè«å€§ãªéã®ç§
åŠç蚌æ ãããã®ã«ãç
é¢åŽãåžæããã°ãã®æ°Žéå
¥ãã®ã¯ã¯ãã³ã¯å¹Ÿãã§ãæã«å
¥ãã
奜ããªã ãä¹³å
ã«æ¥çš®ããããšãåºæ¥ãã®ã§ãã
ããããäžã2005 幎 6 æã«ãããŒã.F. ã±ããã£ãŒ. Jr.ã«ããã¬ããŒããDeadlyImmunity
ãåºããããããèªãã å€ãã®äººã屿©æãæãå§ããŸããã[48]
ãã®ã¬ããŒãã¯ãå
šç·šããªã³ã©ã€ã³ã§ç°¡åã«èŠãããšãã§ããŸããã±ããã£ãŒã¯ãéå» 15
幎éã«è£œè¬æ¥çã®è¡ãªã£ãæ°ã
ã®æªè¡ã®äžã§ããç¹ã«æªèŸ£ãªäºäŸã®å¹Ÿã€ãã«çŠç¹ãåœãŠãŠ
ããŸãããã®äŸã¯ã以äžã®éãã§ãã
ïŒ 2000 幎ã«ãç§åŠè
ãæ¿æ²»é¢ä¿è
ãç£æ»å§å¡åã³ã¯ã¯ãã³è£œé é¢é£ã®ãåæ¹ãããžã§ãŒ
ãžã¢å·ã®ã·ã³ã ãœã³ãŠããã§ç§å¯äŒåãéããæ°Žéãšèªéçã®é¢é£æ§ã蚌æãããå§åç
ãªæ°ç ç©¶ã«é¢ããŠåè°ããããšã
ïŒ 1991 幎ã«çªç¶ãåèçãšïŒ¢åè¡åç
ãäžç𮿷·åãšããæ°Žéãå«ãã ã¯ã¯ãã³
ã 3 çš®é¡ãä¹³å
ã«æ¥çš®ãããšãæãã§ééã£ã決æãäžããããšã
ïŒ çŽåŸã«ãèªéçã®çºçä»¶æ°ã15 åã«æ¿å¢ããããšã
ïŒ äžçæå
ç«¯ã®æ¯ç©åŠè
ãã¡ãè¡ãªã£ããªãµãŒãã®çµæã90 幎代äžããã«åºåã£ããã¡
ããµãŒã«ãèªéçã®å€§æµè¡ã®åå ã ãšããæ±ºå®çãªèšŒæ ãèŠã€ãã£ãããšã
ïŒ ç§å¯äŒè«ã®åå ã°ã«ãŒãã¯ãã®ãªãµãŒããçºè¡šãããåŸãäŒè°ã®æ®ãæéããåœæ°ã«
ããããæ°ãã屿©ã«ã€ããŠããã«èŠåãããããã§ã¯ãªãããã®èšŒæ ãã©ããã£ãŠé æ»
ã
ãããã«ã€ããŠã®è©±ãåãã«è²»ãããããšã
ïŒ ãã®ãžã§ãŒãžã¢äŒè°ã«ãããWHOã®ä»£è¡šè
ããã®ã³ã¡ã³ãïŒãããããããã®ãªãµãŒ
ãã¯ã宿œãããã¹ãã§ã¯ãªãã£ãã®ã ãããã
ãã®äŒè°ã«ãããå
·äœçãªçµè«ïŒCDC ããã®ãªãµãŒãçµæã®å¯Ÿçãšã㊠IOM ã«æ°ããç
ç©¶ãã³ããã·ã§ã³ãããã®ç ç©¶ã¯2004幎ã«å®æããã
ãã®æ°ç ç©¶ã«ãã£ãŠçºèŠãããé©ãã¹ãçµæã®æ°ã
ã¯ãæå³çã«å
å¯ã«ãããããã«ã¯æ
å ±å
¬éã®åé¿ã®ããã«ãåäººäŒæ¥ã§ãã AHIP 瀟ã«å§è²ãããŠããŸããŸããã[48]
ãã¡ããµãŒã«ã«ã€ããŠãIOMãç ç©¶
åœç«ç§åŠã¢ã«ãããŒã«æå±ãã IOM ã¯ãDC ã®äŸé Œãåãããã¡ããµãŒã«ãžã®æ¹å€ã«å¯Ÿ
ããŠæ±ºå®çã«ãããã€ããããšã2004 幎 2 æ 9 æ¥ã«äŒåãéããŸããã圌ãã¯äžçã§å
端
ãè¡ãç¥çµæ¯åŠå°éã®ç§åŠè
ã13 åã¯ã·ã³ãã³ã«æããŠãèªéçãšãã¡ããµãŒã«ã®é¢é£æ§
ã«ã€ããŠã®ããŒã¿ãåèªå ±åããããã«èšããŸããããã ãã圌ãã®ãã¹ã±ãžã¥ãŒã«ãè©°
ãŸã£ãŠããŸãã®ã§ããIOMã¯åèªã®æã¡æéã20 åã«å¶éããŸããã
ãã®äŒåã®è°äºé²é³ã¯ IOMã®ãŠã§ããµã€ãã§èŽãããšãåºæ¥ãŸããããããèŽãã人ã«ã¯
æ¿åºåŽã®æ¬åœã®èŠè§£ãèŠããŠããã§ããããæãããç§åŠè
ã¯æ¬¡ã
ã«ãåèªãäœå¹Žãç¶ã
ãŠããç ç©¶ã®ææããèŠäºã«20 åéãšããå¶éæéå
ã«ãŸãšããŠçºè¡šããŠããŠããããèŽ
ãã°ã¯ã¯ãã³ãå«ãæ°Žéæåãšè³é害ã®åå ãé¢é£ããŠããããšã¯ãã©ããªã«çããæã£
ãŠãã人ã§ãçŽåŸããã«ã¯ããããªããè°è«ã®äœå°ããªãããšã ãšããããšãåãããŸãã
ãã®ããã«çãäœå°ããªãç§åŠçæ ¹æ ãå±±ã»ã©ããã®ã«ãäžäœã©ãããŠã蚌æ ããªãããª
ããŠããæ±ºãŸãæå¥ã䜿ãç¶ããããšãåºæ¥ãã®ã§ãããïŒããã«ã¯ããã¡ããµãŒã«ãèª
éçã«éãããå
šãŠã®ç¥çµæ§é害ãšé¢é£ããŠãããšããèšåºäžã®èšŒæ ãæ¬¡ã
ãšäžŠã¹ãããŠ
ããã®ã§ãããã
ãããã㪠IMO
ãé¢é£æ§ã®èšŒæ ãããæ¶ããããã®éãŸãã«ãããŠããã®åœæ¥å ±åããã蚌æ ã®æ°ã
ãé
ã«é¢é£æ§ãè£ä»ãããã®ã ã£ãããšã«é©ãçŠã£ã IMOã¯ãããŸããæ³ãšããŠãèªéçãšã
ã¡ããµãŒã«ã®é¢é£æ§ãè£ä»ãã蚌æ ã¯ãŸã ååšããªãããšæ£åŒçºè¡šãè¡ãªã£ãŠããŸããã
ããããäŸé Œãè«ããŠãããããšãã£ãŠã[48]ããããªä¹±æŽãªåã«ã¯é©ããŠããŸããŸ
ãããã
ããã©ããã£ãšãããããªã®ã¯ããã®åŸããã«ãç§åŠçã«ãšã£ãŠé©ç°çãªäœçœ®ã«ããïŒïŒïŒIMO
ãããã® 1 ä»¶ã®èª¿æ»ãæã¡åããšãïŒïŒïŒãã®ä»¶ã«ãããŠäžåã®ç ç©¶ãç¶ããªãããã«æšå¥š
çºè¡šãè¡ãªã£ããããšã§ãïŒïŒïŒ[48]
åœæ¥ã®äŒè°ã«ããã蚌èšã®ãŸãšããšããŠããã£ãšãè¯å¿çã ã£ãã®ã¯éºäŒååŠäŒã®éé®ã§
ããããŒã¯ã»ã²ã€ã€ãŒMD PhD ã«ãããã®ã§ãããã
ããã®ä»¶ã¯ããã以äžç¡ããšèšã£ãŠããã»ã©èšŒæ ãæãããªäžä»¶ã§ãããããããã¯ã¯ã
ã³ããã°ã©ã ãå®ãããã«èšŒæ ã®ããŸããè¡çºãè¡ãããŠãããä»®ã«ãèªéçã®åå ãã
ã¡ããµãŒã«ã§ãããšçŽåŸã§ããªãã®ã§ããã°ã10 åã20 åãã«äœ¿ã£ãŠèªéçã®åå ãæ¢ã
åºãã¹ãã§ãããããããã誰ããããªããšã¯ããŠããªããã[59]
ã¢ãŒããã·ã¥ã®èªéçå
ç«¥
ããã¯ãèšåºè©Šéšã®åºæºãšãªãæ¹æ³ã§ããããã調æ»ç±å¿ãªãžã£ãŒããªã¹ãããæ¡ä»¶ãã³
ã³ãããŒã«ãã察象éå£ã«ãããŠãèªéçãšã¯ã¯ãã³ã®é¢é£æ§ã審æ»ããŠã¿ãããšæãã€
ããŸãããUPI ã®ãã³ã»ãªã«ã ã¹ãããã¯ããã³ã·ã«ããã¢å·ã®ã¢ãŒããã·ã¥ã®äººã
ãã
ã¯ã¯ãã³æ¥çš®ãåããŠããªããšããããšãç¥ã£ãã®ã§ããåè¡åœã®å¹³åãããããšãã¢ãŒ
ããã·ã¥ã®äººã
ã¯ããã®äººå£ã®ãã¡130 人ãèªéç眹æ£ã®ã¯ãã§ãããšããããå®éã«ã¯ã
眹æ£è
ã¯ãã£ãã® 4 人ã§ããã®å
3 人ãã¯ã¯ãã³æ¥çš®ãåããŠããŸããïŒïŒïŒ4 人ç®ã¯ãç
掻ç°å¢äžãæ°Žéãšæ¥è§ŠããããŸãããã¯ã¯ãã³æ¥çš®ãåããŠããªããã®éå£ã«ãèªéç眹
æ£è
ãããªã ïŒ ããã¯ãæ£åœãªèšåºããŒã¿ã§ããïŒOlmsted, [49]ïŒ
èªéçããå²ãã®ç³žå£ã«
倧éãçšŒãæ¹æ³ã¯æãããç
æ°ã®åå ã®ç©¶æã§ã¯ãªããç
æ°ã®æ²»çæ³ã®å£²ãåºãã«ãããŸ
ããããããŠä»ãèªéçãå²ãã®åžå ŽãšããŠå£²ãåºãè¡çºãããããŸããå¢ãã§èµ·ãã£ãŠ
ããŸããããããMLMãå¥åº·ãµããªã¡ã³ããããžãã¯ãã¬ãããåã³ãã®äžã§ç¥ãããŠã
ãå
端éçºå€ã®å
šãŠãããã®åžå Žã§ç«¶ãåããã©ã®è£œåãèŠãŠããèªéçã«å¹ãããšè¬³ã£
ãŠããŸãã
èªéçã®æªæ¥ããå¥åº·ãžã®é¢å¿ã§ã¯ãªãåžå Žå£²ãäžããžã®é¢å¿ã«å·Šå³ãããŠããããšãå
ããŠãèªéçåé¡ãåãæ±ãã°ã«ãŒãã®å€ããä»ãŸã§ãšæã£ãŠå€ãã£ãæ
床ãåã£ãŠãã
ã®ãèŠããšã空æãããæ°ãããŸããæ²»çæ³ã売ãåºããæ¹ãå²ããã®ã§ãèªéçã®å€§æµ
è¡ã®åå ãäœã ã£ãã远åããã®ã¯ãããæ¢ããšããããã§ãã倧äžå€«ããå»è
ããã«ãŸ
ãããŠããã°ïŒïŒïŒã¡ãããšæ²»ç代ããã£ãœãæã£ãŠãã£ãŠäžãããŸããïŒ
以äžãæ²»çæ³ãšããŠåºåã£ãŠãããã®ã®å¹Ÿã€ããæããŠã¿ãŸãã
DMSA EDTA
ã¿ãŠãªã³ ã«ã«ãã·ã³
ããŒãã«ãããã¬ãŒã·ã§ã³ ã¢ã«ãã¡ãªãã€ãã¯é
ž
é«å§é
žçŽ çæ³ ãã©ã³ã¹ãã¡ãŒãã¡ã¯ã¿ãŒïŒè»¢å€å åïŒ
æ°ããæµè¡ã£ãŠããç
æ°ãªããŠãå¿é
ãããŸãããã¡ãããšæ²»ããŸãããïŒãšããèš³ã§ã
ãã確ãã«ããããã®æ²»çæ³ã®å¹Ÿã€ãã¯ãç¹ã«ãoral chelationïŒãªãŒã©ã« ãã¬ãŒã·ã§ã³ïŒ
ãšããååãªã©ã¯ãããçšåºŠçç¶ãæ¹åãããããšãããã£ãŠããŸãã[10]ãããã®äžã«ã¯ã
ä¹³å
ã®ããªã±ãŒããªççæ©èœãããæ°Žéæåãæåºãã广ããããã®ãååšããããã§
ãã[171]ããããããã§ã¯çŠç¹ããããŠããŸã£ãŠããŸãããïŒæ¬åœã«åé¡ãã¹ãã¯ããã®
67 人㫠1 人ã®åäŸãèŠããã§ãã倧æµè¡ã®ç
ã®åå ãäœã§ããã®ããã§ã¯ãªãã§ããã
ãïŒããã©ãæ²ããããšã«ãèªéçã AIDS ãç³å°¿ç
ãšåæ§ã§ãæ²»çæ³ãšããŠäž»åŒµã§ãã
å»è¬åãè¬åŠçãªæ²»çæ³ãåºãŠãããŸã§ã¯æ±ºããŠã倧æµè¡ããŠããç«ç
ã ãšèªç¥ãããã
ãšã¯ãªãã§ãããã
èªéçã«é¢ããçŸåšã®è«žç ç©¶ã®èŠçŽã§ä¿¡é Œã§ãããã®ã¯ãageofautism.com ã«æ²èŒãããŠ
ããŸãã[361]
äžãåã®æªæ¥
ã©ããªã«æ³ååãé§äœ¿ããŠæžãäžããŠã¿ãŠããã¢ã¡ãªã«ã«ãããèªéçã®æªæ¥ãèŒããèŠ
ããããšã¯äžå¯èœã§ãããŠã§ãŒã¯ãã£ãŒã«ããã·ã³ã°ãã€ãºããã¯ãã²ã€ã€ãŒã®ãããªç
ã®ç§åŠè
ãã¡ã¯ããã¯ããã®æ²ã¿è¡ãè¹ããç«ã¡å»ãããšããŠããããã§ããåå·ã«ãã
ãŠãæ¥æ¿ã«å¢ãç¶ããŠããèªéçã®çºçä»¶æ°[97]ãæããããã®ãç§éã®å¯äžã®é Œãã§ãã
ãããã®ç§åŠè
éãããªããªã£ãŠããŸãã°ãæªæ¥ã¯ãå
çã£æã ãšèšããã§ãããã
MLMers ããªããšèšãããšãèªéçã¯æ®ã©ã®å ŽåãäžæŠããããšç涯治ããŸããã广ã®
ããèªéçã®è§£æ¯æ³ããã°ã©ã ã¯ããã€ãååšããŸãã[10]ãã¯ã¯ãã³ã«ãã£ãŠé害ãåã
ãåäŸãçŸããŒã»ã³ãå埩ããããšã¯ãããçšãªããšã§ãã
ïŒïŒïŒ²ã¯ã¯ãã³åã³ãã®ä»ãã¡ããµãŒã«å
¥ãã®ã¯ã¯ãã³ã«å¯Ÿãããã®å±éºæ§ãšå¹æã調ã¹
ãç 究調æ»ãè¡ãªãããããšã¯ãäžåºŠããããŸããããã®äºå®ã ããèŠãŠããåœã®ã¯ã¯ã
ã³æ¥çš®çŸ©å衚ã®å§åã«ç²ç®çã«åŸãããšããç§åŠçã«çŽåŸã§ãããã®ã§ã¯ãªããæãåã
å±éºã«ãããè¡çºã§ããããšãã芪éã«ãåããããšã§ãããã芪ã§ãã人ã
ããã£ãšã¯
ã¯ãã³ã«ã€ããŠå匷ãå§ããªãããããç§éã¯ããããäœå幎ã«ãããã£ãŠãåããé害
ãäžçèè² ã£ãŠãããªã°ãªããªã人ã
ããæ¯å¹Žæ¯å¹Žãäœå人ãçã¿åºãç¶ããŠããã®ã§ãã
åäŸã®æ»
å¿çåŠè
ã«ããã°ã人çã®äžã§æãã¹ãã¬ã¹ã䌎ãåºæ¥äºãšã¯é¢å©ãäŒèšç£æ»ããããŠå
äŸã®æ»ã§ããããã§ããèªéçã«é¢ãã现ããç¹ãè²ã
é ã§èããããŠããŸãåã«ãã¡ã
ã£ãšäžæ©äžãã£ãŠãèªéçå
ãæã£ã芪éããå®éã©ã®ãããªäœéšãããŠããã®ãèæ
®ã
ãŠã¿ãŸãããã
ç§éã¯ç人çã®ã©ããã§ãä¹³å
ããšããšãæ©ãã®å¹Œå
ã«æé·ããããããå°ããªäººéã«ãª
ã£ãŠããã®ãç®ã®åœããã«ããããšãããã§ããããåäŸéãæ§ã
ãªæ®µéãçµãŠæé·ãã
è²ã
ãªããšãåºæ¥ãããã«ãªãã®ãèŠå®ãããšã¯ã䞡芪ã«ãšã£ãп倧ã®åã³ã® 1 ã€ãšèšã
ãŸããæããããããªè©±ãäœåºŠãç¹°ãè¿ãèªã£ãŠãå人ã«åããããããšãããã§ãããã
æ¯æ¥åäŸãšäžç·ã«éãã§ããã®åã®å
ãªãå
ãæ¥ããšã«åŒ·ãèŒãã ããæ§ã
ãªçºèŠã«å¿é©
ãããå§¿ãèŠå®ãããšã¯ãæå€§ã®åã³ã®ïŒã€ã§ããã人çã®æå€§ã®ç®çã®ïŒã€ã§ãããã®
ã§ã¯ãªãã§ããããïŒ
ãŸãããã®ããšãèžãŸããŠãããæ¬¡ã®äºæ
ãèããŠã¿ãŠäžããã2幎ãã®éãæ¯æ¥æããæ©
ãŸã§äžå¿äžä¹±ã«æãåãè²ãŠããã®åã³ãèŠåŽãåŒãåããŠããã®ã«ãããæ¥çªç¶ãå
ã
ãµã£ãšæ¶ããæãåãäžååå¿ã瀺ãããç¬ãããšããªããªããäœãåŠã°ãããã°ããã
ããšèŠªã§ããããªãã®ããšãããããªããªã£ãŠããŸã£ããïŒãããããã®åã¯ãã ã®ç
æ°
ã§ã¯ãªããããäžçãæ°žé ã«æ²»ããªããšãããïŒäžåºŠãã§ãåµãå
ã«æ»ãããšãåºæ¥ãªã
ããã«ããã®åãå
ã«æ»ãããšã¯åºæ¥ãªãã®ã§ããåšãã®äžçã«å¯ŸããŠãå¿ãæ»ãã§ããŸ
ã£ãã®ã§ãã
ãã¯ããä»ãŸã§ã®ãããªè§Šãåãããªããªãããã ããã¡ãããäžæ¹çã«èªããããã ã
ã§ããããªãã¯ãããããããã®åã®äžè©±ãããŠãããã°ãªããŸããããåäŸããããªã
ã«ã¯ãããäžåãäœã®åå¿ããè§Šãåãããææ
ããå°æ¥ã®åžæãè¿ã£ãŠããããšã¯ãã
ãŸãããããããç¶æ
ãé·ãããšç¶ããåŸãããããããªãã¯ããã®ç¶æ
ãå®éšå®€å
ã§èµ·
ããŠããäœãã®å®éšã§ã¯ãªããå®ã®æãåã®ããããŸãªã®ã ãšèªåã«èšãèãããªããã
ãªããšãçããŠããããšããªããã°ãªããªãã®ã§ãã
ããªãèªèº«ã®åäŸããããªã£ããã©ãã ããå°ãèããŠã¿ãŠäžããã
ãããã芪éããã¯ã¯ãã³ãšèªéçã®é¢é£æ§ã«ã€ããŠããããç¥ãããéã«èšãèšèã¯ã
倧æµããã®æãç¥ã£ãŠãããïŒïŒïŒãã§ãããããã¿ããªæ±ºãŸã£ãŠãç¥ã£ãŠããã°ããã£ãã
ãšèšãã®ã§ãã
ãã®æ¬ã¯ããã®ããã®ãã®ã§ããããããããç¥ã£ãŠããããã®æ¬ãªã®ã§ããããã©ã誰
ã ã£ãŠå¿
èŠã«è¿«ããããŸã§ã¯ãåŠãŒããšã¯ããªããã®ã§ããïŒã§ããããã§æãããããª
ææªã®æ²åã ã£ãŠãèµ·ããããç¥ããªãã®ã§ãïŒãã®æãã匱ã眪ã®ãªãæãåãå®ãã®
ã¯ã誰ã®ä»äºã§ããããïŒ
ãã¬ãããŒ
2002 å¹Žã«æ¥çš®è¡šã«ä»å ãããŠä»¥æ¥ãã£ãšããã¬ããïŒã¯ã¯ãã³ïŒPCVïŒã¯è«äºã®æžŠäžã«ã
ããŸãããã¬ãããŒã¯ã¯ãã³ãšã¯ãstrep pheumoniae ãšãžãããªã¢ã®ãã¯ããªã¢ãå«ãã¯
ã¯ãã³ã§ãäžè³çãšçŽ°èæ§é«èçãäºé²ãã广ããããšããŠå£²ãããŠããŸãã
ãã®ãã¬ãããŒã¯ã¯ãã³ã®æå€§ã®åé¡ç¹ã¯ãäºé²ã®å¯Ÿè±¡ããéåžžã¯ãã ã®è³ã®çã¿ã§çµã
ã£ãŠããŸãäžè³çã ãšããããšã§ããå®éãä¹³å
ã¯çãäžæçãªè³ã®çã¿ãçµéšãããã®
ã§ãããããããçã¿ã¯è»œåºŠã§ã倧ããŠã²ã©ããªããã« 1 æ¥ã2 æ¥ã§æ²»ã£ãŠããŸããŸãã2007
幎床㮠PDRã§ããã90ïŒ
ã®ä¹³å
ãè³ã®çã¿ãçµéšãããšè¿°ã¹ãŠããŸãã[251]
äžè³çã®å®çŸ©ãèŠãŠã¿ããšãéŒèã®å€èгã«ç°åžžã«æ¶²äœãæºãŸã£ãŠããããšã([251], p3468)
ãšãããŠããŠãé©ããŠããŸããããããŸãããããã©ãããã¯ãèµ€ãåã®è³ã®äžãèŠããŠ
ã¿ããšãéŒèãèµ€ããªã£ãŠããã®ãèŠãããšããæå³ã§ãããã®ãããªçç¶ãªãããã æ³£
ããåŸã§ãèµ·ãããŸãããã®ããããäžè³çãšåŒã°ããŠããçç¶ã蚺æããã®ã«ã¯ãè³ã®
äžãèŠããŠã¿ãã ãã§ååã§ãäœã®è©Šéšç®¡ãã¹ããè¡æ¶²æ€æ»ãå¿
èŠã§ã¯ãããŸããããã
ãŠãåäŸã«ãã®çç¶ãããå Žåã§ããå¥ã«äœã®æ²»çããããªãã®ã§ãã
ãããªã®ã«äœæ
ããã®ãããªè»œåºŠã®çç¶ãäºé²ããããã«ãåäŸã®è¡æ¶²ã䟵害ããããã
å¿
èŠãããã®ã§ãããïŒ
åè¿°ã®åŠãå¿
èŠæ§ã®äœãã¯ã¯ãã³ã§ãããå¯äœçšã¯ã©ã®ãããªãã®ã§ããããïŒ è£œè¬äŒ
瀟ã«ãããå®äŸã®äžéšãæããŠã¿ãŸãã
çºç± ã¢ããã£ã©ãã·ãŒã·ã§ãã¯
çºäœ ãããŸãã
äžå¿å
š èè
žç
æ¹¿ç¹ è£ç
ãããã æ¯ã¥ãŸã
èºçïŒïŒïŒ çµèç
äžè³çïŒïŒïŒ – 2007 PDRp3468 [251]
ã¡ãã£ãšåŸ
ã£ãŠãã ããããã®ã¯ã¯ãã³ãèªåŒããå¯äœçšããäžè³çã§ãã£ãŠïŒ
ãããäºé²ããããã®ã¯ã¯ãã³ãããªãã£ããã§ããïŒãããããèºçïŒ å¥åº·ãªåäŸã®
äœã« strep pheumoniae ãªã©æ³šå°ããŠãèºçãåŒãèµ·ãããããããªãããšããããå€ããª
ãã£ãã®ã§ããããïŒ ãã®ä»ã®å¯äœçšåå¿ã ã£ãŠãããã¶ãæ·±å»ãªçç¶ããããŸãã
補è¬äŒç€ŸåŽã®ãåœåã®èšåºæ€æ»ã®è©³çްãèŠãŠã¿ããšãæ¥çš®ãåããè
ã¯ãã®ä»ã®éåžžèŠå®
ã®ã¯ã¯ãã³å
šéšãåæ¥ã«æ¥çš®ãããšããããšã§ããã§ã¯ããã®ä»ã®ã¯ã¯ãã³ã®äžã§äžè³ç
ãå¯äœçšã«æããŠãããã®ã¯å¹Ÿã€ããã§ããããïŒ çãã¯ã5 çš®é¡ã§ãã
ã€ãŸãããããããã®ä»ã®ã¯ã¯ãã³ã®å¯äœçšåå¿ã«å¯Ÿå¿ããããã«ãæ°ãããã®ã¯ã¯ãã³
ãæ¥çš®ããå¿
èŠãããããšããèš³ãªã®ã§ããããïŒã©ããããã®æ§ã§ãã察象矀ã®åäŸé
ããå
šå¡ã¯ã¯ãã³æªæ¥çš®ã§ãã£ããªãã°ããã®èšåºå®éšã«ãæ£åœæ§ããã£ãã®ã§ããã
ãšããã§ããã®æåã®èšåºæ€æ»ã®çµæã察象è
ã®12 äººãæ»äº¡ããŠããŸãã
次ã«ããã¬ãããŒã¯ã¯ãã³ã®ã»ãŒã«ã¹ã®åããšããã¯ãåè¡åœã§ã¯ããéåžžã«çšãªç
æ°ã§
ããçŽ°èæ§é«èçã®äºé²ã䞻匵ããŠããç¹ã§ãã2007 幎床㮠PDR ã«ã¯ããã®ç
æ°ã®çºç
çã¯ã10 äžäººã« 7 人ã([251] p3463) ã§ãããšæžããŠãããåèè³æãšããŠNew England
Journal of Medicine èª 1997 幎 10 æ 2æ¥ä»ãã®ç ç©¶ãåŒçšããŠããŸãã[143]ããããã
ã® NEJMèªã®ç ç©¶ã®å®æ°å€ãèŠãŠã¿ããšãçŽ°èæ§é«èç㯠1 äžäººã« 1 人以äžã®çºççãšã
ããŠããã§ã¯ãããŸãããïŒ(Schuchat [143], page 970) PDRã®ã»ãŒã«ã¹éšéæ
åœè
ã¯ã
ããããèªåéã®èšèŒããåèè³æãå®éã«èª¿ã¹ãŠã¿ã人éãªã©ããªãã ãããšæã£ãã®
ã§ããããããŸããäžè¬çã«ã¯ãã®åŸåã¯ãããŸããïŒïŒïŒã
ããã§ã次ã®ïŒã€ã®ããšãããããŸããã
ïŒïŒ PDR ã®è³æã¯ãå¿
ãããéµåã¿ã«ããŠä¿¡ããŠã¯ãããªãããš
ïŒïŒ çŽ°èæ§é«èçã¯ã圌ãã®äž»åŒµãã 7 åãçšãªçºççã§ããããšã
å¹èœã®èšŒæ
次ã«ããã¬ãããŒã®å¹çšã«ã€ããŠèŠãŠã¿ãŸãããããã®ã¯ã¯ãã³ã¯å¹æãããã®ã§ããã
ãïŒè±åœã®æè²è
ã§ãããã€ã±ã«ã»ããŒãŠã£ã³ã¯ããã®åé¡ç¹ã«çæ£é¢ããåãçµãã ã
ãPrevner: a critical review of a new childhood vaccineããšããéåžžã«è¯ã調æ»ãããè«
æãæžããŠããŸãã44]ãã¬ãããŒã¯ã¯ãã³ã®æåã®ããã€ãã®å®éšèª¿æ»ã®çµæã§ã¯ããã®
ã¯ã¯ãã³ã«ããè³ã®çã¿ã®çºçäºé²å¹æã¯ãã£ãïŒïŒ
ã«ãããªããŸããã§ããããããŠã
圌ãã®äž»åŒµãããã¬ãããŒã®æå€§ã®æå¹æ§ã¯ããã®ãã£ãïŒïŒ
ãªã®ã§ããåäŸæä»£ã®è»œã
è³ã®çã¿ã®ããã«ãäžèšã®ãããªå±éºãªå¯äœçšã䌎ãã¯ã¯ãã³ãããããæå¹æ§ããã£ã
ïŒïŒ
ãããªãã¯ã¯ãã³ãæ¥çš®ãããšããããã§ãã
æã¡ã€æããã€ãã®é¢ä¿
ããŒãŠã£ã³ã¯æŽã«ããã¬ãããŒåã³ WywthAyerst ã¯ã¯ãã³ãèªå¯ãã FDA ã®é¡§åå§å¡ãš
補è¬äŒç€Ÿãšã®çµæžçãªçµ¡ã¿åãã«ã€ããŠãã詳现ã«åæããŠããŸããããŒãŠã£ã³ã¯ãäžç
çãªè¬çŸ©ãã¢ãŒã宿œããããè«å€§ãªç ç©¶è³éãåãåã£ãããå»åŠéèªã«äœããŒãžãã®
èšäºã§åãäžãããããããŠããå°éå»éãã€ãŸãæãç®ã«ã€ãããããã¬ãããŒæ¯æè
ã§ãã人ãã¡ããå®éã©ã®ããã«è³éå ±é
¬ãåŸãŠãããããæç¢ºã«ç€ºããŠããŸãããã® 2
è
éã®èŠªå¯é¢ä¿ã«ã€ããŠæ°åéèªãã ã ãã§ãããã®åé¡ã®å
šäœåãããªãã¯ã£ããããŠ
ããã§ãããã[144]
çãšäžåŠç
çºããæ§ãåŠå®ããæç« ã¯å€§æµãããªæãã§ããããã¬ãããŒã®è£œè¬äŒç€ŸåŽã®ã2007 幎床
è³æã«ã¯ããæžããŠãããŸãããçºããæ§åã³ç¹æ®æ©èœãžã®å±å®³ã¯å€æããŠããªããã([215]
p3467) ã€ãŸãããã¯ããã®å¿
èŠæ§ã®äœãã¯ã¯ãã³ãçãèªçºããããå°æ¥äžåŠçã«ãªã£
ããçæ®æ©èœã«é害ãæã£ãããããã©ããããã補è¬äŒç€ŸåŽã¯ç¥ããŸãããããšããæ
å³ã§ããå
šãåãæ
床ã§ãããïŒ
æåŸã«ãé©ããŠããŸããããããŸãããããã¬ãããŒã®èšåºæ€æ»ã®æ°ã
ã¯é«èçã§ã¯ãªãã
äžè³çã«é¢ããæ€æ»ã§ãã£ãããšã«æ°ä»ãããŸãããïŒ é«èçã«é¢ããŠã¯ãPDR ã¯å¹å
ãããããšãã䞻匵ããŠããŸãããããã«ãããããããCDC ã®å®£äŒè³æã«ã¯ãäœã®ç§åŠ
çæ ¹æ ããªãããã®ã¯ã¯ãã³ãé«èçã«å¹ããšèŠããŠããã®ã§ããäžèšã«ãããçµ±èšè¡šã¯ã
ãã ã®ãŸãããã«éããªããšããããã§ããã§ããããåœäžã®å°å
ç§ã»ãŒã«ã¹éšéãæã£
ãŠããã¬ãããŒã¯äžè³çãšé«èçãäºé²ãããšãã£ãŠããã®ã«åãã補è¬äŒç€ŸåŽã¯ãé«è
çã®äºé²æ§ã«é¢ããç ç©¶çµæãäžåæ²èŒããããšããªãã®ã§ããããã¯ãã ã®ã»ãŒã«ã¹èž
ã§ããããã®äž»åŒµã«ã¯ãªãã®è£ã¥ãããããŸããã
ãããŠããã¬ãããŒãæ¥çš®çŸ©å衚ã«è¿œå ãããåœæãã³ã£ããããŠããŸãããšã«ãæšå¥šæ¥
çš®åæ°ã¯æåããçåŸïŒãïŒãïŒã12 ã¶æã® 4 åãšãããŠããã®ã§ããããã«ãçåŸ 2 ã¶
æã®æ¥ç𮿥ã«ã¯ããªããšä»ã® 5 çš®é¡ã®ã¯ã¯ãã³æ¥çš®ãè¡ãªãããã®ã§ãïŒåè¿°ã®ããšãã
çŸåšãããã®æ¥çš®æå®è¡šã¯åæ§ãªç¶æ
ã§ç¶ããŠããŸãã
ãçè«äžã®ç
æ°ãã®èªç
ãã¬ãããŒã¯ã¯ãã³ã®ç»å Žã¯ãåŸæ¥ã®æ¥çš®æå®ã¯ã¯ãã³ã®èãæ¹ã«ãæ°é¢šãå¹ã蟌ã¿ãŸã
ãïŒã€ãŸããçè«äžã®ç
æ°å¯Ÿçã®ã¯ã¯ãã³ã§ããä»ãŸã§ã¯ãMMR ã DPTãèçã倩ç¶ç
ãªã©ãç¹æã®ç
åèãåå ãšãããäŒæç
ã«å¯ŸããŠã¯ã¯ãã³ãå¿
èŠã ãšãããŠããŸãããã
9/11 äºä»¶åŸã®çŸåšã§ã¯ããã¯ãæ¬ç©ã®ç
æ°ã§ãªããŠããã¯ã¯ãã³ãå¿
èŠã ãšããããšãåº
æ¥ãããã«ãªã£ãŠããŸããŸãããä»ã§ã¯ãã ãã¯ã¯ãã³ã«ååãä»ããŠããã®åŸäœãã®å±
éºæ§ã宣äŒããã°è¯ãã ãã§ããå±éºæ§ã¯ãã©ããªãã®ã§ãã§ãã
äŸãã°ãè³ã®éŒèãã¡ãã£ãšã®éèµ€ããªã£ãããšããã ãã§ãã
HPV : æåã®çã¯ã¯ãã³
ããã¯ãæ¥ãã¹ãããŠããã¯ã¯ãã³ãšèšããã§ãããã9/11 以éãããã«å€æ§ãªã¯ã¯ãã³
ã売ãåºãããã«ãäºé²ã®å¯Ÿè±¡ãšãªããããªãã°ïŒç
åèããŠã€ã«ã¹ã®ç¥ç§°ïŒãäŒæç
ã宣äŒéš
ã¯ãã£ãã«ãªã£ãŠæ¢ããŠããŸãããããåè¡åœã®æ»äº¡çã§ãããïŒãèªããã®ç
æ°ã«ãæ
ååè£ãšããŠç®ãã€ããã®ã¯åœç¶ãªããšã§ãã
åå®®é žçã¯ãéå» 30 幎éã«ãããŠåŸã
ã«å¢ãç¶ããŠããŠãçŸåšã§ã¯ã¢ã¡ãªã«äººå¥³æ§ã®
13,000 人ãçºçãããã®å
4,000 äººãæ»äº¡ããŠããŸãã1970 幎代ã«ã¯ãherps simplexïŒã
ã«ãã¹ïŒ ãŠã€ã«ã¹ãåå ã®å¯èœæ§ããããšãããŠããŸãããããã®ä»®èª¬ã¯ç«åŠã®ç ç©¶ã«ã
ã£ãŠæ±ºå®çãªçµè«ããªããšèšŒæãããç Žæ£ãããŸããã1980 幎代ã«ã¯ã次ã®åå åè£ãšã
ãŠããããããŒããŠã€ã«ã¹ã瀺åãããŸããã[359]
話ãç¶ããåã«ãç«åŠãšã¯ã©ããããã®ãå°ãèŠãŠã¿ãŸãããã
ç«åŠçãªèå¯
å¥åã人å£èå¯ãšãåŒã°ããŸãããããã¯å®éã®èšåºç ç©¶ãšã¯å
šãçžãé ãçš®é¡ã®ãã®ã§
ããããã¯ãç§åŠçã«èšå®ãããç¶æ³äžã§å®æœããããã³ã³ãããŒã«ãããç ç©¶ã§ã¯ãªãã
åã«ç¹å®ã®äººå£éå£ã«ãããäŒæç
ã®çºçæ°ãæ°ãäžããããšã§ããã仮説ã蚌æããã
ãšãã詊ã¿ãšèšããŸããããã§åé¡ãªã®ã¯ããã®ç«åŠçãªèå¯ãšãããã®ãã誰ãä»¶æ°ã
æ°ãã圹ã«ãªããã誰ã調æ»å¯Ÿè±¡ã®èšå®ãããããåãã®çµæãçºè¡šãããâ¥çã«å€§ãã
å·Šå³ããããã®èå¯çµæã®è§£éãæ£æçã«ãªã£ãŠããŸããšããç¹ã§ãããã®ãããåäžã®
ç«åŠäžã®èå¯ã䜿ã£ãŠãçžåããïŒã€ã®ä»®èª¬ããäž¡æ¹å
±ç«èšŒããŠããŸãããšãåºæ¥ãŠããŸ
ãã®ã§ãã[360]
ç«åŠäžã®èå¯ã¯ææ©ãåºæ¥ãŠè²»çšãå°ãªãäžã«ãã©ã®ãããªäž»åŒµã«å¯ŸããŠããæã¿éã蚌
æ ã«äœ¿ããç ç©¶çµæãåºããŠãããã®ã§ãããã仿¥ã®ççºçãªå¢ãã®ã¯ã¯ãã³è£œè¬æ¥ç
ã«ãããŠã¯ãåœæ°ã«ãã£ãšã¯ã¯ãã³ãå¿
èŠã ãšãã䞻匵ã®èšŒæ ãšããŠããã®ç«åŠèå¯ã䜿
ãã®ããæ±ºãŸãã«ãªã£ãŠããŠããŸãã
ãã«ãã¹ãåå åè£ããå€ããããåŠã, 圌ãã¯ãŸãæ°ãã人å£èå¯ãå©çšããŠãããã
ãããŒããŠã€ã«ã¹ïŒHPVïŒãåå®®é žçã®èŠå ã§ãããšç€ºåããããã§ããããããHPV ã®
ç³»å㯠100 çš®é¡ä»¥äžããããçè«äžã§åå®®é žçãšé¢é£ããŠãããšãããŠããç³»åã§ããã
ãã®å
ã®ãã£ã30 çš®é¡ã«ãããªããŸããã[358]ãã®äžãæ®éã®äººå£ã®å°ãªããšãåæ°ã®äºº
㯠HPV ãæã£ãŠããŠã[359]æ®ã©ã®å Žåãäžçã®éäœã®ç
æ°ãé害ãçºçããããšã¯ãªã
ã®ã§ããå®éãHPV ãäœãã®ç
æ°ã®ç
åèã§ãããšèšŒæãããããšãªã©ãäžåºŠããããŸã
ãã
HPV ãšç
ããŠãçã¯ã©ã®ãããªçš®é¡ã®ãã®ã§ããçªç¶å€ç°ãèµ·ãããéºäŒåãã誰ã«ãæ°ä»ããã
ã«ãåãã³ããŒãäœãåºãããšãæããŸãã
ãHPVãçã®åå ã ããšããç¥è©±ãäœãäžããåŽã¯ãHPVãšãããŠã€ã«ã¹ããã£ãŠããŠæ£
åžžãªçްèã«è¥²ããããããããã现èãçªç¶å€ç°ãããŠãåéäžå¯èœãªã»ã©ã«èªãã®ã³ã
ãŒãå¢ããå§ããããïŒã€ãŸããçãåŒãèµ·ãããã®ã ãšäž»åŒµãããããªäºæ
ãå€§èŠæš¡ã«
çºçããŠããããšããç§éã¯ãã£ãä»çºèŠããŸãããšããã¶ããŠããŸããããã«å§æ«ãæª
ãããšã«ãæ£åžžãªåå®®é žéšã®çްèãžã®ããããæ»æããã¯ã¯ãã³ãäžåããŠããããšèšã
ã®ã§ãã
圌ãã®äž»åŒµã¯ãç§åŠçã«èŠããšéŠ¬é¹¿éŠ¬é¹¿ãããšããèšãããããããŸããã
ããŒã¯ã¬ãŒå€§åŠã® Peter Duesberg PhD.ã¯ããã®ãŠã€ã«ã¹âçãšãã仮説ããèŠäºã«è§£èª¬
ããŠãã人ç©ã§ãã圌ã¯èªèº«ã®è«æã§ãHPV /åå®®é žçèª¬ãæŽå²çã«é¡ããã©ã®ãããªçš®é¡
ã®çã§ãã HPVãåå ã§ãããšããã®ã¯éåžžã«èãã«ãã話ã ãšããããšããçéç«ãŠãŠ
説æããŠããŸãã
ã人éã®åå®®é žçã«ãäžè²«ããŠç¹å®ã®ãŠã€ã«ã¹æ§ã®éºäŒåãååšããããçºèŠããããã
ãããšã¯å
šããªãã[359]âŠHPV ã¯ãã现èã®äžã§è€è£œããªããã
ããŠãçªç¶å€ç°ããåå®®é žçã®ãã现èããç°åžžãªãŠã€ã«ã¹æ§ã®éºäŒåãæ£åžžãªçްèã«æ··
ãã£ãŠèªçºããããšãåå ã§çªç¶å€ç°ãèµ·ãããã®ã§ã¯ãªãã®ãªãããã®çã®åå ã HPV
ã§ããããããããŸãããDuesberg ã¯ããè¿°ã¹ãŠããŸãã
ããŠã€ã«ã¹æ§çºç説ã䞻匵ããŠããè
éã®æå£ã¯ãããã°ã²ãéãåæ§ã®ç¡è²¬ä»»ãªãã®ã§
ãããè
«çå
ã«å®å
šãªåœ¢ã®ãŠã€ã«ã¹ãçºèŠãããªããŠãããããã¯ãŠã€ã«ã¹ã®äžéšåãã
çºèŠãããªããŠãè¯ããšããã®ã ãããããã¯æããã«ãäžåœæ§ã蚌æããããšãäžå¯èœ
ã§ããããããæ£åœæ§ãç«èšŒäžå¯èœãªä»®èª¬ã§ãããã[359]
ãããŸã§ã«èšŒæ ãšããŠç€ºããããã®ãšããã°ãææ HPV ãåå®®é žçã®çްèèã«ãã£ããšã
ãããšã ãã§ãããããããããåç¥ã®ããã«ãå¥åº·ãªäººã®ïŒïŒïŒ
ã«ã HPVãååšããã®
ã§ãããæå³ããããŸããã
åå®®é žçã«çœ¹æ£ãã女æ§ãã眹æ£ããŠããªã女æ§ããã HPV ãæã£ãŠãã床åããé«ããš
ãã蚌æ ãªã©ããŸã£ããååšããŸããã[359ãããã«ããããããããã®ã¯ã¯ãã³ã®çŠç¹
ã¯ããã®ã©ãã«ã§ããããŠã€ã«ã¹ãäœãã远ãæãæ¯ããããããšã«ããã®ã§ãã
æ°çš®ã® HPV ã¯ã¯ãã³
HPV ãšåå®®é žçãé¢é£ä»ããããã« Merck 瀟ãæåã«ã€ãã£ãã»ãªãã¯ããé«ãé¢é£æ§ã
ããããšãããã®ã§ãããïŒ[280] p1964ïŒ
ãã®ã»ãªãããéå» 2 幎ã®éã«ãïœã®åå ã¯ïœã§ãããã«å€ãã£ãèæ¯ã«ã¯ãç§åŠãšãã
ããã¯æ¿æ²»çãªçç±ããããšãããŸãã
Merck 瀟ã¯ãé·å¹Ž HPV ã¯ã¯ãã³ã®åžå Žåºè·æ¡ãæããŠããŠããŠã2006 幎ã«ãããã FDA
ã®èš±å¯ãåããŸããã[21]Merck瀟㮠HPVã¯ã¯ãã³ã¯ Gardasil ãšåŒã°ããŠããŸãã
ã§ã¯ãããã«äœãå
¥ã£ãŠããã§ããããïŒMerck 瀟ã®ããŒã¿ã«ãããšããã®ã¯ã¯ãã³ã¯
ãHPV ã® 4 ç³»åïŒã¿ã€ã5ã11ã16ã18 ããæœåºããããŠã€ã«ã¹ã«äŒŒã埮ç²åãããäœã
ããŠãããã®ã ããã§ããïŒ[251]p1984ïŒãã®å
ã¿ã€ã 16 ãš 18 ã¯ãçŸåš Merck 瀟ã«ãã£
ãŠäœã®èšŒæ ããªããŸãŸãPhysicians Desk ReferenceïŒå»çè
åäžåèæç®ïŒã«ã70ïŒ
以äž
ã®ãåå®®é žçã®åå ã§ãããšæ²èŒãããŠããŸãã
çè«çã«ã¯ãäœããã®ãŠã€ã«ã¹ã«äŒŒã埮ç²åã«è§ŠçºãããŠæäœãäœãåºãããã®æäœã¯èª
ç¶ãªç³»åã®åŒ·åãªHPVã䟵å
¥ããã®ãé²ãã§ãããã¯ãã ããšãããã®ã§ãããšããããã
ïŒå¹Žéã¯æå¹ã§ããããšMerck 瀟ã¯äž»åŒµããŠããŸãã
Gardasil ã®å£²ãåºãæå¥ãšããŠãMerck 瀟ã¯éåžžã«ãã£ã±ããšæ¬¡ã®ããã«å®£èšããŠããŸãã
ãHPVã¯æå¹³çŽ°èæ§ã®åå®®é žçãèªçºãããã
ãããééãã§ããããšã¯ããã§ã«åŠã³ãŸãããïŒ
Merck 瀟ãã¿ãŒã²ããã«æ±ºããã®ã¯ïŒïŒæ³ã®å¥³ã®åéã§ããHPV ã¯æ§è¡çºã§ææãå¯èœãª
ã®ã§ãæ©ããã¡ã«åŠçããŠããŸããŸãããããšããèãã§ãã
ãã®çŽ æŽãããæ°æ¡ã«ææåããããåã«ããŸãå®éã«ç§éã«å£²ãããŠãããã®ã¯ã©ããª
ãã®ãªã®ãã客芳çã«èããŠã¿ãŸãããã
ä¿¡çšæ§ã®æ¬ èœ
MMRïŒéº»ç¹ããããµã颚éªãäžæ¥ã°ããïŒãåèçãããªãªãšãã£ããŠã€ã«ã¹æ§ã®äŒæ
ç
çšã¯ã¯ãã³ã«ã€ããŠã¯ã察象ãšãªãäŒæç
ã®åå ãšãããŠãããèªç¶ã«çºçããéçã®
ãŠã€ã«ã¹ããããã®ã¯ã¯ãã³ã«å«ãŸããŠããªããšããç¹ããç§åŠçã«ççŸããŠããåé¡ç¹
ã§ããããããã¯ã¯ãã³ã¯ãèªç¶ãªãŠã€ã«ã¹ã®ä»£ããã«äººå·¥çã«å€ç°ãããŠã€ã«ã¹ãå«ã
ã§ããŸãããããã«ãããããããäœã«äœçšããŠèªç¶çºççãªäŒæç
ãé²ãæäœãäœãåº
ããå
ç«ãä»ããããŠãããã®ã ãšäž»åŒµãããŠããŸããããã ãã§ããååã²ã©ããã®ã§
ãããä»åºŠã®HPVãšãããããŸãã§å€¢ã®ããšã話ãä¿¡ãããšããããŠãããããªãã®ã§ãã
ã©ã®ççåŠãå
ç«åŠã®æç§æžãèŠãŠããå
ç«ã°ãããªã³ãçºçãããããã«ã¯æ¥µåºŠã«éå®
ãããéçšãäžå¯æ¬ ã§ããããã®çµæãç©¶æ¥µã®æäœã圢æããããšæžãããŠããŸãã[189,
360] ãããŠã€ã«ã¹ã«å¯Ÿããç¹å®ã®æäœãããã®ãŠã€ã«ã¹ã®åŸå§åйããŠã€ã«ã¹ããåã£ã埮
ç²åãèªçºããããšãåºæ¥ããªããŠãããããæç®ã«ã¯ã©ãã«ãæžããŠãããŸããããã
ãªäž»åŒµã¯ãå
šãæ°ãããã®ã§ããäŸãæ¬åœã«ãŠã€ã«ã¹ãäŒæç
ã®åå ã ã£ããšããŠããäž
äœã©ãããŠãããªã¯ã¯ãã³ããæ¬ç©ã®å
ç«ãåŸããããšããã®ã§ãããïŒ
次ã«ãåå®®é žçã®å¹³åçŸæ£å¹Žéœ¢ãïŒïŒæ³ã ãšããã®ã«ïŒMerckManual p1964 [280]ïŒã
Gardasil ã®æ¥çš®äºå®è¡šã§ã¯ãïŒïŒæ³ã察象ã«ãªã£ãŠãããšããç¹ã¯ãéåžžã«ä¿¡ææ§ãå·ã€
ããåé¡ç¹ã§ããããã«ã補è¬äŒç€Ÿã®äž»åŒµããŠããæå¹æéã¯ïŒå¹Žéã§ããã€ãŸãããã®
äž»åŒµã«æ²¿ãã°ã倧æµã®å¥³æ§ãå
ç«ãå¿
èŠãšãå§ããé ã«ã¯ãšã£ãã«å
ç«ãæ¶ãå»ã£ãŠããŸ
ã£ãŠããããã§ãããããã®ã¯ã¯ãã³ã¯é·æçã«ã¯æå³ã®ãªããã®ã ãšããããšã«ãªããŸ
ãã
åå®®é žçã¯ããããŸã§ã«äœäººãšæ§é¢ä¿ãæã£ããã§çºçãªã¹ã¯ãé«ããªãããšãã¯ã£ãã
倿ããŠããŸããã€ãŸããæ§è¡çºã®çžæãå€ãã»ã©ãçºçããå¯èœæ§ã倧ãããªããšãã
ããšã§ãã([280] p1964) ã§ã¯ãïŒïŒæ³ã®åãšïŒïŒæ³ã§ã¯ãã©ã¡ããçžæã®äººæ°ãå€ãã§
ããããïŒäŸããã®ã¯ã¯ãã³ãæ¬åœã«å¹ãããšããŠããæ¥çš®å¯Ÿè±¡ã¯ïŒïŒæ³åŸåã®å¥³æ§ã«ã
ãã¹ãã§ãããã«ãã©ãããŠããããªããã¯ã次ã®çç±ãã芧äžããã
ãã®ã¯ã¯ãã³ã®ãå®å
šæ§ãšå¹èœã«ã€ããŠã¯ãïŒïŒæ³ä»¥äžã®èª¿æ»ã¯è¡ãªã£ãŠããªããã
(2007 [251]p 1987)
ããããã§ãããããããè¥ã女ã®åã«ãããã»ããè¯ãããã§ããïŒïŒïŒã
ããã«ããŠãããªãç·ã®åã«ã宿çã«æ¥çš®ããããŠãããã§ããããïŒ
HPV ã¯ã¯ãã³ã®å¯äœçš
ãŸãã¯ã補è¬äŒç€Ÿãèšè¿°ããŠãããã®ããæããŠã¿ãŸãã
çºç± åãæ°
åœé ç ããŸã
 äžæ°åŒåžåšå®ã®ææ
èè
žç ç²è
žç
 æ°ç®¡æ¯ãããã
– 2007 PhysiciansDeskReference[251] p1987
åŸæ¥å€æãããã®ä»ã®å¯äœçšãšããŠã¯ãæèåªå€±ãèŠååªå€±ãçæ£çºäœãªã©ããããŸãã[20]
ããããã身äœã®éº»çºããããŸãã
è±åœã®ã¡ãã£ã¢ã§ã¯ãïŒïŒã®æ»äº¡ä»¶æ°ãªã©ããããªã Gardasil ã®å¯äœçšãå ±éãããŠããŸ
ãããã¢ã¡ãªã«ã®ã¡ãã£ã¢ã§ã¯äžåå ±éãããŠããŸããã[27]
ããã«ãHPV ã®æ¥çš®ã«ãã£ãŠèµ·ããçç¶ãšããŠã¯ã®ã©ã³ã»ãã¬ãŒçããããŸããããã¯èª
å·±å
ç«åå¿ãèµ·ãããŠããã®çµæèº«äœéº»çºã«ãªã£ãŠããŸãçç¶ã§ãããšã¢ã¡ãªã«ã®äž¡
æ¹ã«ãããŠãã®æ§ãªçºçä»¶æ°ãäœä»¶ããããææªãªäºäŸã¯ã2008 幎 10 æã«è±åœã® 12 æ³ã®
女ã®åããHPV æ¥çš® 2 æ¥åŸã«åããåŸãè
°ããäžã®äžå身äžéã«ãªã£ãŠããŸã£ãäºä»¶ãã
ããŸãã[27]ãã®å°å¥³ã®æåã®çç¶ã¯ãæ¥çš®åŸ30 å以å
ã«èµ·ãããŸããã
çºããæ§
ã§ã¯ãã¯ã¯ãã³èªäœãçãåŒãèµ·ããããšã®å¯èœæ§ã¯ããã®ã§ããããïŒããšããšãçã®
åå ã ãšãããŠããç
åãŠã€ã«ã¹ãæš¡å£ããŠãçãäºé²ããŠãããã¯ã¯ãã³ã ãšäž»åŒµããŠ
ãããã§ããããããã¯ãæ£åœãªè³ªåã ãšãããã§ãããããã®ã¯ã¯ãã³ãçãåŒãèµ·ã
ããŠããŸããªãããå®å
šæ§ã確ãããããªãã®ããåœããåã§ãããïŒã§ã¯ãããã«å¯Ÿã
ãŠã補è¬äŒç€Ÿã®æèŠã¯ãšèšããšïŒïŒïŒ
Gardasil..ïŒïŒïŒçºããæ§åã³çæ®æ©èœã®å·å®³ã«ã€ããŠã¯èª¿æ»ãããŠããªãã
(2007 [251]p1986)
åãã§ãããã¢ã¡ãªã«äžã®12 æ³å
ã«çäºé²ãšããŠã¯ã¯ãã³ãæ¥çš®ããããšããã®ã«ããã®
ã¯ã¯ãã³ãçãåŒãèµ·ãããã©ããããããã¯æ¥çš®ãã人ãäžåŠçã«ãªããã©ããããã®
å±éºæ§ã«ã€ããŠãã確ãã§ãªããšããã®ã§ãããïŒããã§ãããã¡ã®åã«ãã²ãšãåãã
ããªããããšæããŸããïŒ ç·ã®åãã女ã®åããã§ãã
è峿·±ãããšã«ããã®HPV ã¯ã¯ãã³ã¯èå
ã«åœ±é¿ããããšããçç±ã§åŠåš äžã«ã¯æ¥çš®ãå§
ããããŠããŸããã[251]ãããã§ãåæœ®ã«ã¯åé¡ãªãããšããããšãªã®ã§ããããïŒïŒïŒïŒ
ãããµã¹ã®ç¶æ³
HPV ã«ãŸã€ããè«äºã¯ã2007 幎 2 æã«ãããµã¹å·ã®ç¥äºã§ãããªãã¯ã»ããªãŒãããã
ãµã¹å·ã® 12 æ³å
å
šå¡ã« HPV ã¯ã¯ãã³ããèŠè«ããããšæ±ºããããšã§ãæ°ããªå±é¢ãè¿ã
ãŸããã[19]å·è°äŒããããµã¹å·å»åž«äŒããäœã®æ
å ±ãåãå
¥ããã«ãç§åŠé¢é£ã®åŠäœãäž
åæããªãããªãŒç¥äºã¯ããã®å代æªèã§äžæ¹çãªæ±ºæã«ãã£ãŠå³ã
ããã芪éã®ç¹æš©é
åã«æ»ã蟌ã¿ããã®åŸã§ããã¡ãªãåŒè§£ãããŠããŸãããã®ããªãŒç¥äºã®è¡çºã¯ãHPV ã¯
ã¯ãã³ãç§åŠæ§ãæ¬ èœããŠããããšãç¡èŠããå
šå·ã«ãããŠé©å¿ãããã¯ãã®æ¥çš®å
逿³
ããã£ã¡ã®ãã§ãå·ç¥äºã®æš©éãé£ã³è¶ããŠããŸãã§çæ§æ°åãã§ãã
ãéãäžçª
ããªãŒç¥äºã¯ããããå
éšã«éããŠããã®ã§ãããã圌ã®äžä»¶ã®çŽåŸã«ããã®ã¯ã¯ãã³ã¯
æ¥çš®æå®è¡šã«ãã£ãã远å ãããã®ã§ãããã
ããã ãšããŠããå
¬åã§ãæ¿åºã®æ£èŠèšç»ããããªã«å³ã
ãããå ã
ãšç¡èŠããŠè¡åãã
æã«ã¯ããªã«ããéé¢ä¿ãæªãããšèšããã§ãããã
Gardasil ã¯ãäžåã®æ¥çš®ãäžçµã§ 360ãã«ã§ãã[19]
ãããŠãããªãŒç¥äºãšMerck 瀟ã®å
éé¢ä¿ã¯ãå
¬ã«ãç¥ãããŠããŸãã[19]
æ±æµ·å²žåŽã«äœãã§ãã人éã¯ããŸãããã¯ãããµã¹ã®è©±ã ããïŒïŒïŒãšæããããããããŸ
ããããå®ã¯ãã®ã¯ã¯ãã³ãæ¥çš®çŸ©å衚ã«è¿œå ãããåã«ããããããµã¹ã®ç䌌ãããŠå
ãæ§ãªæ³ä»€ãåºãããšããå·ã¯ãä»ã« 17 å·ããã£ãã®ã§ãã[20]
HPV ã¯ã¯ãã³ãå°æ¥ãããã売ãäžãã®äºæ³ã¯ïŒ
ããã®ã¯ã¯ãã³ã®å£²ãäžãã¯æ¥å¹Žã«ã¯ 1 åãã«ã«éãããšäºæ³ãããŠããïŒïŒïŒã¯ 5 幎以å
ã«ïŒïŒïŒGardasil ã®å£²ãäžãã 4 åãã«ä»¥äžã«åŒãäžããå¯èœæ§ããããšãŠã©ãŒã«ã¹ããªãŒ
ãã¯äºæž¬ããŠãããã[21]
æåŸã®è³ªå
å床ã話ããŸãããHPV ã¯ã¯ãã³ã«ãŸã€ãã話ã®å
šäœåã¯ãããã§è¿°ã¹ããããã¯ããã«
è€éãªç¶æ³ã§ããèªè
ã®çããã¯ãäžèšã®æ
å ±æºããèªåã§è¿œæ±ããŠã¿ããšè¯ãã§ãããã
[65]é¢é£ããŒã¿ããããªã«ãæããã«æäœãããé¢é£åé¡ããããªã«ãæå³çã«ããããã«
ããããããªã«ã人ã
ãå¶å©äž»çŸ©ã«è¿œéããŠããä»¶ããããªã«èšç®é«ããçµç¹çã«ãäºå®
ãæ»ãæ²ããããŠäŒããããŠããäºäŸã¯ãçãããã®ã§ãã
äžèšã®ç« ã§æãããããªãHPV ã¯ã¯ãã³ã®å®å
šåã³å¹åã«å¯Ÿããäžç¢ºå®æ§ããããŠç¢ºå®ãª
å¯äœçšã®æ°ã
ãç§åŠçãªã¡ãªãããšã¯ç¡é¢ä¿ã®ããã äžçäžã«ã°ãæãããšã§å²ããå·šé¡
ã®å¯ãé·æçãªåœ±é¿ã«é¢ããèå¯ã®æ¬ èœããããŠèå°è£ã«æœãã§ããç§åŠçãªåé¡ãã人ã
ã®ç®ãããããããã«ãã¡ãã£ã¢ãä»çµãã ã宿ç/é埳çããªè«äºãšããŠã®è¶çªåã®æŒ
åºãªã©ãããããæ€èšããããã§ãããã§ãããªãã®å¹Œãã嬢ããã«ãã®ã¯ã¯ãã³ãåã
ãããããšæããŸããïŒ
FDA ã¯ä¿¡çšã§ãããïŒ
è°äŒã®ã¢ããã€ã¶ãªãŒããŒãïŒè«®åæ©é¢ïŒã¯ãã¯ã¯ãã³ã®ããããèš±å¯ãããã®å€æãä»»
ããã FDAé¡§åããæãç«ã£ãŠããŸããã¯ã¯ãã³ã«é¢ããè°äŒèª¿æ»ã«ãããŠããã³ã»ããŒ
ãã³äžé¢è°å¡ã¯ãã®ã¢ããã€ã¶ãªãŒããŒãã®é¡§åéã®äŒèšå ±åããäžå®å
šã[176]ã§ããã
ãšãçªãæ¢ããŸãããã¢ããã€ã¶ãªãŒããŒããæ¿åºå
ã§å¯äžãäžå®å
šãªäŒèšå ±åãèªå¯ã
ãŠããŸãæ©é¢ã ãšããããšã«è§ŠããŠãããŒãã³ã¯ãã®æ©é¢ã®é¡§åéãšè£œè¬äŒç€Ÿãšã®å
éé¢
ä¿ããå
¬è¡ã®ä¿¡é Œãèžã¿ã«ããè¡çºããšåŒãã§ããŸãããã®è¡çºãšã¯ãã¢ããã€ã¶ãªãŒã
ãŒãã® 70ïŒ
ã®åœ¹å¡ããã¯ã¯ãã³ã®æ ªãç¹èš±æš©ãææããŠããããšãã就任æéã®åãšåŸäž¡
æ¹ã®ææã«è£œè¬äŒç€Ÿãã瀟å¡ãšããŠåœ¹åŸãå ±é
¬ãåãåã£ãããšãèªããŠãããšããäºå®
[176 , 354]ãªã©ãå«ãã§ããŸãã
çã®é¶èçª
FDA ã«ã¯ 8000 人ãã®ã¹ã¿ãããããŠããã®åœã§è²©å£²ãããŠããå
šãŠã®é£æåãšè¬åã®çµ±
æ¬æš©ããã£ãŠããŸããããã¯ã€ãŸããUS ã§äœ¿ã£ã 4 ãã«ã«ã€ãã1 ãã«ãã€ã圌ãã®ãã®
ã«ãªããšããããšã§ãã(Kessler [154])åœç¶ãæš©åãšåœ±é¿åãåºãŠããã§ãããããè²¢ç©ã
ãé¡ãäºãªãããé¢ä¿ããŠãããšæããŸãããïŒ
å
FDA çäºã®ïŒ€ïœïŒããŒããŒãã»ã¬ã€ã®èšèãæãåºããŸãã
ã人ã
ã¯ãFDA ãèªåéãå®ã£ãŠãããŠãããšæã£ãŠãããããããããã§ã¯ãªããFDA
ãå®éã«ããŠããããšãšã人ã
ãæ³å®ããŠããããšã§ã¯æŒãšå€ã»ã©ã®éãããããšèšã
ããã[328]
ã第äžã«ãã®ããšã§ãè¡æ¿æ©é¢ã§åãéèŠäººç©ãã¡ããã®æ©é¢ã®ç®¡èœäžã«ããå£äœããã
ã²ããã«ããããšã§ãæš©åãšå¯ãåŸãããäœå¶ãåºæ¥ãŠããŸã£ãŠããããšã§ãïŒïŒïŒFDA ã®
è·å¡ãè²·åããŠãFDA ãã®ãã®ããå®ã£ãŠãããããã«ä»åããããšãåºæ¥ãã®ã§ããã
ããŸã第äºã«ãïŒïŒïŒé£æååã³è¬åæ¥çã®äŒç€Ÿã¯äŒæ¥é£åããŠããŠãæ¿åºã®èŠå¯æš©åãå©çš
ããŠèªç±åžå Žã«ãããäŒæ¥ã©ã€ãã«ã«åŠšå®³ãå ããããå¶æ¥äžå¯èœã«ããŠããŸãããšãåº
æ¥ããã
2000 幎 2 æãUSA Today èªã¯ãFDA ãå³ãã調æ»ãçŽããé£èŒèšäºãèŒããŸããããã
ã§æžããã調æ»çµæã®å¹Ÿã€ããæããŠã¿ãŸãã[167]
– FDA ã®ç¬ç«ããïŒïŒåã®ã¢ããã€ã¶ãªãŒå§å¡äŒã«ã¯ãå°éã®ã¢ããã€ã¶ãŒã 300 人以äž
ååšããè¬åãšã¯ã¯ãã³ã®èªå¯ã«ãããæ±ºæãäžããŠããã
-ããããã¢ããã€ã¶ãŒã®å
ãå°ãªããšã 54ïŒ
ã¯è£œè¬äŒç€Ÿããå ±é
¬ãããã£ãŠããã
– 1988 幎以æ¥ããã®ãããªå°éå®¶ããå
¬çãšç§å©ã®å¯Ÿç«ãã«å¯Ÿããå
é€ãåããä»¶æ°ã¯ 800
件以äžã«ãªãã
– ãå
¬çãšç§å©ã®å¯Ÿç«ãã®äŸïŒæ ªåžã®ææãé¡§åè²»çšãç 究奚å±éãé
å¶è
ãžã®å°±è·åªéã
è¬æŒæåã³æ
è²»ã®æ¯æã
ããã§ã¯ã€ãºã§ã
FDAã1å¹Žã«æ€æ»ãã¹ãããè¬åã¯ããã€ã§ããããïŒã©ãã§ãããã1äžåã§ããããã
ãããšã500 åïŒããèããŠãã ãããã§ã¯ãçãã§ããããã§ããïŒ
çãã¯ããŒãã§ããFDA ã¯ãèªãè¬åãã¯ã¯ãã³ã®æ€æ»ãããããšã¯äžåãããŸãããFDA
ã¯æ³çã«èªå¯ããæ©é¢ã§ãã£ãŠããæ€æ»ãã¹ããè¡ãªãæ©é¢ã§ã¯ãããŸããã
ããã§ã¯ãæ°çš®ã®è¬åãã¯ã¯ãã³ã®æ€æ»ã«é¢ããæ
å ±ããäžäœã©ããã FDAã¯åãå
¥ããŠ
ããã®ã§ããããïŒ è£œè¬äŒç€Ÿããã§ãïŒããã¯ãæ¬åœã®è©±ã§ããFDA ã¯ãè¬åãèªå¯ã
ããã 1 çªã«åŸãããåŽããæäŸãããç ç©¶ããŒã¿ã«ã®ã¿ãé Œããã£ãŠããã®ã§ãã
蟺å°ã«ãããã¯ã¯ãã³æ»äº¡ä»¶
å»åŠã®å
é§è
ã§ããã¢ãŒããŒã»ã«ãã±ãªãã¹ MD ã¯ãEvery Second Child ãšããçŽ æŽãã
ãèæžã«ãããŠã圌ãè¡ãªã£ããªãŒã¹ãã©ãªã¢ã³ ã¢ããªãžããŒã®ç ç©¶ãšã圌ã®åæ¥è
ã
ã倧ããªåçºãåããããšã«ã€ããŠæžããŠããŸããã¢ããªãžããŒã«ãããä¹³å
æ»äº¡ä»¶ã¯
1000 人㫠500 人ã«ããªããDr.ã«ãã±ãªãã¹ã¯ãã®ç°åžžã«é«ãæ»äº¡çã«æžå¿µãæããŠæ°å¹Žã
Dr.ã«ãã±ãªãã¹ã¯å°é£ãªç ç©¶ãæãéããŠãããããä¹³å
ã®æ»äº¡ã®ããããã®çŽæ¥ã®åå
ã¯ãã¯ã¯ãã³ã§ããããšãçºèŠããŸããïŒãäºé²æ¥çš®ããåããåŸã®ããã¿ãã³ C æ¬ ä¹ã§
ããã¢ããªãžããŒã®åäŸéã¯ãã ã§ãããé£çæŽ»ç¿æ
£ãåå ã§ãã¿ãã³äžè¶³ãªç¶æ
ãªã®ã§
ãããäœãã¯ã¯ãã³ãæ°é³ä»£è¬ããããšããŠãäœå
ã®ãã¿ãã³ C ã䜿ãåã£ãŠããŸãã®ã§
ãã
ãã¿ãã³ C ãæ¬ ä¹ãããšãç°¡åã«ææãæ»äº¡ãåŒãèµ·ãããŸããã¢ããªãžããŒã®åäŸéã®
ç¶æ³ãå
šãèæ
®ããªãã§ãç
æ°ã§ãã£ãããæ é€äžè¶³ã§ãã£ãããææãèµ·ãããŠããä¹³
å
ãç¡å·®å¥ã«ã¯ã¯ãã³æ¥çš®ããçµæãæ°å幎éãä¹³å
ã®å€§éæ»ãç¶ããŠããã®ã§ãããã®
ç ç©¶ã¯ããªãŒã¹ãã©ãªã¢ã«ãããéå» 1 äžçŽã®éã«åã¶ç¥ããããäœå人ãã®ä¹³å
ã®æ»äº¡
ä»¶ããå»åŠçã®é«æ
¢ãªæ
床ãåŠçã®æ
æ§ã«ãã£ãŠã©ã®ããã«åŒãèµ·ãããããã瀺ããŠã
ãŸããã¯ã¯ãã³æ¥çš®ã®çµæããã¿ãã³ C åã³äºéã®æ¬ ä¹ãèµ·ãããšããæç¢ºãªææã¯ãäž
çååœã§èµ·ããŠããèŽåœçãªå¯äœçšåå¿ã«ã€ããŠãåïŒã€èª¬æãå ããŠãããŸããã[236]
AIDS 1980 幎代ã®é»ç
ïŒ2000幎代ã®éã®åµ
AIDS ã®ã¯ã¯ãã³ããçŸåšãã¹ããããŠããŸããäžçäžã§4 åäžäººãã®äººã
ãææããŠãã
ãšãã[20]ããŸã ææããŠããªã人ãäœåããããšããããšããããã®ã¯ã¯ãã³ã®åžå ŽäŸ¡å€
ãèããŠã¿ãã°ããŸãç®çã¯æããã§ãã
Dr.ã¬ãªãã«ãã»ãããŠã£ããã¯èæžã® Emerging Viruses ã§ãäžè¬ã®å ±éã§ã¯èŠã€ãããª
ããAIDSã®æŽå²ãé ã«è¿œã£ãŠç€ºããŠããŸãã[256]
ãããŠã£ããã¯1990 幎åæã«ãDr. David Acer ãšãããããªãå·ã®æ¯ç§å»ã«ãŸã€ããç°æ§
ãªäžä»¶ã®èª¿æ»ãããããã«ããã倧ããªå»è¬åè£œé æ¥ç€ŸããæŽŸé£ãããŠããŸãããDr. Acer
ã¯é£ç¶æ®ºäººè
ã®ããã«ãããããæå³çã«ãæ£è
ã® 6 人㫠AIDS ãææããããšããããš
ã§ããããããŠã£ããã¯ãããããç¹ã®ä¿¡ææ§ã調ã¹ãããã«æŽŸé£ãããã®ã§ãã
Acer ã¯ãæãã«æºã¡ãŠããŸããã圌ã¯ã以äžã®ããã«ä¿¡ããŠããã®ã§ãã
ïŒç±³åœåœé²ç·çãæµã®å
ç«æ©èœãç Žå£ã§ãããããªãã€ãªå
µåšã欲ããã£ããããæ¿åºæ©
é¢ã®å»åŠç ç©¶è
ãã¡ãAIDS ãäœãåºããã
ïŒAIDS ãŠã€ã«ã¹ãäœãåºãããåŸãææãã人éãšç¿ããã¢ããªã«è«žåœããã¥ãŒãšãŒã¯ã
ãµã³ãã©ã³ã·ã¹ã³ã«æå³çã«åæ£ãããã
ïŒãã®ä»¶ã«ã¯ãæ¿åºã®ç ç©¶å©æéãåç©å®éšããŠã€ã«ã¹æè¡ãã¯ã¯ãã³éçºãã¯ã¯ãã³è£œ
é ãåã³ããããããããå®éšã®çµæçããç
æ°ã®æ°ã
ã®æ²»çè¬ãªã©ãè«å€§ãªçµæžå©çã
é¢é£ããŠããã
ãããŠã£ããã¯å§ãã®ãã¡ããããã空æ³ã®é°è¬è«ã®äžçš®ã«éããªããšããããšã蚌æã
ãããšããŸããããããç ç©¶ãé²ããã«ã€ããŠãAcer ã®äž»åŒµããŠããå
容ãšäžèŽããæ
å ±
ããæ¬¡ã
ãšåºãŠããã®ã§ãã
ãããŠã£ããã¯ãThe Strecker Memorandum ãšããåã§ç¥ãããã1988 幎ã«çºèŠãã
ã Robert Strecker, MD, PhD.ã«ãã 3 æéé·ã®ãããªããŒããèŠã€ããŸããã
[257]Strecker ã®è©±ã¯ãAcer ã®äž»åŒµãšäžèŽããŠããŸãããã€ãŸããAIDS ãŠã€ã«ã¹ã¯è£œè¬æ¥
çãå€é¡ã®å©å®³ãçªºãæ¿åºæ©é¢ããèŠè«ãããçºæ³šãããéçºããããã®äžã§äžè¬äººã«ã°
ããŸããããšããããšã§ããStrecker ã®ãã®å ±åã¯ãçå®ã®è§£æã®ããã«åœŒãéã£ã匵æ¬
人éããç¡èŠãããã ãã§ãªããå®å
šã«æŒãé ãããå
šãŠã®ã¡ãã£ã¢ãããã«åŸããŸããã
Strecker ã¯ã1970 幎ã®è³æã«ãããŠãåœé²ç·çãèªç¶ãªå
ç«ãä»ããããšãäžå¯èœãªãã€
ãããã®ã®ãã€ãª ãšãŒãžã§ã³ãããéçºããç®çã§ãç±³åœæ¿åºã®ç§åŠè
éã«ã1000 äžã
ã«ãã®è³éãæäŸããäºå®ãçªããšãããã®ççžã¯åŸã«ãããŠã£ããã«ãã£ãŠç«èšŒãããŠ
ããŸãã(Horowitz, p.99)
StreckerïŒã WHO 㯠1972幎ã«ãT-cell ã®ç Žå£ç©è³ªãäœãããšèšãåºãã…ãããŠå幎ãã
ãã詊éšããŠã¿ãããšèšããæ¬¡ã«ã¯æ¥çš®ãå§ããããšèšãåºããã®ã ããããŠæ¥çš®å®éšã®
å Žæã¯ã¢ããªã«å€§éžâŠãŸãã«ãAIDS ãæŽçºããå ŽæãšäžèŽããŠããããïŒHorowitz, p.99ïŒ
[AIDSâŠã¯æ§æããããã®ã ]
ïŒStrecker Memorandum [257]
The Strecker Memorandum ã¯ä»¥äžã®é
ç®ã«ã€ããŠã®èšŒæ ã瀺ããŠããŸãã
ïŒAIDS ããã¢ã»ã¯ã·ã£ã«ã®ç
æ°ã§ã¯ãªãããš
ïŒAIDS ãæ§ç
ã§ã¯ãªãããš
ïŒAIDS ã¯ã¢ããªã«ç¿ã«èµ·å ããªãããš
ïŒAIDS ã¯ã¢ããªã«ã®ãžã£ã³ã°ã«ããã§ã¯ãªããç 究宀ããçãŸããããš
Ayn Rand ããã€ãŠææãããšãããèªãã®æµãæ¶ãå»ãããã®ãæå
端æè¡ã§æã匷åãª
å
µåšãæã«å
¥ããããã«ã¯ã人ã¯å¹Ÿãã§ããéãè²»ãããã®ã§ããäœå
ã®å
ç«çްèDNA ã
åŠšå®³åºæ¥ãŠãå
ç«ç³»ã«æ°ä»ãããã«äœå
ãé§ãå·¡ãããšã®åºæ¥ããŠã€ã«ã¹ãèŠã€ããããš
ã¯ã60 幎代ã®çµãããã70 幎代å§ãã«ããããã€ãªå
µåšç ç©¶ã«ãããèãªãå²ç« ãšããã
ããææã ã£ãã®ã§ãã
ãããŠã£ããã¯ç¶ããŠãAIDS ããã®äžã«çã¿åºãããšã«äžåœ¹è²·ã£ãŠåºãè
éã®ãªã¹ããå§
åçã«è©³ãã瀺ããŠããŸããããã«ã¯ç ç©¶å§å¡äŒã®ã¡ã³ããŒãWHOã®ã¡ã³ããŒãè£œè¬æ¥çã
代衚åç· åœ¹ãCDC ã®ã¡ã³ããŒãCIAã®ã¡ã³ããŒãè»éã®ã¡ã³ããŒããããŠã¡ãã£ã¢ã®é¢ã
ãªã©ãæããããŠããŸãã
ãŸããå§ãã¯ãã®è©±ããäœãã®ãµã¹ãã³ã¹çªçµã®äºåã¿ããã«æããã§ãããããèªãã§
ããæ¹ãããããããã«ããŠãããã ãšãããã°ãããŠãããšãããããªè©±ã¯èªã¿ãããªãã
ã ãšãã€ã¶ãããŠããŸãããšã§ããããããããŸããªãããã®ãããŠã£ããã®èæžããæ¿
åºã®æ£åŒææžãšç§åŠçãªåèæç®ãå
å®ã«äžèŠ§è¡šåãããã®ã ãšããããšãåããã§ãã
ãããã®æ¬ã®ããŒã¿ã¯éåžžã«æ£ç¢ºã«åŒçšãããŠããã®ã§ãèªè
ããããŠã£ããã®ãããã
åºæ¬çãªçºèŠã®æ°ã
ãééãã ãšã¯è«ç Žåºæ¥ãªããªãã®ã§ãã圌ã®çºèŠãšã¯ä»¥äžã®éãã§
ãã
ïŒç¿ãŠã€ã«ã¹ã¯ãæ¬æ¥ã¯äººäœã«ã¯ç¡å®³ãªãã®ã§ãããã人éã®ã¯ã¯ãã³ãæ±æããåŸãç¿
ãšäººéäž¡æ¹ã«æ³šå°ãããããšã§å®³ã«ãªã£ãããšãïŒ p450,461,åã³ Strecker MemorandumïŒ
ãŸãã§ãšãã¯ãŒãã»ãžã§ããŒã®åæ¥ã§ãã
ïŒæ¬æ¥ãªãããã®ç¿ãŠã€ã«ã¹ã¯ç°çš®éã®çç©ã§ææããããšã¯ãªãã£ãããGallo éããŠã€
ã«ã¹ãå€åããããã®åŸã¯ã¯ãã³ãšãã圢ã§äººéã«æ³šå°ããããšã§ææããããŠããŸã£ã
ããšã( p.118,130) [256]
ïŒHIV çºèŠã®ã¯ãã以åã§ãã 1960幎代åŸåã«ãã¢ã¡ãªã«åœç«ããç ç©¶æã®å€åç ç©¶è
ã§
ããRobart Galloãšãã®ååéããAIDSã«äŒŒããŠã€ã«ã¹ãäœçš®é¡ãäœãåºããŠããããšã
(p 75, 402 [256])
ïŒAIDS ã¯ã誰ããã¢ããªã«ã®ã°ãªãŒã³ç¿ãšæ§è¡çºããããªã£ãããåŒã£ãããããããŠç
ãŸããã®ã§ã¯ãªãããšãåãæåã«ææãã 1 äººã®æ£è
ãäžçã«åºãããã®ã§ããªãããš
(p.95)ãã±ãã¢ã®ã©ããã®æŽçªã®åºã«ãã£ããããã°ã¢ãïŒç³åãããã¡ã³ãŠã¢ãªã®ç³ïŒã
ç±æ¥ã§ããªãããšã(Preston)[256]
ïŒCIAãã倩ç¶çãå«ã倧éã®ãã€ãªå
µåšããã¡ãªãŒã©ã³ãã® Fort Detrick ã«ããå庫ã«
貯èµããŠããŠããããã¯ç Žæ£åœä»€ãäžããŸã§äœå幎ãã®éããã«ãã£ãããšã(p.495)
ïŒMerck 瀟㚠US è»éšãLitton Bionetics 瀟åã³ã¢ã¡ãªã«åœç«ããç ç©¶æããçãèªçºãã
ãŠã€ã«ã¹ãéçºããŠããŠããããã®ãŠã€ã«ã¹ã¯ã1970 幎代ã«ã¢ã¡ãªã«åè¡åœãšã¢ããªã«ã®
éã§è¡ã£ããæ¥ãããšããå
·åã«èŒžéãããŠããã(p.248) [256]
1970 幎代ã«ããããéºäŒåãå€ããè¡æ¶²ãµã³ãã«ãæ¹å€ããããŠã€ã«ã¹ãå®éšçšãŠã€ã«ã¹
ãææãããŠããåè¡åœãšã¢ããªã«ã®éãåŸåŸ©ãããããåç©ãã¡ã®è«å€§ãªæ°ãèŠããšã
ãã®äŒæç
ã倧æµè¡ãããŸã§ã«ãããªã«é·ãããã£ãã®ãäžæè°ã«ãªã£ãŠããã»ã©ã§ãã
ãã®ãããªæ
å ±ãå
šãŠèª¿ã¹ãŠã¿ãã®ã¯ã倧å€ãªä»äºã§ãã倧æµã®äººã¯ããªãã§ããããã
æ®ã©ã®äººã¯ãã®èæžãããèªãŸãªãã§ããããããããããããããªè©±ãTimes èªã§ã
WashingtonPostçŽã§ãèªãã ããšãªãããã°ãã°ãããããšèšã£ãŠããŸãæ¹ãç°¡åã§ãã
ããã§ãã倧æµã®äººã
ãã¯ã¯ãã³ã«å¯Ÿããèããæ¹ããããšããªãã®ãããã®ããã§ãã
圌ãã®æ
å ±æºãšã¯ãèã£ãºãã§åã«ã¯ããããæ°èãéèªããããŠãã¬ãã®ããã¥ãŒã¹ã
ãªã®ã§ãããã
ç§åŠå®éšãåæŸãä»ããªããªã£ãŠããŸã£ãçµæAIDSã倧æµè¡ããŠããã®ã ãšããŠããåã
AIDS ãæå³çã«äžè¬äººå£ã®éã«æµåºããããããã®ã ãšããŠãã補è¬äŒç€Ÿã®ããããšã¯æ
ããã«ãä»çŸåšã®ç¶æ³ãå©çšããŠã¯ã¯ãã³ãæäŸããäœåãã«ã皌ããšãã£ããã®ã§ãã
ãããããŠå®éã«ã圌ãã¯ããããŠããã®ã§ãã
AIDS ã«é¢ããŠãå
šãæ°ããå
šäœåããæã¿ã§ããïŒTownsend Letter ã® 2000 幎 1 æãš7
æå·ã«æ²èŒããããéåžžã«éèŠãªç ç©¶é¢é£ã®èšäºããèªã¿ã«ãªã£ã人ã¯å°ãªãã§ããããã
ããã§Dr. Gary Null ã¯ãåãããªãäºã ããã§å°æããã¡ãª HIV åã³AIDS ã«ãŸã€ãã
è«žäºæ
ãã幟ã€ãæå¿«ã«ããŠãããŠããŸãã[165]Null ã¯ããã® 15 幎éã«èšç»çã«äœãåº
ãããŠãã瀟äŒé念ã«å¯ŸããŠã容赊ãªã確蚌ãèŠæ±ããŠããŸãããã®ç€ŸäŒé念ãšã¯ã以äž
ã®éãã§ãã
ïŒHIVã¯ãã¢ããªã«ããæ¥ãAIDSãšããç¬ç¹ã§æ°çš®ã®ç
æ°ãåŒãèµ·ãããŠã€ã«ã¹ã§ããã
ïŒAIDS ãšã¯ãæ§è¡çºã«ãã£ãŠææããäžçèŠæš¡ã®æµè¡ç
ã§ãæ²»çæ³ã¯ãªããä»ãŸã§äººé¡ã«
ååšããªãã£ãæ°ããç
ç¶ã§ãããç§éã®çåãè
ãããã®ã§ãããçã
HIV/AID ãšããé念ã¯ã1984 幎 4 æ 23 æ¥ã«ãHHS ã®ç§æžã§ãã Heckler ã圌女㮠TV
ã¢ããŠã³ã¹ã§ãRobart Gallo ãããããããAIDS ã®åå ã§ããããŠã€ã«ã¹ãçºèŠãããšã
ã£ãããšããå§ãŸããŸããã[130]ãããã¡ãã£ã¢ã¯ããããŸãã®ãããããããšããç®æ
ãçããŠããŸããããããå
ãããã«ã€ããŠèŠçŽãããšã¯ããŸããã§ããããã®åŸããã«ã
HIV ãçºèŠããã®ãå®ã¯ Luc Montagnier ãšãã人ç©ã§ããããšã蚌æãããããã« HIV
ã®æç¢ºãªååŠæåé
åã確ç«ãããŠããããããã HIV ã§ããããïŒã€ã®æ±ºå®çãªåçç»
åããªããšããã®ã«ããã®è©±ãå®çããŠããŸã£ãã®ã§ããçŸåšã§ãããã¢ã¡ãªã«ã§ 5 æ³ä»¥
äžã®äººã®99ïŒ
ã¯ãAIDS ã HIV ãšããåã®ããç¹å®ã®ãŠã€ã«ã¹ãåå ã§ãªãç
æ°ã ãšä¿¡ã
ãŠããŸã£ãŠããŸãã
Null ã¯ã1984 幎以éã«åºçãããã30 äžä»¶ã® HIV/AIDS é¢é£èå¯ã®å€ãã«å¯Ÿããç°è°ã
å±ããŠããäžçææ°ã®ç ç©¶è
ãã¡ãšååããŠããŸãããããã®ç ç©¶è
éã¯ãHIV ãåå¥ã«
ååšããŠããããšã¯ãã€ãŠãªããAIDS ã®åå ã«ãªãããšã¯æãåŸãªãããšäž»åŒµããŠããŸãã
Null ã¯ãŸããAIDS ã蚺æãããŠããå°åã«ãã£ãŠãçŸæ£ãç°ãªãããšãçåèŠããŠããŸ
ãããã®äºå®ãããAIDS ããããã 1çš®ã®çŸæ£ã§ããã®ããšããã倧ããªãçåãæ¹§ãäž
ãã£ãŠãã ãããšãã£ãŠãå€ãã®åœã
ã§åãæ§ãªçç¶ãæ±ãã人ã
ãæ»ã«è³ã£ãŠãããšã
ãããšã«ã¯å€ãããŸããããããããã ãã§ã¯ãAIDS ãåäœã®å®èšŒå¯èœãªçŸæ£ã®å®äœã§ã
ããšããã«ã¯äžååãªã®ã§ããããããç
æ°ãšãããã®ã¯ãç¬ç«ããïŒã€ã®ç
åäœãåå
ã§çºçãããã®ã§ããããã¢ãã©ã³ã¿ã§ããžã³ãããšã§ãããã³ãã³ã§ãããŸã£ããåã
ç¶æ³ã§ AIDSãåŒãèµ·ããã¯ãã§ã¯ãããŸãããïŒ
Null ã¯ãä»ãŸã§åãä»ããããå
šãŠã®ãŠã€ã«ã¹æ§ã®ç
æ°ããåå ãšãªããŠã€ã«ã¹ãç¬ç«ã
ãŠããŠããã®å®æ
ãèå¥ãããååŠæåãé
ååãããä»ã®ãŠã€ã«ã¹ãšã®åºå¥ãå¯èœã§ã
ç»åããããšèª¬æããŠããŸããHIV ã¯ããããã®ãããã«ã該åœããŸããã
HIV ã«é¢ããŠèšãã°ãç°ãªã 2 äººã®æ£è
ããå
šãåãè€è£œã®ãŠã€ã«ã¹ãã¿ãããããšã¯äž
床ãç¡ããåäžã®æ£è
ããã§ãããç¡ãã®ã§ãïŒäººéãã HIV ãšãããŠã€ã«ã¹ãçºèŠãã
ãããšã¯ãæªã ãã€ãŠãããŸããã
ããã§ã¯ã人ã
ã¯äœãåå ã§æ»ãã§ããã®ãïŒ
å€ãã®å»è
ã¯ãåœã«ãã£ãŠ AIDS ã®çç¶ãç°ãªãããšããåã«ã極端ãªé
žåäœçšã«ããã¹
ãã¬ã¹ãã®çµæã§ãããšèããŠããŸããããã¯ã€ãŸãã现èã倧éã®ç¡å¶éã§åŸ¹åºããã
ã¡ãŒãžãåããå
ç«ç³»ãå±éºãªã»ã©æå§ããããšããæå³ã§ãããã£ããã¯äœã§ããã人
ã¯å
ç«æ©èœãæ
¢æ§çã«äœäžãããšãæ»äº¡ããããšãããããšãèŠããŠããã§ãããïŒãã
ã«ã¯å¥ã«ç¹å®ã®ã°ãèè«ãç
æ°ã¯å¿
èŠãããŸããã
Null ã¯ãHIV ã AIDS ãèªçºããããã«ãAIDS ã HIV ãåŒãèµ·ããããšããããšèãã
ããããšèª¬æããŠããŸãã圌ã¯ãç ç©¶è
éãHIV ãšåŒã¶ãã®ããå®ã¯AIDS æ£è
ã®è¡æ¶²ã®
äžã«ãªãããã®åœ¢ã§ååšãããäžç¹å®å€æ°ã®çްèã®æçãäžãŸãšãã«ããç·ç§°ã§ããããš
瀺ããŠããä¿¡ææ§ã®é«ãè³æã«èšåããŠããŸããå§ãã®çºèŠè
ã§ãã Montagnier ãš
Robert Gallo ãçºèŠããã®ãããããã现èã®ãããã ãã§ããæçœã«ãããããã ããš
確å®ã§ãã HIVãŠã€ã«ã¹ãšãããã®ã¯ãååšããªãã®ã§ãïŒ(Mullis [130])ãããã®ç ç©¶è
ã«ããããšããšã®ç ç©¶å ±åã«ã¯ãHIV ã AIDS ã®åå ã ãšèšŒæããŠããç ç©¶ã¯äžåãããŸ
ããã
äŒçµ±çãªç
çåŠã§ã¯ãAIDS 以å€ã®ç
æ°ã¯å
šãŠãç¬ç«ãã埮çç©ïŒç
åèïŒãããçšåºŠã®æ°
ã§ååšããããšããããšãæ¡ä»¶ã«ãªã£ãŠããŸããåå ãšãªã埮çç©ã確å®ãããŠãããã
ãã®äžå®åºæºéãæ±ºããããŠããªãç
æ°ãªããŠãAIDS ã ãã§ããïŒDuesberg,[314]ïŒ
ããã«ãAIDS ã®æ€æ»ã¯ãåœã«ãã£ãŠå€§ããç°ãªããŸããAIDSæ£è
ã ãšèšºæããã人ã®ã
ã¡å°ãªããšãïŒïŒïŒ
ã®ä»¶æ°ã«ãããŠã¯ãäœã®è¡æ¶²æ€æ»ããªãã«ãçç¶ã ãã§èšºæãããŠã
ããããæ£è
æ°ã¯å®éãããããªãå€ãæ°ããããŠããŸã£ãŠããŸããçç¶ã ãã§å€æãã
ãšãAIDS ã¯ãå°ãªããšã 7çš®é¡ã®ä»ã®ç
æ°ãšäžèŽããçç¶ãæã£ãŠããã®ã§ããTB ãã
ã©ãªã€ãCMVãæ
è¡æã®äžç¢çç¶ãªã©ãã§ãïŒ(Hodgkinson)[256]
1987 幎ã«ãã¡ãã£ã¢ãéåã声ã§äºæ³ããŠãããããªãAIDS ã倧æµè¡ãçºçããªãã®ãã
ããã§èª¬æãä»ããŸãã[147] AIDS ã¯äŸç¶ãšããŠãä»ãŸã§ã®ç
æ°ã«ããããããåºåã®
人ã
ïŒã€ãŸããäžç¹å®å€æ°ãšæ§è¡çºããããªãã²ã€ããæ³šå°ç³»ã®è¬ç©äœ¿çšè
ã人å£éå¯å°
åã«äœãæ é€å€±èª¿ã®äººã
ãšãã£ããå
ç«ãæ¿ããäœäžããŠãã人ã
ã«éãããç
æ°ãªã®ã§
ãã
ãŸããAIDS æ€æ»ã«ã€ããŠããåºæ¬çã«ããããç¹ããããŸãããã®æ€æ»ã§ã¯ãAbbott 瀟
補ã®ããã±ã質æåã«å¯ŸããŠãæäœãèŠãããã AIDS ã§å±ãªãããšããããšã«ãªã£ãŠã
ãŸãã(Maggiore [130]) ãããä»ã®ç
æ°ã®å ŽåãæäœãèŠããããšããããšã¯æ¢ã«ç
æ°ã¯
æ²»ã£ãŠããŠããã®äººã«å
ç«ãä»ãããšããããšã§ããããã AIDS ã®å ŽåãHIV æäœãã
ãããªããã§ãç
æ°ã«ããã£ãŠãããã蚺æããŠããŸã£ãŠããŸããããã¯ãäœå幎ãç¶ã
ãŠããç§åŠçãªå
ç«åŠã«ãå
šãçžåãããã®ã§ããHIV ã¯ãæäœã«ãã£ãŠäžåãããåŸã«ã
ããã§ãç
æ°ãåŒãèµ·ãããšããããå¯äžã®ãŠã€ã«ã¹ã ãšããããã§ãã
Kary Mullis PhDã¯ãAIDS ã®èšºææ€æ»ã®ååãšãªããã®ãçºæãã1993 幎ã«ããŒãã«è³
ãåè³ããŸãããããªã¡ã©ãŒãŒé£éåå¿æ³ãšããããæ€æ»ã§ããDr.Mullis ã¯ãAIDS ãäŒ
æç
ã ãšããããšèªäœã«çåã瀺ããŠããŸãã圌ã¯ã以åã®ãã©ã°ã©çã®éã«ããç§éã
åãééãããããšææããŠããŸããããã¯ãã³ãã³é
žæ¬ ä¹ã®ç
æ°ã§ãããããšããšã¯ã
ãç
åèãåå ã ãšèããããŠããŸããããã ãAIDS ã®éããšããã¯ãç§éããã¯ãåå
ãæ¢ãããšããŠããªãç¹ã§ããåå ã¯ã宿çãªåžåã«åŸã£ãŠæ±ºå®ãããŠããã®ã§ãããã
Mullis ã¯ãAIDS ã®ç§åŠçãžã®ç»å ŽãããããŸã§ã®ã»ãã®ç
æ°ã®ç»å Žã®ä»æ¹ãšããªãéã£
ãŠããããšã«é©ãã®ã³ã¡ã³ããããŠããããæªéã«åãä»ãããªããã°ããããªããšã«ãªã
ãªãã£ãããã«ããšè¡šçŸããŸããããã®é¢šå€ãããªè¡šçŸã¯ãAIDS ãé¢é£ãããšèããããŠ
ããããããããç®å°ãšãªãç
æ°ãã®çç¶ããæ¥ãŠãããã®ã§ãããã®ãç®å°ãšãªãç
æ°ã
ãšã¯ãèºçãçµæ žãEpstein Barr çãmono(ãã¹ç
)çã§ããHIV éœæ§ã®äººã«ãããã®çç¶
ãçŸãããšããšããã«ããã¯èªåçã«ããAIDSãåå ã ããšãããŠããŸãã®ã§ãã [130]
ãªãããããªã«ãŸã§ããŠè€éãªç
æ°ãäœãåºãããšããã®ã§ããããïŒã²ãã£ãšããŠã
AIDS ãšããè«å€§ãªåžå ŽäŸ¡å€ãçç±ã§ããããïŒ
ãAIDS ã®é¢é£åéã«ãã人éã¯å
šå¡ãAIDS ã®ããã«åããŠãããããã¯ãïŒã€ã®å€§èŠæš¡
ãªäŒæ¥ãšããŠèããã¹ããã®ã ãã(Mullis âMaggiore [147])
ããããšãŠã倧ããªäŒæ¥ã§ãã1985 幎以æ¥ããã®åœã®æ¿åºã¯ãAIDS ç ç©¶ã«90 åãã«ãè²»
ãããŠããŸãã([147]) WHO ã«ããã°ãäžçäžã§ 4 å 2 çŸäžäººã HIV ãæã£ãŠãããšã
ãããšã§ããããã®æ°å㯠6 幎éå€ãããªããŸãŸã§ããå€ããå¿
èŠãªã©ããªãã®ã§ããã
ããã空æ³äžã®æ°åã¯åžå Žå®£äŒã®éå
·ã§ã¯ãã£ãŠããç§åŠçãªãã®ã§ã¯ãªãã®ã§ãããã
Null ã¯éæã«ããAIDS ã¯ã¯ãã³ã®ç»å Žã§ããŸããªããç®ã«ãããã§ãããããšãååæ³
ããã®ãã¡äœ¿ãããããšãäºæž¬ããŠããŸãããæäœãããããšïŒHIV éœæ§ïŒã¯ããŸãçªç¶
ã«ãç
æ°ãæ²»ã£ãããããšããŠæ±ããå§ããã§ããããä»ã®ç
æ°ã«ãããŠã¯ãæãããã
ã ã£ãã®ã§ããããäžäœãã©ã£ã¡ãªã®ã§ããããïŒ æäœã¯ãç
æ°ã§ããããšã瀺ããã®
ãªã®ãããããšãç
æ°ãæ²»ã£ãããããªã®ãïŒïŒïŒãã®æã®å£²ãåºãååãäœããããã«ã
ã£ãŠçãã¯å€ãããŸãã[165]
Null ã¯ãã¡ãã£ã¢ã®è¿·ä¿¡ã®æ£äœãããã 1 ã€æŽé²ããŠããŸãïŒç±³åœã®çŸæ£ç®¡çäºé²ã»ã³ã¿
ãŒã¯ãææèª¬ã蚌æããããšã¯ãããŸããã誰ããã AIDS ããã€ããã人ãããŸã第 3
è
ã« AIDS ããã€ãããšããäŸã¯ãäžåºŠãèŠã€ãã£ãŠããªãã®ã§ãã[165]ããã§ããã®æ
æèª¬ããã¿ããªç¥ã£ãŠããŠåœããåãªã¯ãã®äžè¬åžžèã§ããããã® 15幎éã«ã¡ãã£ã¢ãå ±
ããäœçŸãã® HIV/AIDS 説ã®é¢é£èšäºãè£ä»ããŠãã説ã§ãããéå» 20 幎ãã®éã¢ã¡ãªã«
äººã®æ§è¡åãæ©ãŸããŠãã説ãªã®ã§ãã
HIV ã AIDS ã®åå ã§ãªããšãªããšãåå ã¯äœãªã®ã§ãããïŒ
äžè¬åžžèã§ã¯ãHIV ã AIDS ãåŒãèµ·ãããAIDS ãæ»ãåŒãèµ·ããããšãããŠããŸãã
ãããŠãã®èª¬ã¯ãçµ¶ãéãªãã¡ãã£ã¢å ±éãšããã®èª¬ãæ¯æããç ç©¶å
容ããåºçããªã
ããã«å³ããã³ã³ãããŒã«ãããåºçç°å¢ã«ãã£ãŠãäžè¬ã®äººã
ã«ä¿¡ãç¶ããããŠããŸãã
ããããåé¡ã¯ãç§åŠçã«èŠããšãã®èª¬ãæ¯æããããšã¯äžå¯èœã ããšããç¹ãªã®ã§ãã
ãŸã第äžã«ãç§éã AIDS ãšåŒãã§ãããã®èªäœãããç¹å®ã® 1 ã€ã®ç
æ°ã§ã¯ãªãå¯èœæ§
ãæããããŸããããã¯ããªã¹ã¯åºåã«è©²åœãã人ã
ãã䌌ããããªèããçæŽ»ç°å¢ã®çµ
æãšããŠèªåã®å
ç«ç³»ãç Žå£ããŠããŸãã䌌ããããªæ»ã«æ¹ãããŠããããšããã ããªã®
ãããããŸããã
Laurie Garrett ãææããŠããŸããããµã³ãã©ã³ã·ã¹ã³ããã¥ãŒãšãŒã¯ã«äœãã²ã€ã®äººã
ã®å€ãã¯ã80 幎代㫠AIDS ãçºèŠïœ£ãããŠãããã以åãšããŸãå€ãããªãã©ã€ãã¹ã¿ã€
ã«ã§ç掻ããŠããŸãã[223]é¿åŠéå
·ã䜿ããã倿°ã®ã»ãã¯ã¹ããŒãããŒãæã¡ãé£ç掻
ãèããŠããŠãäºç¡é
žã¢ãã«ãä»ã®ããŒãã£ãŒãã©ãã°ãéå£ã§æåããæçç©è³ªå€ãä»
ã®åŠæ¹è¬ãã€ã¥ãããŸã«äœ¿çšããæ°Žåäžè¶³ãæ é€äžè¶³ãªã©ïŒãããïŒã€ã ãã§ããæ·±å»ãª
å
ç«æå¶ã®åå ã«ãªããã®ã§ãããããããå
šãŠè¡ãªãã°ãå
ç«ç³»ãå
šæ»
ãããŠããŸãã
ãšãããããŸãããããŠããããAIDS ã®å®æ
ãªã®ã§ããäœãããŸãã«ãå°æããæ é€äžè¶³
ã§æ¯ã«æº¢ããŠããããã§ãå€éšããã®äŸµå
¥ç©ãšãèªãã®æ¯ããã现èãšã®èŠåããä»ããª
ããªã£ãŠããŸãã®ã§ãããã®ãããäœã¯èªããæ»æãã¯ãããŸãã
ãã®ä»ã®ãã€ãªã¹ã¯é åã«è©²åœãã人ã
ããåãã§ããè²§å°ãIV ãã©ãã°äŸåè
ãäœãæ¯
ããã©ã€ãã¹ã¿ã€ã«ïŒããããå
ç«ç³»ãç
çã«äœäžãããŠããŸããããã§å
šãŠã¯ãããŸãã
ãšããããã§ãã
80 幎代ã«ãããŠã¯ãAIDS ã¯ãã©ã€ãã¹ã¿ã€ã«ãåå ã®ç
æ°ã§ãããããã 90 幎代ã«ãã
ãŠããAIDS ã¯åãçšåºŠã®é »åºŠã§ãAZT ãªã©ã®ãã©ãã°ãåå ã«ãªã£ãŠããããš Null ã¯ç€º
ããŠããŸãã
AIDS é¢é£ã®è¬ãåŒãèµ·ãããããªãã¡ãŒãžããHIV ã ãã§åŒãèµ·ããããšã¯çµ¶å¯Ÿç¡çã§
ããããããAIDS ã¯ã ãã ããšæªåããæ»ã«è³ãç
æ°ãšãããŠããŸããããã©ããç
æ°ã®
çç¶ã§ãã©ãã AIDS ã®è¬ã«ããå¯äœçšããåºå¥ããããšãã人ã¯ããªãã§ãããã[165]
ãããããçæ³ã®åžå Žååã§ã¯ãããŸãããïŒ
AIDS ã§æ»äº¡ãã人ããã¯ãAZT ãã©ãã°ãåå ã§æ»äº¡ãã人ã®ã»ããå€ããšèšããŸãã
çŸåšãAIDS æ£è
ã®æ»äº¡åå ã®ãã¡ãæå€§ã®èŠå 㯠AZT ãªã©ã® AIDS è¬ã䜿çšããçµæã
èèãããããŠããŸããšãããã®ã§ãã(World AIDS Conference,[130])
補è¬äŒç€ŸããFDA ãš NIH æ©é¢ã«ãã補è¬äŒç€ŸåŽã®ä»£ç人éããã®çµ¶ãéãªãå§åãåãã
AZT ã¯ããŸããåè«ã®äœå°ããªã確ããªæ å
ã®åº§ã«é®åº§ããŠããŸãã(Mullis âvideo)[130]
ããã«å¯ŸããAIDS/HIV/AZT ãšããå³ç²ãªãæçŸ©ãã«å¯Ÿæããç ç©¶è
ã¯ããã ã¡ã«è³éæŽ
å©ãéãããèªãã®ç ç©¶çºèŠãåºçããéãã奪ãããŠããŸãã®ã§ãã(Duesberg)[314]
AZT ã¯å
æ¥ã60 幎代ã«ãçã®ååŠçæ³ã§äœ¿ãããŠããè¬ã§ããããããŸãã«ãæ¯æ§ã匷ã
ã£ããã廿¢ãããŸãããããã¯çŽ°èæ¯ïŒãããã现èãã©ãŒïŒãšãã£ãŠãDNA ã®çµåã
黿¢ããŠããŸããŸãããã® AZTããAIDS ã®å°æ¥ãšå
±ã«ãã AIDS ã®æäžäž»ããšããæ°ãã
PR ååãšããŠããŸãå庫ããåŒã£åŒµãåºãããŠããã®ã§ãã忀æ»ãªã©ãäžåè¡ãªãããŠ
ã¯ããŸããïŒNull ã®ææã«ããã°ãAZT ã¯é·æçã«äœ¿çšãããšãéåžžã«æ¯æ§ã®åŒ·ããè¬ãš
ããããšã§ããããAIDSä¿¡ä»°ã®ãªãã§ãããªã«åŸ¡é«ãäœçœ®ã«ããããŠããã®ãããªããªã
çãéã£ãŠããã®ãããããŸãããã[165]
å°çè¡ã
UC ããŒã¯ã¬ãŒå€§åŠã® Peter Duesberg PhDã¯ãã¬ãããŠã€ã«ã¹ã®éºäŒåãæåã«éé¢ãã
ç§åŠè
ã§ããã圌ã¯ãŸãããã®æ°ãã AIDS/HIV ä¿¡ä»°ã®æçŸ©ã«éããããã®ãªãã容赊ãª
ãæŒãã€ã¶ããŠããŸããæªç©ã®ãããªãæ
å ±å§åæ©ãã«ãæåã«å¯Ÿæãã人ç©ã§ããããŸ
ãã[314]
æ¬åœã«æªè³ªãªã®ã¯ãããããå
ç«ãæå¶ãããŠããæ£è
ãã¡ããHIVéœæ§ã§AZT ãåããª
ããã°ãæ»ãã§ããŸããšããèããéµåã¿ã«ããŠããŸã£ãŠãå®éã«çç¶ããªãããŠããã
ãããããªãæ²»çæ³ã«ç®ãåããããšãåºæ¥ãªããªã£ãŠãããšããããšã ãšãDuesberg ã¯
æ€æ
šããŠè¿°ã¹ãŠããŸããAZT ããã®é¡ã®è¬ã§æ²»ã£ã AIDS æ£è
ãªã©ãä»ãŸã§ 1 人ãããªã
ã®ã«ããã®ããšã«ã¯èª°ãæ°ä»ããŠããªãããã§ãã[165]ãããä»ããã®äºå®ã¯äžè¬ã«ãèª
ç¥ããå§ããŠããŠãNIHã®åç· åœ¹ã§ãã Dr.Anthony Fauci ã§ããèªããŠããŸãã[347]
AIDS ã¯ã¯ãã³
AIDS ã¯ã¯ãã³ã¯äœå¹Žãåãããéçºèšç»ãç·ŽãããŠããŸãããããŠã¬ã³ããããªãã©ã³ãã
ã¿ã€ããããŠåè¡åœã«ãããŠæ€æ»ãã¹ããè¡ãªãããŠããŸããã1999 幎ã«ã¯ VaxGen ãšã
ãã·ãªã³ã³ãã¬ãŒã®ãã€ãªæè¡äŒç€Ÿãããã€ãªã¹ã¯åºåã® 5000 人ã®å¿é¡è
ã«ãAIDS ã¯ã¯
ãã³ã詊ãå§ããŸããã(www.jasmyn.org/vaxgen/, Washington Post[198,197] ) 2003 幎
1 æãŸã§ã«ãã¿ã€ã® FDAããµããªã¡ã³ãé£åãšããŠèªå®ããåãå
¥ããAIDS ã¯ã¯ãã³ã¯
1200äžåå以äžã«ããªãã6 äžäººãã®æ£è
ãæ¥çš®ãè¡ãªã£ãŠããŸãã(journalVaccine[105])
é³¥ãšãããã¬ãŒã³ã
2002 幎 3 æã®JAMA èªã«æ²èŒãããèšäºã¯ãã¯ã¯ãã³ç ç©¶ãšãããã®ããæ¬åœã¯ã©ãã ã
ç§åŠçãªãã®ãªã®ããæ±ºå®ä»ãããã®ã ã£ããšèšããã§ãããããã®èšäºã¯ãªããšãå®å
š
ãªã¯ã¯ãã³ã®å¹é€äœãšããŠãã«ããªã€çãã®äœ¿çšã確ç«ããããšå ±éããã®ã§ãïŒ(Vastag
[139])ææããã«ããªã€ã®çްèèããAIDS ã¯ã¯ãã³ãå¹é€ããã®ã«ãã奜ãŸããããšèšã
ã®ã§ãã
ä»ãŸã§äœå¹Žãã®éãäžè¬ã®å ±éãã AIDS ã«ã€ããŠã®ç¥èãåŸãŠããæ®éã®èªè
ã®æ¹ã¯ã
äžèšã®äžç¯ãèªãã§ãæ°ãçã£ãŠããããšæããããšã§ããããããäžåºŠèšããŸãããã
ãã«æžããŠããããšã¯ããããŸä¿¡ããªãã§ããããæ²èŒããŠããåèè³æã調ã¹ãŠã¿ãŠã
ã ããã
AIDS ã¯ã¯ãã³äŒè°
2001 幎 1 æ 20 æ¥ãã¯ã·ã³ãã³ DC ã§å ±éäŒè°ãéãããBarbara Lou Fisher ã attorneys
ã® Walter Kyle,Jim Turner ãªã©ãæ°äººã®ç ç©¶è
ã®ãã¬ãŒã³ããŒã·ã§ã³ãè¡ãªãããŸããã
ãã®äŒè°ã®ç®çã¯ãïŒã€ã® AIDS ã¯ã¯ãã³éçºã®ããã«ã¯ãäœçŸäžãã«ãšããè²»çšããã
ãããšã«ã人ã
ã®æ³šç®ãåããããšã§ãã[315] ãã§ã«åœæãä»ã®ã¯ã¯ãã³éçºã«ããã
è²»çšã® 4 åãã®é¡ããAIDS ã¯ã¯ãã³éçºã®ããã«äœ¿ãããŠããŸããã
ãã®ã¯ã¯ãã³ã®æšé²è³éæºã®ã»ãšãã©ã¯ããã®ã¯ã¯ãã³ã®äžççãªå¯èœæ§ãææ¡ããŠããã
Bill Gates ãåºè³ããŠããŸãããã®åŸãBush 倧統é ã 2002 幎ãAIDS ã¯ã¯ãã³ç ç©¶è³é
ãïŒïŒïŒ
å¢ãã® 3 å 6 å 7 çŸäžãã«ã«åŒãäžãããšææ¡ããŸãããïŒGerrettïŒ[160]
ããã§æ€èšãããŠããæ¡ãšã¯ãææã¯ç§å¯ã§ããå°æ¥ã«ãããŠãäžçäžã® 12æ³å
ãã¹ãŠã«
AIDS ã¯ã¯ãã³ãäžããããããã«ããããšãããã®ã§ãã[315]
ãã® 2001 幎äŒè°ã§ææ¡ãããç¹ãããã€ãæããŠã¿ãŸãã
ïŒæ°ããã¯ã¯ãã³ã¯ãä»ãŸã§ã«äžåºŠã AIDS ã®åå ã ãšèšŒæãããããšã®ç¡ããHIV çšã®
ã¯ã¯ãã³ã«ããããšã
ïŒãã®ã¯ã¯ãã³ãåãã人ã¯ãHIVéœæ§ã«ãªããšããããš [281]
ïŒç§åŠçã«ã¯ãŸã£ããåãå
¥ãããã説ã ããPR æšé²éšã¯ãã®ã¯ã¯ãã³ã AIDS ã«å¯ŸããŠ
å
ç«ãã€ããŠãããããšå®£äŒããããšã
ïŒãã®ã¯ã¯ãã³ã®ã¿ãŒã²ããã¯ãå
šãŠã® 12æ³å
ã§ããããšã
ïŒUS ã®è»äºå
µãã¡ã«ãæ¬äººéã«ã¯æ°ä»ãããããšãªãã«ãAIDS ã¯ã¯ãã³ã®æ¥çš®ãã¹ãã
宿œããå¯èœæ§ã
HIV ããçºèŠããã 2 人ã®ç§åŠè
ãLuc Montagnier ãšRobert Gallo ã¯äž¡è
ãšããHIV ã¯
AIDS ã®åå ã§ã¯ãªããšäž»åŒµãç¶ããŠããŸãã
æŽãªãæé²
2003 幎 7 æãäžçAIDS ããã°ã©ã ã¯é£èºçãªå±éãè¿ããŸããã
ãBush 倧統é ã 補è¬äŒç€Ÿã®å
é圹ããã¢ããªã«ãšã«ãªãæµ·å°åã«ããã AIDS 察çãšã
ãŠæ°ããèšããã 15 åãã«ã®ããã°ã©ã ã®åç· åœ¹ã«ä»»åœãããã®ã§ãã
倧統é ã䜿ç¯ã«ä»»åœããRandal Tobiasãšã¯ãEli Lilly & Co瀟ã®åCEOã ã£ã人ç©ã§ãã
[81]Eli Lilly 瀟ãšèšãã°ãã¯ã¯ãã³è£œé äŒç€Ÿã§ã¯ãããŸãããïŒ
ããã« 15 åãã«ïŒãã®é¡ã¯ãããŸãŸã§ã«ã¯ã¯ãã³ã®åžå Žå£²ãåºãã«äœ¿ãããŠããè²»çšã®ã
100 åã«ããªããŸããããããããã¯ããåãªãçµæžçãªçç±ãããªããã®ã§ããAIDS ã¯
ã¯ãã³ã¯äžçèŠæš¡ã§å£²ããåžå Žååãªã®ã§ãããã
AIDS ã¯ã¯ãã³ããŠã§ãæ€çŽ¢ããŠã¿ããšãäžåºŠãç¹å®ãããããšããªããç§åŠçé
åãåã
ã£ãŠããªããHIV ãŠã€ã«ã¹ãšãã芳ç¹ããæžãããã確ããªããšã¯äœãæããŠãããªãã
空èã§ãŸãããã®èšäºã°ãããäœçŸä»¶ã該åœããŠåºãŠããŸãã
æ¥ããªããŠã倧äžå€«
æããã€ã«ã€ããAIDSã¯ã¯ãã³éçºã«é¢ãããã®ç±ççãªç§°è³ãåŸã
ã«çŽãŸã£ãŠããã®ã«
ãæ°ã¥ãã§ããããïŒBill Gates 㯠2007 幎ã«ããã®ã¯ã¯ãã³ã売ãåºãããã®ã¯ããš 10
幎åŸã ãããšäºæž¬ããŠããŸãã[53] 90 åãã«ãã®R&Dæ¥ãæ¯æ°ããé²ãã§ããã®ã§ãã
ãã売ãåºããæ¥ãå¿
èŠã¯ãªãããšããããšã§ããã¯ã¯ãã³æ¥çã®ä»ã®ã»ãšãã©ã®ååãš
åæ§ãAIDS ã¯ã¯ãã³ããã°ã©ã ããç§éãæãç
æ°ããæã£ãŠãããããšãç®çã§ã¯æ±ºã
ãŠãªããç§éãæãç
æ°ããæã£ãŠãããŸãããšå®£äŒã売ãåºãããšãç®çã ãšããããš
ããå¿ããŠã¯ãããŸãããããããããã°ã©ã ã«ã¯ãæ¯å¹Žã®å€é¡ã®äžççµè²»ãå®éã«ç ç©¶
ææãæ±ããããããšã¯æ±ºããŠãªãç ç©¶ãžã®å·šé¡ã®è£å©éããããŠäœåäžäººãšããç ç©¶å¡
ã®ç§åŠè
éã®ãã£ãªã¢ãé¢ãã£ãŠããã®ã§ãã
èå°å¹æãèããŠãããã
æè¿ã®å€±æç¶ãã®äººäœå®éšã®ããããAIDS ã®åœãã®æ å
ã¯ãåŸã
ã«ç¶æãé£ãããªã£ãŠã
ãŠããŸãã2008 幎ã«ã¯å°ãªããšãïŒã€ã® AIDSã¯ã¯ãã³è©Šéšãäžæ¢ã«ãªããŸãããããã
ã¯çŽæããå
ç«å¹æãç¡ãããã ãã§ã¯ãªãããã£ãšæªãããšã«ãå®éšäœãšãªã£ã人ã
ã®
AIDS ãžã®æµæåããã¯ã¯ãã³ã®ããã§ãã匱ããªã£ãŠããŸã£ãããšãçç±ã§ãã[11] 25
幎éã®ææ¥ãšãæ¯å¹Žäœåãã«ãã®è³éãè²»ãããŠç ç©¶ãè¡ãªã£ãçµæãå
端ãããç§åŠè
éãæ¬¡ã
ãšãAIDS ã¯ã¯ãã³ã®è£œé æ¹æ³ã¯æªã ã«åãããªããšå
¬ç¶ã«èªããŠããŠããŸãã
HIV ãŠã€ã«ã¹ã®æ£äœããæããã«ãªã£ãŠããªãã®ã§ããããå¥ã«ããã«ã¯é©ããŸãããã
2008 幎ã®ããã¢ããªã«èª¿æ»ç ç©¶ã§ã¯ã詊éšã¯ã¯ãã³ ãåãã人ã
ã®æ¹ããã¯ã¯ãã³ã®åœ±
é¿ã§ãããã« AIDS ã«ãããããããªããšããçµæãåºãŠããŸããã¡ããã©ã倩ç¶çãã
ãªãªãçŸæ¥å³ã®å Žåãšåãã§ãã
以äžãããHIVãAIDSã®åå ã ãšèšŒæãããããšã¯1床ããªãããAIDSã¯ã¯ãã³ãAIDS
ã®åå ã«ãªãããšã¯èšŒæãããããšããããšã«ãªããŸãã
ç§åŠçã«ã¯ SARS ãé³¥ã€ã³ãã«ãšã³ã¶ããããç
ãšåãããæ²ã¿ããã®æ³¥èã«ä¹ã£ãç¶æ
ã® AIDS ã¯ã¯ãã³ããã°ã©ã ã§ãããäžçã®æ¿æ²»äºæ
ã«å¿
èŠãšãããŠããããããããŠã
ãã«ã¯ãéã絡ãã§ããããã«ãä»ãŸã§ãã£ãšçŽ æŽããããã®ã ãšèŠããããå·¥äœããªã
ããŠããŸãããå®éã«äœã®è£œåãäœãäžããã«ããããªã«é·ãéçãæ®ããç£æ¥ã¯ãAIDS
ã¯ã¯ãã³ã®ããžãã¹ã ãã§ããããã¯ã100ïŒ
çè«äžã«ã®ã¿ååšãããã®ã§ããããããã
ã®çè«èªäœãæåããééã£ãŠããã®ã§ãããããŠä»ã§ã¯ãç§åŠçã«ãããäžçææ°ã®æ¯
æè
éã§ãããééã£ãç§åŠçæ ¹æ ã«ãããè³éãã€ã蟌ãã§ããèªç¶ã®æçãå€ããã
ãšã¯åºæ¥ãªãã®ã ãšçè§£ãå§ããŠããŸããããããç§åŠè
ã®å€ãã¯ãäœå¹Žãã®éãããã
çå¿µãæ±ããŠããã®ã§ãããæãšä»ãšã®éãã¯ããã€ãŸã§ããã£ãšåã®æ¯ããããŠããã®
ã¯äžå¯èœã ãšåœŒãã«ãåãã£ãŠãããšããããšãªã®ã§ãããã
ãã®ããã°ã©ã ã¯ãåœåçµäºãããäºå®ã§ã¯ãããŸããããæäžéšã®éã§ã¯ AIDS ã¯ã¯ã
ã³ã®çµããã®éã®é³ãããããã«èãããŠããŠãããšã®ããšã§ãã
ãã®ã¯ã¯ãã³ã¯ãã¡ããã©å€©ç¶çã¯ã¯ãã³ãšåãæ§ã«ãé·ãã²ã£ãããšããæ»æãè¿ãã
ããšã§ãããã10 幎åŸãããã«ã¯ããããããŸãã§æåããååšããªãã£ããã®ããã«ãª
ãã§ããããã§ããããä»ãçãããããã§èªãã ããšã¯å¿ããªãæ§ã«ããŠäžããã
SARSããããç
ãé³¥ã€ã³ãã«ãšã³ã¶ïŒ æµè¡ç
ã®é«çŽå°éåºã®åºçŸ
2003 幎 2 æãäžåœã«çªç¶ãæ°çš®ã®ææç
ãçºçããŸãããåå ã¯äžæã§ããäžççãªãã
ãã¯ã«ãªããæ€ç«ãè¡ãªããããããã ãéŠæž¯ãã«ãããªã©ã§æ
è¡äŒæ¥ãçµæžå°é£ã«é¥ã
ãŸããã
SARS ã¯å€ãã®åœã«çºçããèªç©ºã¯æ··ä¹±ç¶æ
ã§ããã
åã«ç
åè説ã«ã€ããŠåŠãã ããšãèããã°ããã®ç
åèãæåã«æ»æã仿ããŠç
æ°ã
çºçããããã§ã¯ãªãããšãåãããŸããç
åèãç
æ°ãåŒãèµ·ããã®ã§ã¯ãªãããSARS
ã®å Žåã ãäŸå€ïŒïŒïŒãªã®ã§ããããïŒ
ç®çãæãããåŸãSARS ã¯ãã£ããšæ¶ããŠããªããªããŸããããã§ã¯äžäœ SARS ãšã¯äœ
è
ã ã£ãã®ã§ããããïŒå°ãåã«æ»ã£ãŠèŠãŠã¿ãŸãããã
SARS ã®çç¶
CDC ã®ãŠã§ããµã€ã[99]ã«ãããšããã®ãæ°çš®ã®ç
æ°ãã®çç¶ãšã¯æ¬¡ã®éãã ããã§ãã
ã»100.4 床ãè¶
ããçºç±
ã»é ç
ã»äœã®çã¿
ã»å³
ããã ãã§ãïŒãªãããæ®éãããããŸãããïŒ ãããšåãçç¶ã®ç
æ°ãªããã30 ã 40
ããããŸãããïŒ
åå ã®ã°ãè
æåã«çãããã®ã¯ãã³ãããŠã€ã«ã¹ã§ããè±èªã®ç¶Žããã¡ãã£ãšé·ãååãªã®ã¯ãCDC
ã®å¥œã¿ãªã®ã§ããããïŒ2003 幎 4 æ 16 æ¥ã«ã¯ãWHO ããåå ã¯ã³ãããŠã€ã«ã¹ã ããšäž»
匵ããŠããŸããã(Altman [93])
ããŠãã³ãããŠã€ã«ã¹ã¯ããèªäœã«ãåé¡ããããŸãããªããšããã¯ããŠã€ã«ã¹ã®ïŒç³»çµ±
ã ãšããã§ã¯ãããŸããããéåžžã®äººã
ãæã£ãŠããããããµãã系統ã§ããDorland ã®
Medical Dictionaryã«ããã°ïŒ[200]
ã³ãããŠã€ã«ã¹ïŒã圢æ
åŠäžã§åæ§ãªãŠã€ã«ã¹çŸ€ã¯ãäœã§ã該åœããïŒïŒïŒé³¥ã®æ°ç®¡æ¯çãã
ãºãã®èèçã人äœã«ãããŠã¯åŒåžåšç³»ã®ææãªã©ãåŒãèµ·ããããšãããŠããŸãã
3 çš®é¡ã®çãç©ã«å
±éãªããã§ãããåããããªãã§ãããããããæ¿æ²»ãç§åŠã«å¥è¥²ãã
ãããšå€§æµãããªããŸãããä»åããã¯ãä»ã®ç§åŠè
éããã³ãããŠã€ã«ã¹ãäžéšã® SARS
æ£è
ã«ããååšããªãããšã«æ°ä»ãå§ããŸããã2003 幎 4 æ 23 æ¥ä»ã® London Times ã«
ããã°ã[92] ã«ããå
šåœã«ããã SARS åé¡ã®ç£èŠãä»»åœããããã«ããã®å°éå®¶
Dr.Frank Plummer ãšãã人ç©ãã3000 人以äžã® SARS æ£è
ã®ãã¡ãã³ãããŠã€ã«ã¹ãæ
ã£ãŠãã人㯠40ïŒ
ã«ããªããªããšããçºèŠãããããšãããŸããããã«ãã¿ã€ãã£ããŠã€
ã«ã¹ãããå°éã«ãããªããªãã£ããããPlummer ã¯ã³ãããŠã€ã«ã¹ãåå ã§ããå¯èœæ§
èªäœçããããšããŠããŸãã(Altman)[93]
ããããªããšã«å€§æµã®ãã¥ãŒã¹ã§ã¯ããã®åŸãçžå€ããããã®ã³ãããŠã€ã«ã¹ã SARS ã®
åå ã ãšããåœãã®èª¬ãéãããŠããŸããããããŠãäœçŸäžãã«ã䜿ããã¯ã¯ãã³ã®ãæ¢
æ±ãã¯ããã®èª¬ãå
ã«è¡ãªãããã®ã§ããïŒBBCNews[61]ïŒ
ç
§æ»åºæºãªãã®ç ç©¶
ããïŒã€å€ãªã®ã¯ãæåã«SARSãã³ãããŠã€ã«ã¹ãšé¢é£ä»ãããªã©ã³ãã®ç ç©¶ã®æ°ã
ãã
人éã§ã¯ãªãããµã«ã察象ãšããç ç©¶ã ã£ãããšã§ãããããŠããã«ã²ã©ãããšã«ããã
ããç ç©¶ã«ã¯ç
§æ»åºæºïŒcontrol groupïŒã䜿ãããŠããªãã£ãã®ã§ãïŒ ç
§æ»åºæºãšã¯ã
ã¡ãããšããç§åŠçãªç ç©¶ã§ããã°åœããåã®ãã®ã§ãå
šãæãå ããªã察象ã°ã«ãŒãã®
ããšãæããŸãããã®ã°ã«ãŒããšãå®éšã®å¯Ÿè±¡ã«ãªã£ãã°ã«ãŒããšãæ¯èŒããã®ã§ãã[93]
ç
§æ»åºæºã®ãªããã®ãªãã§ãç ç©¶ãšã¯åŒã¹ãŸããã
ãããäŸã®ããšããCDC ãWHOã®æš©åè
éã¯ãããããç§åŠã®åºæ¬ãç¡èŠããŠããŸããŸ
ããããããŠã圌ããçšéã®ãå°éå®¶ãéã¯ãã¿ã€ã¿ãŒãšããæž¬å®éã®æ³åãŸã§çããŠã
ãŸã£ãã®ã§ããã¿ã€ã¿ãŒãšã¯ïŒ
ç§åŠã«ãããŠãããäœããç
æ°ã®åå ã ãšèããããããã«ã¯ã次ã®ïŒã€ã®æ¡ä»¶ãæºãã
ãŠããããšãå¿
èŠã§ãã
ïŒïŒç
æ°ã®åªäœããäžå®æ°ã¿ãããããš
ïŒïŒãã®åªäœããç¹å®ã®çç©åŠçãªãã¡ãŒãžãåŒãèµ·ãããŠããããšã瀺ãããããš
-Duesberg [314]
ãã®äžå®ã®æ°ããããã¯ãŠã€ã«ã¹è² è·ãšãããç
æ°ã®ç¶æ
ãèŠå®ããåºæºãã¿ã€ã¿ãŒã§ãã
ããã SARS ã®å Žåããã®ã¿ã€ã¿ãŒã 1 床ãèšããããŠããŸããããŸããç
åäœãäœãã
ãæèŠãäžèŽããŠããªãã®ã§ããããã¿ã€ã¿ãŒã®èšå®ãåºæ¥ãã¯ãã¯ãããŸããããã³ã
ããŠã€ã«ã¹ãïŒã€ããããã£ãã ãã§ã¯ããã®äººãSARSã«ããã£ããšã¯èšããªãããšã¯ã
æããã§ããããããå€ãã®å»çè
éããããã蚺æããå§ããŠããŸããŸãããã³ãããŠ
ã€ã«ã¹ãããã€ã§ããSARS ã ãšèšºæããŠããŸã£ãã®ã§ããä»ã«ã¯ãçç¶ã ãã§èšºæããŠã
ãŸãå»è
éãããŸããã
åå ãã¯ã£ãã蚌æãããªããã°ã確ããªèšºæãããããšã¯åºæ¥ãŸãããã§ã¯èšºæãäžç¢º
ãã§ãã£ãã®ãªãã圌ããçµ±èšã§æ°ããŠããã®ã¯äžäœãªãã ã£ãã®ã§ããããïŒç§åŠçãª
æ°åã§ã¯ãªããåžå Žå£²ãäžãé¢ä¿ã®æ°ã ã£ãã®ã§ã¯ïŒãããšããã ã®ã€ãã話ã ã£ãã®ã§
ããããïŒ
åœæã®WHOã®ãŠã§ããµã€ãã¯ããŸãã§ã¹ããŒãã®åŸç¹è¡šã®ããã«ãã仿¥ã¯äœäººææããã
ããããä»ãŸã§ã§æ»äº¡è
ã¯äœäººã«ãªã£ãããªïŒããšããå
·åã§ãã
åå ãæªã ã«è§£æãããŠããªãã®ã«ããã®ç
æ°ã«ãææããããšããããããã人æ°ãæ°
ããããšãªã©ãäžäœã©ããã£ãŠåºæ¥ããšèšãã®ã§ãããïŒ
èšç®ãåã£ãŠããªããšæãããšãã¯å€§æµãã財åžã調ã¹ãŠã¿ããšè¯ããšèšããŸãããã§ã¯
ããã§å®éã«åœŒããç§éã«ãããããšããããšãšã¯ãäœã ã£ãã®ã§ããããïŒãã®åœã®æµ
è¡ç
ã§äžå²ããã人éãã¿ãŠãã¡ãã£ãšèããŠã¿ãŸãããã
ïŒãã¹ããªãã¯ãªè奮ã売ãåºãããã¡ãã£ã¢
ïŒç ç©¶è³éé¢é£
ïŒè£œè¬/å»è¬å/é²è¡/æ³åŸã®å·è¡
ïŒæ°çš®ã®ã¯ã¯ãã³é¢é£ [96]
ãSARS ã«ããæ»äº¡ãããå®ã¯ãã ã®ã€ã³ãã«ãšã³ã¶ã«ããæ»äº¡ã§ãªãã£ããšããä¿èšŒã¯ã
ã©ãã«ããããŸããã
ãªãŒããŒã¡ã€ãã®ç
æ°
ã§ã¯ããã®åŸ SARS ã¯ã©ããªã£ãã®ã§ããããïŒäžäœã©ãã«è¡ã£ãã®ã§ãããïŒãããã
ããç
ã倩ç¶çãé³¥ã€ã³ãã«ãšã³ã¶ãççç
ãšåæ§ãããæ¶ãå»ã£ãŠããŸã£ãŠã2 床ãšåž°ã£
ãŠããããšã¯ãªãã®ã§ããããããç
æ°ã¯ãã人ã
ãææã«èœãšããããèµ·ãã£ãŠããæŠäº
ã®åãããæ³šæãéžããããããšããæ¬æ¥ã®ç®çãã¡ãããšæããã蚌æããããŠããªã
ãã°ãå
šãäžå¿
èŠãªæ°ç ç©¶ãæ°çš®ã®å»è¬åã®ããã«ãäœåãã«ããããããŠãããã®ã§ã
ãããææãšã¯ãã¡ããã©èã®æé²ããææ¥ãšå
±ã«æ¶ããŠããããã«ãæ¶ãå»ã£ãŠããŸã
ã°ããã£ããã®ãã®ãªã®ã§ãã
ããã»ã©ã®ãã¹ããªãŒç¶æ
ã®åŸããã®äºå®ã ãã¯ã¯ã£ããæ®ã£ãŠããŸãïŒSARS ã®ãããªãŠ
ããŒã¯ãªç
æ°ãå®åãããšãã蚌æ ã¯ã©ãã«ããªãããšã
SARS ãå¿ããã«èŠããŠããããšã«ã¯ãäœåºŠãç¹°ãè¿ãããŠãããããã¿ãŒã³ãèŠæ¥µããã
ãšãã倧åãªæçŸ©ããããŸããäžçã®ã¡ãã£ã¢ã¯ããŸããåœã®è
ãã仿ããæ©äŒãä»ã
ä»ããšåŸ
ã¡æ§ããŠããŸãããèªè
ã®çããã¯ããå°ãäžè¬ã®å ±éé£ã«å¯ŸããŠæ³šææ·±ããªãã
è£ã«æœãã¡ãã£ã¢ã®çµæžçãªææãããªãŒããŒã¡ã€ãã§äœãããã¡ãã£ãšç¹å¥ãªç
æ°ãã
å®ã£ãŠããããæé£ããè¬ãã¯ã¯ãã³ãã®æå³ãææ°ã®ææã®å°æ¥ãšãã£ããã®ãèŠæ¥µã
ãåãæã€ã¹ãã§ãããããããã襲æäœæŠã¯ããŸããªããå¿
ããã£ãŠããŸãã
Edward L Bernays ãSARS ã®ä»¶ã§ã¯ãå¢å Žã®é°ã§ã«ããŸãããŠããããšã§ãããã[334]
湟岞æŠäºçå矀
çããã®åäŸéã«ãå»è
ããã©ã®ã¯ã¯ãã³ãæ¥çš®ãã¹ããæ±ºããã®ã¯ãFDA ãšããæ©é¢ã§
ãããå»è
ã®èšºæã®äŸ¡å€ã¯ãè¬ãã¯ã¯ãã³ãåžããã®æ©é¢ã®å«ç芳ãšåããããã ãšèšã
ãã§ããããFDA ãã¯ã¯ãã³ãèªå¯ããéã«ãã©ããããã®è²¬ä»»æãšå«ç芳ããã£ãŠè¡ãª
ã£ãŠãããã¯ã次㮠U.S.äžé¢è°äŒå ±åæžã«æç¢ºã«ç€ºãããŠããŸãã(Rockefeller)[268]
湟岞æŠäºïŒå¥åãç æŒ ã®åµãã¯ã1991 幎㮠1 æã2 æã«ãããŠèµ·ãã£ããããã«å·»ã蟌ãŸ
ããã¢ã¡ãªã«å
µã¯ 696,000人ã«ãªãããã®å
šå¡ããæž¡èªåã«æ°çš®ã®ã¯ã¯ãã³æ¥çš®ãåããã
ãã®åŸ 3 幎éã«ãããŠããã®å
ã® 80,000 人ã®ã¢ã¡ãªã«å
µããä»ãŸã§ã«ã¯èªåã®ç
æŽã«ã¯ãª
ãã£ãã倿§çŸæ£ãç¥çµæ§çŸæ£ã§VA ç
é¢ã«ããã£ãŠããŸããããããäžå¯è§£ãªæ°çš®ã®ç
ç
ã®äžé£ã¯ããŸãšããŠæ¹Ÿå²žæŠäºçå矀ãšåŒã°ããããã«ãªããŸããã
å§ãã®ãã¡ãæ¿åºã¯è²¬ä»»ãåŠèªããŸããããããæ£è
æ°ãå¢ããã«åŸããæ¿åºã¯ãããã
èŠæ
ã«å¯Ÿãä¿éãåºãããšã決å®ããŸããããã ããå
µéã¯æ¿åºãå
責ãããšããæ£æš©èšŒ
æžã«ãµã€ã³ããããšãæ¡ä»¶ããšããåŒè·å£«ãªã¿ã®ããè³¢ãããæ¹ã§ãã
責任ãåã声ãéåžžã«å€ãã£ããããäžé¢ã§èª¿æ»ãè¡ãªãããããšã«ãªããŸããããã®èª¿
æ»å§å¡äŒãä»åãã®ã¯ãäžé¢è°å¡ã®è¥¿ããŒãžãã¢å·ã® JD Rockfeller IV ã§ãããã®å§å¡
äŒã«ããæèŠã¯ã1994 幎ã®ç¬¬ 103 åç®ã®è°äŒã«ãããã23 ããŒãžã®å ±åæžã«ãŸãšããã
ãŠããŸãã[268] å ±åæžã®å
容ã«ã¯ãç®ãèŠåŒµããã®ããããŸãã
以äžã«æããæ
å ±ã¯ãäžé¢ã®è³æããçŽæ¥åŒçšãããã®ã§ãã
倧éšåã®ç
æ°ã®åå ã§ããã¯ã¯ãã³ã¯ã3 çš®é¡ãšãªãã
èåããªãã¹ãã°ãã³ ïŒååŠç¥çµã¬ã¹ããè·ã£ãŠããããšããããã蚌æã¯ãããŠããª
ãååŠè¬å
ãããªãã¹äžæ¯çã¯ã¯ãã³ ïŒæµããããªãã¹æ¯ãå
µåšãšããŠäœ¿ã£ãŠããå Žåã«åããã
æªèªå¯ã§ãæ€æ»ããããŠããªãæ¯æ§ç©è³ª
ãããç
ã¯ã¯ãã³ ïŒåç©ã®ç
æ°ãäºé²ããããã®ãæªèªå¯ã¯ã¯ãã³
äžé¢ã®å調ã¹ã¯ã培åºããŠããŸããã圌ãã¯ãªããš 50 幎åãŸã§ããã®ãŒã£ãŠç ç©¶ããé²è¡
å±ïŒDDCïŒã第 2 次äžç倧æŠä»¥åãããã£ãšãè»éå
µã«æå®³ãªè¬åã䜿ã£ãŠå±éºãªå®éšã
è¡ãªã£ãŠããããšãçºèŠããŠããŸããïŒ4ããŒãžç®ïŒDDC ã¯ãã¹ã¿ãŒãã¬ã¹ãç¥çµã¬ã¹ãå¹»
èŠå€ãæŸå°èœããããŠã¯ã¯ãã³ããããããäžããé·æçãªåœ±é¿ãç¥ãããäœãç¥ããªã
è»éå
µãã¡ã«åŒ·å¶ããŠããã®ã§ãã
éåžžãããããå®éšå
µãã¡ã®èšºçå±¥æŽã¯ããçŽå€±ããããŸããåŸã«ãªã£ãŠãå
µéããèªåã
åããããè¬ãäœã ã£ãã調ã¹ãããšããŠããåãããªãããã«ããããã§ããä»ã«ã¯ã
蚺çãã¡ã€ã«ã«ãããããæ³šå°ãããããšãæªèšå
¥ïœ£ã«ãããšããæ¹æ³ãããåãããŠã
ãŸããã(18 ããŒãžç®) ã€ãŸãããç æŒ ã®åµãã§èµ·ãã£ãäžé£ã®åºæ¥äºãšã¯ãä»èµ·ãã£ãŠã
ãæ¿æ²»æ¹éã®ãããªãå»¶é·ã«éããªãã£ããšããããã§ãã
ãããç
ãããç
ã¯ã¯ãã³ãæ¥çš®ããå
µã®æ°ã¯ã150,000 人ã«ãªããŸãã(p.13) ãã®ãããç
ã¯ã¯
ãã³ãšããã®ã¯ããããŸã§ã«ã¯çŸãå®¶çã«ããäžããªããã®ã§ãããã人éãžã®ãã¹ãã
ãŒã¿ã¯äžåç¡ãã«ãããããããç§éã®åœã®å
µéã«æ¥çš®ãããã®ã§ãïŒ(p.13) ããã«ã
ä»®ã«æµãæ¬åœã«ãããç
ãå
µåšãšããŠäœ¿ã£ããšããŠããç
é§ç¶ã®ãã®ã§ãã£ãã§ãããã
泚å°ããã¯ã¯ãã³ããç
é§ç¶ã®ãããç
ã«å¯ŸããŠãŸã§å
ç«ãã€ããŠããããªã©ãšãã蚌æ
ã¯ãã©ãã«ããããŸããã(Senete Report[268])p150,åã³JournaloftheAmericanMedical
Association, 6 Aug 97,p.402)ãã®æ€æ»ããããŠããªãååŠè¬åã 1 ååïŒ4.70 ã®ãããç
ã¯ã¯ãã³ããè»éã® 2 å 4 çŸäººå
šå¡ã«ãããã 6 ååæ¥çš®ãããããšãšãçµ±ååè¬ã®ïŒäºº
ããããç
ã¯ã¯ãã³ã®è£œè¬äŒç€Ÿã®åç· åœ¹ã§ãã£ãããšãšã¯ãäœã®é¢é£ããªãã§ããããïŒ
1999 幎 3 æãABC News ã¯ãæ¿åºãšå¯æ¥ãªé¢ä¿ã«ããã6000äžãã«çžåœã®ãããç
ã¯ã¯
ãã³ã補é ããŠãã補è¬äŒç€ŸãBioport 瀟ããåçµ±ååè¬ã§ãã William Crowe åžä»€å®ãš
èšã人ç©ã«ãã£ãŠåµç«ãããåœŒã¯æ ªã®ïŒïŒïŒ
ãææããŠããããšã調ã¹äžããå ±éããŸã
ãã(Rosenberg)[269]
2001 幎ã«ãããç
ã®è
ãèŠåãåºåã£ãéã«ïŒçããã«ãç¥ããã®ã¡ãããéµéãããŠæ¥
ãã®ãèŠããŠããã§ããããïŒïŒãéå» 1 äžçŽã®éãåè¡åœå
ã§èµ·ãããããç
ã®çºçä»¶ 18
ä»¶ã«ã¯ãæçç©è³ªãæ²»çæ³ãšããŠäœ¿ãããŠãããšç€ºãããŠããããšã¯ãè峿·±ãç¹ã§ãã
ã¯ã¯ãã³ã䜿çšããã®ã¯ãè»éã ãã§ãïŒ[159]
å
µåšåãããããç
ãšã¯ãéåžžã«ç²Ÿå¯ãªè£œåã§ãéåžžã«æ
éã§ç²Ÿå¯ãªè£œé æè¡ãå¿
èŠã§ãã
ã§ã¯ãªããã€ã©ã¯ããã®ãããç
å
µåšã䜿ãå±éºãæããªããã°ãªããªãã£ãã®ã§ãã
ãïŒ æãåœãã売ãã€ããããã§ãïŒ
(Gulflink.org, 28 June 88) ãªããšã1988幎ãŸã§ã売ãã€ããŠããã®ã§ãããéããããã°
誰ã§ããããŒãžãã¢å·ã®ãããµã¹ã«ãã American Type Culture Collection 瀟ããããã®
å
µåšãè²·ãåãããšãåºæ¥ãã®ã§ããä¿¡ããããªãã§ããïŒ ãèªåã§ãã®ç€Ÿã«é»è©±ããŠ
ãèãã«ãªããšè¯ãã§ããããé»è©±çªå·ã¯ 703-365ïŒ2700 ã§ãã
ãã¹ãããããŠããªããã°èªå¯ããããŠããªãã®ã«ããã®ãããç
ã¯ã¯ãã³ã¯ã1988 幎ã
ã 2004 幎 10 æãŸã§ã®éã1100 äžäººã®ç±³è»å
µã«åœä»€ã§æ¥çš®ãããŠããã®ã§ãã[40] äœçŸ
人ãã®å
µãã¯ã¯ãã³æ¥çš®ãæåŠããŠæçãããããå
è·ããããããŸããã[272] 2004 幎
10 æã«ããããç
ã¯ã¯ãã³ã¯åã³æ³ã§çŠæ¢ãããŸããããããªã®ã« 2005 幎 4 æã«ã¯ãå
µ
ééã¯æ¥çš®ããå¿é¡ãããã°åããããããšã«ãªã£ãã®ã§ãïŒ[40]
ãããŠã2007 幎åãã«ã¯ãã€ã©ã¯é§çã®ç±³è»å
µã«ããããç
ã¯ã¯ãã³ã®åŒ·å¶çãªæ¥çš®ãã
åã³éå§ãããŸããã(Nass[37])
ãããç
ã¯ã¯ãã³ã«é¢ããããã培åºããæŽå²ã®è©³çްãçµæžçãªå§åã«ã€ããŠç¥ãããæ¹
ã¯ãthedoctorwithin.comã®Vaccines,Anthrax,andWarãšããç« ãã芧ã«ãªã£ãŠãã ããã
[317]
湟岞æŠäºçå矀ã«é¢ãããRockfeller ã® 1994 幎äžé¢å ±åæžã¯ãäž»ã«æ¬¡ã®ç¹ã«æ³šç®ããŠããŸ
ãã
æ
å ±ãäžããªãã§æ¿è«Ÿããããšããç¹
å
µå£«éã«ã¯ãå
šãæ
å ±ãäžããããªãã£ãã®ã§ããå
µå£«éã«ã¯ã¯ãã³ãæ¥çš®ãããéã«ã
æ¬åœã«åé¡ãªã®ã¯ãåžžã«ãã®ç¹ã§ããå
µå£«ã®å€§éšåã«ã¯ããããäœã®ã¯ã¯ãã³ã§ãããã
ç¥ããããã«ãèµ·ããããå¯äœçšãäŒãããããã¯ã¯ãã³ãæ¥çš®ãããããªãããæ±ºãã
æš©éãäžåäžããããªãã£ããšãã蚌æ è³æãå±±ã»ã©ãããŸãã[271]
ããããå®éšçãªæ³šå°ã«å¯ŸããŠãæ
å ±ãäžããã«å諟ããããšããè¡çºã¯ã倧ããªç¯çœªã§
ããããã¯äœå幎ãç¶ããŠãããžã¥ããŒãè°å®æžãªã©ãåœéçãªå»åŠå«çã«æããã«åã
ãè®è¡ã§ãããŸãã1946 幎ã«ãããã¹ã®æŠäºç¯çœªã調æ»ããéã«äœããããã¥ã«ã³ãã«ã¯
ã³ãŒããšããèŠå®ã¯ããããªãå®éšçããæ€æ»çšãã®ã¯ã¯ãã³ãè¬åã§ãã£ãŠããæ¥çš®å¯Ÿè±¡
è
ãããã®ç©è³ªãäœã§ããããç¥ãããã®å¯äœçšãæ¿ç¥ããŠããŠãèªç±æå¿ã§æ¥çš®ãæ¿è«Ÿ
ãããšããæ¡ä»¶ãæºãããªããã°ãªããªãããšå®ããŠããŸãã[332] Rockfeller ã®å ±åæžã«
ã¯ã泚å°ãæãã è
ãžã®æåãè
è¿«ãšãã£ãè¡çºã倿°èšèŒãããŠããŸãã
Rockfeller ã®èª¿æ»å ±åæžã«ã¯ããã®ã説æãåããäžã§åæããããšããç¹ã§ãé²è¡çãš
FDA ã®éã§ãããªãã®äž»å°æš©äºãããã£ããšèšãããŠããŸããé²è¡çã¯FDA ã«ãã説æã
åããäžã§ã®åæããšããæš©å©ã®å
é€ãèŠæ±ããŸãããã€ãŸãé²è¡çã¯ãããèš±å¯ããã
ãšã§ FDA ã«ãåœéçãªå«çèŠå®ããå€ããŠãå
µéã«éžæã®æš©å©ãããããšãç¥ãããã«ã¯
ã¯ãã³ãæ¥çš®ãããŠãããšé Œãã ã®ã§ãã
é²è¡çã¯ãŸããFDA ã«ããã¯ã¯ãã³ã®èªå¯ãŸã§ãå
é€ãæ±ããŸããããããã®ã¯ã¯ãã³ã¯
ãŸã FDA ã®èªå¯ãããã£ãŠããªãã£ãã®ã§ãã(p.7) 圌ãã®èšãåã¯ãŸã£ããããå æžãª
ãã®ã§ãæéãç¡ãã ãšãããæŠäºèå°ãã«ãããŠå
µå£«ã«æ
å ±ã·ãŒããé
ãã®ã¯å¥œãŸãããª
ããšããä»ã«æºè¶³ã§ãã代ããã®æ²»çæ³ãç¡ãããšããããã®ã§ããã
FDA ã¯ãããã«åæããŸãããæ€æ»ãã¹ããããŠããªãã¯ã¯ãã³ã®æ¥çš®ãèš±å¯ããæ¥çš®å¯Ÿ
象è
ã¯æžé¢ã«ãåæããããšæžãå¿
èŠã¯ãªããå£ã§èšãã°ãããšããããšã«ããã®ã§ãã
FDA ã¯åãåŠåš äžã®å¥³æ§ã¯æ¥çš®å¯Ÿè±¡å€ã«ããããã«å§ããŸããã
é²è¡çã¯ãå
µéã«ã¯ã¯ãã³ãäœã§ããããäŒããæåŠããæ©äŒãäžããããšã«åæããŸã
ãã
ãšããããRockfeller ã®å ±åæžã«ã¯ãåŸã«è³ªåãåããå
µéã® 74ïŒ
ãããã¯ã¯ãã³ã®æ¥çš®
ãåãå
¥ããã»ãã«éžæã®äœå°ã¯ãªãã£ãããšçããŠããã®ã§ãã(p.9) ãããŠãæ¥çš®ãå
ããã®ã¯å
šå¡ã®å
µã§ããå¯äœçšåå¿ãã§ããããšãã£ãŠå¯Ÿå¿ããŠããã£ãããæ¥çš®å¯Ÿè±¡ã
ãå€ããã人ã¯ã1 人ãããŸããããã®éã«ãæ¿ããå¯äœçšåå¿ãåºãŠããããã«ã¯ã¯ãã³
ãè¿œå æ¥çš®ããããããïŒïŒïŒãšå€ãã®å
µéã蚌èšããŠããŸãã
å°ãªããšãããæãåœã®è»å
µã®ïŒïŒïŒ
ããæ¹Ÿå²žæŠäºäžã«ã¯ã¯ãã³ã«ããå¯äœçšåå¿ãçµéšã
ãããšã®ããšã§ãã
äžé¢å ±åæžã¯ãéèŠãªä»»åãéè¡ããæãåœã®è»éã«ã蚌æããããŠããªãã¯ã¯ãã³ãäž
ãããšããè¡çºã¯ãèªåœã®å®å
šãè
ããè¡çºã«çããããšåçºããŠããŸãã
ç°¡åã«ãŸãšãããšã次ã®éãã§ãããæ¬åœã¯ãããã§ç€ºããŠãããããé¥ãã«é
·ãç¶æ³ã§
ããããããå®éã«è»éã«ããããšã®ãã人ãªãããã®äžé¢å ±åæžã®ããŒã¿ãããå®éã®
ç¶æ³ãæ³åããããšãåºæ¥ãã§ãããã
ãã®ç« ã¯ãFDA ãããã«æ¿æ²»çãªå§åã«åœ±é¿ãããŠãããããã®å§åã®äžã§ã¯åœéçãªæ³
ã§å®ããããŠããåºæ¬ç人暩ãç¡èŠããæªæ€æ»ã®ã¯ã¯ãã³ãŸã§èš±å¯ããŠããŸãããçãã
ã«ç€ºãããã«ä»ãå ããŸããããã®ç« ã¯ãããããªè©±ã¯ãå»è
ã®å°éã ããç§ãèªãå¿
èŠã¯
ãªãããšèšã芪éã®ããã®ãã®ã§ããçããã®ãå»è
ããéããå®éã«ã©ã®ã¯ã¯ãã³ãæ¥
çš®ããã¹ãããæ±ºããæ¿åºæ©é¢ããã©ããªä»çµã¿ã«ãªã£ãŠããã®ãããããçãã蚌æ ãš
èšãããã®ã§ãããã
ãã®åŸã®ã¢ãã¬ãã¹ã¿ã³ãšã€ã©ã¯éã®èª€è§£åé¡ã®éã«ã¯ãå€ãã®ã¢ã¡ãªã«å
µã¯ã湟岞æŠäº
çå矀ã®äžä»¶ããåŠãã§ãããããã¯ã¯ãã³ãä¿¡çšããæ°ã«ãªãããæ¥çš®ãæåŠããŸããã
ããããããã§ãåãããšãèµ·ãããŸãããå
µéã¯æçãããéçŽãèœãšãããè
ããã
眰éãåãããå
è·ãããã®ã§ãã
ã¯ã¯ãã³ãæåŠããå
µéãäœãã«ãå¢ãããããç±³è»ã¯æ°ããè»èŠåïŒïŒïŒïŒãèšå®ããŸ
ããããã®èŠåã® 5.4 ç« ã® B2a ãš B2b ã«ã¯ãããèšèŒãããŠããŸãã
ãå
µéã¯ãäºé²æ³šå°ãåãããåŠãã®éžææš©ãæããªãããšãšããïŒïŒïŒãã®ä»»åã«åœããã
è»å»ã¯äºé²æ¥çš®ãåããããããã«å¿
èŠãªã ãã®æš©éã䜿ãã¹ããšãããæä»€ã«åŸã£ãŠå
ããŠããè»å»ããå
µå£«ã®äºé²æ¥çš®ã«å¯ŸããæåŠææãå
æããããã«ã¯ãå¿
èŠãªå¹åã¯åŠ
äœãªãææ®µã®ãã®ã§ãæäŸããããã®ãšããïŒïŒïŒå
µå£«éã«ã¯ã圌ãã®åæã®æç¡ã«é¢ãã
ããäºé²æ³šå°ãåãããããšããããšãå¿ åããŠããã¹ãã§ããã [355]
çŸåšã®ã€ã©ã¯ ïŒ ç¬¬ 2ã®æ¹Ÿå²žæŠäºçå矀
2001 幎ã«ãããç
ã¯ã¯ãã³ãåä»»ãããŠããã¯ãç±³è»å
µã¯ 6 ååã®æ¥çš®ã匷ããããããš
ã«ãªããŸãããæ€ç«ã§éé¢ãããŠããã¯ã¯ãã³ã®åšåº«ããçªç¶ãèªå¯ããããæ°ããæ€æ»
ãã¹ããªã©ã¯äžåè¡ãªãããŸããã§ããããããŠæã£ããšããã2002 幎 10 æã«ã¯ã補è¬
äŒç€Ÿãããã®ãããç
ã¯ã¯ãã³ããéè»äººïŒã€ãŸããäžè¬äººå
šå¡ã«ãæ¥çš®ããããã«æšå¥š
ããŠããã®ã§ãã
2004 幎 3 æãåè¡åœæ¿åºã¯ïŒã€ã®è£œè¬äŒç€Ÿã«ã2 å 5 çŸäžäººåã«ãªã 7500 äžååã®ãã
ãç
ã¯ã¯ãã³ã泚æããŸããããã®æã®è²»çšã¯å
šé¡ 1 åãã«ã¡ããã«ããªããŸãããã®ç
ç±ãšã¯ïŒããã€ãªããã®æ»æãããã£ããã峿ã«å€§éœåžã§ã¯ã¯ãã³æ¥çš®ã宿œã§ãããã
ã«ããããšã§ãããŸãããã®éæ³ã®äžèšã䜿ãããŸããã
2003 幎ã®ã€ã©ã¯ãæŠäºãã®æºåãšããŠã2 çŸäžäººä»¥äžã®ç±³è»å
µã倩ç¶çããããç
ããã®
ãæ²¢å±±ã®ã¯ã¯ãã³æ¥çš®ãåããŸããã圌ãã¯ã¯ã¯ãã³åžå Žã®ç ç²ã«ãªã£ãã®ã§ãããã®çµ
æã第äºã®æ¹Ÿå²žæŠäºçå矀ãçãŸããæåã«çºçããã±ãŒã¹ãšããŠã¯ã2005 幎 6 æã«ãã
ãç
ã¯ã¯ãã³ã«ããè² å·ã1200 ä»¶ãå ±åãããŠããŸãã[47]ãã®äºä»¶ãããã€ãã®ããã«
ãã¿æ¶ãããŸããããããã ãã¯èšã£ãŠãããŸãïŒç¬¬äºã®æ¹Ÿå²žæŠäºçå矀ã¯ãæåã®ã±ãŒ
ã¹ãã¡ã£ãœãã«èŠãããããã«ãéåžžã«å€§èŠæš¡ã§çç¶ãæ·±å»ãªãã®ã ã£ãã®ã§ãã
ã¯ã¯ãã³æ¥çš®ãåããªãå»è
é
Jane Orient MDã¯ãAmerican Association of Physicians and SurgeonsïŒå
šç±³å»åž«é£åïŒ
ã®å»åŠé¡§åã§ããããã®é£åäŒã®å
¬åŒãªæèŠçºè¡šã«ããã°ïŒ
ãã¯ã¯ãã³ïŒïŒïŒåŠç«¥ãç ç©¶å®éšã®å¯Ÿè±¡ã«äœ¿çšïŒïŒïŒã«ã
ããã¹ããèŠå®ã«éåããŠãæ
å ±ã
äžããäžã§ã®åæããªãã«å®æœãã
ãã¯ã¯ãã³è£œé äŒç€ŸãšAMAãå
šç±³å°å
ç§å»åž«é£åäŒãªã©ã®ãã¯ã¯ãã³æ¿èªæ
åœã®å»çã°ã«
ãŒãã®éã«ã¯ãééçãªç¹ããããããšæãããïŒïŒïŒã[177]
åœã®æ¿åºã¯åå·ã«å¯Ÿãããå
šçš®é¡ã®ã¯ã¯ãã³ãåãããå
ç«¥ïŒäººã«ã€ãïŒïŒïŒïŒã®ããŒãã¹
å ±é
¬ãäžããŠããïŒïŒïŒã – U.S.Newswire [341,340]
奚å±è£å©é
çããã®åäŸéãã¯ã¯ãã³ãåãããã©ãããåŠæ ¡ã®ä¿å¥å£«ããããããªã«æ°ã«æããã®
ã¯ãªãã§ããããïŒ ã©ãããŠæ¥çš®å
逿³ã«ã€ããŠãåãã€ãããããã®ã§ãããïŒ äžæ
è°ã«æã£ãããšã¯ãããŸãããïŒ çãã¯ããéã§ããã¯ã¯ãã³æ¥çš®ãåããåäŸãå€ãã»
ã©ããã®å·ãæ¿åºããåãåãéé¡ãå¢ãããããªã®ã§ãã
ãåœã®äºé²æ¥çš®ç®æšéæçãå®çŸãããããå·ããšã®å®æœåªåã®æ¹åã«ããããç±³åœäžé¢
æ³åºå§å¡äŒã¯ïŒïŒïŒ1993 幎ã«ïŒïŒïŒå·ã®ã€ã³ãã©å¥šå±éã®ãã¡æ¯å¹Ž 3200 äžãã«ããã®å¥šå±è£
å©éãšããŠïŒïŒïŒåã眮ããŠãããã
ããããã®è³éã¯ãåè³å¯Ÿè±¡ã®å·ã«ããã®å·ã®äºé²æ¥çš®éæçã«å¿ããŠé
åœããããã[342]
ãã®å¥šå±è£å©éã¯ãåœããå·ã«äžããããå
šãŠã®å¥šå±éã®ç·é¡ã®ãã¡ãå°ãªããšã 24ïŒ
ã®
å²åãå ããŠããŸãã[342]
ããã§ããŸã ãçåã«æãããšããããŸããïŒ
å
šç±³å»åž«é£å
2000 幎 10 æãå
šç±³å»åž«é£åïŒAAPSïŒã¯ St.Louis ã«ãããŠå®æç·äŒãè¡ãªããŸãããã
ã®äŒè°ãã幟ã€ãã®ç¹ãæœåºããŠã¿ãŸãïŒ
ãïŒïŒïŒã¢ã¡ãªã«ã®åäŸäžä»£å
šè¬ã«é¢ããéèŠãªæ±ºæã®æ°ã
ã¯ãæš©åãçãæ©é¢ããããã¯
è«å€§ãªå©çãç²åŸããããšãããã補è¬äŒç€Ÿãšã®éã«ãããŠãæä»çãªçµãæã€åœ¹å¡ãã
æããå°æ°ã®å§å¡äŒã«ãã£ãŠäžãããïŒïŒïŒã¯ã¯ãã³æ¥çš®ã®å®æœã«ãããŠã¯ãå»åž«ãšæ£è
é
ã®é¢ä¿ã¯äžè»¢ããïŒïŒïŒå·ã®åŸæ¥å¡ãšããŠã®åœ¹å²ãæããå»åž«ã¯ïŒïŒïŒæ£è
ãç¬èªã®è£éã§èšº
æããããšãããã«ããã å·ã«åŸãã ãã§ããïŒïŒïŒã
ãã¯ããããããµã颚éªãäžæ¥ã¯ããã B åèçããããŠåäŸæä»£ã«ãããç
æ°ãå
šéšãŠ
ããçãã«ããŠãããã®å±éºã¯ãç±çãªäžççã¯ã¯ãã³æ¥çš®ã®éè¡ã®ããã§ïŒïŒããäžä»£ã®
ïŒ10ïŒ
ãšããïŒå€ãã®äººæ°ãåŠç¿æ©èœé害ãæã€ããã«ãªã£ãŠããŸãããšã®æ·±å»ãã«ã¯ãš
ããŠãåã°ãªããã
ãã¯ã¯ãã³ã«é¢ããå
¬åºã¯ãæ ¹æ¬çã«èå»ããŠããïŒïŒïŒå
¬è¡ã®å©çã«åãããç§çãå
æº
ããŠããŠïŒïŒïŒå°èŠæš¡ãããããããŸãã«çæçã§ãã£ãããå¶éãæ¥µç«¯ã§ãã£ãããšããïŒïŒïŒ
è³ªã®æªãç§åŠç ç©¶ã«åºã¥ããŠãããã
ãããåœã®åäŸéã¯ãäžå¿
èŠã§ãããéãããå¹èœãããªãã¯ã¯ãã³ã®æ¥çš®æå®ã«ãã£ãŠã
æ»äº¡ãé·æçãªå¯äœçšåå¿ã®åœ±é¿ã被ãå¯èœæ§ãšåãåãã¯ãã«ãªã£ããã
ãèªåã®åäŸã«æããã«äžå¿
èŠã§ãããããå±éºã§ãããå»çåŠæ¹ãæåŠãããšããçç±
ã§ã芪ããåäŸã没åãããšããè
ãã¯ãæ±ãããããã®ã§ããïŒïŒïŒAAPS ã¯ãåäŸéãã©
ã®æ§ãªèšºçãåãããã¯ããã®åã®äž¡èŠªãä¿ãä»ãã®å»è
ãšçžè«ã®äžã§æ±ºããã¹ãã§ãã£
ãŠãæ¿åºã®å®åãæ±ºãããã®ã§ã¯ãªããšèãããã
Dr.Orient ã¯ãããå°ãèžã¿èŸŒãã§é£åã®èŠè§£ã瀺ããŠããŸãã
ãAAPS ã¯ãã¯ã¯ãã³æ¥çš®æå®ã®è³æ¥åæ¢ãèŠæ±ãããã€ãã¯ã¯ãã³ã®äœ¿çšã«éããŠãåå
ã«èª¬æãåããäžã§ã®åæãå¿
èŠã§ãããšãå»çé¢ä¿è
ãã¡ã䞻匵ããããšãæ±ãããã®
ã§ããã[305]
å·ã®æå
ãã®èšèèªäœãå€ããç©èªã£ãŠããŸããèªãã®æ¥çš®å
逿š©ãå®è¡ãã人ãå¢ããã«ã€ãã
ãããã人ã
ãä¿ãä»ãã®å°å
ç§ããèŠæŸãããããšãã話ãè¯ãèãããã«ãªããŸããã
å°å
ç§å»ã®å€ãã¯ã芪ãèªåã®åäŸã«ã¯ã¯ãã³æ¥çš®ãåããããªããšæ±ºæããããšããå»
è
ã®å°ãæš©åšãå·ã€ããè¡çºããšèãããããã®å®¶æã®å°éå»ã«ã¯ãªããªãããšèšãæž¡ã
ã®ã§ããå»è
éã®ãã®ã·ã§ããã³ã°ãªæ°ããæ
床ã¯ã圌ãã®ãåžžã«æ£è
ã®å©å®³ãåªå
ããŠ
è¡åããããšããåã ããã®çŽæäºããããã«èã£ãºããªãã®ã§ãã£ãããæããã«ããŠ
ãããŸããããã®ç¹ããèŠããšãå°å
ç§å»ãšãããã®ã¯ãæ²»çãæœã人ãšãããããå·ã®
ã¯ã¯ãã³æ¥ç𮿹éã®å·è¡äººã§ãããæ¥çš®æå®ãããè¬åã®ä»å
¥ã人ã匷å¶çãªã¯ã¯ãã³æ¥
çš®æ³ãæšé²ããååšã§ãããšãããã§ããããä¿¡é Œã§ããæ²»ç人ãšãã圹å²ãèŠäºã«è£å
ããäžæ°å³ã«ç«å Žãäžè»¢ããŠã倧æµã®å°å
ç§å»ã¯ãèªããå·ã«åžããè
ãšã¿ãªããããŸãå·
ã第äžã§ã次ã«å»è
ãåŸãããšæããŠããã®ã§ãã
ã¯ã¯ãã³ããªããªã£ãŠããŸãã°ããèµ€ã¡ããã®å¥åº·ããã°ã©ã ãã«æ¥ãåäŸãããªããªã£ãŠ
ããŸããŸããå»è
ã®ç®ã«ã¯ããéãé£ã³å»ã£ãŠããã®ãèŠããããã§ãïŒããããããã
芪éã«ã€ã€ãŒãã¥ãŒããæçç©è³ªããªã¿ãªã³çã売ãã€ããããšãåºæ¥ãªããªã£ãŠããŸã
ãŸãããã
芪ãã¡ã«æ¥çš®å
é€ã®æš©å©ãããããšãæããŠãããŠãããã«ãã®æš©å©ãå·è¡ããã®ãæ£ã
ãæ±ºæã ãšå§ããŠãããå°å
ç§å»ããçããã¯ãåç¥ã§ããïŒ
ã¯ã¯ãã³æ¥çš®ãåããªãå»è
éïŒç¶ç·š
Mendelson, Phillips, Scheibner, Hay, Orient ãšãã£ãå»è
éããããŠåœŒããšåãæèŠã®å»
è
éã®çµè«ãšã¯ãã¯ã¯ãã³ã¯é¿ããã¹ããã®ã§ããããšãããã®ã§ãã
ãåäŸæä»£ã®ç
æ°ã§äžçªæãããšãšã¯ãéå£äºé²æ¥çš®ã«ãã£ãŠããããç
æ°ãé²ãããšã
ããå±éºã§å¹åã®ãªãè¡çºã§ããçãããå
ç«ã«ã€ããŠæã蟌ãŸãããŠããããšã®å€§éšå
ã¯ãåœãã®å
容ã§ããç§ãèªåã®ããæ·±ã確信ã«åŸã£ãŠè¡åãããšãªãã°ãçããã«ã¯ã
èªèº«ã®ãåããã«å¯Ÿãããã¹ãŠã®äºé²æ¥çš®ãæåŠããããã«å¿ åããã§ããããã
ãéå£äºé²æ¥çš®ããåäŸã®äŒæç
ã®æ²æ»
ã«åœ¹ç«ã£ããšèšŒæã§ããç§åŠçãªç¢ºããªèšŒæ ã¯ã©
ãã«ããªããä»®ã«åè¡åœã«ãããå
ç«¥éã®äŒæç
æ¶æ»
ããäºé²æ¥çš®ã®ãé°ã ãšãããªãã
åœæãéå£äºé²æ¥çš®ãè¡ãªãããŠããªãã£ããšãŒããã諞åœã«ãããŠããåæã«ãããã
ç
æ°ãæ¶ãå»ã£ãŠãã£ãããšããã©ããã£ãŠèª¬æããã®ã ãããïŒã[246]
– How to Raise a Healthy Child, Robert Mendelson, MD
ãªãŒã¹ãã©ãªã¢ã®ç ç©¶è
ãViera Scheibner,PhD ã¯ãã¯ã¯ãã³æ¥çš®ã«é¢ããå»çæç®ã 6
äžããŒãžåããªãµãŒãããæ«ã«ããè¿°ã¹ãŠããŸãã
ãä¹³å
ã察象ãšãããã®ãå«ããäºé²æ¥çš®ãšããè¡çºã¯ã1ã€ã®äŒæç
ãäºé²ããŠãããªã
ã£ãã°ããããå»çè¡çºã®æŽå²äžã§ä»ã«é¡ãèŠãªãã»ã©ãå€ãã®èŠãã¿ãšæ»äº¡ããããã
ããå
ç«¥ã®ã¯ã¯ãã³æ¥çš®ãåå ã§èµ·ãã被害ã®åŸå§æ«ã«ã¯ãããšäœå幎ããããã§ãããã
å
šãŠã®ã¯ã¯ãã³æ¥çš®ã¯çŽã¡ã«äžæ¢ãããã¹ãã§ããããå¯äœçšåå¿ã®è¢«å®³ã«ãã£ãå
šãŠã®
人ã
ã«ãé©åãªè£åãããªããã°ãªããªããã[243]
100 幎åã«ãDr.Raspal ã®äžèšïŒ
ãããã¯ã人é¡ãå°ããã€æ¯æ®ºããŠããè¡çºã§ã¯ãªãã ãããïŒæã«ã€ãã人éã«å±å®³ã
äžããŠãããããã®ææç©ããããŸã 人ã
ã«äžããŠãããšã¯ãäœã𿥵æªééãªè¡çºã§ãã
ãïŒ ãã®ããããªæœè¡ãè¡ãªãããšã§ããã®å ±ããšããŠãç
åèãšã®çµ¶ãéãªãæŠããå§
ãŸããšããã®ã«ã人ã
ã®è¡æ¶²ãç
åèã®ã«ã¯ãã«ã«ããŠããŸããªããŠãäœãã®æããã«é©
ãã°ããã ãã[335]
150 幎åãåœæãŸã ç¡åã«ãªãåã®ãã©ã³ã¹ã®ç§åŠè
ãAntoine Bechamp ã®èšèïŒ
ããã¯ããªã¢ããŠã€ã«ã¹ã¯ç
æ°ã®åå ã§ã¯ãªããããã«è¡æž
ãã¯ã¯ãã³ã§ã¯ç
æ°ãäºé²ã
ãããšããæ²»ãããšãåºæ¥ãªããã[128]
ãããŠãèªåã®èŠªãåäŸã«ã¯ã¯ã¯ãã³æ¥çš®ãããªãæ¹éã®å»è
ãæ²¢å±±ããŠãUK ã®ç·åçãª
ã¯ã¯ãã³é¢é£ãŠã§ããµã€ãã«ã¯ããã®ãªã¹ããæ²èŒãããŠããŸãã[336]çŸåšãåè¡åœã«ã
ããŠãèªåã®åäŸã«ã¯ã¯ãã³æ¥çš®ãåããããªã芪ããäœäžäººãšããŸãã
å
é€ã«ã€ããŠïŒ æ¥çš®æå®ãšçŸ©åæ¥çš®ã®éã
åŠæ ¡ã§ã®ã¯ã¯ãã³æ¥çš®ã«é¢ããŠã芪éã«ã¯äœå¶çã«åœã®æ
å ±ãäžãããšãããé©ãã¹ãä»
çµã¿ãããã®ã§ãã芪éã«äŒããããããšãšããã°ãããæãåã«ã¯ã¯ãã³æ¥çš®ãåãã
ããªããªãããã®åã¯åŠæ ¡ã«å
¥ããŠããããªãããšãããã®ã ãã§ããããã¯ãå
šãã®å
ã§ãã
ïŒæ¥çš®ïŒæå®ãšããã®ã¯ãããã«é¢ããŠäœããã®æ³åŸãååšãããšããæå³ã§ããããã«
察ãã矩ååãšããã®ã¯ãäœããããªããã°ãããªããšæ±ºããããŠãããšããæå³ã§ãã
ãã®ïŒã€ã¯ãå
šãéãæå³ã®èšèã§ããã¯ã¯ãã³ã¯æ¥çš®æå®ã§ã¯ãã£ãŠããæ¥çš®çŸ©åã§ã¯
ãããŸããã圹æã®äººéã¯ãæ¥çš®çŸ©åã§ãããã®ããã«èšãããããŸããã
æ°èãéèªã«ã©ãæžããŠããããšãåŠæ ¡ã®ä¿å¥å£«ããªããšèšãããšãã倧æµã®å·ã«ãããŠ
ã¯ãçããã®åäŸã¯ã¯ã¯ãã³æ¥çš®ãåããŠããªããŠãå
¥åŠã§ããŸããã©ã®å·ã«ããæ¥çš®å
é€ã®å¶åºŠãããã®ã§ãããããã®å¶åºŠããªããšãã¯ã¯ãã³ã§è¢«å®³ãåããä»¶ã¯å
šãŠã責任
ãæçœã«ãªã£ãŠããŸããŸããããæ³åŸçã«å
é€å¶åºŠãå¿
èŠãªã®ã§ããããã¯è²¬ä»»åé¡ã®ã
ãã®ãã®ã§ãå
é€å¶åºŠã¯å·ã®éãéãšããŠããã®ã§ãã
å
é€ã«ã¯ãïŒã€ã®åœ¢æ
ããããŸãã
ïŒïŒå
šãŠã®å·ã«ã¯ãå»çäžã®å
é€ãšãããã®ããããŸããååçãªãå»è
ãããèŠã€ããŠã
çããã®ãåãããã¯ã¯ãã³ãåããã®ã¯å±éºã ãšæžããŠãã®æžé¡ã«ãµã€ã³ããŠãããã°ã
äžçã®éããã§æ¥çš®å
é€ãåããã®ã«ååã§ãã
ïŒïŒå®æäžã®å
é€ãã¯ã¯ãã³ã宿äžã®çç±ã§å
é€ããå¶åºŠã¯ãããã€ãã®å·ã«ãããŸãã
æ£åŒãªå®æã«å±ããŠãã蚌æãå¿
èŠãªãšãããããã°ãå¥ã«ç¹å®ããªããŠãè¯ããšããã
ãããŸãã
ïŒïŒææ³äžã®å
é€ããã®ã¿ã€ãã®å
é€ã宿œããŠããã®ã¯ãçŽ 15 å·ã»ã©ã§ããçããã¯ã
èªåã®ææ³äžãã¯ã¯ãã³æ¥çš®ã«å¯Ÿãäœããã®äžç¹å®ãªç°è«ããããšèšããå
é€ç³è«æžã«ãµ
ã€ã³ããã ãã§ããåããã¯èŠéãããããšã«ãªããŸãã
ã«ã«ãã©ã«ãã¢ãªã©ã幟ã€ãã®å·ã§ã¯äºé²æ¥çš®ã®èšé²è¡šã®è£é¢ã«å
é€ç³è«æžãããªã³ãã
ããŠããŠããã°ãã°æ
æã«è¡šé¢ããã³ããŒããªãããšã«ãªã£ãŠããŸããã§ããããå
é€ç³
è«æžãããããšãç¥ããªããã°ãé Œãã§åãåãããšãåºæ¥ãªããªã£ãŠããã®ã§ãã
人ã
ã¯ãã€ãããã§ããäºé²æ¥çš®ãåããªããšåäŸãå
¥åŠãããªãããšèšããããã§ãããš
èšã£ãŠããŸããããããªãã®ã§ãïŒå
é€å¶åºŠã¯å
šãŠã®å·ã«ãããåŠæ ¡ã®åãå
¥ãåŽã芪ã«
å
é€å¶åºŠã®ããšãç¥ãããªããã°ãããªããšæ³åŸã§æ±ºãŸã£ãŠããã®ã«ãå®éã«ç¥ãããŠã
ããšãã話ã¯ã»ãšãã©èããŸãããçããã¯åºãããåã«ããèªåã®å·ã®å
é€å¶åºŠã«ã€ã
ãŠæ¿ç¥ããŠãããªããã°ãªããªãã®ã§ããããããã°ãããšã¯æåºããã ãã§ãã倧æµã®
å ŽåãäžæŠçãããæ
å ±ããã£ãŠããããšãåãããšã圌ãã¯æãåŒããŸãã
ãªããããªãæ
å ±ãè±èœãããŠåœããšããè¡çºãè¡ãããŠããã®ã§ãããïŒããã¯ãäžèš
ã®å¥šå±è£å©éã®ç« ãèªãã°åããããšã§ãã[342]
å
š 50 å·ã®å
逿³
åå·ããããã®ã¯ã¯ãã³æ¥çš®å
é€å¶åºŠã«ã€ããŠã®æ
å ±ã¯ããã®å·ã®éŠéœã«ããæ¿åºã®ä¿å¥
æ©é¢ã«ãŠãåã³äžèšã®ããããŠã§ããµã€ãã«ãŠå
¥æããããšãåºæ¥ãŸãã
http://home.san.rr.com/via/STATES/allstates.htm
å
é€ã®å®£èªäŸè¿°æž
å°åŠæ ¡ãã髿 ¡ãšãã£ãå Žå以å€ã«ããã¯ã¯ãã³æ¥çš®ãä»»æã«èŠæ±ãããããšã¯å€ããã
ãŸãïŒ
ã»å€§åŠ
ã»æ¿åºæ©é¢ã®ä»äº
ã»ãã€ã±ã¢ã»ã³ã¿ãŒ
ã»çŠç¥å»çæ©é¢ã«å€ãã人ã
ã»åäººäŒæ¥
ãã®ä»ã«ããè²ã
ãããŸããéåžžãã¯ã¯ãã³æ¥çš®ãå¿
èŠã§ããšãããç¥ãããæ¥ãã ãã§ã
åçç¡çšã§ããå
ã»ã©ç€ºãããšãããå
é€å¶åºŠã«ã€ããŠã®æ
å ±ãæäŸãããããšã¯ããçš
ãªè©±ã§ãããã æ¥çš®ãæåŠããã ãã§ã¯äžæããããªãã£ãå Žåã«ã¯ãããïŒã€ã倧æµã®
å Žåã¯æåããæãéããããŸããããã«ã¯ãæ¬¡ã®æé ãèžãã§ãã ããã
ïŒïŒçŽã 1æçšæãã
ïŒïŒäžçªäžã«ãæ¥çš®å
é€ã®å®£èªäŸè¿°æžïŒAffidavit of ExemptionïŒããšã¿ã€ããã
ïŒïŒã€ã¥ããŠãç§ã®å¥åº·ã害ããæãããããåã³å
ç«ç³»ã«æå·ãäžããå±éºããããšã
ãçç±ãããç§ã¯ãã®å Žã«ãããŠã¯ã¯ãã³æ¥çš®ã®å
é€ãèŠæ±ããŸããããšã¿ã€ããã
ïŒïŒå
¬èšŒäººã®ãšããã«ããã宣èªäŸè¿°æžã«æ¥ä»ãšçœ²åãèšå
¥ãããäœæãã³ããŒããšãã
ïŒïŒåæ¬ã®æ¹ããæ¥çš®ãèŠæ±ããæ©é¢ã«éãã
ïŒïŒã³ããŒã 1 æã蚌æã€ãéµäŸ¿ã§ãæ¥çš®ãèŠæ±ããæ©é¢ã®æ³çéšéã«éãã
ïŒïŒèªåçšã«ãã³ããŒãæã£ãŠããã
ãããªããšãçããã®å®£èªäŸè¿°æžã«å察ããã«ã¯ãäœããã®å¯Ÿå¿ãã€ãŸãäœããã®è¡åã
åããªããã°ãªããŸããããããšã倧æµã®å Žåã¯èŠéãããšã«æ±ºããŸãã®ã§ãããã§äžä»¶
èœçã§ããçããã®äŸè¿°æžã«å察ãã人ã¯ããã§ã«çããããæå®³ã®æããããããšäŒã
ãå»çæç¶ããæ¬äººã«åŒ·ãããšããè¡çºã®æå³ïŒãããããšäœããã®å¯äœçšåå¿ãåºãå Ž
åã«ã¯ãæ¥çš®ã匷ããèªåéåŽã®è²¬ä»»ã«ãªããšããæå³ãã¡ãããšçè§£ããŠããªãã®ãã
ç¥ããŸãããæžé¢ã«æžãããšã§çããã¯ãç§ãåããè² å·ã¯å
šãŠãããªãæ¹ã®è²¬ä»»ã«ãªãã
ãšããæ±ºå®çãªèšŒæ ãèŠãä»ããããšã«ãªãã®ã§ãããã°ãããŒã®åœ¹å¡ã«ã¯ãããããã»
ã®ããããçè§£ã§ããªããããããŸããããæ³çæ©é¢ã®æ¹ã¯èŠéããªãã§ãããããã²ã
詊ããŠã¿ãŠãã ããïŒããã¯ã广ããããŸãã
æè¿ã®ã¯ã¯ãã³ç±çã¶ããšã次ã
ãšæ¥çš®äºå®è¡šã«ç»å ŽããŠããæ°çš®ã®æªæ€æ»ã¯ã¯ãã³ã®
æ°ã
ãèããã°ãå
é€ç³è«æžã¯åã«ããŸããŠå€§äºãªãã®ã§ããçŸåšã«ãããŠã¯ãäŸãã¯ã¯
ãã³ãä¿¡ããŠãã芪ã§ããå
é€ç³è«æžã«ã¯çœ²åããŠããããã«ãèŠãããŸããããããã°ã
é±ããšã«å€ããæ¥çš®æ¹éã«æããããã«ãåãããã¯ã¯ãã³ã ãèªåã§éžã¶ããšãåºæ¥ãŸ
ããå
é€ç³è«æžã¯ãæ¬æ¥ã®æã¡äž»ã§ãã芪ã«ãéžææš©ãäžãæ»ããŠãããã®ã§ãã
æ°çš®ã®ã¯ã¯ãã³ã®æ¯æãã¯ã誰ãããã®ãïŒ
NIHã«ããåœã®è£å©éå¶åºŠã«ãããŠãæ°çš®ã®ã¯ã¯ãã³ã®ãç ç©¶ããåã³ãã®åžå Žå£²ãåºãè²»
çšãšããŠäžãããã 100 äžïœ300 äžãã«ã®å€§éšåã¯ãå
¬ã®è²¡åžãã€ãŸãçšéããæãç«ã£
ãŠããã®ã§ãïŒ ããã§ããç§éã¿ããªãããã®åœã®åäŸéã«äººäœå®éšçã«äœ¿ããããçµã
ãã®ãªãæ°çš®ã¯ã¯ãã³ã®éçºã®ããã«ãã£ããšãéãæã£ãŠããã®ã§ãã
åç©èåŸ
ããªããããã«
çããã¯ãèªåã®é£Œãç¬ãç«ã銬ãªã©ãããããã§ãããïŒ ãã®åç©éã«ãç¡å·®å¥ã«ã
äœã§ãæ°ããéçºãããã¯ã¯ãã³ãåããããŠã¯ããªãã§ããããïŒ ãã®æ¬ãèªãã åŸ
ã«ã¯ãåç©ã®ã¯ã¯ãã³æ¥çš®ã®è£œé åã³è²©å£²ã®é°ã«ãå
šãå¥ã®ç ç©¶ã販売ãåžå Žå®£äŒãæ¿æ²»
ãšãã£ããã®ãæ·±ã絡ãã§ããããšãã倧äœäºæ³ãä»ãããšæããŸãããããŠããã®æ¥ç
ã®å«ç芳ãšã¯ã人éçšã®ã¯ã¯ãã³æ¥çãããããã«é«æ
¢ãªãã®ã§ããããšããäºæ³ã§ãã
ã§ãããã圌ãã®å«ç芳ãªããŠãåãããªãã®ç©ä»¶ã売ãã€ãããããã³ã¿ãŽã³ã«çªã£èŸŒ
ãã ããŒã€ã³ã°æ©ã®ç Žçã§ããåç£ã«ãããã§ããïŒ ãšãããããªãã®ã§ãã
é©ãããšããããŸãããããã®æ¥çã§ããã¯ããäžããäžãŸã§ãŸã£ããåãã²ãŒã ãè¡ãª
ãããŠããŸãã詳现ãè¿°ã¹ãã«ã¯ããã®æ¬ã¯ãã§ã«é·ããªããããŠããã®ã§ãæ¬¡ã«æãã
ïŒåã®æ¬ïŒã©ãã ãæããè©±ãæ³åã§ããã§ãããïŒããèŠãããã ãã«ããŠãããŸãã
How To Protect Your Dog From a Vaccine [344]ãåã³ Dr.Mason èã® They Shoot Horses
[345]ã§ãã
æ
è¡æã®ã¯ã¯ãã³æ¥çš®
ããããåã売ãäžãåæ³ã§ãããã¡ãã®ããšãæå¥ã¯ãä»ããåœãé¢ããŠæªç¥ã®å Žæã«
ããã®ã ããããšãããã®ã§ããã€ãŸããçãããå
ç«ãæã£ãŠããªããæªç¥ã®ã°ãèã
ããããšããæå³ã§ããïŒã§ããããã¯ééãã§ããå¿è«ãã¢ã¡ãŒãæ§ã®èµ€ç¢ããžã£ã³ã°
ã«ã§ã®è
æç
ãMontezumaâs revenge ãšãã£ãæ
è¡è
äžç¢çãªã©ã軜èŠããããšã¯åºæ¥ãŸ
ããããã ããã§èšãããã®ã¯ããã®ãæªç¥ãžã®æããã¯ãçãããåžžèããã£ã¡ã®ãã§
ææ°ã®éæ³è¬ã«é£ã³ã€ãããã«ã¯ã¯ãã³æ¥è
ãä»çµãããã®ãçµ¶å¥œã®æ©äŒã ãšããããšã§
ããããã§ããå 100 ããŒãžãã§ç¹°ãåºãããããç§é人éãç¬ã銬æ±ãããŠãã圌ãã®
æ
床ã¯å€ãããããã©ãã«æã®ã¯ã¯ãã³ãæ±ã£ãŠããã®ã¯ããŸã£ããåãæ¥è
éãªã®ã§ãã
çããã¯æ
è¡äžã«ãä»ãŸã§ãšã¯ãŸã£ããéãç°å¢ã«èº«ã眮ãããšã«ãªããŸãïŒã¹ãã¬ã¹æº
ãéãã°ãé£ã¹ç©ãéããè
žå
ã®èãéãã°ã空æ°ã®è³ªãå€ãããŸãããã®ãããããã
ãçããã®äœã®åè¡¡ãä¿ãšããšããäžã§ããããŸã§èããŠããå
ç«ã詊ãããããšã«ãªã
ã®ã§ãããããªã®ã«ãå
ç«ç³»ãæãå¿
èŠãšããããã®æ
è¡æã«ã人工ã®ç
åèãæ·»å ç©ã
å±±ã»ã©å
¥ã£ãå®éšã¯ã¯ãã³ãªãããåããŠèå¿ãªå
ç«ç³»ã«ãã³ãã£ãã£ãããè² ããããª
ããŠãã©ããããŠããŸããæ
è¡æã«å¿
èŠãªã®ã¯ã¯ã¯ãã³ã§ã¯ãªããåžžèçãªå€æåã§ãã
é£ã¹ç©ãé£²ã¿æ°Žã«æ°ãã€ããå°åç¹æã®æ€ç©ã空æ°ãç°å¢ã«æ³šæããå
ç«ç³»ã«è¯ãããšã
ããïŒåœå
ã ãããæµ·å€ã ãããã人ãå®ã£ãŠãããã®ã¯ããã ãã§ããæåŸã«ããäžåºŠ
ã ãèšããŸãããç
åèã¯ç
æ°ã®å
åã§ã¯ãã£ãŠããåå ã§ã¯ãããŸãããäœã®ç¥å¥ªè
ã§
ã¯ãªãããŽãæŒããããã ãã§ãã
å°æ°æŽŸã®èãæ¹
ãã®ç« ã«æããŠããã®ã¯ãäžè¬çã§ã¯ãªããããïŒïŒ
ã®èãæ¹ã§ãããã®èª²é¡ã«ã€ããŠç
ãããç®ã«ããæ
å ±ã®ïŒïŒïŒ
ã¯ããã®æ¬ã§çãããåŠãã å
容ã«çæ£é¢ãã察ç«ããæ¿ã
ãåè«ãããã®ã§ããã§ãããããããããäºé²æ¥çš®ãã«ã€ããŠã®æ¬ããŠã§ããµã€ãã®æ®
ã©ã¯ãä¿¡ææ§ã確信床ãé«ããã«èŠããããšã§ããããã§ãããããããŠã§ããµã€ãã®å·§
åŠããšä¿¡ææ§ãšã¯ã鿝äŸãããã®ã§ããããšã«æ°ãã€ããŠäžãããéèªãåãããšã§ãã
èŠæ ãããããã°ã©ãã£ãã¯ãåããã°åãã»ã©ãäŒæ¥ç²Ÿç¥äžçã®ç§åŠã®ãŽãã®ãããªã
ã®ãæžãããŠããã®ã§ããåèè³æãæªããã£ããããããã¯å
šãæ²èŒãããŠãªãã£ããã
çµ±èšã¯ã§ã£ã¡ããã ã£ãããè©æžãåŽæãæ
å ±ã®ãã¿æ¶ããèªåŒµãªã©ïŒïŒïŒãã¯ã¯ãã³æ¥ã¯ã
å²äžã§æã倧ããªå®è¹ãªã®ã§ãããŠã§ããµã€ãã§ãéèªã§ããæ¬ã§ã人ã§ããå»çå ±éã§
ãã£ãŠããç©ãèšãã®ã¯ãéã§ãã
ç®èãªããšã§ããããã®æ¬ã®æ¬åœã®äŸ¡å€ããã©ãã ãã²ã©ãäžå·ããããã§åããããšã§
ãããã
ã¡ãã£ãšããç ç©¶ãããžã§ã¯ã
æãåã« 1 床ãã¯ã¯ãã³æ¥çš®ãåããããããšãç¡ãããšãã人ã誰ãèŠã€ããŠã¿ãŠãã
ãããããæ¹ã¯ã©ãã§ããããšã«ããèŠã€ããã®ã§ãããããŠãã®äººã«ãåäŸã颚éªãåŒ
ãããã¢ã¬ã«ã®ãŒæã¡ã§ããããç
æ°ã«ææããããããããæã¡ãïŒïŒïŒãªã©ãèããŠã¿
ãŠããããªããããããã人ã
ã«ãèªåã®åäŸéãšä»äººã®åäŸéã®å¥åº·ç¶æ
ãæ¯ã¹ãŠã©ã
æãããèããŠã¿ãã®ã§ãã10 人ã20 人ã30 人ã«è³ªåããŠã¿ãŸããããã¡ãã£ãšããéž
話ã«ãªãã§ãããã[320]
ææªã®ç¶æ³èšå®
ã¯ã¯ãã³ã«ããå¯äœçšåå¿ã®çºçå ±åä»¶æ°ãæšå®ããéãFDA ã CDCã¯å€§æµã®å Žå10ïŒ
ãšèŠç©ãããŸãã(NVIC [253])FDA ã®çäºã§ãã David Kessler ã¯ããªããšJAMAèªã«å®
éã®æ°ã¯ïŒïŒ
ã«è¿ãããªã©ãšèšè¿°ããŠããŸãïŒ[346] ãããã1991 幎以åã«ã¯ãå ±åä»¶æ°
ã¯ãŒãä»¶ã§ãããããã®ïŒïœ10ïŒ
ãšããæ°åãè£ä»ããç ç©¶ã¯çç¡ã§ããããæ¬åœã®æ°ã¯
誰ã«ãåãããŸãããã§ããããã¹ã€ã«æ²èгçã«ãèŠå䞻矩è
ã«ããªãããã§ã¯ãªããã
ã å®éã®ç¶æ³ã¯ã©ããªã®ãçŸå®çã«èŠã€ããããã«ãææªã®äºæ
ãäºæ³ããŠããããšã¯å¿
èŠã ãšèããããŸãã
ã§ã¯ãä»®ã«æ¬åœã«ãã®10ïŒ
ãšããæ°åããå®ã¯5ïŒ
ããããã¯ïŒïŒ
ã§ãã£ããšããŸãããã
蚌æ ãšãªãè³æã¯ãªãã®ã§ãããã誰ããããäžå¯èœã ãšã¯èšããŸãããå®ã¯ãNVIC ã
1998 幎ã«ããã¥ãŒãšãŒã¯åžã®å°å
ç§å»é¢ã察象ã«å®æœããã¢ã³ã±ãŒã調æ»ã«ãããšããã¯ã¯
ãã³æ¥çš®åŸã«èµ·ããæ»äº¡ãè² å·ä»¶æ°ãå ±åããå»è
ã¯ã40 人㫠1 人ãã ãšããããšã§ãã
(DPTVaccine Reports)[222] ã€ãŸãããã®å°åã§ã¯ã¯ã¯ãã³ã«ããæ»äº¡ä»¶æ°ã® 97.5ïŒ
ã¯å ±
åãããŠããªãããšããããšã«ãªããŸããããã¯ãããããããå
šåœå
±éã®å²åãããã
ãŸããã
ã§ã¯ãããã¯ã¯ãã³ã«ããé床ã®å¯äœçšåå¿ã® 97ïŒ
ãå ±åãããŠããªãããšãããã©ãã§
ãããïŒåã«ãåŠã³ãŸããããã¯ã¯ãã³ã¯äœã®ã©ããã«äœå¹Žãæœãã§ããããšãåºæ¥ãã¹
ããŒãŠã€ã«ã¹ãšãããã®ãå«ãã§ããŸããã§ããããããããå¯äœçšåå¿ã®å€ãã¯ããŸã
çºçããŠããªãã ãããç¥ããŸããããã®å¯èœæ§ã¯ãååãããŸãã
2009 幎ã«åå äžæã®ç
æ°ã«ãªã£ã人ã¯ãæ¬åœã¯ 1980 幎代ã«åããã¯ã¯ãã³æ¥çš®ã®å¯äœçš
åå¿ãåºãŠããã®ãããããŸããããããŠããããäºæ
ããå€§èŠæš¡ãªã¹ã±ãŒã«ã§èµ·ããŠã
ãå¯èœæ§ã¯ååã«èããããŸãã
ãã®åœã«ãããéè¡æ§ã®ç
æ°ãææç
ã®å€§æµè¡ãèŠããšãç§éåœæ°ã®çæŽ»åºæºãå»çäºç®
ãšå
šç¶é£ãåãããšããŠããŸãããããã¯ãã©ãããŠã§ããããïŒ è¬ãè¶³ããªãã®ãïŒ ã¯
ã¯ãã³ãäžè¶³ããŠããã®ã§ããããïŒ ãããªããšã¯ãããŸãããä»ç§éã®å¥åº·ç¶æ
ãæžŠå·»
ãã®äžãåç¶æ
ãªã®ã¯ãã¯ã¯ãã³ã®å¯äœçšã倧ããªåå ã§ããã®ã«ãç§éã¯ããã«æ°ä»ã
ãŠããªãã®ã§ããã ã£ãŠã誰ããããªããšãæããŠãããã§ããããïŒ æ°èãéèªïŒ ã
ããšããå»è
ããïŒ
ç§éãåãå·»ãç°å¢æ±æç©ã®å€ãããããŠå€ãã®äººã现èã害ãããããªé£ç掻ãããŠã
ãããšãèããã°ãèªåéã®ã²ã©ãå¥åº·ç¶æ
ãå
šéšã¯ã¯ãã³ã®å¯äœçšã®ããã§ãããšã¯èš
ãã«ããã§ããã§ããããã§ã®ãã€ã³ãã¯ãããã®å¯èœæ§ãããããšããããšã§ããå°ãªã
ãšãã以äžã«æããçç¶ãè¿å¹Žå¢ãã€ã€ããåå ãšããŠããã£ãšãçãããã®ã¯ã¯ã¯ãã³
ã®å¯äœçšã ãšãããŸãïŒ
å¿èç
ã¢ã¬ã«ã®ãŒ æ¶åç³»ã®ç
æ°
é¢ç¯ç ç¡åŒåž çµæ ž
AIDS ãããã èªå·±å
ç«ç
ç ç³å°¿ç
ç¥çµé害
ç²ç¶è
ºã®ç
æ° æ
¢æ§ç²åŽ èŠåäœäž
äžåŠç èªéç åŠç¿èœåã®é害
ãããã®ç
æ°ãç©åãå¢ãã§å¢ãã ããã®ã¯ãç§éãã¯ã¯ãã³éããŸã£ãããã«é§ãåºã
å§ããåŸã®ããšã§ãã
確ãã«ãªãã ãæã話ã§ã¯ãããŸãããç§ã¯ãã ãèªåéãã©ãããŠãããªã«ç
æ°ãã¡ãª
ã®ãããã®çç±ãæããã«ãããã ããªã®ã§ããçããã®åšããèŠæž¡ããŠã¿ãŠãã ããïŒ
20 幎åãšæ¯ã¹ãŠãä»ã®åäŸéã¯ããå¥åº·ã§ããããïŒ ãããšãããç
æ°ãã¡ã§ããããïŒ
ããæ©æã§ããããïŒãããšãããéããªã£ãŠããã§ããããïŒ åŠæ ¡ã§åæ¯çšã®åŒåžåš
ã¯å¢ããŠããŸããïŒ æžã£ãŠããŸããïŒ Mark Leppeâã¯èªç¶ã®éžæã匱è匷é£ã®æ³ãèªãã
ã¯ã¯ãã³ãããã«äººé¡ã®é²åã人工çã«å©ããç§éããç§ã® DNA ã®æ¹è¯ã«åœ¹ç«ã£ãŠããã
ãã説ããŠããŸããããããæ¬åœãªããå®éã«é·æçåç·ã§åã¡æ®ãã®ã¯
ã¯ã¯ãã³ãåããŠããªã人
ã¯ã¯ãã³ã«å¯ŸããŠå
ç«åã®ãã人 [316]
ãšãªãã§ãããã
ç§éå®¶çåãã®æ°ããã¯ã¯ãã³
ãã¹ããŒã«ããžã§ããŒã®æä»£ä»¥æ¥ãã¯ã¯ãã³ã®å£²ãäžãã¯å»è¬åäŒæ¥é£åã®äžã§å®ã«äž»èŠ
ãªå²ãã©ãããšãªã£ãŠããŸãããä¹³å
㯠1床ã«10,000 åã®ã¯ã¯ãã³æ¥çš®ã«èããããšãã§
ãããšäž»åŒµããããã® Offit ã®éŠ¬é¹¿ããèšäº[119]ããã£ãŠãçŸåšäœçš®é¡ãã®æ°ã¯ã¯ãã³ãé
çºäžã§ããã1 ã€ã®äŒç€Ÿã§ãæ°çš®ã®ã¯ã¯ãã³ã 20 çš®é¡ã詊ããŠãããããã§ãã[61]ãã
ããçããã 1ã€ã®ãŽãŒã«ããèªå¯ããç®æããŠãŸã£ãããã«é²ãã§ããã®ã§ããåèšã§è«
ãã AIDS ã¯ã¯ãã³ã®ä»ã«ããããããã®ã²ãŒã ã«åããŠãã³ãã«é£åã£ãŠããã¯ã¯ãã³
ã¯æ²¢å±±ãããŸãã以äžã¯ããã®äŸã§ãã
ãµã€ãã¡ã¬ããŠã€ã«ã¹ ã¯ã©ããžã¢
C åèç è¥æºç
åçŽãã«ãã¹â
¡ æ·ç
åŒåžåšå€æ žäœãŠã€ã«ã¹ ãããã
SARS ã¿ãã³äžæ¯
ç çé· [45] [307]
ãã以å€ã«ãããã©ãªã¢ãTBãé«èçãã¢ã«ããã€ããŒçãã¢ã¬ã«ã®ãŒãããŒãè±ç²çã
ç³å°¿ç
ãææ¡çã®ã¯ã¯ãã³ãªã©ãéçºäžã§ãããããã®ã¯ã¯ãã³ã¯ããã ã®æºäžã®ç©ºè«ã§
ã¯ãããŸãããããããã¯ã¯ãã³ã®ãéçºãã®ããã«ããã§ã«å·šé¡ã®è²»çšã䜿ãããŠããŠã
ååãšããŠç»å Žããã®ãããã¯ãç®åç¶æ
ã§ãã
ãããæ°çš®ã®ã¯ã¯ãã³ã®å¹Ÿã€ãã¯ãããã€ãªããããšããèŒãããçŽ æµãªå®£äŒæå¥ã«æµãŸã
ãŠããŸãããŸãã«åºåæ¥ã®å€¢ãå®çŸããŠã倩ç¶çããããç
ãšãã£ã倿 ªã¯ã¯ãã³ããã
SARS ã HPVãé³¥ã€ã³ãã«ãšã³ã¶ãšãã£ãæ°çš®ã®ã¯ã¯ãã³ãŸã§ãããããä¹³å
ã®ã¿ã§ãªã
èè¥ç·å¥³ãåãã¬å
šãŠã®äººã«åããŠæ¥çš®æå®ãããããšã«ãªãã®ã§ãã
圢åŒã倧äº
FDA ã®èªå¯ã決ããã®ããç§åŠçæ ¹æ ã§ã¯ãªãæ¿æ²»çãªçç±ã§ãããªããè£œè¬æ¥è
ã®åŽã
ãããªãã«è¶³å
ãåºããŠãããããšãããã®ã§ãã圌ãã¯ãã¯ã¯ãã³ãå¹ããªãããšãæ¿
ç¥ã®äžã§ãããå®ã®ãšããããã®ç
æ°èªäœãå®åšããªããŠãããŸããªãã®ã§ããå¿
èŠãªã®
ã¯ãããã«ãã®ç
æ°ã®å±éºæ§ãæŒåºãããã®æ²»çæ³ãæ«é²ãããããšãã圢åŒã§ãããã
ãŠããããæŒåºã¯ãå»çç ç©¶ãå»çé¢ä¿ã®åºçã倧æã®å ±ééšã FDA ã®ä»£è¡šåç· åœ¹äŒãã
ããŠè°äŒãã³ã³ãããŒã«ããã°åºæ¥ãããšã§ãã[331]ããããããã¯å¥ã«é°è¬ãªãããã
ãããŸããïŒãã ãäžçã¯ãã®æ§ã«åããŠãããšããã ãã®ããšã§ãã
äžã«æããã¯ã¯ãã³åè£ã¯ããã¹ãŠå®åšã®ãã®ã§ãããããŠä»ãã 2 幎ãçµãŠã°ã補è¬äŒ
ç€Ÿã¯æ°ãã« 50çš®é¡ã»ã©ã®ã°ãèã«å¯ŸããŠãã¯ã¯ãã³ãéçºãããŠããããšã§ãããããã
ããã¹ããŒã«ã®æãïŒç
åèèª¬ã®æ®ããéºç£ã§ããä»ãŸã§ã«ãäœåã®ããã¯ããªã¢ããŠã€
ã«ã¹ãæè¿ãçºèŠãããŠããŸããããããŠçŸä»£å»åŠã«ãããŠã¯ããããã®å
šãŠãçè«äžã¯
ã¯ãã³éçºã®å¯Ÿè±¡åè£ã«åœããã®ã§ãããŸã£ãã銬鹿ãã話ã§ãã
ããã®äžã«ååšããå
šãŠã®åŸ®çç©ã«å¯ŸããŠããªãã§ãããã§ãã¯ã¯ãã³ãéçºããå¿
èŠã¯
ãªããã -Stephanie Cave, MD [172]
éåžžã®ãã¿ãŒã³ãšããŠã¯ããããªæãã§ãïŒ
ã»ããã°ãèãèŠã€ãã
ã»ç
æ°ãåœåãã
ã»ãã®ã°ãèãç
æ°ã®åå ã ãšå®£äŒãã
ã»ãã®ç
æ°ãåå ã§æ»äº¡ä»¶ãæ°ä»¶ãããšèšŒæãã
ã»ãã®ã°ãèã®æŽ»åãç·©åããã¯ã¯ãã³ãäœã
ã»åäŸéã®è¡æ¶²ã«ãã®ã¯ã¯ãã³ãæãŠãããåæ³åãã
ããããã¢ã¡ãªã«åŒã®ããããã§ããããã§éèŠãªããšã¯ã人ã
ã®å¥åº·ãªããã§ã¯ãããŸ
ãããä»ãŸã§ãããããããã
å®å
šãªã¯ã¯ãã³
ãã® 2 幎ã®éã«ãæ°ãããã®å Žéãã®ç©ºæ³è©±ã®ãããªèŠ³å¿µããã©ããããšããªãäœãåºã
ããŸããïŒçãããç®ã«ããããšãããããç¥ããŸãããïŒã°ãªãŒã³ïŒç°å¢ã«ããïŒã¯ã¯
ãã³ãšãããã®ã§ãã圌ãã®åãè¿ãæ¹ã¯ãããã§ãããããã確ãã«å¹Ÿããå±éºæ§ã®ãã
ã¯ã¯ãã³ãããã€ããããŸããã§ããã¯ã¯ãã³ã®ããããåé¡ç¹ã解決ããä»ãŸã§ãã£ãš
宣äŒããŠããããã«ãæ¬åœã«åœãæã£ãŠãããéæ³ã®æ¥çš®è¬ã«ããããã«ãå°éå®¶éãæŒ
ãå€ãå°œåããŠããŸãã®ã§ãã€ãŸããç§éã«ã¯ããã«ã¯ã¯ãã³ãå¿
èŠãªã®ã§ãããã ãã
ããè¯ãã¯ã¯ãã³ãšããæå³ã§ããããããç§éãããè³ã«ãããæ©ã¿ã®çš®ã®å¯äœçšåå¿
ãæ»äº¡ãåæ°žä¹
çãªè³é害ãªã©ãåŒãèµ·ãããã广ããã倧ããã¯ã¯ãã³ãå¿
èŠã§ãã
ãã®äžãããããæ°ããæ¹è¯çã¯ã¯ãã³ã®ã°ã«ãŒãã«ã¯ãããååã ã£ãŠèããŠããã®ã§
ããç§éã¯ãããããã°ãªãŒã³ã¯ã¯ãã³ãšåŒã¶ããšã«ããŸããããŸããæ¬åœã¯å®åšããŸã
ãããããããããããããããªãã®ã¯æãåŸãªãã§ãããããã§ãç©ã¯è©ŠããšãããŸã
ãããïŒã
ã°ãªãŒã³éåïŒç°å¢éåïŒã«ãããã£ãŠäžå²ãããããšããäžå¿çãªå©ç以å€ã«ãåäŸé
ã®æªçºéãªå
ç«ç³»ã«ééå±ã DNA ãå€ããŠããŸããããªçç©ã泚å
¥ãããšããè¡çºãã
ãããç°å¢çãªå©çãªã©ãäœããããšããã®ã§ãããïŒ ã§ã¯ã圌ãããã®ã°ãªãŒã³ã¯ã¯ã
ã³ãšãã衚çŸã§èšãããšããŠããããšãèŠãŠã¿ãŸããããèªç¶ãšã®èª¿åãç°å¢ç Žå£ã®äžæ¢
ãç®æãæ¬åœã®ã°ãªãŒã³éåãšãããã»ã©çžåãããã®ã¯èãã«ããã§ããã圌ãã䞊ã¹
ç«ãŠãèã£ãºããªäž»åŒµã®è£ãèŠãã°ããã®åããåååã®å
ã«ãªã£ãŠããé埳ãå«ç芳ã
ããã»ã©ã®ãã®ãã¯æããã§ãã
ã°ãªãŒã³ã¯ã¯ãã³ãšã¯ãE.L.Bernays ã®ã¡ãã£ã¢åæ³ã®å®çŸçã§ãããããŸããã察æç©
ã®ã³ã³ãããŒã«ãšããææ³ã§ããããã¯ããããšããããåéã«ãããäž»æµæŽŸã®æ¹éã«å¯Ÿ
ãããè³æ¥µãŸã£ãšããªæ¹å€è«ã匱äœåãããããã«ä»åããæã§ã話ãè±ç·ãããŠããŸã
ãããšãããã®ã§ããä»åã®ä»¶ã«é¢ããŠèšãã°ããã¥ãŒã¹ãéèªããã¿ã€ãã®å€§å€æ°ã«å
ããŠããã亀æžè²æ©ããããã§ãããã¯ãã確ãã«ã¯ã¯ãã³ã«ã¯äºçްãªåé¡ç¹ããããŸããã
ãããŠç¡å®³ãªãã®ãæ°ããåºãŠããŸãããããšã
ãã®ããšãç¥ã£ãŠããŸã£ãããã«ã¯ããã®èµ€æã«ã¯ååæ³šæããŠãã ããããããªççŸã
ã説ãèªããŠããŸã£ããã䞻匵ããŠãã圌ãã®æã壺ã§ããäœããã°ãªãŒã³ãªã¯ã¯ãã³ãª
ãã®ã§ããïŒã次ã¯äœã§ããããã°ãªãŒã³ãªå£åãŠã©ããŠã ã§ããããïŒ
瀟äŒããŒãŠã£ã³äž»çŸ©
ãã®æ¬ã®ã·ãªãŒãºãåè¡ãããŠããããã 10 幎ãçµã¡ãŸããã¯ã¯ãã³ã®åé¡ã«ã€ããŠã人ã
ã¯é¢å¿ã瀺ãå§ããŠããã§ããããïŒ
ã¯ã¯ãã³ã®å®£äŒãæšèŠã®ããã«äœåäžãã«ã䜿ãããŠããããšãèããã°ãå
šãŠã®èŠªéã¯
ãããã§ã«å®å
šã«äžžã蟌ãŸããŠããŸã£ãŠããããšæããã§ããããããããã§ã¯ãããŸã
ãããçµ¶ãéãªãã¡ãã£ã¢ã®æ¯æãåŠæ ¡åŽããã®èŠæ±ãããå°æ°æŽŸã®èŠè§£ã§ããããšããšã
ã£ããã¯ã¯ãã³æ¯æåŽã«æç¶æå©ãªç¶æ³ã«ãããããããåè¡åœã§ã¯ã¯ãã³æ¥çš®ãåããŠ
ããªãåäŸéã®æ¯çã¯ãæ¯å¹Žå°ããã€å¢ããŠããŸãã
ã¯ã¯ãã³ãæåŠããã«ã¯ãèªå·±æè²ïŒããããªã«ã¯ã¯ãã³ãéšãããŠããã®ã«ã¯æ¬åœã«èš³
ãããã®ãããããªããªãæãåãå®ããããªãã芪ãšããŠã¯äœã§ããã£ãŠã¿ãªããããš
決å¿ããŠå€å€§ãªå人åªåãããããšããå¿
èŠã§ãããã«ãããããããããã人ããããª
ã«å¢ããŠããŠããããšã«ã¯é©ããŠããŸãã»ã©ã§ããäžè¬çè·¯ç·ãå€ããŠæ©ãã®ã¯ãšãŠã倧
å€ã§ããããããã¯ããããæ¶èæŠã§ããäžæ©äžæ©ãåªåãç©ã¿éããŠãããªããŠã¯ãªã
ãŸãããã¯ã¯ãã³ã«å¯Ÿããçã®èªèããäž»æµã«ãªãããšã¯æ±ºããŠãªãã§ããããèªåèªèº«
ãé Œãã«ãèªå·±æè²ãè¡ããåäŸã®å
ç«ç³»ãäœã«ãå·ã€ããããªããŸãŸã«çºéãããŠãã
ãããšããå§¿å¢ã«ã¯ãçµ¶ãéãªãæ»æã仿ããããŠãããã®ã§ãããã
æ¬æžã§ç€ºããèŠè§£ãã倧è¡ã®ã¡ãã£ã¢ã§åãäžããããããšã¯ç¡ãã§ããããäŸãã©ããª
ã«å€§å¢ã®åäŸã被害ã«ãã£ãŠããã¯ã¯ãã³ã«å¯ŸããåŸæ¥ã®èŠæ¹ã«æã¡åã€ããšã¯ãŸãç¡ã
ã§ããããã¯ã¯ãã³ã¯ããããããæ¶ããŠãªããªãã¯ããŸãããåè¡åœã®åäŸéã®å€§å€æ°
ã¯ãããããããã£ãšã¯ã¯ãã³ãåãç¶ããã§ãããããã¯ã¯ãã³ã«ãã被害ã®ä»¶æ°ã¯ã
å¢ãç¶ããããšã§ãããã
ããããæãæªæ¥äºæ³å³ã«ãäœãåžæã®å
ã¯ããã§ããããïŒããã§ããïŒïŒïŒçããã¯ã
人é¡ããŸããå°çäžã®ä»ã®å
šãŠã®çãç©ãšåæ§ã«ãèªç¶ã®éžææ³ã®æ¯é
åã«ãããšããã
ãšãèŠããŠããŸããïŒ å
ç«ç³»ã匱ããã®ãããè±èœããŠããã®ã§ããã¯ã¯ãã³ã«ãã£ãŠå
äŸéã«è«å€§ãªãŠã€ã«ã¹è² è·ãçµ¶ãéãªã匷ããŠãå
ç«æ©èœãæå¶ãããšããããšãé·æç
ã«ç¶ããã°ãçµæãšããŠããããåéã®å®¶ç³»ã¯æãçãæ®ãå¯èœæ§ãå°ãªããªããŸãã圌
ãã®åå«ä»£ã
ãŸã§ããã® DNA ãæ°žä¹
çã«åŒ±ããŠããŸãããã§ããéå» 50 幎éã§ã¯ã¯ãã³
è² è·ã 2500ïŒ
ã«ãŸã§å¢ãããã®åè¡åœã«ãããŠãåäŸéã®å¥åº·ç¶æ
ãšç¥èœã«ãããã©ããª
圱é¿ãäžãããããã¯æããã§ãããããã®ãã¿ãŒã³ãããš 50 幎ã100 幎ã200 幎ãšç¶ã
ãŠåŸ¡èЧãªãããèªç¶ã®æ³ã¯æ±ºããŠæ²ããããšã¯ãããŸããã
ã¯ã¯ãã³é¢é£ã®èª²é¡ãã瀟äŒãããŠäººã
ã®èªèã«ãããŠã©ã®ãããªåãæã£ãŠããããå
åã«ç ç©¶ããŠãããšããã®ãã¡ã«ãã®åé¡ãçæ£é¢ããæ»æããŠãçµå±ã¯ããããç¡é§ãª
åªåã«çµããã®ã ããšãã€ã®æ¥ãæãç¥ãããã矜ç®ã«ãªããŸãããã®èª²é¡ã«é¢ããŠç¥è
ãæããªã人ã
ããè»éã«ãã£ãŠç¥èãæããªãããã«ä»åãããã人ã
ã¯ããã®å
ãã
ã£ãšèªåã®åäŸã«ã¯ã¯ãã³ãåãããç¶ããããšã§ãããïŒãããŠãã®çµæãæãçµã€ã
ã¡ã«èªç¶ã®æ³ã®éžæã«ãããçµ¶æ»
ã®éã蟿ãã®ãããããŸãããããã¯ãå¥ã«è¯ãããšã§
ãæªãããšã§ããªãããã éºäŒååŠäžãããªããšããã ãã®è©±ã§ãã
ç§éãäœãäžããŠãããã®æãæ¿ã£ãã¯ã¯ãã³äžçã®çŸç¶ã«ãããŠã¯ããããããã®éºäŒ
åäžã®æ©ã¿ãäžçã®åžæã®å
ãšããŠæã¡ç¶ãããããªãã®ãããããŸããã
éå»ããã®ã¡ãã»ãŒãž
ç§åŠçããã€æè¡çãªåé¡ãäžè¬äººã«ã¯å°éçããããšããçç±ã§ãèªåã®åäŸã«ã¯ã¯ã
ã³ãåãããããã©ããã®å€æãå»è
ã«ä»»ããŠããŸã人ãã¡ã«ãDr.Hadwen ããéå»ã®ã¡
ãã»ãŒãžããéãããŸãããã
ãïŒïŒïŒããå»çæœè¡ãæ³å¶åããŠåãå
¥ããç¥èäººã®ææãåæã®èšŽãã眰éãåçœ°ã§æŒ
ãã蟌ã¿ãç¡çããå·è¡ããããšããæãããã¯ãã¯ãçŽç²ã«æ²»çã®ããã®åé¡ã§ã¯ãªãã
ç€ŸäŒæ¿çãæ¿æ²»æ¹éã«ã®ã£ãšãããåé¡ãšãªã£ãŠããŸããã
äžäžçŽãçµã£ãçŸåšã§ãããã®ã¡ãã»ãŒãžã¯çŸå®ãšããŠé¿ããŠããŸããã¯ã¯ãã³åé¡ã¯ã
ã¯ãããããããå°éå®¶ãã«ä»»ããŠããã°ããåãªãç§åŠäžã®èª²é¡ã§ã¯ãªãã®ã§ãããã®
åé¡ãæ¿æ²»ãšå€§èŠæš¡ãªéå²ãã«ã®ã£ãšãããŠããŸã£ãä»ããã®åœã®ã¯ã¯ãã³ã«é¢ããå»ç
å ±éãèšåºç ç©¶ãæ³åŸã®è£èå°ã«ã誰ãè³éæäŸè
ãšããŠæœãã§ããããã¡ãããšèª¿ã¹ãŠ
ã¿ãã°ããã®ããšå
šäœå³ãèŠããŠããã¯ãã§ããå
ç«ç³»ã«ã€ããŠç§åŠçã«è©³ããç¥ããªã
ãŠããã¯ã¯ãã³ãå±éºãã©ããã®å€æãããã¯åºæ¥ãã¯ãã§ãã
ã¯ã¯ãã³ãå±éºãªã®ã¯ãç§åŠè
éã人éã®å
ç«ç³»ã«ã€ããŠååã«ææ¡ããŠããªãããã ã
ã§ã¯ãããŸãããç§åŠè
ãã¡ã人éã®å
ç«ç³»ã«ã€ããŠååã«ææ¡ããŠããªãã«ãæããã
ã¯ã¯ãã³ãæ³å¶åããæ¥çš®èŠæ±ãããŠãããããå±éºãªã®ã§ãã
ããã¢ããªæ°ãã«ããŸãã®çŸç¶
ãããããä»ãŸã§ã®çµéã®çµæã®äžã§ãææªãªã®ã¯ãç§éã®ãã¡å€ãã®äººã
ãäœã«çãŸã
ã€ãåãã£ãŠããç¥æµãããªãã¡èªç¶ã®å
ãªãæ²»çåãä¿¡ããããªããªã£ãŠããŸã£ããšã
ãç¹ã§ãããã幎ã
æ³ã
ãäžæ¥ã«çŸåãã¡ãã£ã¢ã«èšããããããæ«ãç§éã¯ä¹³å
ã® 99.9ïŒ
ã¯ãã®ãŸãŸã§ååå¥å
šãªç¶æ
ãªã®ã§ã¯ããšããç¹ã«ã€ããŠèããããšãããåºæ¥ãªããªã£
ãŠããŸã£ãã®ã§ããèµ€ãåã®çŽç²ãªè¡æ¶²ããããã®å®å®äžã§æãããããã®ãªããã®ã§ã
ãããã®çŽç²ãªè¡æ¶²ã®äžã§ãã人éã®ã²ãã ãå±éºããå®ãããäžä»£ãè¶
ããŠåãç¶ãã
ãŠããããšãåºæ¥ãã®ã ãšããç¹ããèæ
®ããããšãã§ãããå
ç«ç³»ã¯æãå ããã«ç¬èª
ã«æé·ãããªããã°ã(人éã®ç§åŠã§ã¯ããŸã èšãç¥ããªã)æ¬æ¥ã®èœåãååã«çºæ®ã§ããª
ããšããã®ã ãšããç¹ããèããŠã¿ãããšããåºæ¥ãªããªã£ãŠããŸã£ãã®ã§ãããããã
ããèªç¶ã§ããã€èå¿ãªææã¯ãç§éã«ã¯èããªããªããçä¿¡çãã«ã«ãæã¿ããã®ã«æ
ããããŠããŸããŸãããããšããããéèŠãªèª²é¡ã«ãããŠãäžããäžãŸã§ééãªããéœå
ã®ããåžžèãã§åºããããŠããç§éã®äžçã§ã¯ãéœåã®è¯ãåžžèç¬ç«ãããæç¢ºã§çè«ã®
éã£ãæèã¯ããã¯ãããçšã§ããããéåžžã«æãããæè¿ããããè¡çºãšãªã£ãŠããŸã£
ãã®ã§ãããã®åœé ãããããŸããã®äžçã¯ã人ã
ãããèãã€ããªãããã«ãšãããã
ãåªåãæããŸãèŠåŒµã£ãŠããŸãããç§éã¯çãèªåã®çŽæãä¿¡ããçå®ãèŠã€ããããã«
åŸã£ãŠè¡åãèµ·ããèœåããŸã 倱ã£ãŠã¯ããªãããšã
çŸåšã®ã¯ã¯ãã³æ¥ç𮿹éãšã¯éè¡ããå
å®¹ã®æç®ã¯èšå€§ãªæ°ã§ãããããã«èšèŒããåè
è³æã®ãªã¹ãã¯ãããã倧éæã«æç²ããã ãã«éããŸãããããã¯ã¯ãã³æ¥çš®ãæ¬åœã«
å®å
šã§å€§åãªãã®ãªãããªãç§éã®æ¿åºã¯ãæãåœãããå¥åº·ç¶æ
ãåªããŠããäžçäžã®
ä»ã®èªç±äž»çŸ©ã®åœã
ã§ã¯èŠæ±ãããŠããªãã¯ã¯ãã³ã®æ°ã
ãåœæ°ã«åŒ·å¶ãããããªæ³åŸã
èªããªããŠã¯ãããªãã®ã§ããããïŒ å
µééãåããã§æŒããã€ããŠãç¡çããã¯ã¯ãã³
ãæã£ãŠããŸãããã«ãšæç€ºãã[356]ãããªæ³åŸããæ¥çš®ãæåŠãã人ã
ã«å眰ãäžãã
ãã財ç£ã没åããããããããªæ³åŸãããã®ã¯ããªãã§ããããïŒ 2007 幎ã«Maryland
ã®äººã
ããéå£ãçªãã€ããããŠã¯ã¯ãã³æ¥çš®ã匷ããããã®ã¯ãã©ãããŠã§ãããïŒ
20 äžçŽå§ãã®æåãªåŒè·å£«ã§ãã Clarence Darrow ã¯ãã¯ã¯ãã³æ¥çš®ã®åŒ·å¶ã«å¯ŸããŠå察
ã®å£°æãæããŸããããã®å£°æã¯ããåŒçšãããŠããŸããããã®å
容ã¯ä»æ¥ã§ãæå¹ãªã
ã®ã§ãã圌ã®åããšã¯ãããã§ãããããã¯ã¯ãã³æ¥çš®ãæ¬åœã«å¹ããã®ãªããã¯ã¯ãã³æ¥
çš®ãåãã人éã¯å
ç«ãåºæ¥ãŠç
æ°ã«ããããªããªãããã§ãããïŒ ãããªããã¯ã¯ãã³
æ¥çš®ãåããªãããšãéžãã 人éãããã£ãŠãå¥ã«åé¡ãªããããããŸãããïŒã¯ã¯ãã³
æ¥çš®ãåãã人éãå¿é
ããããšãªã©ããããŸããããïŒ å®å
šã«é²è¡ãããŠããã¯ããªã
ã ããïŒã
å¿è«ãçãã¯æ±ºãŸã£ãŠãŸããããã«ã ããéã ããéïŒãïŒNullïŒ[220]
倧åãªè³ªå
ãã®ç« ã®å§ãã«ãåºæ¥ãã°ããŸãèããããªãããïŒã€ã®è³ªåã«ã€ããŠã¡ãã£ãšè§ŠããŸã
ãããããããç¥ã£ãŠããŸã£ãä»ãšãªã£ãŠã¯ãããçããã¯ãã®çåãåããããã«ã¯ã
ãããªãã§ãããã
ãã®åœã®æš©åè
ããç§éã®åäŸã®å¥åº·ã 50 åãã«ãã©ã¡ããéžã¹ãšèšãããããã©ã¡ãã
éžã¶ã ãããïŒ ã€ãŸãèšãæ¹ãå€ããã°ãFDA ã CDCãNIHããããšãçªç¶ã蚌æ ãå
åã§çãã®äœå°ããªãã»ã©ã«ãã¯ã¯ãã³æ¥çš®ã¯å¹ããªãã ãã§ã¯ãªããå€ãã®ç
æ°ãšæ»äº¡
ã®åå ã§ãããççŸã ããã®çŸç¶ãåŒãèµ·ããã匵æ¬äººã ãšæ°ä»ãããšããŠãããããçº
èŠãç§éã«äŒããããšããã ãããïŒ ãããªå
容ã®èšäºããNew York Times çŽã«æ²èŒã
ãããããã ãããïŒ ã¯ã¯ãã³æ¥çš®ããçªç¶äžæ¢ããããããã ãããïŒ
çãããåäŸã ã£ãé ãå®ã£ãŠãããã®ã¯èª°ã§ãããïŒ
åŠæ ¡ãªãå
¬ã®ãã®ãããããåäŸãŸã§ããã¯ãããªã
—B J Palmer
OK OK OK ã»ã倧äžå€«ã
Just a little pinprick ã¡ãã£ãšéã§ã¡ãã£ãšããã ã
Thereâll be no more aaaaah! ããçããªãã
ãïŒ
But you may feel a little sick ã§ãã¡ãã£ãšæ°åãæªããªãããã
Can you stand up? ç«ã¡ããããããïŒ
I do believe itâs working, good⊠ãããå¹ããããã ãâŠ
– P. Floyd
“I finished your book this morning. Simply the best and most
accessible deconstruction on vaccines Iâve read… proud of
your courage.”
– Anthony Maniotis, PhD
Dept. of Pathology, University of Illinois
“Every new mother and father should have the opportunity to
read it before subjecting their children to mandatory vaccinations.”
– Kilmer McCully, MD,TheHeartRevolution
“a book I recommend to parents so they can make an informed
decision on vaccines… 300 references add credibility…”
– Pamela Middleton, MD, pediatrician, Newport Beach, California
“The most comprehensive book I have read over the past 25
years on this subject.”
– Roy Kupsinel, MD, AutismandtheVaccineConnection
“Dr. O’Shea records the shameful history of what has been done
by the drug companies and the institutions that are supposed to
make sure they are honest… the role played by vaccinations over
the past 100 years has been grossly exaggerated and the harm
done has been carefully hidden from public view.”
– Abram Hoffer, MD, JournalofOrthomolecularMedicine
“…the most well-documented analysis of the vaccination cult
of modern medicine. Be informed of the dangers, lack of
scientific proof of immunity, and other concerns of vaccines.
…the best source for public and professionals, I highly
recommend it.”
– William Deagle, MD, GCNsyndicatedradio
“This book is the best source I have in my library about the
history and the horrors of the vaccine industry. …the three
generations of wholesale poisoning… Thanks for doing the
research for the rest of us.”
– Gary Kohls, MD, PreventivePsychiatry
“…one of the most shocking yet thoroughly researched
exposes on the vaccine industry…an issue that is vital to
our childrenâs health and future.”
– Hyla Cass, MD, Pacific Palisades, California
“You are right about pure blood…. that is the key.”
– Ted H Spence, DDS, ND
“Keep going after the truth — just make sure your bulletproof
vest fits.”
– Hal Huggins, DDS, Colorado Springs
“…a careful collection of irrefutable facts…spent several
days reading and re-reading it, and it is fantastic!”
– Hans Raible, Esq., Stuttgart Germany
“…dispels the myths and blatant lies that the public is told by
their pediatricians and community leaders… an absolute must
for any parent.”
– Dr. Mark Cymerint, Mission Viejo, California
“Wow! Yours is the most current, best referenced
presentation on vaccines I have ever seen. You have taken
a very complex subject and organized it so that it can be
comprehended by the average person.”
– Dr. TF, Tustin, California